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Abstract
This thesis is concerned with the design of half-sandwich iridium(III) complexes of
the type [(η5-Cp*)Ir(2-(Rˈ-phenyl)pyridine-R)X]0/+ (Cp* =
pentamethylcyclopentadienyl), X = Cl- or pyridine derivatives) as anticancer agents,
with particular focus on the effects that functionality in the chelating and
monodentate ligands has on their chemical and biological properties. A set of
phenyliminopyridyl (ImPy) complexes of the type [(η5-Cpx)Ir(ImPy)Cl]PF6 (Cpx =
Cp*, tetramethyl(phenyl)-cyclopentadienyl (CpxPh) or tetramethyl(biphenyl)-
cyclopentadienyl (CpxBiPh) was also synthesised and their solution chemistry and
potential applications as antibacterial and anticancer agents investigated.
Electron donating (-CH3, -OH, -CH2OH and –OCH3) or electron withdrawing
(-F, -CF3 -CHO and –NO2) groups were introduced to various positions on the
2-PhPy ligand, giving rise to seventeen complexes [(η5-Cp*)Ir(2-(Rˈ-
phenyl)pyridine-R)Cl]. Three X-ray crystal structures were determined, showing the
expected pseudo-octahedral configuration. The functional groups have a profound
effect on the resulting anticancer activities against a range of cell lines. Some
complexes showed activity against A2780 human ovarian cancer cells comparable to
cisplatin, and similar activity to [(η5-CpxPh)Ir(2-phenyl)pyridine)Cl]. The complexes
all show similar extents of hydrolysis. The complexes preferentially bind to the
model nucleobase 9-EtG over 9-MeA, and show the ability to catalytically oxidise
the coenzyme NADH to NAD+. Contrasting anticancer activities were found for
structural isomers. The hydrophobicity is related to substituent type and position on
the ligand. The more hydrophobic complexes accumulated in A2780 cells to a
greater extent. The extent of accumulation appeared to correlate with the potency of
the complexes.
The most potent complex [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)Cl] 13 (IC50 =
1.18 µM against A2780 cells) was modified via replacement of the chlorido
monodentate ligand with pyridine derivatives (18 = pyridine (Py), 19 = 4-
dimethylaminopyridine (Py-NMe2), 20 = 4-trifluoromethylpyridine (Py-CF3). The
X-ray crystal structure was determined for 19. These pyridine complexes show less
monodentate ligand release in aqueous solution and less binding to 9-EtG than
parent complex 13. Complexes 13 and 19 show mild catalytic activity towards the
oxidation of NADH to NAD+. Reactivity towards glutathione (GSH) decreased only
vii
in the case of 19 when compared with the parent complex 13. The reaction products
include [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)(S-O)G] (sulfenate) and [(η5-
Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)(S-O2)G] (sulfinate) which are reliant on the
presence of O2. The antiproliferative activity against A2780 cells increased upon
enhancement of stability at the monodentate site (19 > 18 > 20 ~ 13) when activity
was measured with no cell recovery time, with 19 exhibiting nanomolar activity
(IC50 = 650 nM). All of the complexes induced high levels of total reactive oxygen
species (ROS). Apoptotic cell death after 24 h recovery time was only observed for
the pyridyl complexes.
The ability to functionalise 2-PhPy complexes via Schiff base formation was
examined using the aldehyde-containing complex [(η5-Cp*)Ir(2-phenyl-5-
pyridinecarboxaldehyde)Cl] 6, and new conjugates were synthesised by conjugation
to primary amines. Reactions with lysine-containing peptides were analysed by ultra-
high resolution mass spectrometry (UHR-MS) techniques which showed formation
of new iridium-peptide conjugates via Schiff base formation with the free amino
group of lysine. The imine bond in a complex bearing the fluorescent dansyl moiety
(for fluorescence microscopy) was reduced using the hydride source Et3SiH, which
appears to involve the metal centre through proposed formation of an Ir-H species.
Eighteen [(η5-Cpx)Ir(ImPy)Cl]PF6 complexes with various ImPy ligands were
synthesised and characterised, and six X-ray crystal structures were reported. They
were found to exhibit more complex aqueous chemistry than the 2-PhPy complexes,
but exhibit minimal hydrolysis at biologically-relevant concentrations of chloride,
remaining predominantly as the chlorido species. The hydrophobicity of the
complexes increased upon extension of the Cpx capping ligand: CpxBiPh > CpxPh >
Cp*. The complexes show minimal activity against Gram-negative E. coli but
CpxBiPh complexes show good activity (MIC = 8 – 15 µM) against Gram-positive S.
aureus bacteria. The antibacterial activity is generally dependent on the
hydrophobicity and extension of the Cpx capping ligand. Disruption of the bacterial
cell membrane appears to be involved in the mechanism of action. The
antiproliferative activity against A2780 cells follows the trend CpxBiPh > CpxPh >
Cp*, where the complex [(η5-CpBiPh)Ir(ImPy-NMe2)Cl]PF6 31 exhibits an IC50 value
against A2780 cells of 640 nM.
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1.1 Metals in Medicine
The use of metals in medicine can be dated back to ancient civilisations, where for
example, the Greeks and Egyptians used silver to treat wounds and copper to purify
water for drinking. Historically, the development of the arsenic based arsphenamine
(salvarsan) in the early 1900’s for the treatment of syphilis is considered to be the
foundations of chemotherapy.1
In modern medicine, metal complexes have found a wide variety of uses as
diagnostic and therapeutic agents (Figure 1.1). Gadolinium(III) complexes
[Gd(DOTA)]-C7H18NO5+ (Dotarem) and [Gd(DTPA)]2-(C7H18NO5)2+ (Magnevist)
are used extensively as MRI contrast agents,2 which exploit the paramagnetic nature
of the Gd(III) ion to increase the T1 (longitudinal) relaxation rate of surrounding
water protons.3 The radiopharmaceutical agent [99mTc(sestamibi)]+ (Cardiolite) is
used for the evaluation of cardiac problems and as a diagnostic test for breast cancer
utilising single photon emission computed tomography (SPECT). Gold(I) complexes
such as auranofin are anti-inflammatory drugs for the treatment of rheumatoid
arthritis,4,5 while bismuth compounds such as bismuth subsalicylate (Pepto-Bismol)
is used to treat minor digestive discomfort.6 Metal-based compounds have also been
explored as anticancer and antibacterial agents which are the focus of this thesis.7
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Figure 1.1. Some metal-based compounds currently used in medicine for diagnosis
and therapy.
1.2 Cancer
Cancer is defined as the rapid division of abnormal cells which can infiltrate healthy
cells and spread throughout the body, forming secondary tumours otherwise known
as metastases. There are over 200 types of different cancers, and it is now estimated
that 1 in 2 people in the UK will develop cancer in their lifetime.8 Cancer is also one
of the leading causes of death in both developed and developing countries.9 This vast
prevalence makes the effective treatment of cancer a research priority within
medicine.
Cancer is commonly treated using either one or a combination of different methods.
Surgery is used to remove a solid tumour mass when localised around a particular
tissue, radiotherapy utilises ionising radiation to destroy cancerous tissue and
Chapter 1
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chemotherapy exploits the antiproliferative nature of particular chemical compounds
to kill cancer cells. Platinum-based treatments account for around 50% of the total
chemotherapeutic drugs used to treat patients, either alone or in combination therapy
with other antiproliferative agents.10
1.3 Metal-based Anticancer Agents
1.3.1 Platinum and Ruthenium Coordination Complexes
The most successful metallodrug to date for the treatment of cancer is the square-
planar Pt(II) complex cis-[PtCl2(NH3)2] cisplatin (Figure 1.2 a). Its antiproliferative
properties against sarcoma 180 (Lewis lung model) and leukaemia L1210 in mice
were first reported in 1969 by Rosenberg et al.11 Since the discovery of its
remarkable anticancer activity, it has been used either alone or in combination to
treat bladder, cervical, lung, ovarian, head and neck, and testicular cancers, in which
cisplatin has helped achieve a 95% cure rate against the latter.12
The mechanism of action (MoA) is widely accepted to involve the direct binding to
nuclear deoxyribonucleic acid (DNA) via predominantly 1,2-intrastrand cross-links
with guanine bases.13,14 This occurs through hydrolysis of the chloride ligands which
is favoured in the cell cytoplasm, due to a decrease in the chloride ion concentration
from around 104 mM (blood plasma) to 23 mM, forming the “active” cis-
[Pt(H2O)2(NH3)2]2+ species (Figure 1.2 b). The binding causes a kink in the DNA
duplex and recognition by high mobility group (HMG) proteins prevents DNA
repair, eventually leading to apoptosis (programmed cell death).15
Cisplatin suffers from a lack of specificity, leading to associated side-effects
including nephrotoxicity, neurotoxicity, ototoxicity and nausea and vomiting. This is
due to its primary target being DNA which is also present in non-cancerous cells.
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The second generation Pt(II) drugs [Pt(NH3)2(cyclobutane-1,1-dicarboxylate-O,O')]
carboplatin and [(1R,2R)-cyclohexane-1,2-diamine]Pt(ethanedioato-O,O')]
oxaliplatin (Figure 1.2 a) also exert their antiproliferative mechanism through DNA
damage, however, they exhibit less side-effects due to their greater chemical
stability.16
Figure 1.2. (a) Structures of clinically used Pt(II) drugs cisplatin, carboplatin and
oxaliplatin. (b) Activation of cisplatin via hydrolysis, promoting binding to the DNA
duplex (red = Pt). The kink is recognised by the HMG protein (grey) which inserts a
phenylalanine group (yellow) in the groove formed. Picture taken from reference.17
Inert low-spin octahedral Pt(IV) complexes, which can be activated by intracellular
reduction to Pt(II) species by reaction with ascorbic acid or glutathione (GSH), have
shown some success as potential anticancer agents,18,19 such as cis,cis,trans-
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[PtCl2(isopropylamine)2(OH)2)] iproplatin (Figure 1.3).20,21 Another promising
approach studied by Sadler et al. have been Pt(IV) complexes that can be
photoactivated by irradiation with UV or blue light as anticancer agents, the most
notable example being trans,trans,trans-[Pt(N3)2(OH)2(pyridine)2] (FM190) (Figure
1.3).22-24
Figure 1.3. Inert octahedral Pt(IV) complexes which exhibit anticancer activities
upon reduction to Pt(II) by either reaction with intracellular reducing agents or
irradiation with UV/blue light.
The successes and failings of Pt(II)-based treatments have led to the exploration of
transition metal complexes as new antiproliferative agents. The octahedral Ru(III)
complexes [trans-RuCl4(dimethylsulfoxide)(imidazole)]imidazolium NAMI-A (Sava
et al.) and [trans-RuCl4(indazole)2]indazolium KP1019 (Keppler et al.) (Figure 1.4)
have shown promise for the treatment of metastases25 and colorectal cancers,26
respectively, and have both entered phase I clinical trials. It is believed that the
intracellular reduction from Ru(III) to Ru(II) is responsible for their antiproliferative
action, in which the Ru(II)-Cl bond is believed to be more kinetically labile than in
Ru(III).27 This intracellular reduction is more easily achieved in cancer cells than in
healthy cells due to the more reducing environment, contributing to greater
selectivity than the clinically used Pt(II) drugs.
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Figure 1.4. Anticancer Ru(III) coordination complexes NAMI-A and KP1019 which
are currently in clinical trials
1.3.2 Organometallic Anticancer Complexes
The study of organometallic complexes (a metal compound which contains at least
one metal-carbon bond) as anticancer agents is a rapidly expanding field of research,
contributing to the now widely used term of bioorganometallic chemistry.28,29 Along
with coordination complexes, organometallic complexes can exhibit a wide range of
coordination modes and numbers, oxidation states and can accommodate a variety of
different ligands.
The first organometallic compound to show promise as a potential chemotherapeutic
agent was the bent-metallocene titanocene dichloride [(η5-Cp)2TiCl2] (Cp =
cyclopentadienyl) (Figure 1.5 a),30 which reached stage II clinical trials for treatment
of renal-cell carcinoma31 and metastatic breast cancer.32 The mechanism of action
was proposed to be similar to cisplatin, involving DNA cross-links, however, it is
now believed that it binds more strongly to the DNA phosphate backbone.33 Issues
arising from complicated aqueous behaviour and drug formulation prevented further
clinical investigations. Derivatives of titanocene dichloride have been studied by
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McGowan et al. Functionalisiation of the Cp ring with ionic amine tethers led to
increase in activity and better aqueous solubility.34,35 Tacke et al. synthesised ansa-
bridged derivatives which led to greater aqueous stability of the Cp rings and
increased activity compared to titanocene dichloride.36
Another promising organometallic drug candidate is ferrocifen (Jaouen et al.), in
which one Cp ring in ferrocene is conjugated to one of the active metabolites of the
organic breast cancer drug tamoxifen (Figure 1.5 b), which showed good activity
against both ER+ and ER- breast cancer cells.37 Proposed mechanisms of action
include binding to the ERα subtype, suppressing estradiol-mediated DNA 
transcription (similar mechanism to tamoxifen)38 and the production of reactive
oxygen species (ROS) which may be related to the redox activation by the ferrocene
moiety.39
Figure 1.5. (A) Structures of the organometallic anticancer agents (i) titanocene
dichloride, (ii) ionic tether derivative and (iii) ansa-bridged derivative. (B) The
organometallic iron anticancer agent ferrocifen.
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1.3.3 Half-sandwich Complexes
One of the most promising series of organometallic anticancer agents is half-
sandwich complexes. The general structure of half-sandwich complexes can be
described in relation to a piano-stool, where the seat is represented by the
coordination of a neutral arene for Ru(II) and Os(II), or negatively charged Cp* (Cp*
= pentamethylcyclopentadienyl) ring for Rh(III) and Ir(III) by binding of all 6 (η6) or
5 (η5) carbons present in the ring system, followed by the three legs of piano stool
which correspond to mono- (X, Y and Z), bi (X-Y with Z monodentate) or tridentate
(X-Y-Z) ligands (Figure 1.6). The surrounding ligands can provide control of the
reactivity towards biomolecules and can also govern physicochemical properties
such as hydrophobicity, a property which has been demonstrated to be of importance
for the anticancer activity of many organometallic complexes.40,41
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Figure 1.6. General structure of half-sandwich “piano-stool” complexes with typical
arenes and Cp rings commonly used.
1.3.3.1 Ruthenium
Half-sandwich complexes of ruthenium have been shown to be encouraging
anticancer agents,42 and may be attractive alternatives to the platinum complexes
currently used in the clinic. One of the most successful examples
[(η6-biphenyl)Ru(ethylenediamine)Cl]PF6 (RM175) was reported by Sadler et al.,
which showed excellent anti-tumour activity in vitro with an IC50 value
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(concentration which inhibits 50% cell growth) against A2780 human ovarian cancer
cells of 5 μM,43 and demonstrated activity in vivo (Figure 1.7).44
The primary target of RM175 is believed to be DNA, where it can form
monofunctional adducts via binding to guanine residues, leading to different metal-
adducts compared with cisplatin. This occurs after aquation of the chloride
monodentate ligand. The Ru(II)-guanine interaction is enhanced by the formation of
strong hydrogen-bonds between the NH2 protons on the ethylenediamine chelating
ligand and the C6 carbonyl of guanine (Figure 1.7), resulting in a strong preference
for binding to guanine residues over adenine.45 It was found that the complex
[(η6-p-cymene)Ru(1,2-bis(dimethylamino)ethane)Cl]PF6 which has no hydrogen
bonding donors exhibits no cytotoxic activity against A2780 cells, suggesting that
this interaction is integral to the mechanism of action.46
The in vitro anticancer activity of [(η6-arene)Ru(ethylenediamine)Cl]+ complexes is
directly related to the type of arene capping ligand present. Increasing the size of the
coordinated arene results in enhanced antiproliferative activity. The order of activity
based on the presence of the capping ligand is benzene < p-cymene < biphenyl <
dihydroanthracene < tetrahydroanthracene.44 This can be attributed to increased
hydrophobicity which can lead to enhanced cellular accumulation via passive
diffusion into the cell. The presence of extended arene systems can also increase the
ability to intercalate between DNA base pairs.45
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Figure 1.7. Activation via aquation of [(η6-biphenyl)Ru(ethylenediamine)Cl]PF6
(RM175) and subsequent binding to guanosine on DNA, as illustrated in the X-ray
crystal structure [(η6-biphenyl)Ru(ethylenediamine)guanosine](PF6)2. The strong H-
bond interactions (1.890 Å) between the C6 carbonyl and NH2 protons on the
chelating ligand stabilise the Ru-guanine interaction.
Work by Hartinger et al. has shown that the coordination of bioactive chelating
ligands such as 3-hydroxyflavones and lapchol to half-sandwich Ru(II) complexes
(Figure 1.8 i) can lead to highly active anticancer complexes, where mechanisms
such as DNA binding and metal-centred ROS production may be involved.47,48
Another interesting class of Ru piano-stool complexes are the RAPTA series (Figure
1.8 ii) developed by Dyson et al. which show excellent antitumor activities against
metastases rather than primary tumours.49 It is proposed that DNA binding via
protonation may be responsible for the selective activity towards cancer cells over
healthy cells due the slightly acidic microtumour environment exhibited by cancer
cells.50,51 It is also believed that interaction with proteins such as Cathepsin B may
also be responsible for the antiproliferative activity.52 Meggers et al. have also
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developed a series of Ru(II) Cp kinase inhibitors bearing a pyridocarbazole chelating
ligand which exhibit promising anticancer activity. It was demonstrated that
blocking the inhibitory kinase action by methylation of the nitrogen in the ligand
abolished the antiproliferative activity, showing that the active complex is acting as a
structural scaffold for kinase inhibition.53,54 These scaffolds are inert and do not
interact with DNA via the monodentate site unlike RM175.
Figure 1.8. Half-sandwich Ru(II) complexes with promising anticancer activities, (i)
lapchol derived complex, (ii) RAPTA-C and (iii) the substitutionally inert kinase
inhibitor.
1.3.3.2 Osmium
Half-sandwich osmium(II) complexes have been less studied compared to
ruthenium, presumably due to being considered less kinetically labile and the general
consensus of being a toxic metal ion, a phobia which can be traced to the highly
toxic OsO4. Osmium compounds are now gaining increasing interest as potential
anticancer agents.55
Studies by Sadler et al. on the osmium analogue of RM175 [(η6-
biphenyl)Os(ethylenediamine)Cl]BF4 (Figure 1.9 i) showed an IC50 value against
A2780 human ovarian cancer cells of 7 μM.56 The rate of aquation was found to be
40 times slower than RM175, and the pKa* of the aqua adduct was also lower than
Chapter 1
14
RM175 (6.3 vs. 7.7), indicating that the hydroxide adduct is likely to be dominant at
physiological pH. In contrast, studies on anionic O,O-chelated complexes like [(η6-
biphenyl)Os(acetyl-acetonate)Cl] (Figure 1.9 ii) showed no anticancer activity. They
rapidly hydrolyse forming the biologically inactive hydroxo-bridged dimer,57
indicating that the chelating ligand can have a dramatic effect on the chemical
reactivity and the observed biological activity of half-sandwich metal complexes.
Another series of osmium half-sandwich complexes bearing N,O-chelated picolinic
acid ligands showed encouraging in vitro anticancer activities in the low-micromolar
range.41,58 One of the most promising Os(II) arene complexes to date is [(η6-p-
cymene)Os(azpy-NMe2)I]PF6 (Figure 1.9 iii)) which exhibits nanomolar activity
against a range of cancer cell lines including ovarian, lung and colon.59 Interestingly,
the iodido monodentate ligand exhibits minimal hydrolysis in aqueous media, yet is
10 times more potent than its chloride analogue,60 suggesting that “activation via
aquation” is not always required for anticancer activity within chelated half-
sandwich complexes. It is believed that a redox-based MoA involving mitochondrial
dysfunction may be responsible for its antiproliferative activity.
Figure 1.9. Os(II) arene complexes studied as anticancer agents.
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1.4 Iridium
Iridium is a late-transition metal element and is one of the six platinum group metals.
First discovered in 1803 as an impurity in platinum metal, it is named after the Greek
Goddess Iris, the personification of the rainbow, due to the numerous different
colours of its salts. A relatively rare metal, the global consumption of iridium was
5,540 kg in 2012.61 The oxidation state of iridium complexes can range from -1 to
+5, allowing for a range of adopted geometries including square planar (+1),
tetrahedral (-1, 0), trigonal-bipyramidal (+1) octahedral (+3) and pseudo-octahedral
(+3, +4). Iridium has only two naturally occurring isotopes, 191Ir and 193Ir where the
latter is the most abundant. Upon formation of coordination/organometallic
complexes, the presence of organic compounds and halogens such as Cl and Br
create a distinctive isotopic pattern which aids the assignment of compounds by
mass spectrometry (Figure 1.10).
Figure 1.10. Calculated isotopic pattern of (i) iridium natural abundance, and the
calculated mass spectra of the positive ions of representative organometallic
complexes (ii) [Ir(2-phenylpyridine)2(2,2ˈ-bipyridine)]+ and (iii) [(η5-CpxPh)Ir(2,2ˈ-
bipyridine)Cl]+.
Chapter 1
16
Iridium complexes can exhibit interesting catalytic and photochemical properties, for
example, the highly active Crabtree’s catalyst is a square-planar Ir(I) complex for
homogeneous hydrogenation of highly-substituted olefins.62,63 Cyclometalated
octahedral Ir(III) complexes exhibit favourable luminescence properties which have
been shown to be potentially useful as biological probes.64,65 Half-sandwich Ir(III)
complexes are also excellent catalysts for a range of organic transformations,
including hydrogenation reactions of ketones66 and imines,67 and have also recently
been reported as efficient water oxidation catalysts in the presence of a chemical
oxidant.68,69
To date, iridium is only currently used in the clinic as a brachytherapy agent, a type
of internal radiotherapy, where sealed radioactive iridium-192 (ß-, half life – 73.83 d)
is placed inside the body next to or in the tumour site. It is most commonly used for
cervical, womb, vaginal and prostate cancers.70,71 Research into iridium cancer
chemotherapeutic agents is still in its infancy, compared with the years of research
on platinum and ruthenium complexes.
1.4.1 Iridium(I) Anticancer Complexes
Following the success of square-planar Pt(II) anticancer complexes, early research
was focussed on 5d8 square-planar Ir(I) complexes of the type
[IrCl(cyclooctadiene)]272 and [Ir(acetyl-acetonate)(cyclooctadiene)]73 (Figure 1.11 i-
ii) which exhibited antimetastatic activity against the Lewis lung model and
inhibition of primary Lewis lung carcinoma in mice, respectively. At the time of
discovery their mechanisms of action were not investigated. The rhodium analogues
showed no interaction with DNA, in which the authors claim a potentially different
mechanism of action than cisplatin.
Chapter 1
17
More recently, some Ir(I)-NHC (NHC = N-heterocyclic carbene) complexes with
anticancer activity have been reported.74 One of the more promising candidates was
reported by Metzle-Nolte et al. The complex [IrCl(NHC)(cyclooctadiene)] (Figure
1.11 iii) showed good activity against the human breast MCF-7 and colon HT-29
cancer cell lines (IC50 = 14.6 and 19.3 μM, respectively).75 Preliminary mechanistic
studies have shown that the complex can bind to proteins such as cytochrome c via
loss of the chloride and cyclooctadiene ligands, followed by oxidation of Ir(I)
allowing formation of kinetically inert Ir(III) octahedral protein adducts.
Figure 1.11. Squre-planar Ir(I) complexes studied for anticancer activity.
1.4.2 Octahedral Iridium(III) Anticancer Complexes
Due to the success of Ru(III) octahedral complexes NAMI-A and KP1019, Ir(III)
analogues have been studied for their anticancer properties (Figure 5.13).
Interestingly, no anticancer activity was observed for either [trans-
IrCl4(dimethylsulfoxide)(imidazole)]imidazolium76 or [trans-
IrCl4(imidazole)2]imidazolium,77 suggesting that the greater kinetic stability of the
octahedral Ir(III) ion results in poor activity.
Octahedral complexes of Ir(III) exhibit interesting luminescence properties.
Emission tends to occur via triplet metal-to-ligand charge-transfer (3MLCT). They
have been widely studied as biological probes. Interaction with the analyte of interest
(e.g. DNA, proteins) generally results in an increase in luminescence. Lo et al. have
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reported a series of cyclometallated polypyridyl Ir(III) complexes that have been
extensively studied for this purpose.65,78 Interestingly, some of these complexes also
exhibit antiproliferative activity against cancerous cells, such as [Ir(2-
phenylquinoline)2(N,N)]PF6 (where N,N = indole-functionalised 2,2’-bypyridine)
(Figure 1.12 i) with IC50 values of down to 1.1 μM against the HeLa cell line. 
Hydrophobicity appears to be an important characteristic for good activity.79
Ruiz et al. have reported cyclometallated Ir(III) complexes bearing
thiosemicarbazone ligands (Figure 1.12 ii) that show potent activity against A2780
human ovarian cancer cells with no cross-resistance against A2780cisR (cisplatin
resistant human ovarian cancer cell line) observed.80 The complexes are capable of
inhibiting Cathepsin B as well as binding to the minor groove of DNA. No direct
binding to the model nucleobase 9-ethylguanine (9-EtG) was observed by 1H NMR
spectroscopy.
Octahedral Ir(III) complexes can also be designed as structural scaffolds for the
inhibition of kinases, as demonstrated by Meggers et al.81,82 An interesting example
is the complex trans,trans-[(CH3)SeCNIr(pyridocarbazole)-
(dibenzo[a,e]cyclooctatetraene)] (Figure 1.12 iii) which shows dual anticancer
activity through both antiangiogenic activity via inhibition of vascular endothelial
growth factor receptor kinases (VEGFR) and photoinduced antiproliferation via
irradiation with visible light, resulting in loss of the selanocyanide ligand, allowing
binding to biological targets.83 Recently, Ma et al reported the first metallo-inhibitor
of the tumour necrosis factor-α converting enzyme (TACE) based on an octahedral 
Ir(III) complex (Figure 1.12 iv) which shows promise in the development of
treatment of inflammatory diseases and cancer.84
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Figure 1.12 Octahedral iridium(III) complexes that show promise as potential
anticancer agents.
1.4.3 Half-sandwich Iridium(III) Anticancer Complexes
There is an increasing interest in the use of half-sandwich iridium(III) complexes for
biological use.85,86 The first examples were reported by Sheldrick et al. They initially
studied DNA intercalators using complexes of the general structure
[(η5-Cp*)Ir(N,N)X]+/2+ (N,N = polypyridyl (pp) chelating ligand, X = chloride/L-
methionine) (Figure 1.13 a). Enhanced interactions with DNA were observed upon
an increase in the surface area of the pp ligand. DNA intercalation was detected
using 2D NOESY for the complex [(η5-Cp*)Ir(dppz)(L-methionineH)]3+ (dppz =
dipyridophenazine) with the hexanucleotide d(GTCGAC)2.87 Studies on the
antiproliferative activity showed that the ability to intercalate between DNA bases
could be responsible for their biological activity. Complexes containing
ethylenediamine or 1,10-phenanthroline were poor intercalators and showed no
antiproliferative activity.88 The complexes were also shown to bind to DNA
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nucleobases directly at the metal centre, showing a dual-mode of DNA interaction.
The increase in size of the polypyridyl ligand also results in an increase in
hydrophobicity, which can increase cellular accumulation of compounds via passive
diffusion through the lipophilic cell membrane.
McGowan et al. have recently reported cytotoxic neutral half-sandwich Ir(III)
complexes bearing anionic picolinamide and ß-ketoiminate chelating ligands (Figure
1.13) which show promising activity against a variety of different cancer cell
lines.89,90 The picolinamide complexes were shown to be potent inhibitors of
thioredoxin reductase 1 (Trx-R) which may contribute towards their mechanism of
action. The ß-ketoiminate complex [(η5-Cp*)Ir(3′-fluorophenyl-3(phenylamino)-2-
buten-1-one)Cl] also showed Trx-R inhibition and was able to retain modest
antiproliferative activity under hypoxic conditions against the HT-29 colon cancer
cell line, demonstrating that it can act as normoxic and hypoxic antitumor agent.91
Within the Sadler laboratory, a series of Ir(III) complexes bearing phenyl- or
biphenyl-substituted cyclopentadienyl capping ligands have been developed using
neutral N,N-chelating ligands (2,2ˈ-bipyridine, 1,10-phenathroline and 
ethylenediamine), Figure 1.14. An increase in activity against A2780 human ovarian
cancer cells was observed following the order CpxBiPh > CpxPh > Cp*.92
Determination of the log P values indicated that an increase in extension of the Cpx
ligand resulted in greater hydrophobicity, which correlates with the extent of Ir
accumulation in A2780 cells.
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Figure 1.13. Half-sandwich Ir(III) complexes studied for anticancer activity (a) use
of extended pp chelating ligands results in enhanced activity and (b) neutral
anticancer complexes that show Trx-R inhibition.
This study was extended further by replacing the neutral N,N-chelating ligands with
isoelectronic anionic C,N-chelating ligands (2-phenylpyridine, 7,8-benzoquinoline,
Figure 1.14).93 An increase in activity was observed which was attributed to an
increase in hydrophobicity of the resulting neutral complex ([(η5-Cp*)Ir(2,2ˈ-
bipyridine)Cl]PF6 log P = -0.95 vs. ([(η5-Cp*)Ir(2-phenylpyridine)Cl] log P =
1.57).94 The same trend was also observed upon introduction of the extended Cpx
ligands as determined for the N,N-chelated compounds, resulting in highly potent
complexes. Furthermore, the replacement of the chloride monodentate ligand with
pyridine (Py) in ([(η5-CpxBiPh)Ir(2-phenylpyridine)Py]PF6 resulted in enhanced
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anticancer activity against A2780 cells (Ir-Cl IC50 = 0.7 μM vs. Ir-Py IC50 = 0.12
μM) and selectivity over healthy cells comparable to cisplatin.95
Despite Ir(III) being normally an inert low spin d6 metal ion, the monodentate ligand
in organo-Ir(III) chelated half-sandwich complexes can be kinetically labile.96
Hydrolysis studies show that equilibrium between Ir-Cl and Ir-OH2/OH in
[(η5-Cpx)Ir(X-Y)Cl]0/+ (X-Y = neutral N,N- or anionic C,N- chelating ligands)
complexes is reached within under 5 mins at 310 K. The extent of hydrolysis is
greatest for the neutral complexes over charged complexes (as monitored by 1H
NMR spectroscopy), which can be attributed to the anionic C,N-chelating ligand
facilitating chloride loss by increasing the electron density on the metal centre. This
also leads to the aqua adducts having higher pKa values in C,N-chelated complexes
over N,N-chelated systems ([(η5-Cp*)Ir(2,2ˈ-bipyridine)OH2]2+ pKa = 6.86 vs.
[(η5-Cp*)Ir(2-phenylpyridine)OH2]+ pKa = 8.75).94 Interestingly, the use of pyridine
as a monodentate ligand dramatically decreases the rate of hydrolysis, where the
half-life (t1/2) of hydrolysis for ([(η5-CpxBiPh)Ir(2-phenylpyridine)Py]PF6 is
77.8 min.95 This complex also shows 18% conversion to the chloride complex under
104 mM NaCl (chloride concentration in blood plasma) after 1 h incubation.
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Figure 1.14. Half-sandwich Ir(III) anticancer complexes investigated within the
Sadler laboratory with IC50 values against A2780 human ovarian cancer cells.
Studies into potential mechanisms of action have been focussed initially on
interactions with DNA, which have been shown to be of importance for many
metallo-anticancer complexes.97,98 Both N,N- and C,N-chelated complexes can bind
to 9-EtG, but only the C,N-chelated complexes show any affinity towards 9-
methyladenine (9-MeA), although binding to 9-EtG appears to be preferred in
competition experiments.94 DNA replication mapping also showed that guanine was
the preferred binding site for complexes [(η5-Cpx)Ir(1,10-phenanthroline)Cl]PF6.
(Cpx = Cp*, CpxPh, CpxBiPh).92 The ability to intercalate between DNA base pairs as
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determined by ethidium bromide (EtBr) displacement is strongly dependent on the
type of capping ligand used, in which the more extended ligands result in enhanced
EtBr displacement, suggesting that intercalation as well as direct nucleobase binding
may be important for antiproliferative activity. This has also been observed for
Ru(II) and Os(II) half-sandwich complexes that bear extended arene ligands.99,100
More recently, Ir(III) half-sandwich complexes bearing N,N- and C,N chelating
ligands have been shown to induce high levels of ROS causing mitochondrial
dysfunction.101,102 Incubation with L-buthionine sulfoximine (L-BSO), which reduces
the cellular levels of the ROS scavenger GSH,103 results in a two-fold increase in
antiproliferative activity for ([(η5-CpxBiPh)Ir(2-phenylpyridine)Py]PF6, confirming the
role of ROS in the MoA of these complexes. Therefore, it is likely that these
complexes not only bind to DNA, but also cause mitochondrial damage.
Interestingly, it has been demonstrated that half-sandwich Ir(III) complexes can
catalytically oxidise reduced ß-nicotinamide adenine dinucleotide (NADH) to
NAD+.104,105 The disruption of the NAD+/NADH redox couple could have
implications for cellular energy processes, including the citric acid cycle and the
oxidative phosphorylation of adenosine diphosphate (ADP) to adenosine
triphosphate (ATP).106 It has also been reported that the levels of NADH in cancer
cells can be twice as high as in healthy cells, which may make NADH a good
biological target for cancer therapy.107
The oxidation of NADH by complexes [(η5-Cpx)Ir(1,10-phenanthroline)OH2]2+ (Cpx
– Cp*, CpxPh) has been proposed to proceed by interaction of the amide unit with the
Ir centre (displacing H2O), along with ring slippage of the Cpx from η5to η3 allowing
formation of the Ir-H species (detected by 1H NMR spectroscopy).104 The hydride
species can then become protonated to form H2 gas or can reduce biological
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substrates such as the quinone vitamin K3 to the semiquinone derivative, where
coordination of another water molecule completes the catalytic cycle (Figure
1.15).108
Figure 1.15. Proposed catalytic cycle for the oxidation of NADH to NAD+ by the
half-sandwich Ir(III) anticancer complex [(η5-CpxPh)Ir(1,10-phenanthroline)OH2]2+
(taken from reference).104
The complex [(η5-CpxBiPh)Ir(2-phenylpyridine)Py]PF6 is also able to oxidise NADH
to NAD+ forming H2O2 via hydride transfer to molecular oxygen and protonation.95
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This may contribute to the elevated levels of ROS observed in A2780 cells for this
complex. The rate of reaction with NADH is slower than its chloride analogue.
However, it has been hypothesised that the more stable pyridine ligand protects the
complex from deactivation from biomolecules such as GSH (present in mammalian
cells at a concentration of between 0.5-10 mM),109 which may inhibit the desired
reaction, ultimately leading to a more active complex (Figure 1.16).
Figure 1.16. Proposed reaction pathway of [(η5-CpxBiPh)Ir(2-phenylpyridine)Py]PF6
with NADH forming H2O2, and the protection from deactivation with GSH.95
It was demonstrated that these complexes can increase the ratio of NAD+/NADH in
A2780 cells, presumably as a consequence of their ability to oxidise NADH to
NAD+, potentially a novel mechanism of action.104 Recently, arene Ru(II)
sulfonamido ethyleneamine complexes were shown to perform the reverse function.
Addition of non-toxic amounts of formate (hydride source) leads to catalytic
reduction of NAD+ to NADH in A2780 cells.110 Indeed, performing catalysis in cells
by synthetic metal complexes is an expanding field of research, which includes
carbon-carbon bond formation and the removal of protection groups by
organometallic compounds of palladium, ruthenium, iron and iridium.111,112
Chapter 1
27
1.5 Bacterial Resistance
The rise of antibacterial resistance is becoming an increasing issue. Simple medical
procedures may soon become dangerous due to the risk of infection,113 with strains
of bacteria such as methicillin resistant Staphylococcus aureus (MRSA) becoming
more prominent in hospitals. Therefore, new antibacterial agents are required that
can overcome this resistance. The resistance to traditional antibiotics has been
partially blamed on overuse and misuse. Bacteria can build resistance through
various mechanisms, including modification of the particular protein target site, the
up- or down-regulation of specific membrane pumps which facilitate transport of the
antimicrobial agent in/out of the cell, and the production of enzymes that can break
down the active agent.114
1.5.1 Metal-based Antibacterial Agents
Metal-based antibacterial agents may provide hope for the treatment of bacterial
infections that are becoming resistant to many organic drugs. To date, silver nitrate
and silver sulfadiazine (Figure 1.17 a i) are used to prevent infections developing in
burn wounds.115 The Ag(I) ion is believed to exhibit the antibacterial activity (as well
the organic fragment in silver sulfadiazene), in which silver ions may react with thiol
groups in enzymes and also cause disruption of bacterial cell membranes.116 There
appears to be no intrinsic toxicity of Ag(I) ions to the human body at low
concentrations, however, over-exposure to silver salts can lead to the condition of
argyria in which the skin turns a silver-grey colour.117 Silver-NHC complexes have
started to receive attention as alternatives to the traditionally used silver salts as
antibacterial agents (Figure 1.16 a ii).118,119
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Although not an antibacterial, it is worth highlighting the success of the
organometallic antimalarial agent ferroquine, which contains the organic antimalarial
chloroquine combined with ferrocene (Figure 1.16 b) and has reached phase II
clinical trials.120 Ferroquine shows a similar mechanism of action as chloroquine
against chloroquine-sensitive P. falciparum, centred on the inhibition of hemozoin
formation. However, it is also highly active against chloroquine-resistant strains, in
which it has been proposed that the change in the physicochemical, geometrical and
electronic properties result in its activity.121 It has also been hypothesised that the
ability to induce ROS and interference with lipids may contribute to the enhanced
antimalarial activity of ferroquine over chloroquine.122
Figure 1.16 (A) Silver antibacterial agents and (B) the antimalarial agent ferroquine.
Other transition metal ions have also been investigated for antibacterial activity,123
including Cu(II), Zn(II), Co(II), Ni(II) and Mn(II) bearing Schiff base chelating
ligands, and have shown promising activities against Gram-negative E. coli.124
Recently, research by Metzle-Nolte et al. have shown the promise of tri-metallic
complexes containing a rhenium carbonyl moiety as a new class of antibacterial
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agent. They show high activity against Gram-positive bacteria such as S. aureus and
MRSA,125 where a recent study highlighted that the Re-(CO)3 unit is essential for
activity.126
Research on the platinum-group metals as antibacterial agents has centred
predominantly on Ru(II) complexes.127 Early studies on Ru(II) coordination
complexes by Dwyer et al. in the 1960’s were focussed on inert pp scaffolds which
showed good activity against Gram-positive bacteria.128 However, further
development was not performed, which may be as a consequence of the large
number of antibacterial agents being investigated at that time. Due to the increasing
concern over antibacterial resistance, new interest has arisen. Aldrich-Wright et al.
have reported a series of antibacterial Ru(II) complexes that are DNA intercalators
(Figure 1.17 i).129 It appears that lipophilicity and charge are of importance for high
activity against Gram-positive bacteria.130 However, these properties can also make
them toxic to healthy cells, especially when DNA is a biological target.
Organometallic Ru(II) complexes have also shown promise,131-133 for example, a
ruthenocene complex conjugated to 6-aminopenicillic acid (6-APA), incorporating
an organometallic fragment with a novel ß-lactam unit (Figure 1.17 ii) shows high
activity against MRSA strains.134 The complex exhibits enhanced activity over the
ferrocene derivative and 6-APA on its own, showing that the metal fragment plays a
role in activity as well as the ß-lactam unit.
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Figure 1.17 Ru(II) complexes which show promising antibacterial activity.
There are very few previous studies on the antibacterial activity of iridium
complexes, with most reports being over the past 5 years. Inert polypyridyl Ir(III)
octahedral complexes analogous to the Ru(II) complexes previously discussed have
been studied, but showed no antibacterial activity.135 This was attributed to switching
from an overall Ru 2+ to Ir 3+ charge resulting in decreased cellular accumulation.
Despite this initial result, it was then demonstrated that dinuclear octahedral Ir(III)
complexes with one labile coordination site show high activity against S. aureus and
MRSA, Figure 1.18 (i).136 However, the complexes were shown to be bacteriostatic
rather than bactericidal.
Studies into antibacterial half-sandwich Ir(III) complexes are limited, but it has been
demonstrated that [(η5-Cp*)Ir(quinolin-8-olato)Cl] showed mild activity against
Gram-positive bacteria but no activity against Gram-negative bacteria (Figure 1.18
ii).137 The complex also exhibits antiproliferative activity against the SK-MEL
human melanoma cell line. Further to this, a recent report on Ru(II), Rh(III) and
Ir(III) piano-stool complexes bearing a hydrazone Schiff base chelating ligand
showed good antibacterial activity for Ru(II) analogue against S. aureus and E. coli,
while the Rh(III) and Ir(III) derivatives showed no activity.131 More promising are
aminoacidato complexes of the type [(η5-Cp*)Ir(aminoacidato)Cl] (Figure 1.18 iii)
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which show good activity against Mycobacterium strains. Intriguningly, the L-amino
acid complexes exhibit better activity than D-amino acids. Hydrophobicity appears
to be important, where coordinated amino acids such as phenylalanine exhibit
enhanced activity compared to glycine.
Figure 1.18 Ir(III) complexes which exhibit antibacterial activity.
1.6 Functionalising Metal Complexes
One of the major advantages of the use of metal complexes in medicinal chemistry is
their ability to affect a wide range of chemical and biological properties by
modification of the coordinated ligands.29,138 Traditionally, these properties are tuned
via the binding of different ligands to the metal complexes. For example, the use of a
pyridine monodentate ligand in N,N-chelated Ru(II) arene complexes blocks the
reactivity of the monodentate site towards hydrolysis and nucleobase binding, but
the complex can be photoactivated to release the pyridine ligand.139,140 This allows
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for controlled DNA binding and hence a greater control over the cytotoxic properties
of the complex.
The ability to add organic fragments that exert a particular function in the resulting
complex, such as aiding selectivity towards uptake in cancerous cells over healthy
cells, or delivery to a particular organelle, is an expanding area of research.141 Pt(II)
anticancer complexes cisplatin, carboplatin and oxaliplatin have been functionalised
for active drug transport and delivery via conjugation to organic/bioorganic moieties
such as estrogens, carbohydrates and peptides.142 Metal complexes can also be
modified to attach them to nanoparticles, carbon-nanotubes and polymers.143-145 This
can be advantageous for exploiting the enhanced permeability and retention (EPR)
effect, where molecules of high molecular weight (such as polymers) accumulate in
tumour tissue to a greater extent than in healthy cells. Polymer systems can also be
decorated with molecules to enhance receptor-mediated targeting, further increasing
their drug delivery and selectivity.146
Post-modifications to metal complexes allow for a diverse range of new complexes
to be prepared from one “parent” complex, without the need to make individual
ligands for coordination to the metal. In order to post-functionalise metal complexes,
a functional group is generally required on one of the ligands (unless the complex is
functionalised via addition of a ligand) that confers a particular reactivity towards
another functional group. Metzler Nolte et al. have pioneered the bioconjugation of
peptides and PNA oligomers to ferrocenyl and octahedral metal complexes using
click chemistry147 and Sonogashira coupling148 which require the presence of an
azide/alkyne or alkyne/iodide group, respectively (Figure 1.19).
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Figure 1.19 Bio-conjugation of ferrocenyl and octahedral metal complexes to the
peptide enkephalin using (A) Sonogashira coupling and (B) “click-chemistry”.
The use of aldehyde groups on ligands to functionalise metal complexes has recently
gained some attention. The advantage of using this system is the high reactivity that
aldehydes have towards nucleophilic attack by amines, which allows both organic
and bioorganic amines such as peptides and proteins (which contain a free amino
group) to be conjugated without using highly forcing conditions. The condensation
reaction produces the imine functional group (Figure 1.20), also known as a Schiff
base, which is susceptible to hydrolysis and is enhanced at acidic pH. In polymer
research, this has led to the development of polymers that contain pH-sensitive imine
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bonds as drug delivery vehicles for cancer drugs, where upon hydrolysis in the more
acidic microtumour environment the drugs are preferentially released in cancer
cells.149,150
Figure 1.20 Reaction of benzaldehyde with 2-methoxylethylamine to form the
corresponding imine conjugate.
The exploitation of the reactivity of aldehyde groups on a Pt(II)-NHC complex was
recently demonstrated by Bellemin-Laponnaz et al., who showed that either primary
amines or hydroxylamines can form imines or oximes, respectively.151 C-protected
amino acids can be easily conjugated to the complex to form Schiff bases, and it was
even demonstrated that the reduction of the imine to the secondary amine can be
performed using the weak reducing agent NaHB(OAc)3. Lo et al. have also
demonstrated how an octahedral Ir(III) complex bearing aldehyde substituents can
react with bovine serum albumin (BSA) via surface lysine residues, followed by
reduction using NaCNBH3 to form stable Ir(III)-bioconjugates with luminescent
properties.152
1.7 Aims
Due to promising results reported for the use of C,N-chelated iridium(III) half-
sandwich complexes as anticancer agents, a major part of this thesis is concerned
with the further study of this series, with particular focus on tuning the properties
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and activities of Cp* compounds via functionalisation of chelating and monodentate
ligands. Iminopyridine N,N-chelated iridium(III) complexes were also investigated,
examining the effects that functionality on the Cpx ring and chelating ligand have on
the chemical, antibacterial and anticancer activity. More specific aims were as
follows.
1. Synthesis, characterisation and evaluation of the chemical, physicochemical
and anticancer properties that arise from functionalising 2-phenylpyridine
ligands in complexes of the type [(η5-Cp*)Ir(2-phenylpyridine)Cl] with
electron-donating and electron-withdrawing groups.
2. Studying the effects on the chemical and anticancer properties of chlorido
and pyridyl monodentate ligands on the complex [(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)X]0/+.
3. Exploring the functionalisation of the anticancer complex
[(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] by reactions with amines
and peptides to form new Schiff base conjugates, including the addition of a
fluorescent dansyl moiety. Reduction of the dansyl conjugate to the
secondary amine was investigated to enable investigations into tracking the
complex via confocal microscopy.
4. The synthesis, characterisation and evaluation of the solution chemistry of
complexes of the type [(η5-Cpx)Ir(phenyliminopyridyl)Cl]PF6 with
investigations into their antibacterial and anticancer activity.
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This chapter describes the experimental techniques and instrumentation used
throughout this thesis. The syntheses of the iridium dimers used to make the half-
sandwich complexes are described. Detailed procedures for specific experiments are
described in the appropriate chapters.
2.1 Synthesis of Iridium Dimers
2.1.1 Materials
IrCl3.3H2O (99%) was purchased from Precious Metals Online (Australia). 1,2,3,4,5-
Pentamethylcyclopentadiene (95%), 2,3,4,5-tetramethyl-2-cyclo-pentenone (95%),
4-bromobiphenyl (98%), n-butyllithium (1.6 M in hexanes) and phenyllithium (1.6
M in dibutylether) were purchased from Sigma-Aldrich (UK). All solvents used for
synthesis were anhydrous and used without further drying/purification. The synthesis
of 3-phenyl-1,2,4,5-tetramethyl-1,3-cyclopentandiene (CpxPhH)1 and 3-biphenyl-
1,2,4,5-tetramethyl-1,3-cyclopentandiene (CpxBiPhH)2 was carried out as previously
reported (Figure 2.1).
Figure 2.1. Synthetic route to (A) CpxPhH and (B) CpxBiPhH.
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2.1.2 Preparation of Iridium Dimers
The preparation of [(η5-Cp*)IrCl2]2 was carried out using two different routes
reported in literature.
Method A:3 1,2,3,4,5-pentamethylcyclopentadiene (7 g, 51.5 mmol) was dissolved
in anhydrous MeOH (200 mL) under N2 and was stirred at ambient temp for 5 min.
IrCl3.3H2O (2 g, 5.67 mmol) was added and the reaction mixture was heated under
reflux for 48 h. The solution was cooled to ambient temperature and the precipitate
was isolated via filtration under reduced pressure and washed with Et2O without
further purification (1.815 g, 80%). 1H NMR (400 MHz, CDCl3) δ = 1.59 (s, 30 H). 
Method B:4 1,2,3,4,5-pentamethylcyclopentadiene (1.16 g, 1.34 mL, 8.56 mmol)
was placed in a microwave vial, MeOH (10 mL) was added and the solution stirred
at ambient temp for 5 min. IrCl3.3H2O (1 g, 2.84 mmol) was added and the vial was
placed in a microwave reactor (413 K, 150 W, 250 psi, 5 min). The reaction was
cooled to ambient temp, where the product was isolated via filtration under reduced
pressure and washed with Et2O without further purification (0.92 g, 81%). 1H NMR
(400 MHz, CDCl3) δ = 1.59 (s, 30H). 
[(η5-CpxPh)IrCl2]2 2 3-phenyl-1,2,4,5-tetramethyl-1,3-cyclopentandiene (1.7 g, 8.5
mmol) was dissolved in anhydrous MeOH (60 mL) under N2 and was stirred at
ambient temp for 5 min. IrCl3.3H2O (1.7 g, 4.82 mmol) was added and the reaction
mixture was heated under reflux for 48 h. The solution was cooled to ambient
temperature and the precipitate was isolated via filtration under reduced pressure and
washed with Et2O without further purification (1.01 g, 46%). 1H NMR (400 MHz,
CDCl3) δ = 7.57-7.56 (m, 4H), 7.36-7.35 (m, 6H), 1.72 (s, 12H), 1.63 (s, 12H). 
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The synthesis of [(η5-CpxBiPh)IrCl2]2 has been previously reported2 but not via
microwave synthesis. The yield obtained using the microwave reactor (65%) is
higher than that obtained using the previously reported route (22%).
[(η5-CpxBiPh)IrCl2]2 3-biphenyl-1,2,4,5-tetramethyl-1,3-cyclopentandiene (1.5 g,
5.47 mmol) was placed in a microwave vial, MeOH (13 mL) added and the solution
stirred at ambient temp for 5 min. IrCl3.3H2O (0.814 g, 2.31 mmol) was added and
the vial was placed in a microwave reactor (413 K, 150 W, 250 psi, 5 min). The
reaction was cooled to ambient temp, where the product was isolated via filtration
under reduced pressure and washed with Et2O without further purification (0.802 g,
65%). 1H NMR (400 MHz, CDCl3) δ =7.67-7.64 (m, 4H), 7.60-7.56 (m, 8H), 7.45-
7.41 (m, 4H), 7.37-7.32 (m, 2H), 1.75 (s, 12H), 1.69 (s, 12H).
2.2 Methods and Instrumentation
2.2.1 Microwave Reactor
Some syntheses were performed using microwave-assisted chemistry, which utilises
the ability to increase the temperatures at which reactions take place beyond
traditional laboratory techniques, and increase solvent molecular vibrations, allowing
reactions to proceed at a faster rate.5 The CEM Discovery-SP microwave reactor was
used with specific conditions given in the appropriate chapters.
2.2.2 Nuclear Magnetic Resonance (NMR) Spectroscopy
1H NMR spectra were obtained in 5 mm NMR tubes at 298 K (unless stated
otherwise) on either Bruker DPX-300, Bruker DPX-400, or AV III 600 NMR
spectrometers. 1H NMR chemical shifts were internally referenced to
(CHCD2)(CD3)SO (2.50 ppm) for dmso-d6, CHCl3 (7.26 ppm) for chloroform-d1,
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(CHD2)(CD3)CO (2.05 ppm) for acetone-d6, (CHD2)CD2OD (1.11 ppm) for ethanol-
d6, and 1,4-dioxane (3.75 ppm) for aqueous solutions.
1D 1H NMR spectra were recorded using standard pulse sequences. Data were
typically acquired using 16-128 transients into 32 k data points over a spectral width
of 14 ppm. For detection of Ir-H species, data was acquired using 128-256 transients
into 32 k data points over a spectral width of 40 ppm, with the centre at 0 ppm
relative to the signal for dioxane (3.75 ppm) and T1 relaxation time of 2 s. 2D
correlation spectroscopy (COSY) spectra were acquired using 8 transients into 1024
data points.
Experiments in aqueous solution were performed using the Shaka (Double Pulse
Field Gradient Spin Echo - DPFGSE) water suppression technique to reduce the
intensity of the HOD signal.6
2.2.3 Mass Spectrometry
2.2.3.1 Electro-Spray Ionisation Mass Spectrometry (ESI-MS)
Positive-ion ESI spectra were obtained on a Bruker Esquire 2000 ion trap
spectrometer. Samples were prepared in either MeOH or CH3CN. The mass spectra
were recorded with a scan range of either m/z 50-500 or m/z 400-1000. Data were
processed using Data Analysis 3.3 (Bruker Daltonics). Assignment of iridium
species was aided by the Ir isotopic pattern as described in section 1.4.
2.2.3.2 High-Resolution Mass Spectrometry (HR-MS)
Positive-ion spectra were obtained on a Bruker MaXis UHR-TOF spectrometer by
Dr. Lijang Song and Mr. Phillip Aston (Department of Chemistry, University of
Warwick). Samples were prepared in either MeOH or CH3CN and typically injected
at 2 μL min–1. Source conditions used were as follows: nebuliser gas (N2) 0.4 bar;
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dry gas (N2) 4 L min–1 and dry temp 453 K; funnel RF 200V; multiple RF 200;
quadrupole ion energy 4 eV; collision cell 5 eV; ion cooler RF settings, ramp from
50 to 250 V. Data were processed using Data Analysis 3.3 (Bruker Daltonics).
Assignment of iridium species was aided by the Ir isotopic pattern as described in
section 1.4.
2.2.4 Elemental Analysis
CHN elemental analyses were carried out on a CE-440 elemental analyser by Exeter
Analytical (UK) Ltd.
2.2.5 High Performance Liquid Chromatography (HPLC)
HPLC was utilised to determine the purity of samples, the relative hydrophobicity of
a series of complexes and to resolve enantiomeric mixtures chirally. Where reactions
or stability have been analysed by HPLC, specific conditions are stated in the
relevant chapter.
2.2.5.1 Purity Determination
Purity determinations by RP-HPLC were made using the Agilent 1200 system with a
VWD and 100 μL loop. The column used was an Agilent Zorbax Eclipse Plus C18, 
250 × 4.6 mm with a 5 μm pore size. The mobile phase was H2O 0.1% TFA and
CH3CN 0.1% TFA, with a flow rate of 1 mL min-1. The detection wavelength was
set at 254 nm and the reference wavelength at either 360 nm or 510 nm. Sample
injections were half the loop volume (50 μL) with needle washes of MeOH and H2O
between injections. It was assumed that all species in a sample have the same
extinction coefficient at 254 nm. All peaks were manually integrated to gain the
percentage area. The gradient used is shown in Figure 2.2.
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Figure 2.2. HPLC method used the solvent gradients for purity determinations using
H2O 0.1% TFA (solvent A) and CH3CN 0.1% TFA (solvent B).
2.2.5.2 Relative Hydrophobicity Measurements
RP-HPLC relies on the relative interactions of the species of interest with the
hydrophobic stationary phase and the hydrophilic mobile phase, in which a more
hydrophobic compound will have a higher retention time (tR) than a less
hydrophobic compound under the same conditions. This allows the evaluation of the
relative hydrophobicity of a series of structurally similar compounds.
Measurements were performed using the Agilent 1200 system with a VWD and
100 μL loop. The column was an Agilent Zorbax Eclipse Plus C18, 150 × 4.6 mm 
with a 5 μm pore size. The mobile phase was H2O (50 mM NaCl)/H2O/CH3CN 1:1
(50 mM NaCl), with a flow rate of 1 mL min-1. The detection wavelength was set at
254 nm with the reference wavelength at 360 nm. Sample injections were half the
loop volume (50 μL) with needle washes of H2O between injections. All compounds
were dissolved in 10% MeOH/90% H2O (v/v) in 50 mM NaCl to ensure that
hydrolysis was prevented. The gradient used is shown in Figure 1.3.
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Figure 2.3. HPLC method used for relative hydrophobicity measurements using
H2O 50 mM NaCl (solvent A) and H2O/CH3CN 1:1 50 mM NaCl (solvent B).
2.2.5.3 Chiral Resolution
Enantiomeric separation of complexes was performed using chiral NP-HPLC with
the assistance of Dr. Ruth McQuitty (Department of Chemistry, University of
Warwick). The Agilent 1200 system with a VWD and 50 µL loop was used together
with a CHIRALPAK® IA column (amylose tris(3,5-dimethylphenylcarbamate))
immobilised on 3 μm silica-gel, 250 × 4.6 mm. The mobile phase was heptane (70%) 
and ethanol (30%) with both solvents containing 0.5% TEA and 0.3% TFA. The
detection wavelength was 260 nm, with a volume injection of half the loop volume
(25 µL) at a concentration of 1 mg mL-1.
2.2.6 Liquid Chromatography – Mass Spectrometry (LC-MS)
LC-MS analyses were carried out on amaZon X Agilent system coupled to a Bruker
HCT-Ultra ETD II PTR PTM mass spectrometer. The mass spectrometer was
operated in electrospray positive ion mode with a scan range of 50 – 2,000 m/z.
Source conditions used were: end plate offset at – 500 V; capillary at -4500 V;
nebuliser gas (N2) 1.7 bar; dry gas (N2) 8 L min–1 and dry temp 473 K; funnel RF
309 Vpp; multiple RF 309 Vpp; quadrupole ion energy 4 eV; collision cell 5 eV; ion
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cooler RF settings, ramp from 50 to 250 V. Data were processed using Data Analysis
3.3 (Bruker Daltonics). Assignment of iridium species was aided by the Ir isotopic
pattern as described in section 1.4.
2.2.7 Electronic Absorption (UV-Vis) Spectroscopy
UV-Vis absorption spectra were recorded on a Varian Cary 300 UV-Vis
spectrophotometer in 1 cm path-length quartz cuvettes (600 μL) with a PTP1 Peltier 
temperature controller. Spectra were recorded at either 298 or 310 K (specific
solvents are specified in relevant chapters) over a spectral width of 200-800 nm,
bandwith of 1.0 nm and a scan rate of 600 nm min-1. The spectra were processed
using UV-Winlab software for Windows.
2.2.8 X-ray Crystallography
X-ray diffraction data were collected and processed by Dr. Guy Clarkson
(Department of Chemistry, University of Warwick). Diffraction data were obtained
on an Oxford Diffraction Gemini four-circle system with a Ruby CCD area detector
using Mo Kα radiation. Absorption corrections were applied using ASPACK.7 The
crystals were mounted in oil and held at either 100 or 150 K with the Oxford
Cryosystem Cobra. The structures were solved by direct methods using SHELXS
(TREF)8 with additional light atoms found by Fourier methods. Complexes were
refined against F2 using SHELXL.9
Mercury 3.3 was used to analyse the data and to generate the structural images.
To assess whether bond distances were statistically different (bond difference > 3σ), 
σ was defined as: 
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where σ1 and σ2 are the bond length standard deviations of the two bond lengths
being compared.
2.2.9 Density Functional Theory (DFT) Calculations
This work was carried out under the guidance of Prof. Rob Deeth (Department of
Chemistry, University of Warwick). All calculations were performed using the
Gaussian 03 package.10 Geometry optimisation calculations were performed in the
gas phase with the hybrid functional PBE1PBE.11 The LanL2DZ basis set and
effective core potential12 were used for the Ir atom, and the 6-31+G** basis set was
used for all other atoms.13 The nature of all stationary points was confirmed by
performing a normal-mode analysis. The calculations performed were used to
generate electrostatic potential surfaces (EPS) of the complexes. Positive and
negative regions are represented by a colour scale of blue and red, respectively, and
mapped on electron density (isovalue = 0.04) of the molecules.
2.2.10 Inductively Coupled Plasma – Optical Emission
Spectroscopy (ICP-OES)
ICP-OES analyses were carried out on a PerkinElmer Optima 5300 DV series ICP-
OES instrument. The water used for ICP-OES analysis was doubly deionise water
(DDW) using a Millipore Milli-Q water purification system and a USF Elga UHQ
water deionizer. The iridium Specupure plasma standard (Alfa Asar, 1000 ppm in
10% HCl) was diluted with 2.5% HNO3 DDW to prepare calibrants freshly at the
required concentration range (see appropriate sections for concentration of standards
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used). The calibrants and blanks were all spiked with NaCl to match the salt content
of the samples being analysed.
2.2.11 Inductively Coupled Plasma – Mass Spectrometry (ICP-
MS)
ICP-MS analyses were carried out on an Agilent Technologies 75000 series ICP-MS
instrument, using DDW from a Millipore Milli-Q water purification system and a
USF Elga UHQ water deionizer. The iridium Specupure plasma standard (Alfa Asar,
1000 ppm in 10% HCl) was diluted with 2.5% HNO3 DDW to prepare calibrants
freshly at the required concentration range (see appropriate sections for
concentration of standards used). The ICP-MS instrument was set to detect 193Ir in
no-gas mode.
2.2.12 pH and pH* Measurements
All pH and pH* (pH meter reading without correcting for the effect of deuterium on
the glass electrode) values were recorded using a minilab IQ125 pH meter equipped
with a ISFET silicon chip pH sensor referenced in KCl gel. The electrode was
calibrated with Aldrich buffer solutions of pH 4, 7 and 10. The pH values of reaction
mixtures and buffers were measured at 298 K with adjustment (when required) by
addition of HClO4 (aq) or KOH (aq). The pH* of aqueous NMR samples were also
measured at 298 K and adjusted (when required) by addition of DClO4 (aq) and
KOD (aq).
2.2.13 pKa* Determination
pKa* (pH* at which half of the aqua ligand in a compound is deprotonated, where *
denotes the measurement was performed in D2O) measurements were made on the
acidity of the aqua ligand in complexes by following shifts in the 1H NMR chemical
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shifts for protons on the chelating ligands caused by a change in the pH* of the
solution. pH* was measured and adjusted as described in section 2.2.12. 1H NMR
spectra were recorded at 298 K on a 600 MHz spectrometer and spectra were
referenced to dioxane (3.75 ppm). The change in chemical shift as a function of pH*
was plotted and fitted to the Henderson-Hasselbalch equation using Origin 9.1:
  	 = 	     + log    [  ][  ] 
2.2.14 Eukaryotic Cellular Biological Studies
This work was performed by Dr. Isolda Romero-Canelón (Department of Chemistry,
University of Warwick). General cell maintenance and antiproliferative assays are
outlined here, with more specific experiments described in the appropriate chapters.
2.2.14.1 Cell Maintenance14
The cell lines used in this work, A2780 human ovarian carcinoma, A549 human
Caucasian lung carcinoma, HCT116 human colon carcinoma, MCF7 human
Caucasian breast carcinoma and MRC5 human fetal lung fibroblasts were obtained
from the European Collection of Cell Cultures (ECACC). A2780 ovarian and MRC5
cells were grown in Roswell Park Memorial Institute medium (RPMI-1640), A549
and MCF7 in Dulbecco's Modified Eagle medium (DMEM) and HCT116 in
McCoy′s Modified 5A medium. All media were supplemented with 10% v/v of fetal 
calf serum, 1% v/v of 2 mM glutamine and 1% v/v penicillin/streptomycin.
All cells were grown in 75 cm2 culture flasks as adherent monolayers, and they were
split two to three times a week when around 80-90% confluence was reached, using
0.25% v/v trypsin for A2780 or 0.25% v/v trypsin/EDTA for all other cell lines.
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2.2.14.2 In Vitro Growth Inhibition Assays
96-well plates were used to seed 5000 cells per well; they were left to pre-incubate in
drug-free media at 310 K for 48 h before adding various concentrations of the
compounds to be tested. Stock solutions of the Ir complexes were firstly prepared in
5% v/v dmso and a mixture of 0.9% w/v saline and medium (1:1) followed by serial
dilutions in the corresponding cell culture medium. A drug exposure period of 24 h
was allowed. After this, the supernatant was removed by suction and each well was
washed with PBS. A further 72 h was allowed for the cells to recover in drug-free
medium at 310 K. The sulforhodamine B (SRB) assay was used to determine cell
viability. This assay, first developed by Skehan et al. in 1990, is based on the ability
of the sulforhodamine B to bind electrostatically to basic amino acid residues of
proteins from fixed cells.15 Absorbance measurements of solubilised dye allowed the
determination of the amount of viable treated cells against an untreated control.
These measurements were carried out using a BioRad iMark microplate reader with
a 470 nm filter. IC50 values (concentrations which cause 50% of inhibition of cell
growth) were determined as duplicates of triplicates in two independent sets of
experiments, and their standard deviations calculated.
2.2.15 Prokaryotic Cellular Biological Studies
This work was performed with the help of Dr. Evyenia Shaili (Department of
Chemistry, University of Warwick) with guidance from Mr. Daniel McFeely (School
of Life Science, University of Warwick).
2.2.15.1 Cell Maintenance
The bacterial cell lines used in this work, Staphylococcus aureus (strain R34) and
Escherichia coli (strain Top10), were all obtained from cultures in the School of Life
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Sciences, University of Warwick. Bacterial stocks were made by plating cells on
Lysogeny Broth (LB) agar plates and allowing growth at 310 K overnight. Colonies
were then collected and dissolved in glycerol (which had been previously
autoclaved) to an optical density at 600 nm (OD600) of 0.01, then placed in
Eppendorf tubes and stored at 193 K until required.
2.2.15.2 In Vitro Growth Inhibition Assays
Bacteria stocks for growth inhibition assays were made by dissolving concentrated
stocks of OD600 = 0.01 by dilution with LB to OD600 = 0.002. Stock solutions of Ir
complexes were prepared by dissolving compounds in dmso (5 mM) and then
diluting to desired concentrations by addition of LB medium. The bacterial solutions
were then plated onto 96-well plates (100 μL), and then solutions of Ir complexes 
were added (100 μL) to give a final OD600 = 0.001. The 96-well plate was covered
with a clear gas permeable seal and placed in an iEMs plate reader with the
following settings; incubation temperature = 310 K, shaking for 10 s every 5 min at a
speed of 360 RPM; measurement under stepping mode every 30 min; filter = 600
nm; time = 22 h. Data were processed using Ascent software version 2.6. The
experiments were performed as duplicates of duplicates and were undertaken on
separate days.
The minimal inhibitory concentration (MIC) is defined as the minimum
concentration of compound that inhibits visible growth of a microorganism over a
given incubation period (22 h). This is the value that is reported as a measure of a
compound’s antibacterial activity.
The minimum bactericidal concentration (MBC) is defined as the minimum
concentration of compound that will kill a particular bacterium. This was evaluated
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by plating an LB agar plate with bacterial solutions (10 μL) which showed no growth 
over the initial 22 h incubation period. The agar plate was then incubated at 310 K
overnight. The MBC was determined as the concentration of iridium complex that
prevented colony growth overnight.
2.2.15.3 Cell Membrane Viability Assay
The membrane integrity of S. aureus after exposure to complexes was performed
using the BacLight™ DEAD/ALIVE bacterial viability kit (Invitrogen) according to
the supplier’s instructions.16 The kit works on the premise that the dye SYTO 9 can
penetrate through both intact and compromised cell membranes and fluoresce green
when bound to nuclear DNA. The dye propidium iodide (PI) only enters membrane
compromised cells and fluoresces red when bound to nuclear DNA.17 The ratio of
green/red fluorescence indicates the degree of membrane-damage when compared to
prepared standards.
Briefly, 96 well plates were plated with cells (90 μL) at OD600 = 0.310 dissolved
with 0.85% w/v NaCl solution, followed by addition of iridium complexes (10 μL) 
to give final a concentration of compound at 4 × MIC value. The well plate was
incubated at 310 K for 25 min. SYTO 9 and PI (1:1 mix) were added (100 μL) and 
incubated at ambient temperature in the dark for 15 min before taking fluorescence
readings (530 and 630 nm) on a Variascan Flash Multimode microplate reader by
excitation at 470 nm at 298 K. Confocal microscopy images were also taken using an
IX71 Olympus microscope with a 100× objective by Mr Ian Hands-Portman (School
of Life Sciences, University of Warwick).
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Iridium(III) Half-Sandwich Anticancer Complexes Bearing
Functionally Diverse 2-Phenylpyridine Ligands
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3.1 Introduction
There is an increasing interest in the design of organometallic anticancer
complexes,1-5 especially complexes which are active against cisplatin resistant
cancers.6-8 One of the most successful anticancer organometallic complexes to date
include titanocene dichloride9 which reached stage II clinical trials for advanced
renal-cell carcinoma10 and metastatic breast cancer.11 A major focus has been on the
development of organometallic complexes of the platinum group metals, with the
majority of research being performed on half-sandwich ruthenium(II)
complexes. 5,12-16
Increasing interest in the chemical reactivity and unique structural scaffolds
organometallic complexes can offer compared with organic-based pharmacores has
led to other metal ions being studied for their anticancer activities, where organo-
iridium(III) complexes are showing promise in this regard.17-25
The biological activity of half-sandwich pentamethylcyclopentadienyl (Cp*)
iridium(III) complexes can be increased by the incorporation of phenyl substituents
as in CpxPh and CpxBiPh ligands.26,27 This increase in activity may be due in part to an
increase in hydrophobicity resulting in enhanced cellular uptake and accumulation.
Extended cyclopentadienyl systems have also been shown to strengthen interactions
with DNA via intercalation between DNA base pairs.26
The introduction of the negatively-charged C,N-chelated ligands in place of neutral
N,N ligands has also been shown to improve antiproliferative activity.28 Again, the
increase in activity may be attributed to an increase in hydrophobicity of the
resulting neutral complex. The incorporation of anionic ligands in place of neutral
ligands in other iridium systems have also been explored.22,29
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Chelated half-sandwich pseudo-octahedral iridium(III) complexes have been shown
to bind to DNA nucleobases via the monodentate site, and can inhibit the synthesis
of DNA by DNA polymerases.26 It has also been shown that they can bind to the
minor-groove of CT-DNA.30 Some of these complexes also inhibit thioredoxin
reductase 1 (Trx-R).19 Intriguingly they can also catalyse the oxidation of NADH to
NAD+ and modulation of the NAD+/NADH ratio has been demonstrated in A2780
human ovarian cancer cells.31,32 Disruption of this redox process may contribute to a
multi-targeting mechanism of action.33
The effect of incorporating functionality on the chelating ligand in half-sandwich
iridium(III) complexes has not been widely explored, although previous studies have
indicated that the incorporation of simple functional groups on the chelating ligand,
such as fluoro, nitro and methyl groups, enhances the activity.19,30,34 This chapter
evaluates the effect that functionality on the 2-phenylpyridine (2-PhPy) chelating
ligand has on the chemical, physio-chemical and biological properties of complexes
of the type [(η5-Cp*)Ir(2-(Rˈ-phenyl)-R-pyridine)Cl] where R/Rˈ is an electron-
withdrawing or electron-donating group. Investigations into the resulting electronic
effects, aqueous chemistry (including nucleobase binding and catalytic NADH
oxidation) and antiproliferative activity have been carried out. The rationalisation of
anticancer activity has been investigated for pairs of structural isomers, including
studies into hydrophobicity, cellular-iridium accumulation and distribution to
determine structure activity relationships (SARs), with the overall goal of finding
novel complexes that exhibit high potency without using extended cyclopentadienyl
capping systems.
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Chart 3.1. [(η5-Cp*)Ir(2-(Rˈ-phenyl)-R-pyridine)Cl] complexes studied in this work 
3.2 Experimental Section
3.2.1 Materials
IrCl3.3H2O (99%) was purchased from Precious Metals Online (Australia). 1,2,3,4,5-
pentamethylcyclopentadiene, NaCl (>99.999%), tetrakis(triphenylphosphine)-
palladium (99%), phenylboronic acid, 6-bromo-3-pyridinecarboxaldehyde, 2-bromo-
4-nitropyridine, 4-formylphenylboronic acid, 4-(hydroxymethyl)phenylboronic acid,
4-hydroxyphenylboronic acid, 2-bromo-4-hydroxymethylpyridine, 2-bromo-4-
Complex Rˈ4 Rˈ2 R3 R4 R5
1 H F H H H
2 F H H H H
3 H H F H H
4 H H H H F
5 CHO H H H H
6 H H H H CHO
7 NO2 H H H H
8 H H H NO2 H
9 CH2OH H H H H
10 H H H CH2OH H
11 OH H H H H
12 H H H H OH
13 H CH3 H H H
14 H H H CH3 H
15 H H H H CH3
16 CF3 H H H H
17 OCH3 H H H H
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methylpyridine, 2-bromo-5-fluoropyridine (97%), p-tolylboronic acid (97%), 4-
nitrophenylboronic acid (95%), 9-ethylguanine (≥98%), 9-methyladenine (97%) and 
β-nicotinamide adenine dinucleotide - reduced dipotassium salt (NADH) (≥95%) 
were purchased from Sigma-Aldrich (UK). 2-Bromopyridine, 2-flurophenylboronic
acid and 4-fluorophenylboronic were purchased from Fisher Scientific (UK), 2-
bromo-5-hydroxypyridine and 2-bromo-5-methylpyridine from VWR International
Ltd. (UK) and 2-bromo-3-fluoropyridine from Tokyo Chemical Industry Ltd. (UK).
Solvents used for synthesis were of laboratory grade and used without further
purification. Solvents for RP-HPLC (water and acetonitrile) were of HPLC grade
with added trifluoroacetic acid (purchased from Sigma-Aldrich (UK)) for purity
measurements. [(η5-Cp*)IrCl2]2 was synthesised as described in Chapter 2.
3.2.2 Syntheses
3.2.2.1 Synthesis of 2-(Rˈ-phenyl)-R-pyridine Ligands.  
The synthesis of ligands L1-17 was performed using the following adapted literature
procedure.35 Phenylboronic acid/derivatives (1.4 mol eq) and 2-
bromopyridine/derivatives (1 mol equiv) were dissolved in 1:1:1 (v/v) of
tetrahydrofuran:water:1 M aqueous sodium carbonate solution and stirred at ambient
temperature under nitrogen for 1 h. Tetrakis(triphenylphosphine)palladium (2% cat)
was added in one portion and the reaction mixture was heated under reflux at 373 K
for 24 h. The reaction mixture was cooled to ambient temperature, and extracted
with dichloromethane. The organic layer was washed with saturated sodium
hydrogencarbonate solution and brine, then dried with magnesium sulphate and
concentrated to dryness, yielding the crude material. Purification by silica flash
chromatography was performed using chloroform/ethyl acetate as the eluent mixture.
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2-(2ˈ-Fluorophenyl)pyridine (L1) As described in the above method using 2-
fluorophenylboronic acid (400 mg, 2.86 mmol), 2-bromopyridine (195 μL, 2.04 
mmol), a 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (24
mL) and tetrakis(triphenylphosphine)palladium (47 mg, 0.041 mmol). Purification
by silica flash chromatography was performed using 3:1 chloroform:ethyl acetate (Rf
= 0.75) yielding a yellow oil (156 mg, 44%). 1H NMR (300 MHz, CDCl3) δ = 8.65 
(d, 1H, J = 5.0 Hz), 7.89 (td, 1H, J = 7.8, 1.8 Hz), 7.72-7.60 (m, 2H), 7.30-7.26 (m,
1H), 7.20-7.15 (m, 2H), 7.10-7.05 (m, 1H). ESI-MS (MeOH) m/z = 174.1 [M+H]+.
2-(4ˈ-Fluorophenyl)pyridine (L2) As described in the above method using 4-
fluorophenylboronic acid (400 mg, 2.86 mmol), 2-bromopyridine (195 μL, 2.04 
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (24
mL) and tetrakis(triphenylphosphine)palladium (47 mg, 0.041 mmol). Purification
by silica flash chromatography was performed using 3:1 chloroform:ethyl acetate (Rf
= 0.73) yielding a yellow oil (254 mg, 72%). 1H NMR (400 MHz, acetone-d6) δ = 
8.66 (dq, 1H, J = 4.8, 1.0 Hz), 8.20-8.15 (m, 2H), 7.92 (dt, 1H, J = 8.0, 1.0 Hz), 7.86
(td, 1H, J = 8.0, 1.8 Hz), 7.31 (ddd, 1H, J = 7.3, 4.8, 1.2 Hz), 7.27-7.21 (m, 2H).
ESI-MS (MeOH) m/z = 174.1 [M+H]+.
2-Phenyl-3-fluoropyridine (L3) As described in the above method using
phenylboronic acid (243 mg, 1.99 mmol), 2-bromo-3-fluoropyridine (144 µL, 1.42
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (15
mL) and tetrakis(triphenylphosphine)palladium (33 mg, 0.028 mmol). Purification
by silica flash chromatography was performed using 1:1 chloroform:ethyl acetate (Rf
= 0.837) yielding a yellow oil (130 mg, 53%). 1H NMR (400 MHz, dmso-d6) δ = 
8.56-8.54 (m, 1H), 7.91 (d, 2H, J = 8.3 Hz), 7.83 (m, 1H), 7.54-7.46 (m, 4H). ESI-
MS (MeOH) m/z = 174.1 [M+H]+.
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2-Phenyl-5-fluoropyridine (L4) As described in the above method using
phenylboronic acid (243 mg, 1.99 mmol), 2-bromo-5-fluoropyridine (250 mg, 1.42
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (15
mL) and tetrakis(triphenylphosphine)palladium (33 mg, 0.028 mmol). Purification
by silica flash chromatography was performed using 1:1 chloroform:ethyl acetate (Rf
= 0.897) yielding a yellow oil (165 mg, 67%). 1H NMR (400 MHz, acetone-d6) δ = 
8.57 (d, 1H, J = 2.7 Hz), 8.07 (d, 2H, J = 7.3 Hz), 7.99 (dd, 1H, J = 8.8, 4.2 Hz), 7.69
(td, 1H, J = 8.6, 2.9 Hz), 7.50-7.40 (m, 3H). ESI-MS (MeOH) m/z = 174.1 [M+H]+.
2-(4ˈ-formylphenyl)pyridine (L5) As described in the above method using 4-
formylphenylboronic acid (250 mg, 1.67 mmol), 2-bromopyridine (114 μL, 1.19 
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (15
mL) and tetrakis(triphenylphosphine)palladium (27 mg, 0.024 mmol). Purification
by silica flash chromatography was performed using 1:1 chloroform:ethyl acetate (Rf
= 0.780) yielding a yellow oil (164 mg, 75%). 1H NMR (400 MHz, acetone-d6) δ = 
10.12 (s, 1H), 8.74 (dq, 1H, J = 4.7, 0.9 Hz), 8.35 (d, 2H, J = 8.3 Hz), 8.08-8.02 (m,
3H), 7.93 (td, 1H, J = 7.6, 1.8 Hz), 7.41 (ddd, 1H, J = 7.5, 4.8, 1.1 Hz). ESI-MS
(MeOH) m/z = 183.8 [M+H]+.
2-Phenyl-5-pyridinecarboxaldehyde (L6) As described in the above method using
phenylboronic acid (300 mg, 2.46 mmol), 6-bromo-3-pyridinecarboxaldehyde (327
mg, 1.76 mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium
carbonate (15 mL) and tetrakis(triphenylphosphine)palladium (40 mg, 0.034 mmol).
Purification by silica flash chromatography was performed using 1:1
chloroform:ethyl acetate (Rf = 0.800) yielding a dark yellow oil that solidified upon
standing (152 mg, 47%). 1H NMR (400 MHz, acetone-d6) δ = 10.18 (s, 1H), 9.15 (d, 
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1H, J = 2.0 Hz), 8.30-8.28 (m, 1H), 8.24-8.18 (m, 2H), 8.12 (d, 1H, J = 8.2 Hz),
7.56-7.50 (m, 3H). ESI-MS (MeOH) m/z = 184.1 [M+H]+.
2-(4ˈ-nitrophenyl)pyridine (L7) As described in the above method using 4-
nitrophenylboronic acid (250 mg, 1.50 mmol), 2-bromopyridine (102 μL, 1.07 
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (15
mL) and tetrakis(triphenylphosphine)palladium (25 mg, 0.021 mmol). Purification
by silica flash chromatography was performed using 1:1 chloroform:ethyl acetate (Rf
= 0.708) yielding an off white solid (150 mg, 70%). 1H NMR (400 MHz, CDCl3) δ = 
8.75 (d, 1H, J = 5.0 Hz), 8.63 (d, 2H, J = 8.6 Hz), 8.19 (d, 2H, J = 8.6 Hz), 7.87-7.81
(m, 2H), 7.37-7.34 (m, 1H). ESI-MS (MeOH) m/z = 201.0 [M+H]+.
2-Phenyl-4-nitropyridine (L8) As described in the above method using
phenylboronic acid (210 mg, 1.72 mmol), 2-bromo-4-nitropyridine (250 mg, 1.23
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (15
mL) and tetrakis(triphenylphosphine)palladium (28 mg, 0.025 mmol). Purification
by silica flash chromatography was performed using 3:1 chloroform:ethyl acetate (Rf
= 0.915) yielding a yellow solid (175 mg, 71%). 1H NMR (400 MHz, dmso-d6) δ = 
9.03 (d, 1H, J = 5.4 Hz), 8.58 (d, 1H, J = 1.7 Hz), 8.20 (d, 2H, J = 8.0 Hz), 8.08 (dd,
1H, J = 5.3, 2.0 Hz), 7.58-7.52 (m, 3H). ESI-MS (MeOH) m/z = 201.0 [M+H]+.
2-(4ˈ-hydroxymethylphenyl)pyridine (L9) As described in the above method using
4-hydroxymethlphenylboronic acid (250 mg, 1.64 mmol), 2-bromopyridine (112 μL, 
1.17 mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate
(15 mL) and tetrakis(triphenylphosphine)palladium (27 mg, 0.024 mmol).
Purification by silica flash chromatography was performed using 1:1
chloroform:ethyl acetate (Rf = 0.260) yielding a yellow oil (125 mg, 57%). 1H NMR
(400 MHz, acetone-d6) δ = 8.65 (d, 1H, J = 5.1 Hz), 8.08 (d, 2H, J = 8.2 Hz), 7.90 
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(dt, 1H, J = 8.1, 1.1 Hz), 7.83 (td, 1H, J = 7.4, 1.9 Hz), 7.48 (d, 2H, J = 8.4 Hz), 7.29
(ddd, 1H, J = 7.3, 4.8, 1.2 Hz), 4.70 (d, 2H, J = 5.3 Hz), 4.34 (t, 1H, J = 5.6 Hz).
ESI-MS (MeOH) m/z = 186.1 [M+H]+.
2-Phenyl-4-hydroxymethylpyridine (L10) As described in the above method using
phenylboronic acid (227 mg, 1.86 mmol), 2-bromo-4-hydroxymethylpyridine (250
mg, 1.33 mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium
carbonate (15 mL) and tetrakis(triphenylphosphine)palladium (31 mg, 0.027 mmol).
Purification by silica flash chromatography was performed using 1:1
chloroform:ethyl acetate (Rf = 0.360) yielding a dark yellow oil that solidified upon
standing (176 mg, 71%). 1H NMR (400 MHz, acetone-d6) δ = 8.59 (d, 1H, J = 5.2 
Hz), 8.13-8.10 (m, 2H), 7.90 (s, 1H), 7.50-7.45 (m, 2H), 7.42 (td, 1H, J = 7.3, 1.5
Hz), 7.31 (dd, 1H, J = 5.1, 1.0 Hz), 4.76 (s, 2H). ESI-MS (MeOH) m/z = 186.1
[M+H]+.
2-(4ˈ-hydroxyphenyl)pyridine (L11) As described in the above method using 4-
hydroxyphenylboronic acid (250 mg, 1.81 mmol), 2-bromopyridine (124 μL, 1.29 
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (15
mL) and tetrakis(triphenylphosphine)palladium (30 mg, 0.026 mmol). Purification
by silica flash chromatography was performed using 1:1 chloroform:ethyl acetate (Rf
= 0.800) yielding an off-white solid (50 mg, 23%). 1H NMR (400 MHz, dmso-d6) δ 
= 9.72 (s 1H), 8.58 (d, 1H, J = 4.6 Hz), 7.93 (d, 2H, J = 8.5 Hz), 7.83-7.76 (m, 2H),
7.23 (ddd, 1H, J = 6.4, 4.8, 1.5 Hz), 6.86 (d, 2H, J = 8.6 Hz). ESI-MS (MeOH) m/z
= 172.0 [M+H]+.
2-Phenyl-5-hydroxypyridine (L12) As described in the above method using
phenylboronic acid (245 mg, 2.01 mmol), 2-bromo-5-hydroxypyridine (250 mg, 1.44
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (15
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mL) and tetrakis(triphenylphosphine)palladium (33 mg, 0.029 mmol). Purification
by silica flash chromatography was performed using 1:1 chloroform:ethyl acetate (Rf
= 0.556) yielding an off-white solid (80 mg, 33%). 1H NMR (400 MHz, dmso-d6) δ 
= 10.01 (s, 1H), 8.21 (d, 1H, J = 2.9 Hz), 7.95 (d, 2H, J = 7.6 Hz), 7.78 (d, 1H, J =
8.7 Hz), 7.44-7.40 (m, 2H), 7.33 (tt, 1H, J = 7.3, 1.4 Hz), 7.24 (dd, 1H, J = 8.7, 2.9
Hz). ESI-MS (MeOH) m/z = 172.1 [M+H]+.
2-(2ˈ-methylphenyl)pyridine (L13) As described in the above method using o-
tolylphenylboronic acid (250 mg, 1.84 mmol), 2-bromopyridine (125 μL, 1.31 
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (15
mL) and tetrakis(triphenylphosphine)palladium (30 mg, 0.026 mmol). Purification
by silica flash chromatography was performed using 1:1 chloroform:ethyl acetate (Rf
= 0.725) yielding a yellow oil (140 mg, 63%). 1H NMR (400 MHz, dmso-d6) δ = 
8.66 (dq, 1H, J = 4.8, 0.8 Hz), 7.86 (td, 1H, J = 7.7, 1.8 Hz), 7.50 (d, 1H, J = 7.8 Hz),
7.38-7.34 (m, 2H) 7.32-7.26 (m, 3H), 2.31 (s, 3H). ESI-MS (MeOH) m/z = 170.1
[M+H]+.
2-Phenyl-4-methylpyridine (L14) As described in the above method using
phenylboronic acid (248 mg, 2.03 mmol), 2-bromo-4-methylpyridine (162 µL, 1.45
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (15
mL) and tetrakis(triphenylphosphine)palladium (34 mg, 0.029 mmol). Purification
by silica flash chromatography was performed using 1:1 chloroform:ethyl acetate (Rf
= 0.765) yielding a yellow oil (64 mg, 22%). 1H NMR (400 MHz, acetone-d6) δ = 
8.50 (d, 1H, J = 5.0 Hz), 8.12 (d, 2H, J = 8.1 Hz), 7.76-7.74 (m, 1H), 7.49-7.44 (m,
2H), 7.41 (tt, 1H, J = 7.2, 1.5 Hz), 7.14 (dd, 1H, J = 5.0, 0.8 Hz), 2.41 (s, 3H). ESI-
MS (MeOH) m/z = 170.1 [M+H]+.
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2-Phenyl-5-methylpyridine (L15) As described in the above method using
phenylboronic acid (248 mg, 2.03 mmol), 2-bromo-5-methylpyridine (250 mg, 1.45
mmol), 1:1:1 mixture of tetrahydrofuran:water:1 M aqueous sodium carbonate (15
mL) and tetrakis(triphenylphosphine)palladium (34 mg, 0.029 mmol). Purification
by silica flash chromatography was performed using 1:1 chloroform:ethyl acetate (Rf
= 0.869) yielding a yellow oil (153 mg, 62%). 1H NMR (400 MHz, CDCl3) δ = 8.53 
(s, 1H), 7.97 (d, 2H, J = 8.2 Hz), 7.63 (d, 1H, J = 8.4 Hz), 7.56 (dd, 1H, J = 8.1, 2.4
Hz), 7.48-7.45 (m, 2H), 7.39 (tt, 1H, J = 7.5, 1.5 Hz), 2.37 (s, 3H). ESI-MS (MeOH)
m/z = 170.1 [M+H]+.
2-(4ˈ-Trifluoromethylphenyl)pyridine (L16) As described in the above method
using 4-trifluoromethylphenylboronic acid (372 mg, 1.96 mmol), 2-bromopyridine
(134 μL, 1.40 mmol), 1:1:1 mixture of tetrahydrofuran:water:1M aqueous sodium 
carbonate solution (15 mL) and tetrakis(triphenylphosphine)palladium (32 mg, 0.028
mmol). Purification by silica flash chromatography was performed using 3:1
chloroform:ethyl acetate (Rf = 0.844) yielding a pale yellow solid (162 mg, 52%). 1H
NMR (400 MHz, dmso-d6) δ = 8.72 (d, 1H, J = 4.3 Hz), 8.29 (d, 2H, J = 8.2 Hz), 
8.05 (d, 1H, J = 8.0 Hz), 7.93 (td, 1H, J = 7.8, 1.8 Hz), 7.83 (d, 2H, J = 8.3 Hz), 7.43
(dd, 1H, J = 7.3, 4.7 Hz). ESI-MS (MeOH) m/z = 223.8 [M+H]+.
2-(4ˈ-methoxyphenyl)pyridine (L17) As described in the above method using 4-
methoxyphenylboronic acid (250 mg, 1.645 mmol), 2-bromopyridine (112 μL, 1.175 
mmol), 1:1:1 mixture of tetrahydrofuran:water:1M aqueous sodium carbonate
solution (15 mL) and tetrakis(triphenylphosphine)palladium (27 mg, 0.024 mmol).
Purification by silica flash chromatography was performed using 1:1
chloroform:ethyl acetate (Rf = 0.757) yielding a yellow solid (160 mg, 74%). 1H
NMR (400 MHz, dmso-d6) δ = 8.61 (dq, 1H, J = 5, 1 Hz), 8.04 (d, 2H, J = 9 Hz), 
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7.88 (dt, 1H, J = 8, 1 Hz), 7.82 (td, 1H, J = 7, 2 Hz), 7.29-7.26 (m, 1H) 7.04 (d, 2H, 9
Hz), 3.81 (s, 1H). ESI-MS (MeOH) m/z = 186.1 [M+H]+.
3.2.2.2 Synthesis of [(η5-Cp*)Ir(2-(Rˈ-phenyl)-R-pyridine)Cl] 
complexes
The synthesis of complexes 1-17 was performed using an adapted literature
procedure.27 2-(Rˈ-phenyl)-R-pyridine (2 mol equiv) was dissolved in anhydrous 
dichloromethane, sodium acetate (4 mol equiv) was added in one portion and stirred
at ambient temperature under nitrogen for 30 min. [(η5-Cp*)IrCl2]2 (1 mol equiv) was
added in one portion and the reaction mixture stirred at ambient temperature for 18
h. The mixture was filtered through celite under suction and the filtrate was
concentrated to dryness on a rotary evaporator. The crude product was recrystallized
from chloroform/hexane at 273 K to yield purified complexes.
[(η5-Cp*)Ir(2-(2ˈ-fluorophenyl)pyridine)Cl] (1) As described in the above method
using 2-(2ˈ-fluorophenyl)pyridine (40 mg, 0.231 mmol), dichloromethane (20 mL), 
sodium acetate (38 mg, 0.462 mmol) and [(η5-Cp*)IrCl2]2 (92 mg, 0.115 mmol) The
crude product was recrystallised from chloroform/hexane at 273 K to yield an orange
crystalline solid (57 mg, 46%). 1H NMR (300 MHz, CDCl3) δ = 8.75 (d, 1H, J = 5.8 
Hz), 8.26 (d, 1H, J = 8.5 Hz), 7.72-7.65 (m, 1H), 7.58 (d, 1H, J = 7.5 Hz), 7.20-7.08
(m, 2H), 6.73-6.66 (m, 1H) 1.67 (s, 15H). ESI-MS (MeOH) m/z = 550.0 [M-PF6]+.
CHN analysis calc. for C21H22NClFIr.H2O C – 45.60%, H – 4.37%, N – 2.53%.
Found C – 45.44%, H – 3.97%, N – 2.29%. HPLC Purity 254 nm – 98.8 %.
Crystals suitable for X-ray diffraction were obtained by slow evaporation of a
chloroform/hexane solution at 278 K.
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[(η5-Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] (2) As described in the above method
using 2-(4ˈ-fluorophenyl)pyridine (30 mg, 0.173 mmol), dichloromethane (18 mL), 
sodium acetate (28 mg, 0.340 mmol) and [(η5-Cp*)IrCl2]2 (69 mg, 0.087 mmol). The
crude product was recrystallised from chloroform/hexane at 273 K to yield an orange
crystalline solid (48 mg, 52%). 1H NMR (400 MHz, acetone-d6) δ = 8.77 (d, 1H, J = 
5.7 Hz), 8.01-7.98 (m, 1H), 7.85-7.81 (m, 2H), 7.44 (dd, 1H, J = 8.7, 2.6 Hz), 7.28-
7.24 (m, 1H), 6.74 (td, 1H, J = 8.8, 2.6 Hz), 1.68 (s, 15H) ESI-MS (MeOH) m/z =
500.1 [M-Cl]+. CHN analysis calc. for C21H22NClFIr C – 47.14%, H – 4.14%, N –
2.62%. Found C – 46.83%, H – 4.02%, N – 2.66%. HPLC Purity 254 nm – 99.4 %.
Crystals suitable for X-ray diffraction were obtained by slow evaporation of a
chloroform/hexane solution at 278 K.
[(η5-Cp*)Ir(2-phenyl-3-fluoropyridine)Cl] (3) As described in the above method
using 2-phenyl-3-fluoropyridine (38 mg, 0.218 mmol), dichloromethane (20 mL),
sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2 (87 mg, 0.109 mmol). The
crude product was recrystallised from chloroform/hexane at 273 K to yield an orange
crystalline solid (35 mg, 30%). 1H NMR (400 MHz, CDCl3) δ = 8.59 (dd, 1H, J = 
5.6, 1.1 Hz), 8.13 (dd, 1H, J = 8.0, 1.3 Hz), 7.83 (dd, 1H, J = 7.7, 1.2 Hz), 7.43-7.38
(m, 1H), 7.21 (td, 1H, J = 7.4, 1.4 Hz), 7.07-7.03 (m, 2H), 1.67 (s, 15H). ESI-MS
(MeOH) m/z = 500.1 [M-Cl]+. CHN analysis calc. for C21H22NClFIr C – 47.14%, H
– 4.14%, N – 2.62%. Found C – 46.85%, H – 3.90%, N – 2.58%. HPLC Purity 254
nm – 99.4 %.
[(η5-Cp*)Ir(2-phenyl-5-fluoropyridine)Cl] (4) As described in the above method
using 2-phenyl-5-fluoropyridine (38 mg, 0.218 mmol), dichloromethane (20 mL),
sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2 (87 mg, 0.109 mmol). The
crude product was recrystallised from chloroform/hexane at 273 K to yield an orange
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crystalline solid (56 mg, 48%). 1H NMR (400 MHz, dmso-d6) δ = 8.60 (t, 1H, J = 
2.6 Hz), 8.18 (dd, 1H, J = 9.3, 5.5 Hz), 7.95-7.90 (m, 1H), 7.79 (d, 1H, J = 7.8 Hz),
7.69 (d, 1H, J = 7.7 Hz), 7.12 (td, 1H, J = 7.3, 1.3 Hz), 6.99 (td, 1H, J = 7.8, 1.0 Hz),
1.61 (s, 15H). ESI-MS (MeOH) m/z = 500.1 [M-Cl]+. CHN analysis calc. for
C21H22NClFIr.0.5H2O C – 46.36%, H – 4.26%, N – 2.57%. Found C – 46.54%, H –
4.14%, N – 2.40%. HPLC Purity 254 nm – 98.2 %.
[(η5-Cp*)Ir(2-(4ˈ-formylphenyl)pyridine)Cl] (5) As described in the above method
using 2-(4ˈ-formylphenyl)pyridine (32 mg, 0.173 mmol), dichloromethane (18 mL), 
sodium acetate (28 mg, 0.346 mmol) and [(η5-Cp*)IrCl2]2 (69 mg, 0.087 mmol). The
crude product was recrystallised from chloroform/hexane at 273 K to yield a red
crystalline solid (70 mg, 74%). 1H NMR (300 MHz, dmso-d6) δ = 10.08 (s, 1H), 
8.79 (d, 1H, J = 5.4 Hz), 8.27-8.21 (m, 2H), 8.04 (d, 1H, J = 8.1 Hz), 7.95 (td, 1H, J
= 7.8, 1.4 Hz), 7.51 (dd, 1H, J = 8.1, 1.6 Hz), 7.44-7.40 (m, 1H), 1.63 (s, 15H). ESI-
MS (MeOH) m/z = 510.1 [M-Cl]+. CHN analysis calc. for C22H23NClIrO.0.5H2O C
– 47.69%, H – 4.37%, N – 2.53%. Found C – 47.55%, H – 4.16%, N – 2.31%.
HPLC Purity 254 nm – 99.0 %.
[(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] (6) As described in the above
method using 2-phenyl-5-pyridinecarboxaldehyde (40 mg, 0.218 mmol),
dichloromethane (20 mL), sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2
(87 mg, 0.109 mmol). The crude product was recrystallised from chloroform/hexane
at 273 K to yield a red crystalline solid (76 mg, 64%). 1H NMR (400 MHz, dmso-d6)
δ = 10.13 (s, 1H), 9.13 (d, 1H, J = 1.5 Hz), 8.29 (d, 1H, J = 8.5 Hz), 8.24 (dd, 1H, J = 
8.4, 1.8 Hz), 7.95 (dd, 1H, J = 7.7, 1.0 Hz), 7.77 (dd, 1H, J = 7.6, 0.8 Hz), 7.16 (td,
1H, J = 7.4, 1.2 Hz), 7.04 (td, 1H, J = 7.0, 1.2 Hz), 1.64 (s, 15H). ESI-MS (MeOH)
m/z = 510.1 [M-Cl]+. CHN analysis calc. for C22H23NClIrO.0.5H2O C – 47.69%, H
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– 4.37%, N – 2.53%. Found C – 47.51%, H – 4.16%, N – 2.23%. HPLC Purity 254
nm – 99.1 %.
[(η5-Cp*)Ir(2-(4ˈ-nitrophenyl)pyridine)Cl] (7) As described in the above method
using 2-(4ˈ-nitrophenyl)pyridine (44 mg, 0.218 mmol), dichloromethane (20 mL), 
sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2 (87 mg, 0.109 mmol). The
crude product was recrystallised from chloroform/hexane at 273 K to yield a red
crystalline solid (95 mg, 78%). 1H NMR (400 MHz, dmso-d6) δ = 8.81 (d, 1H, J = 
5.9 Hz), 8.44 (d, 1H, J = 2.4 Hz), 8.31 (d, 1H, J = 8.0 Hz), 8.12 (d, 1H, J = 8.6 Hz),
8.00 (td, 1H, J = 7.7, 1.5 Hz), 7.84 (dd, 1H, J = 8.5, 2.4 Hz), 7.47 (ddd, 1H, J = 6.6,
5.6, 1.2 Hz), 1.63 (s, 15H). ESI-MS (MeOH) m/z = 527.1 [M-Cl]+. CHN analysis
calc. for C21H22N2ClIrO2 C – 44.87%, H – 3.95%, N – 4.98%. Found C – 44.51%, H
– 3.77%, N – 4.88%. HPLC Purity 254 nm – 98.3 %.
[(η5-Cp*)Ir(2-phenyl-4-nitropyridine)Cl] (8) As described in the above method
using 2-phenyl-4-nitropyridine (34 mg, 0.17 mmol), dichloromethane (18 mL),
sodium acetate (28 mg, 0.341 mmol) and [(η5-Cp*)IrCl2]2 (69 mg, 0.086 mmol). The
crude product was recrystallised from chloroform/hexane at 273 K to yield a dark
brown solid (76 mg, 64%). 1H NMR (400 MHz, dmso-d6) δ = 9.00 (d, 1H, J = 6.4 
Hz), 8.73 (d, 1H, J = 2.5 Hz), 8.08 (d, 1H, J = 7.8 Hz), 7.93 (dd, 1H, J = 6.4, 2.5 Hz),
7.76 (d, 1H, J = 7.7 Hz), 7.21 (td, 1H, J = 7.5, 1.2 Hz), 7.07-7.04 (m, 1H), 1.63 (s,
15H). ESI-MS (MeOH) m/z = 527.1 [M-Cl]+. CHN analysis calc. for
C21H22N2ClIrO2.0.5H2O. C – 44.17%, H – 4.06%, N – 4.91%. Found C – 44.51%, H
– 3.93%, N – 4.66%. HPLC Purity 254 nm – 99.5 %.
[(η5-Cp*)Ir(2-(4ˈ-hydroxymethylphenyl)pyridine)Cl] (9) As described in the
above method using 2-(4ˈ-hydroxymethylphenyl)pyridine (40 mg, 0.218 mmol), 
dichloromethane (20 mL), sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2
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(87 mg, 0.109 mmol). The crude product was recrystallised from chloroform/hexane
at 273 K to yield a yellow crystalline solid (26 mg, 22%). 1H NMR (300 MHz,
dmso-d6) δ = 8.68 (d, 1H, J = 6.6 Hz), 8.04 (d, 1H, J = 8.6 Hz), 7.83 (t, 1H, J = 7.6 
Hz), 7.75 (d, 1H, J = 8.1 Hz), 7.66 (s, 1H), 7.26 (t, 1H, J = 6.8 Hz), 6.94 (d, 1H, J =
8.4 Hz), 5.18 (t, 1H, J = 5.6 Hz), 4.55 (d, 2H, J = 5.8 Hz), 1.60 (s, 15H). ESI-MS
(MeOH) m/z = 512.2 [M-Cl]+. CHN analysis calc. for C22H25NClIrO.0.5H2O C –
47.52%, H – 4.71%, N – 2.52%. Found C – 47.44%, H – 4.39%, N – 2.41%. HPLC
Purity 254 nm – 97.1 %.
[(η5-Cp*)Ir(2-phenyl-4-hydroxymethylpyridine)Cl] (10) As described in the
above method using 2-phenyl-4-hydroxymethylpyridine (40 mg, 0.218 mmol),
dichloromethane (20 mL), sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2
(87 mg, 0.109 mmol). The crude product was recrystallised from chloroform/hexane
to yield a yellow solid (95 mg, 80%). 1H NMR (400 MHz, dmso-d6) δ = 8.62 (d, 1H, 
J = 5.9 Hz), 7.95 (s, 1H), 7.75 (dd, 1H, J = 7.7, 1.1 Hz), 7.70 (dd, 1H, J = 7.6, 0.8
Hz), 7.25 (dd, 1H, J = 6.1, 1.3 Hz), 7.11 (td, 1H, J = 7.4, 1.3 Hz), 6.98 (td, 1H, J =
7.7, 1.1 Hz), 5.59 (t, 1H, J = 5.9 Hz), 4.73 (d, 2H, J = 5.9 Hz), 1.60 (s, 15H). ESI-
MS (MeOH) m/z = 512.2 [M-Cl]+. CHN analysis calc. for C22H25NClIrO.H2O C –
46.76%, H – 4.82%, N – 2.48%. Found C – 46.58%, H – 4.35%, N – 2.34%. HPLC
Purity 254 nm – 99.2 %.
[(η5-Cp*)Ir(2-(4ˈ-hydroxyphenyl)pyridine)Cl] (11) As described in the above
method using 2-(4ˈ-hydroxyphenyl)pyridine (37 mg, 0.218 mmol), dichloromethane 
(20 mL), sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2 (87 mg, 0.109
mmol). Yellow precipitate formed after 24 h which was isolated via vacuum
filtration and washed with hexane (80 mg, 69%). 1H NMR (400 MHz, dmso-d6) δ = 
9.32 (s, 1H), 8.58 (d, 1H, J = 5.7 Hz), 7.85 (d, 1H, J = 8.0 Hz), 7.74 (t, 1H, J = 7.4
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Hz), 7.62 (d, 1H, J = 8.5 Hz), 7.16-7.11 (m, 2H), 6.41 (dd, 1H, J = 8.3, 2.2 Hz), 1.59
(s, 15H). ESI-MS (MeOH) m/z = 498.0 [M-Cl]+. CHN analysis calc. for
C21H23NClIrO.H2O C – 45.77%, H – 4.57%, N – 2.54%. Found C – 45.64%, H –
4.00%, N – 2.47%. HPLC Purity 254 nm – 99.4 %.
[(η5-Cp*)Ir(2-phenyl-5-hydroxypyridine)Cl] (12) As described in the above
method using 2-phenyl-5-hydroxypyridine (37 mg, 0.218 mmol), dichloromethane
(20 mL), sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2 (87 mg, 0.109
mmol). The crude product was recrystallised from hot chloroform to yield a yellow
powder (19 mg, 16%). 1H NMR (400 MHz, dmso-d6) δ = 10.44 (bs, 1H), 8.31 (d, 
1H, J = 2.7 Hz), 7.88 (d, 1H, J = 8.9 Hz), 7.65-7.60 (m, 2H), 7.32 (dd, 1H, J = 8.7,
2.5 Hz), 7.03 (td, 1H, J = 7.3, 1.2 Hz), 6.92 (td, 1H, J = 7.4, 1.1 Hz), 1.59 (s, 15H).
ESI-MS (MeOH) m/z = 498.0 [M-Cl]+. CHN analysis calc. for
C21H23NClIrO.0.5H2O C – 46.53%, H – 4.46%, N – 2.58%. Found C – 46.71%, H –
4.19%, N – 2.50%. HPLC Purity 254 nm – 99.5 %.
[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)Cl] (13) As described in the above
method using 2-(2ˈ-methylphenyl)pyridine (37 mg, 0.218 mmol), dichloromethane 
(20 mL), sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2 (87 mg, 0.109
mmol). The crude product was recrystallised from chloroform/hexane at 273 K to
yield a yellow crystalline solid (81 mg, 70%). 1H NMR (400 MHz, dmso-d6) δ = 
8.81 (dd, 1H, J = 5.6, 1.5 Hz), 8.12 (d, 1H, J = 8.5 Hz), 7.89-7.84 (m, 1H), 7.59 (d,
1H, J = 7.8 Hz), 7.31-7.27 (ddd, 1H, J = 7.0, 5.6, 1.2 Hz), 6.97 (t, 1H, J = 7.5 Hz),
6.78 (d, 1H, J = 7.5 Hz), 2.64 (s, 3H), 1.59 (s, 15H). ESI-MS (MeOH) m/z = 496.1
[M-Cl]+. CHN analysis calc. for C22H25NClIr C – 49.75%, H – 4.74%, N – 2.64%.
Found C – 49.65%, H – 4.71%, N – 2.61%. HPLC Purity 254 nm – 98.8 %.
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[(η5-Cp*)Ir(2-phenyl-4-methylpyridine)Cl] (14) As described in the above method
using 2-phenyl-4-methylpyridine (37 mg, 0.218 mmol), dichloromethane (20 mL),
sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2 (87 mg, 0.109 mmol). The
crude product was recrystallised from chloroform/hexane at 273 K to yield a yellow
crystalline solid (58 mg, 50%). 1H NMR (400 MHz, acetone-d6) δ = 8.60 (d, 1H, J = 
6.0 Hz), 7.83 (s, 1H), 7.77-7.73 (m, 2H), 7.11-7.07 (m, 2H), 6.95 (td, 1H, J = 7.7, 1.2
Hz), 2.54 (s, 3H), 1.66 (s, 15H). ESI-MS (MeOH) m/z = 496.0 [M-Cl]+. CHN
analysis calc. for C22H25NClIr C – 49.75%, H – 4.74%, N – 2.64%. Found C –
49.48%, H – 4.66%, N – 2.58%. HPLC Purity 254 nm – 98.2 %.
[(η5-Cp*)Ir(2-phenyl-5-methylpyridine)Cl] (15) As described in the above method
using 2-phenyl-5-methylpyridine (41 mg, 0.242 mmol), dichloromethane (20 mL),
sodium acetate (40 mg, 0.484 mmol) and [(η5-Cp*)IrCl2]2 (96 mg, 0.121 mmol). The
crude product was recrystallised from chloroform/hexane at 273 K to yield an orange
crystalline solid (60 mg, 47%). 1H NMR (400 MHz, dmso-d6) δ = 8.48 (s, 1H), 7.98 
(d, 1H, J = 8.3 Hz), 7.76-7.66 (m, 3H), 7.09 (td, 1H, J = 7.3, 1.2 Hz), 6.96 (td, 1H, J
= 7.4, 0.9 Hz), 2.39 (s, 3H), 1.60 (s, 15H). ESI-MS (MeOH) m/z = 496.0 [M-Cl]+.
CHN analysis calc. for C22H25NClIr C – 49.75%, H – 4.74%, N – 2.64%. Found C –
49.36%, H – 4.61%, N – 2.51%. HPLC Purity 254 nm – 98.6 %.
[(η5-Cp*)Ir(2-(4ˈ-trifluoromethylphenyl)pyridine)Cl] (16) As described in the
above method using 2-(4ˈ-trifluoromethylphenyl)pyridine (39 mg, 0.173 mmol), 
dichloromethane (18 mL), sodium acetate (28 mg, 0.340 mmol) and [(η5-Cp*)IrCl2]2
(69 mg, 0.087 mmol). The crude product was recrystallised from chloroform/hexane
at 273 K to yield an orange crystalline solid (51 mg, 52%). 1H NMR (400 MHz,
acetone-d6) δ = 8.86 (d, 1H, J = 5.7 Hz), 8.18 (d, 1H, J = 8.2 Hz), 8.03 (d, 1H, J = 6.3 
Hz), 7.98-7.91 (m, 2H), 7.41-7.37 (m, 1H), 7.29 (dd, 1H, J = 8.1, 1.5 Hz), 1.69 (s,
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15H). ESI-MS (MeOH) m/z = 550.1 [M-Cl]+. CHN analysis calc. for
C22H22NClF3Ir C – 45.16%, H – 3.79%, N – 2.39%. Found C – 44.86%, H – 3.66%,
N – 2.26%. HPLC Purity 254 nm – 99.1 %. Crystals suitable for X-ray diffraction
were obtained by slow evaporation of a chloroform/hexane solution at 278 K.
[(η5-Cp*)Ir(2-(4ˈ-methoxyphenyl)pyridine)Cl]36 (17) As described in the above
method using 2-(4ˈ-methoxyphenyl)pyridine (40 mg, 0.218 mmol), dichloromethane 
(20 mL), sodium acetate (36 mg, 0.436 mmol) and [(η5-Cp*)IrCl2]2 (87 mg, 0.109
mmol). The crude product was recrystallised from chloroform/hexane at 273 K to
yield a yellow crystalline solid (60 mg, 50%). 1H NMR (300 MHz, dmso-d6) δ = 
8.63 (d, 1H, J = 5.9 Hz), 7.95 (d, 1H, J = 7.8 Hz), 7.82-7.74 (m, 2H), 7.21-7.17 (m,
2H), 6.59 (dd, 1H, J = 8.4, 2.4 Hz), 3.83 (s, 3H), 1.60 (s, 15H). ESI-MS (MeOH)
m/z = 512.2 [M-Cl]+. CHN analysis calc. for C22H25NClIrO C – 48.30%, H –
4.61%, N – 2.56%. Found C – 47.96%, H – 4.29%, N – 2.52%. HPLC Purity 254
nm – 98.5 %.
3.2.3 Methods
3.2.3.1 X-ray Crystallography
The X-ray crystal structures of complexes 1, 2 and 16 were determined by Dr. Guy
Clarkson (Department of Chemistry, University of Warwick) as described in Chapter
2 (section 2.2.8).
3.2.3.2 HPLC
3.2.3.2.1 Purity Measurements
RP-HPLC purity measurements of complexes 1-17 (ca. 100 µM, 2.7% dmso/97.3%
H2O v/v) were performed as described in Chapter 2 9 (section 2.2.5.1).
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3.2.3.2.2 Separation of Enantiomers
The enantiomeric separation of complexes 1, 2, 6 and 16 was performed using chiral
NP-HPLC as described in Chapter 2 (section 2.2.5.3) with the assistance of Dr. Ruth
McQuitty (Department of Chemistry, University of Warwick).
The stability of the separated enantiomers of complex 6 was determined by multiple
collections of each peak where the fractions were stored at 273 K for 3 days before
being concentrated to dryness under vacuum with no heating, followed by re-
dissolution and injection into the HPLC to analyse the stability of each enantiomer.
3.2.3.2.3 Relative Hydrophobicity Measurements
Relative hydrophobicity measurements of complexes 2, 4, 7, 8 and 11-14 using RP-
HPLC were performed as described in Chapter 2 (section 2.2.5.2). Samples were
dissolved in 10% MeOH/90% H2O (v/v) in 50 mM NaCl at ca 100 µM. Reported
retention times (tR) and standard deviations (SD) are from duplicate of triplicate
measurements.
3.2.3.3 Computation
DFT calculations were performed as described in Chapter 2 (section 2.2.9).
Electrostatic potential surfaces (EPS) for complexes 2, 4, 7, 8 and 11-13 where the
EPSs are shown both in space (with positive and negative regions in blue and red,
respectively) and mapped on electron density (isovalue 0.04) of the molecules. The
electrostatic potential is represented with a colour scale ranging from red (-0.040 au)
to blue (+0.250 au).
3.2.3.4 Hydrolysis Studies
The aquation of complexes (ca. 500 µM) was monitored by 600 MHz 1H NMR
spectroscopy over 24 h in 26.7% MeOD/73.3% D2O (v/v) at 310 K using a Bruker
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AV III 600 NMR spectrometer. All spectra were internally referenced to 1,4-dioxane
(3.75 ppm) and water suppression was performed using Shaka techniques.37 NaCl
was added to aid assignment of species to either the Ir-OD2/OD or Ir-Cl adducts.
Percentages of each adduct were based on 1H NMR peak integrations.
3.2.3.5 Reactions with Model Nucleobases
The reactions of complexes 2, 4, 7, 8 and 11-14 (ca. 500 µM) with 9-EtG and 9-
MeA (ca. 500 µM) were monitored by 1H NMR spectroscopy. Typically, one mol
equiv of 9-EtG in D2O was added to a solution of complex in MeOD-d4/D2O to give
a final complex concentration of ca. 500 µM in 26.7% MeOD-d4/73.3% D2O (v/v).
1H NMR spectra were recorded at various time intervals at 310 K and samples
incubated at this temperature during the course of the reaction. Percentage binding
was based on peak integrations.
3.2.3.6 Catalytic Oxidation of NADH to NAD+
Complexes 2, 4, 11 and 12 were evaluated for the catalytic oxidation of NADH to
NAD+ by UV-visible spectroscopy over a 24 h period in 0.5% MeOH/99.5%
H2O.(v/v) at 310 K in 5 mM Na2HPO4/NaH2PO4 buffer, pH 7.5. The complex
concentration remained fixed at 2.5 µM with NADH concentrations of 69, 103, 127
and 146 µM. The conversion of NADH to NAD+ was followed by absorption at 339
nm (εNADH = 6220 cm-1 M-1) to allow evaluation of kinetic data.
The reaction between complex 2 (250 µM) and NADH (750 µM) in 50%
MeOD/50% H2O (v/v) at 310 K, pH* 7.4 was monitored by 1H NMR spectroscopy.
Detection of the production of H2O2 was attempted during the reaction between
complex 2 (250 µM) and NADH (750 µM) in 1:1 MeOH:H2O at 310 K using
quantofix peroxide test sticks.
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Detection of the production of H2 was investigated for the reaction between complex
2 (250 µM) and NADH (750 µM) in 50% MeOD/ 50% H2O (v/v) at 310 K after 24 h
reaction time by gas chromatography by taking aliquots (100 µL) of the headspace.
The instrument used was an Agilent GC 7890A equipped with a thermal
conductivity detector; a 5-Å molecular sieve column, using N2 as the carrier gas.
Under these conditions, H2 has a retention time of 0.39 min.
3.2.3.7 Antiproliferative Activity
Antiproliferative activity assays were performed by Dr. Isolda Romero-Canelón
(Department of Chemistry, University of Warwick) as described in Chapter 2
(section 2.2.14.2). Complexes 1-17 were evaluated for activity in the A2780 human
ovarian cancer cell line and complexes 1, 2, 5, 6, 8, 10, 11 and 14 in HCT-116
(colon), MCF-7 (breast) and A549 (lung) cancer cell lines. Concentrations of stock
solutions were determined by ICP-OES measurements.
3.2.3.8 Metal Accumulation in A2780 Cancer Cells
Metal accumulation studies for complexes 2, 4, 7, 8 and 11-14 were conducted on
the A2780 ovarian carcinoma cell line by Dr. Isolda Romero-Canelón (Department
of Chemistry, University of Warwick). Briefly, 1.5 x 106 cells were seeded on a 6
well plate, after 24 h of pre-incubation time in drug-free medium, at 310K in a 5%
CO2 humidified atmosphere; the test complexes were added to give final
concentrations equal to IC50 and then allowed a further 24 h of drug exposure under
similar conditions. These experiments did not include any cell recovery time in drug-
free media. After this time, cells were treated with trypsin, counted, and cell pellets
were collected. Each pellet was digested overnight in concentrated nitric acid (73%)
at 353 K; the resulting solutions were diluted to 5% v/v HNO3 using doubly
Chapter 3
84
deionized water, and the amount of iridium taken up by the cells was determined by
ICP-MS. They were all carried out in triplicate in two set of independent
experiments and the standard deviations were calculated.
3.2.3.9 Metal Distribution in A2780 Cancer Cells
Metal distribution studies for complexes 2 and 4 were conducted on the A2780
ovarian carcinoma cell line by Dr. Isolda Romero-Canelón (Department of
Chemistry, University of Warwick). Cell pellets were obtained as described above
(section 3.2.3.8), and were fractionated using the FractionPREP kit from BioVision
according to the supplier’s instructions. Each sample was digested overnight in
concentrated nitric acid (73%) and the amount of Ir taken up by the cells was
determined by ICP-MS. The experiments were all carried out in triplicate and the
standard deviations were calculated. Statistical significance between results was
established from the Student’s T test where ** = (p < 0.01).
3.2.3.10 ICP-OES Analysis
ICP-OES analyses were carried out as described in Chapter 2 (section 2.2.10).
Calibrants were freshly prepared at concentrations of 1000, 800, 600, 400, 200 and
100 ppb which and were spiked with NaCl to match the salt content of the samples
being analysed.
3.2.3.11 ICP-MS Analysis
ICP-MS analyses were carried out as described in Chapter 2 (section 2.2.11).
Calibrants were freshly prepared at concentrations of 100, 80, 60, 40, 20, 5, 1, 0.8
and 0.5 ppb.
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3.3 Results
3.3.1 Synthesis and Characterisation
Seventeen iridium(III) half-sandwich complexes bearing functionally diverse 2-PhPy
ligands (Chart 3.1) were synthesised and characterised by 1H NMR spectroscopy,
ESI-MS, CHN analysis and RP-HPLC. Functionalised 2-PhPy ligands bearing either
electron-withdrawing or electron-donating substituents were synthesised using
Suzuki-Miyaura palladium cross-coupling chemistry following an adapted literature
protocol.35 They were purified using flash silica gel chromatography with mixtures
of chloroform/ethyl acetate yielding 2-(Rˈ-phenyl)-R-pyridine ligands L1-17. The
synthesis of the corresponding complexes [(η5-Cp*)Ir(2-(Rˈ-phenyl)-R-pyridine)Cl]
(1-17) was carried out using an adapted literature procedure,27 involving stirring of 2
mol equiv of 2-(Rˈ-phenyl)-R-pyridine ligand in DCM with 4 mol equiv of sodium 
acetate followed by addition of 1 mol equiv of [η5-Cp*)IrCl2]2 at ambient
temperature for 18 h. After filtering the reaction mixture through celite, the mixture
was concentrated to dryness then recrystallised in chloroform/hexane at 278 K. The
synthetic routes for the complexes are shown in Scheme 3.1. The introduction of
electron-withdrawing nitro (-NO2) and aldehydic (-CHO) groups and the electron-
donating hydroxymethyl group (-CH2OH) in complexes 5-10 are the first to be
reported in complexes of the type [(η5-Cp*)Ir(2-PhPy)X]0/+. Complex [(η5-Cp*)Ir(2-
(4ˈ-methoxyphenyl)pyridine)Cl] 17 has been previously reported36 but investigations
into its biological activity have not been performed.
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Scheme 3.1. Synthetic route for 2-(Rˈ-phenyl)-R-pyridine ligands L1-17 (A) and
[(η5-Cp*)Ir(2-(Rˈ-phenyl)-R-pyridine)Cl] complexes 1-17 (B).
The X-ray crystal structures of complexes [(η5-Cp*)Ir(2-(2ˈ-
fluorophenyl)pyridine)Cl] 1, [(η5-Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2 and [(η5-
Cp*)Ir(2-(4ˈ-trifluoromethylphenyl)pyridine)Cl] 16 were determined and are shown
in Figure 3.1, with X-ray crystallographic data listed in Table 3.1 and selected bond
lengths and angles in Table 3.2. The complexes exhibit the expected pseudo-
octahedral half-sandwich structure, with the Cp* ring occupying three coordination
sites. The 2-PhPy chelating ligand occupies two sites and the monodentate chlorido
ligand occupies the sixth coordination position. The Ir-centroid distances range from
1.828-1.837 Å, Ir-C distances from 2.0346-2.0482 Å, Ir-N distances from 2.0797-
2.093 Å and Ir-Cl distances from 2.4026-2.4159 Å. The bond angle between the
chelating ligand and iridium centre (C-Ir-N) is the smallest in all cases, ranging from
77.84-78.13°.
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Complex 1 was modelled as disordered over two positions related by swapping the
position of the pyridine and the 2-fluorophenyl rings. The disorder was simply
modelled by interchanging the carbon (C12) and the associated carbon and fluorine
atoms on that ring with the nitrogen (N1) bound to the metal. This was refined to an
occupancy of 80:20. Therefore, in any particular position the site is occupied 80% by
one enantiomer and 20% by the other enantiomer. As there is an inversion centre in
the space group (P2(1)/n), there is another position occupied by 80% of the time by
the other enantiomer and 20% of the time by the other. This results in an overall
50:50 racemate.
Figure 3.1. X-ray crystal structures of [(η5-Cp*)Ir(2-(2ˈ-fluorophenyl)pyridine)Cl] 1,
[(η5-Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2 and [(η5-Cp*)Ir(2-(4ˈ-
trifluoromethylphenyl)pyridine)Cl] 16. Hydrogen atoms have been omitted for
clarity and thermal ellipsoids are shown at 50% probability. Disorder found in
complex 1 is omitted for clarity.
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Table 3.1. Summary of the X-ray crystallographic data for complexes [(η5-Cp*)Ir(2-
(2ˈ-fluorophenyl)pyridine)Cl] 1, [(η5-Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2 and
[(η5-Cp*)Ir(2-(4ˈ-trifluoromethylphenyl)pyridine)Cl] 16
Table 3.2. Selected bond lengths (Å) and bond angles (deg) for complexes [(η5-
Cp*)Ir(2-(2ˈ-fluorophenyl)pyridine)Cl] 1, [(η5-Cp*)Ir(2-(4ˈ-fluorophenyl)-
pyridine)Cl] 2 and [(η5-Cp*)Ir(2-(4ˈ-trifluoromethylphenyl)pyridine)Cl] 16
Bond/angle 1 2 16
Ir-C (Cp* ring) 2.163(2) 2.160(2) 2.157(4)
2.1675(19) 2.1609(19) 2.169(5)
2.177(2) 2.172(2) 2.170(4)
2.239(2) 2.2522(19) 2.265(5)
2.247(2) 2.272(2) 2.284(4)
Ir-C (centroid) 1.828 1.833 1.837
Ir-C 2.0482(18) 2.0346(19) 2.045(5)
Ir-N 2.0797(17) 2.0931(16) 2.093(4)
Ir-Cl 2.4056(5) 2.4026(5) 2.4159(11)
C-Ir-N 77.84(7) 78.13(7) 77.95(18)
C-Ir-Cl 85.96(5) 85.68(5) 88.40(13)
N-Ir-Cl 87.60(5) 87.30(5) 85.94(11)
1 2 16
Formula C21H22ClFIrN C21H22ClFIrN C22H22ClF3IrN
MW 535.05 535.05 585.06
Crystal Colour Yellow Yellow Yellow
Cryst size (mm) 0.30 x 0.20 x 0.12 0.40 x 0.18 x 0.10 0.20 × 0.20 × 0.08
λ (Å) 0.71073 0.71073 1.54184
Temp (K) 150 150 100
Cryst system Monoclinic Monoclinic Monoclinic
Space group P2(1)/n P2(1)/n P2(1)/c
a (Å) 8.37197(9) 8.27453(11) 15.4953(4)
b (Å) 15.71819(18) 15.70747(16) 7.76677(19)
c (Å) 13.73371(17) 13.83772(14) 16.4333(3)
α (°) 90 90 90
β (°) 92.8873(11) 93.1162(11) 92.690(2)
γ (°) 90 90 90
Vol (Å3) 1804.95(4) 1795.86(3) 1975.54(8)
Z 4 4 4
R(Fo2) 0.0172 0.0199 0.0363
Rw(Fo2) 0.0381 0.0490 0.0997
GOF 1.092 1.095 1.050
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Weak off-set intermolecular π-π stacking between the 2-PhPy ligands is observed in 
the X-ray crystal structures of complexes 1 and 2 with a centroid-centroid distance of
4.140 Å and 4.059 Å, respectively (Figure 3.2).
Figure 3.2. Diagram showing the π-π stacking interaction in the X-ray crystal 
structures of complexes [(η5-Cp*)Ir(2-(2ˈ-fluorophenyl)pyridine)Cl] 1 (A) and [(η5-
Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2 (B) where the centroid – centroid distance
between pyridyl-phenyl rings of independent molecules is 4.140 and 4.059 Å for 1
and 2, respectively. Thermal ellipsoids drawn at 50% with hydrogen atoms removed
for clarity.
The electrostatic potential surfaces (EPS) of complexes [(η5-Cp*)Ir(2-(4ˈ-
fluorophenyl)pyridine)Cl] 2, [(η5-Cp*)Ir(2-phenyl-5-fluoropyridine)Cl] 4, [(η5-
Cp*)Ir(2-(4ˈ-nitrophenyl)pyridine)Cl] 7, [(η5-Cp*)Ir(2-phenyl-4-nitropyridine)Cl] 8,
[(η5-Cp*)Ir(2-(4ˈ-hydroxyphenyl)pyridine)Cl] 11, [(η5-Cp*)Ir(2-phenyl-5-
hydroxypyridine)Cl] 12 and [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)Cl] 13 were
calculated using DFT methods at the PBE0/Lanl2DZ/6-31+G** level,38-40 based on
the crystal structure of complex 2, with functional group modifications being made
with GaussView 3.0.41 for the rest of the complexes. The resulting EPS of each
complex is shown in Figure 3.3. The phenyl ring in the chelating ligand exhibits a
more negative electrostatic potential than the pyridyl ring due to the deprotonated
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carbon bonded to the Ir centre. There are no major differences in the charge
distribution at the iridium centre, Cp* ring or chlorido ligands among the complexes,
indicating that the substituent on the chelating ligand causes only a localised effect.
Complexes 7 and 8 contain the electron-withdrawing nitro group on the phenyl and
pyridyl ring, respectively, causing a more positive surface. Complex 13 bears a
methyl group on the phenyl ring which pushes electron density into the ring, causing
a more negative EPS. The substituents themselves cause the outer EPS of each
complex to alter significantly.
The calculated bond lengths at the metal centre are shown in Table 3.3, which shows
minimal difference among the complexes, with the exception of 13 which exhibits a
shorter Ir-N bond. Generally, the calculated bond lengths of complex 2 are in good
agreement with those obtained by X-ray diffraction.
Figure 3.3. Electrostatic potential surfaces for complexes 2, 4, 7, 8 and 11-13
(calculated at the PBE0/Lanl2DZ/6-31+G** level) where the EPS are shown both in
space (with positive and negative regions in blue and red, respectively) and mapped
on electron density (isovalue 0.04) of the molecules. The electrostatic potential is
represented with a colour scale ranging from red (-0.040 au) to blue (+0.250 au).
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Table 3.3. Calculated bond lengths for complexes 2, 4, 7, 8 and 11-13 (calculated at
the PBE0/Lanl2DZ/6-31+G** level).
Calculated bond lengths (Å)
Complex Ir-Cp* (centroid) Ir-C Ir-N Ir-Cl
2 1.862 2.008 2.078 2.410
4 1.862 2.011 2.076 2.411
7 1.861 2.006 2.078 2.412
8 1.864 2.009 2.069 2.408
11 1.862 2.009 2.078 2.411
12 1.862 2.012 2.077 2.412
13 1.868 2.004 2.058 2.414
3.3.2 Separation of Enantiomers
The complexes studied in this chapter exhibit chirality at the metal centre, resulting
in the formation of a racemic solution of R and S enantiomers. The enantiomeric
separation of complexes [(η5-Cp*)Ir(2-(2ˈ-fluorophenyl)pyridine)Cl] 1, [(η5-
Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2, [(η5-Cp*)Ir(2-phenyl-5-pyridine-
carboxaldehyde)Cl] 6 and [(η5-Cp*)Ir(2-(4ˈ-trifluorophenyl)pyridine)Cl] 16 was
attempted using chiral HPLC, where the stationary phase (CHIRALPAK® IA) is a
chiral sugar (amylose tris(3,5-dimethylphenylcarbamate)) immobilized on 3 μm 
silica-gel. The resulting HPLC traces from the injection of the racemic solutions of
each complex (EtOH, 1 mg mL-1) are shown in Figure 3.4. Two peaks are present in
each case, indicating the presence of two enantiomers in each solution. Integration of
each peak shows that a racemic mixture is present for 1, 6 and 16, while 2 appears to
have a slight excess of one enantiomer. Complexes 1, 2 and 6 show good separations
of enantiomers while the enantiomers of 16 exhibit similar retention times (6.94 and
7.50 min).
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Figure 3.4. Chiral HPLC traces of complexes 1 (A), 2 (B), 6 (C) and 16 (D) (1 mg
mL-1, λ = 260 nm) 
The stability of the separated enantiomers of complex 6 was assessed by collecting
the two eluting peaks. The fractions were stored at 273 K for 3 days before being
concentrated to dryness under vacuum with no heating, followed by re-dissolution
and injection into the column. The resulting HPLC traces are shown in Figure 3.5,
which show that each enantiomer epimerises to a racemic mixture of R and S under
the conditions they were stored under.
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Figure 3.5 Chiral HPLC traces of complex 6 after re-injection of collected peaks.
The appearance of two peaks in each fraction indicates epimerisation to a racemic
mixture has occurred.
3.3.3 Hydrolysis Studies
The hydrolysis of complexes 1-17 (ca 500 µM) was studied by 1H NMR
spectroscopy in 26.7% MeOD-d4/ 73.3% D2O at 310 K. Methanol was required to
ensure sufficient solubility of the complexes in aqueous solution. Hydrolysis
equilibrium was reached before the time taken to acquire the first spectra (15 min),
consistent with previous reports of Ir(III) C,N-chelated half-sandwich complexes.27
Hydrolysis was confirmed by the sequential addition of NaCl, showing an increase
in the peaks associated with the Ir-Cl species and a decrease in the peaks associated
with the Ir-OD2/OD species, as exemplified for complex 11 in Figure 3.6 a. Between
66-80% was found to be in the hydrolysed form, based on peak integrations (Figure
3.6 b). With 4 mM NaCl present, almost all of the Ir-OD2/OD species had been
converted to the Ir-Cl complexes. Above this concentration of NaCl, precipitation of
the complexes was observed. The hydrolysed complexes exhibit a down-field shift of
the aromatic protons of around 0.15 ppm compared to the parent chlorido complexes.
Determination of the pKa values of the complexes was attempted, but solubility
issues prevented reliable analysis by 1H NMR spectroscopy.
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Figure 3.6. (A) 1H NMR (600 MHz) spectra of complex 11 (c.a. 500 µM) in 26.7%
MeOD-d4/73.3% D2O (v/v) at 310 K. Hydrolysis equilibrium was reached within the
time taken to acquire the first spectrum. Sequential addition of NaCl resulted in
conversion from the 11-OD2/OD (★) complex to the 11-Cl (▲) complex. (B)
Percentage of hydrolysis (Ir-OD2/OD) for complexes 1-17 at equilibrium (15 min).
3.3.4 Binding to Nucleobases
As DNA is believed to be a major target for anticancer coordination complexes,
compounds 2, 4, 7, 8 and 11-14 (ca 500 µM) were evaluated for their ability to bind
to model nucleobases 9-EtG and 9-MeA in ca. 1:1 mol ratios of complex:nucleobase
by 1H NMR spectroscopy in 26.7% MeOD-d4/ 73.3% D2O at 310 K, pH* 7.4 after
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incubation for 15 min and 24 h (shown for complex 2 in Figure 3.7). All complexes
showed 100% binding to 9-EtG and ca. 50-80% binding to 9-MeA after 15 min,
which remained unchanged over a period of 24 h (Table 3.4). The binding of
complex 2 to 9-EtG was confirmed by ESI-MS where the m/z peak 679.2 was
observed which corresponds to the species [(η5-Cp*)Ir(2-(4ˈ-
fluorophenyl)pyridine)9-EtG]+ (calculated m/z = 679.22). Binding of 9-EtG to 2 and
4 in the presence of 4 mM NaCl, where the complexes exist primarily as the Ir-Cl
species, reached 100% after 24 h. Complex 11 shows markedly higher affinity
towards 9-MeA binding at 82%, while the structural isomer 12 exhibits the next
highest 9-MeA binding (64%). In most cases, only one set of peaks corresponding to
9-MeA binding was observed, with the exception of complex 12 where two peaks
were present, perhaps indicating binding through both N1 and N7 atoms.
Competitive binding of 9-EtG and 9-MeA was also investigated under the same
conditions. This resulted in mostly 9-EtG binding for all the complexes (Table 3.4).
Complexes 2, 4 and 14 show 5-10% binding to 9-MeA in the presence of 9-EtG.
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Figure 3.7. Interaction of complex 2 (ca. 500 µM) with equimolar amounts of 9-
EtG, 9-MeA and competition binding by 1H NMR spectroscopy (600 MHz, 26.7%
MeOD-d4/ 73.3% D2O (v/v) at 310 K, pH* 7.4, 24 h). Complex 2 shows 100%
binding to 9-EtG (▲) and around 50% binding to 9-MeA (★) and a preference for
binding to 9-EtG upon co-incubation with 9-EtG and 9-MeA.
Table 3.4. Percentage binding of complexes 2, 4, 7, 8 and 11-14 (ca 500 µM) with 9-
EtG, 9-MeA and competition binding upon co-incubation at 1:1 mol ratios.
Percentage binding was determined by 1H NMR spectroscopy (600 MHz, 26.7%
MeOD-d4/ 73.3% D2O at 310 K, pH* 7.4, 24 h) based on peak integrations.
Complex Percentage binding (%)
Competitive binding
9-EtG 9-MeAa 9-EtG 9-MeA
2 100 56 90 10
4 100 54 90 10
7 100 54 100 0
8 100 58 100 0
11 100 82 100 0
12 100 64 100 0
13 100 58 100 0
14 100 50 95 5
aOverlapping peaks in the 1H NMR spectra made accurate quantitative analysis
difficult.
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3.3.5 Catalysis of NADH oxidation
The ability to disrupt the redox balance of cells by the catalytic oxidation of NADH
has been suggested to be of importance to the mechanism of action of iridium(III)
half-sandwich complexes.31,32,42 The reaction between NADH and complexes 2, 4,
11 and 12 was monitored by UV-Vis spectroscopy at varying concentrations of
NADH (69, 103 and 146 µM) with a fixed concentration of complex (2.5 µM) over a
period of 24 h at 310 K, pH 7.5 (Na2HPO4/NaH2PO4 buffer, 5 mM). The decrease in
the band at 339 nm was monitored as it corresponds to conversion of NADH to
NAD+ (Figure 3.8 a). The data were also the basis for the calculation of the turnover
number (TON) and turnover frequency (TOF, h-1) for each complex at different
concentrations (Table 3.5). After 24 h, the maximum TON was found for each
complex at the highest concentration of NADH (146 µM), and ranged from 22-28.
Maximum TOF was also reached at 146 µM NADH, ranging from 1.1-3.2 h-1. The
reaction proceeded via first order kinetics with respect to [NADH] (Figure 3.8 b),
with an average rate constant k of 3.79 × 10-4 min-1 for 2 and 4.03 × 10-4 min-1 for 4.
However, complexes 11 and 12, which bear the hydroxyl group, gave a non-first
order reaction with respect to [NADH] during the first 3 h, followed by the expected
first-order kinetics (exemplified for complex 11 in Figure 3.8 c). These results
indicate that each of these complexes shows catalytic behaviour towards the
oxidation of NADH.
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Table 3.5. TONs and TOFs for complexes 2, 4, 11 and 12 for the catalytic oxidation
of NADH to NAD+ monitored via UV-visible spectroscopy at various concentrations
of NADH (69, 103 and 146 µM) with a fixed complex concentration of 2.5 µM over
a 24 h period in 0.5% MeOH/99.5% H2O (v/v) at 310 K in 5 mM
Na2HPO4/NaH2PO4 buffer, pH 7.5. The conversion of NADH to NAD+ was
followed from the absorption at 339 nm.
Complex NADH
(µM)
TON
(24 h)
TOF
(h-1)a
[(η5-Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2 69 11 0.6
103 19 1.1
146 22 1.2
[(η5-Cp*)Ir(2-phenyl-5-fluoropyridine)Cl] 4 69 13 0.7
103 20 1.2
146 22 1.1
[(η5-Cp*)Ir(2-(4ˈ-hydroxyphenyl)pyridine)Cl] 11 69 14 1.9
103 21 2.6
146 28 3.2
[(η5-Cp*)Ir(2-phenyl-5-hydroxypyridine)Cl] 12 69 13 1.4
103 15 1.8
146 22 2.6
aTOFs were calculated as the gradient of time vs. TON during the first 2 h of the
reaction time.
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Figure 3.8. (a) UV-Visible spectra for the catalytic oxidation of NADH (146 µM) to
NAD+ in the presence of complex 2 (2.5 µM) over a 24 h period in 0.5%
MeOH/99.5% H2O at 310 K in 5 mM Na2HPO4/NaH2PO4 buffer, pH 7.5. (b) First
order kinetic plot for complex 2 [NADH] = 69 µM (green), 103 µM (purple) and 146
µM (orange). (c) First order kinetic plot for complex 11 [NADH] = 69 µM (green),
103 µM (purple) and 146 µM (orange) showing unusual kinetics for first 3 h
followed by first-order reaction kinetics.
In order to probe whether the oxidation proceeds via the formation of an iridium-
hydride species, the reaction of complex 2 (250 µM) with NADH (750 µM) in 50%
MeOD-d4/ 50% D2O (v/v) at 310 K was monitored by 1H NMR spectroscopy over a
15 h period. After 15 min, a peak corresponding to an Ir-H species was observed at
-14.84 ppm (Figure 3.9), which was no longer visible after 15 h. The conversion of
NADH to NAD+ was also confirmed by the appearance of a new set of peaks
corresponding to the formation of NAD+.
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Complex 2 (250 µM) was studied for the production of hydrogen by gas
chromatography after 24 h as a by-product of the reaction with NADH (750 µM) in
1:1 MeOH:H2O at 310 K in 5 mM Na2HPO4/NaH2PO4 buffer, pH 7.5. Analysis of
the head space revealed no detectable H2 production. The production of H2O2 upon
reaction of complex 2 (250 µM) with NADH (750 µM) in the presence of O2 in 1:1
MeOH: H2O at 310 K was measured by Quantofix peroxide sticks after periods of 8,
12 and 24 h reaction times, but no H2O2 was detected during the course of the
reaction.
Figure 3.9. 1H NMR (600 MHz, 50% MeOD-d4/50% D2O (v/v), 310 K) of the
reaction between complex 2 (250 μM) and NADH (750 μM). The iridium-hydride 
species is observed after 15 min at -14.84 ppm, alongside the conversion of NADH
(★) to NAD+ (▲).
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3.3.6 Antiproliferative Activity
The antiproliferative activity of complexes 1-17 in A2780 (ovarian) cancer cells and
complexes 1, 2, 5, 6, 8, 10, 11, 14 and 16 in HCT-116 (colon), MCF-7 (breast) and
A549 (lung) cancer cells is shown in Table 3.6. The activity of previously reported27
iridium complexes [(η5-Cp*)Ir(2-PhPy)Cl] and [(η5-CpxPh)Ir(2-PhPy)Cl] with no
substituents on the chelating ligand are also shown for comparison.
It is evident that the presence of substituents on the chelating ligand greatly affects
the antiproliferative activity of the complexes with IC50 values ranging from 1 to 60
µM in the A2780 cell line. Complex [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)Cl] 13
is the most potent with an IC50 value of 1.18 µM in A2780 ovarian cancer cells
making it more potent than the extended cyclopentadienyl complex [(η5-CpxPh)Ir(2-
phenylpyridine)Cl] (IC50 = 2.14 µM). Complexes 2, 8, 13 and 15 also show similar
potency to the clinical drug cisplatin (CDDP). Interestingly, structural isomers
exhibit contrasting activities against A2780 cells; for example, complexes [(η5-
Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2 (2.7 µM) and [(η5-Cp*)Ir(2-phenyl-5-
fluoropyridine)Cl] 4 (>60 µM), and complexes [(η5-Cp*)Ir(2-(4ˈ-
hydroxyphenyl)pyridine)Cl] 11 (47.3 µM) and [(η5-Cp*)Ir(2-phenyl-5-
hydroxypyridine)Cl] 12 (13.29 µM). Contrasting activity for structural isomers also
occurs for other cell lines, most notably against the A549 lung cancer cell line for
complexes [(η5-Cp*)Ir(2-(2ˈ-fluorophenyl)pyridine)Cl] 1 (10.36 µM) and [(η5-
Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2 (2.1 µM). There is also variation in activity
of complexes in different cells lines, most notably complex [(η5-Cp*)Ir(2-phenyl-4-
nitropyridine)Cl] 8 with IC50 values of 2.7, 27.4, 11.4 and 20.1 µM in A2780,
HCT-116, MCF-7 and A549 cell lines, respectively. In general, the most sensitive
cell line to this set of complexes is the A2780 ovarian cancer cell line, followed by
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MCF-7 breast cancer cells. The complexes are less effective against HCT-116 colon
and A549 lung cancer cells.
Table 3.6. IC50 values for complexes 1-17 in A2780 cells and complexes 1, 2, 5, 6,
8, 10, 11, 14 and 16 in HCT-116, MCF-7 and A549 cells. Drug exposure time was
24 h followed by a 72 h recovery time.
IC50 values (µM)
Complex A2780 HCT-116 MCF-7 A549
1 4.5 ± 0.2 3.7 ± 0.3 9.6 ± 0.4 10.36 ± 0.07
2 2.7 ± 0.3 6.8 ± 0.1 4.8 ± 0.3 2.1 ± 0.3
3 >50 n.d. n.d. n.d.
4 >60 n.d. n.d. n.d.
5 6.9 ± 0.3 21.3 ± 0.7 11.6 ± 0.5 15.8 ± 0.4
6 4.4 ± 0.4 18.8 ± 0.5 6.5 ± 0.3 5.9 ± 0.1
7 24.73 ± 2.30 n.d. n.d. n.d.
8 2.7 ± 0.1 27.5 ± 0.9 11.4 ± 0.4 20.1 ± 0.3
9 ˃50 n.d. n.d. n.d.
10 47 ± 1 57.3 ± 0.9 47 ± 2 89 ± 1
11 47.3 ± 0.1 29.3 ± 0.8 28.6 ± 0.9 56.67 ± 0.04
12 13.29 ± 0.88 n.d. n.d. n.d.
13 1.18 ± 0.08 n.d. n.d. n.d.
14 3.9 ± 0.2 9.6 ± 0.6 3.7 ± 0.1 8.7 ± 0.3
15 1.26 ± 0.01 n.d. n.d. n.d.
16 4.4 ± 0.2 7.0 ± 0.2 8.9 ± 0.2 2.7 ± 0.1
17 6 ± 1 n.d. n.d. n.d.
[(η5-Cp*)Ir(2-PhPy)Cl]a 10.78 ± 1.72 n.d. n.d. n.d.
[(η5-CpxPh)Ir(2-PhPy)Cl]a 2.14 ± 0.50 n.d. n.d. n.d.
cisplatin 1.2 ± 0.2 5.2 ± 0.3 7.0 ± 0.1 3.5 ± 0.2
a From ref 27.
3.3.7 Relative Hydrophobicity
Hydrophobicity can be an important design feature for metallodrugs and has been
correlated with enhanced potency.43-45 The relative hydrophobicities of complexes
2/4, 7/8, 11/12 and 13/14 (four pairs of structural isomers) were determined by RP-
HPLC. The more hydrophobic complexes have longer retention times (tR). To ensure
solubility of the complexes, methanol was used (MeOH:H2O 1:9 v:v) with NaCl (50
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mM) present to suppress the hydrolysis of the complexes in both sample preparation
and in the HPLC solvents. The resulting retention times are shown in Table 3.7.
Complex 11 shows the shortest retention time (least hydrophobic) at 15.11 min while
complex 14 shows the longest retention time (most hydrophobic) at 20.9 min.
Table 3.7. Retention times (tR) by RP-HPLC of complexes 2, 4, 7, 8 and 11-14.
Measurements were taken as an average of duplicate of triplicate experiments.
Complex 2-PhPy ligand tR (min)
2 2-(4ˈ-fluorophenyl)pyridine 18.74 ± 0.05
4 2-phenyl-5-fluoropyridine 18.60 ± 0.02
7 2-(4ˈ-nitrophenyl)pyridine 18.8 ± 0.2
8 2-phenyl-4-nitropyridine 18.0 ± 0.1
11 2-(4ˈ-hydroxyphenyl)pyridine 15.11 ± 0.03 
12 2-phenyl-5-hydroxypyridine 17.8 ± 0.2
13 2-(2ˈ-methylphenyl)pyridine 20.4 ± 0.2
14 2-phenyl-5-methylpyridine 20.9 ± 0.9
3.3.8 Cellular-Iridium Accumulation
Accumulation of metal drugs in cancer cells can be related to the hydrophobicity of
the complexes. Cellular-iridium accumulation in A2780 cells after 24 h exposure to
complexes 2, 4, 7, 8 and 11-14 at equipotent (IC50) concentrations was determined
by ICP-MS and is shown in Table 3.8. Complex 11 shows the lowest accumulation
of 1.6 ng Ir/106 cells while complex 13 exhibits the highest extent of accumulation of
18 ng Ir/106 cells.
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Table 3.8. Cellular-iridium accumulation in A2780 cells for complexes 2, 4, 7, 8 and
11-14 determined at equipotent (IC50) concentrations as duplicate of triplicate
experiments.
Complex 2-PhPy ligand Cellular-Ir
(ng Ir/106 A2780 cells)
2 2-(4ˈ-fluorophenyl)pyridine 13.5 ± 0.3
4 2-phenyl-5-fluoropyridine 11.1 ± 0.1
7 2-(4ˈ-nitrophenyl)pyridine 8 ± 1
8 2-phenyl-4-nitropyridine 9.0 ± 0.2
11 2-(4ˈ-hydroxyphenyl)pyridine 1.6 ± 0.1
12 2-phenyl-5-hydroxypyridine 10.2 ± 0.2
13 2-(2ˈ-methylphenyl)pyridine 18 ± 1
14 2-phenyl-5-methylpyridine 16.0 ± 0.3
3.3.9 Cellular-Iridium Distribution
To examine if small structural changes on the chelating ligand affect intracellular-
localisation of iridium complexes, structural isomers [(η5-Cp*)Ir(2-(4ˈ-
fluorophenyl)pyridine)Cl] 2 and [(η5-Cp*)Ir(2-phenyl-5-fluoropyridine)Cl] 4 (which
show contrasting anticancer activities) were examined for their cellular-iridium
distribution in A2780 human ovarian cancer cells at IC50 concentrations, Figure 3.10.
The cytosol contains the highest amount of iridium (51.4% for 2 and 69.2% for 4),
followed by the cell membrane and particulate fractions (28.4% for 2 and 17.9% for
4). Complex 4 localises in the cytosol to a greater extent than complex 2 (p < 0.01),
which in turn localises in the cell membrane to a greater extent than 4 (p < 0.01). The
nuclear fraction contains different amounts of iridium, with 10.4% and 6.7% (p <
0.01) for complexes 2 and 4, respectively, while the cytoskeletal fraction contains
similar levels of iridium with 9.8% and 6.1% (p > 0.05) for 2 and 4, respectively.
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Figure 3.10. Cellular-iridium distribution of structural isomers 2 and 4 in A2780
human ovarian cancer cells. Complex 4 localises in the cytosol to a greater extent
than 2, while complex 2 localises in the membrane and particulate fractions to a
greater extent than 4. Student’s t-test at p < 0.01 level indicated by **.
3.4 Discussion
3.4.1 Characterisation
The X-ray crystal structures of complexes [(η5-Cp*)Ir(2-(2ˈ-
fluorophenyl)pyridine)Cl] 1, [(η5-Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2 and [(η5-
Cp*)Ir(2-(4ˈ-trifluoromethylphenyl)pyridine)Cl] 16 show the “piano-stool” structure
expected for half-sandwich metal complexes with bond lengths/angles comparable to
similar previously-reported structures.27,46,47 The position of the fluorine on the
phenyl ring does not appear to influence exhibited bond lengths. Complexes 1 and 2
exhibit weak off-set π-π stacking between the 2-PhPy ligand (Figure 3.2), with a 
centroid-centroid distance of 4.140 Å for 1 and 4.059 Å for 2.
DFT calculations on complexes 2, 4, 7, 8 and 11-13 indicate that the presence of
substituents does not affect the electronic density on the iridium centre, Cp* ring or
chlorido ligands (Figure 3.3), which implies that the reactivity at the metal centre
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may remain relatively the same for all complexes. The EPS also show that the
phenyl ring in the chelating ligand has a more negative electrostatic potential than
the pyridyl ring, due to the negative charge associated with the deprotonation of the
bound carbon. The electron-withdrawing/electron-donating nature of the substituents
affects the EPS of the chelating ligand by either diminishing or enhancing the
electronic charge density on the ring system to which the substituent is bound. The
electron-withdrawing –NO2 and -F groups provide a more positive EPS within the
ring while the electron-donating –OH and –CH3 groups generate a more negative
EPS within the ring. The presence of the substituents significantly changes the EPS
of the chelating ligand, with areas of higher electronic charge density for complexes
2, 4, 7, 8, 11 and 12 due to the presence of heteroatoms with differing
electronegativities. As weak electrostatic forces are often important for binding and
recognition interactions with biomolecules such as peptides, proteins and enzymes,48
the nature and position of substituent may play a significant role in the interaction of
the complexes studied here with target sites.
3.4.2 Separation of Enantiomers
The detrimental effects caused by the antimetic drug thalidomide,49 which occurs as
two enantiomers due to the presence of a chiral carbon centre, where the (-)(S)-
thalidomide enantiomer is responsible for the teratogenic effects, has led to the
increasing importance of the separation of enantiomers of any racemic drug
candidate. The separation of the enantiomers of complexes [(η5-Cp*)Ir(2-(2ˈ-
fluorophenyl)pyridine)Cl] 1, [(η5-Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2,
[(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] 6 and [(η5-Cp*)Ir(2-(4ˈ-
trifluoromethylphenyl)pyridine)Cl] 16 was performed using chiral HPLC, where the
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presence of two peaks in the HPLC trace is indicative of the R and S enantiomers
(Figure 3.4). The stability of the enantiomer of complex 6 was assessed by the
collection of each peak which contains either the R or S enantiomer and storage of
the solution at 273 K for 3 days. The solutions were then concentrated to dryness at
ambient temperature, re-dissolved and re-injected into the column. The appearance
of two sets of peaks from each collected peak shows that the enantiomers epimerise
in solution to a racemic mixture (Figure 3.5). It has been previously observed that
half-sandwich Ir(III) complexes can exhibit fast exchange between IrR and IrS
configurations for complexes bearing a disasterotopic centre in the chelating
ligand.50 Under the conditions used, the assessment of the biological properties of
each enantiomer is unlikely to be feasible. Time studies would be useful to see if the
epimerisation occurs on a scale that would make the isolation, characterisation and
assessment of biological activity of the R and S enantiomers possible.
3.4.3 Hydrolysis
Hydrolysis studies by 1H NMR showed that all complexes are converted to an
equilibrium mixture of Ir-Cl and Ir-OD2/OD at 310 K within the time taken to
complete the first spectrum (15 min) with 67-80% existing as the aqua/hydroxido
adduct (Figure 3.6). This is consistent with previous findings that iridium(III) half-
sandwich complexes can exhibit fast rates of ligand exchange26,51 in comparison to
their non-“piano stool” octahedral counterparts.52 The rate of aquation in iridium(III)
half-sandwich complexes has been shown to be dependent on the charge associated
with the chelating ligand, where anionic ligands like 2-PhPy show faster rates of
hydrolysis than neutral ligands such as 2,2ˈ-bipyridine.26,27 The type of substituent
on the 2-PhPy chelating ligand does not appear to greatly affect the rate or extent of
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hydrolysis. The hydrolysis can be readily reversed by addition of NaCl, and a
concentration of 4 mM NaCl almost completely suppresses hydrolysis. This would
imply that at biologically relevant chloride concentrations (i.e. in the nucleus) the
complexes would exist as the Ir-Cl rather than aqua species.
Analysis of the pKa of aqua adducts of these complexes proved difficult due to the
concentrations of complex in solution, however, previous reports on C,N-chelated
half-sandwich iridium(III) complexes showed that the pKa values are in the range of
8.3-8.9.27 Therefore the complexes studied here are likely to exist as the aqua rather
than the hydroxido adduct at physiological pH.
3.4.4 Interactions with Nucleobases
DNA is a major target for many transition-metal anticancer compounds.53-55 The
interaction of complexes 2, 4, 7, 8 and 11-14 with model nucleobases 9-EtG and 9-
MeA indicated a strong preference for 9-EtG, with 100% binding after 15 min
(Figure 3.7 and Table 3.4). Complexes 2 and 4 also exhibited 100% binding to 9-EtG
after 15 min even in the presence of 4 mM NaCl where the complex exists as the Ir-
Cl species. All complexes were able to bind to 9-MeA, but to a lesser extent than
with 9-EtG. Intriguingly, hydroxyl complex 11 binds to 9-MeA to a far greater
extent than the other complexes studied. Its structural isomer 12 exhibits the second
greatest extent of binding. This may indicate that a secondary interaction such as
hydrogen-bonding between the 9-MeA and the hydroxyl group may be stabilising
the interaction, although this was not further investigated.
In competitive binding experiments between 9-EtG and 9-MeA, only complexes 2, 4
and 14 formed 9-MeA adducts (5-10%), highlighting that binding to 9-MeA was less
strong than to 9-EtG. Complex 11 formed no 9-MeA adducts in competitive binding
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studies despite exhibiting the highest extent of binding to 9-MeA (82%) when no 9-
EtG was present. The weaker binding of 9-MeA may be attributed to the steric
hindrance caused by the –NH2 group at the 4 position. Guanine is also known to be a
stronger electron-donor than adenine, which may also contribute to the selectivity in
9-EtG binding.56 Guanine is therefore a potential binding site on DNA, as it is for
cisplatin,53 and other transition metal anticancer complexes.57-59
3.4.5 Catalytic oxidation of NADH to NAD+
The potential for complexes [(η5-Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2, [(η5-
Cp*)Ir(2-phenyl-5-fluoropyridine)Cl] 4, [(η5-Cp*)Ir(2-(4ˈ-hydroxyphenyl)-
pyridine)Cl] 11 and [(η5-Cp*)Ir(2-phenyl-5-hydroxypyridine)Cl] 12 to modulate the
NAD+/NADH ratio in cells catalytically was examined. All complexes exhibited
catalytic activity towards the conversion of NADH to NAD+ by first order reaction
kinetics with respect to [NADH]. Complex 11 exhibits the best catalytic activity with
a TON of 28 and TOF of 3.2 h-1 ([NADH] = 146 µM) while 2 and 4 have the lowest
TON of 22 and TOF of 1.2 and 1.1 h-1, respectively (Table 3.5). The presence of the
hydroxyl group in 11 and 12 seems to enhance the catalytic activity. Complexes 11
and 12 also exhibited an unusual kinetic profile for the first 3 h of reaction time,
followed by the expected first order kinetics (Figure 3.8). The hydroxyl group on
complex [(η5-Cp*)Ir(2-phenyl-6-hydroxypyridine)Cl] has been previously reported
to be important for the catalytic activity towards the dehydrogenative oxidation of
organic compounds,60 which implies that the hydroxyl group may be involved in the
catalytic cycle. Although the position of the hydroxyl group in 11 and 12 is further
from the metal centre than in [(η5-Cp*)Ir(2-phenyl-6-hydroxypyridine)Cl], the
unusual kinetics observed may indicate that it is initially playing a role in the
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catalytic activity. It has been suggested that the rate-limiting step in this catalytic
reaction is the formation of the Ir-NADH adduct leading to first-order reaction
kinetics with respect to [NADH],32 therefore the unusual kinetic profile of 11 and 12
may be a result of participation by the hydroxyl groups. The involvement of the
ligand in the oxidation of NADH in half-sandwich iridium(III) complexes has not
been previously observed.
It has been well documented that half-sandwich iridium(III) complexes can form
iridium-hydride species in the presence of a hydride source like sodium borohyride,
which allows the complex to partake in a range of catalytic reactions. The oxidation
of NADH proceeds via formation of an Ir-H species as observed in the 1H NMR
spectrum (Figure 3.9), in agreement with previous work on related complexes,31,61
showing that the H4 protons in NADH can be accessed as a hydride donor.
Further studies into the catalytic cycle of complex 2 with NADH involved
determination of the by-product of the reaction. It has been previously demonstrated
that both hydrogen gas and hydrogen peroxide can be formed in these
reactions,32,42,61 by protonation of the Ir-H species or by direct hydride transfer to
molecular oxygen, respectively. Under the experimental conditions used, neither H2
or H2O2 was detected. This may be a result of the low concentration of complex 2
(250 µM) used. It was found that increasing the concentration resulted in
precipitation of the complex upon addition of NADH and inhibited the catalytic
reaction. The precipitation may be the result of an increase in ionic strength of the
solution upon addition of NADH which was used as the di-potassium salt.
As these complexes can convert NADH to NAD+ catalytically, it may be possible to
disrupt this important redox couple in cells, which could have implications for cell
metabolism, including lactate dehydrogenase-catalysed lactate-pyruvate
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conversions,62 enhancement of ROS levels,42,63 as well as reducing the concentration
of one of the major electron-donors in the electron transport chain.
3.4.6 Antiproliferative Activity
The antiproliferative activity of the seventeen complexes covered a wide range, from
1 to 60 µM in A2780, 3.7 to 54.3 µM in HCT-116, 3.7 to 47 µM in MCF-7 and 2.1
to 89 µM in A549 cells, showing that the substituent on the chelating ligand has a
significant effect on the antiproliferative activity of the complex (Table 3.6).
Complexes 2, 8, 13 and 15 are all just as, or more, potent than the previously
reported phenyl-extended CpxPh complex 17 (IC50 = 2.14 µM) towards A2780 cells,
showing that the addition of functional groups to the 2-PhPy ligand can provide a
strategy for increasing potency rather than functionalising the Cpx capping ligand. In
contrast, complexes 3, 4, 7, 9, 10 and 11 are less active towards A2780 cells than the
parent complex [(η5-Cp*)Ir(2-PhPy)Cl]. It is apparent that the presence of
hydroxymethyl groups in complexes 9 and 10 decreases the antiproliferative activity.
However, the presence of methyl groups enhances the activity, making them
potentially interesting for further study. Methyl groups are inherently more likely to
contribute to increased lipophilicity than hydroxymethyl groups, perhaps indicating
that hydrophobicity is important for high potency.
The fluoro complexes 1 and 2, in which the fluorine atom is situated on the phenyl
ring, have promising activity of 2.7 and 4.4 µM, respectively, whereas complexes 3
and 4 in which the fluorine substituent is on the pyridyl ring have IC50 values of >50
µM, demonstrating the contrasting biological activity of the structural isomers. This
difference in activity for isomers is also observed for complexes 11 (IC50 = 47.3 µM)
and 12 (IC50 = 13.29 µM) which contain hydroxyl groups on the phenyl and pyridyl
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ring, respectively. Similarly for the nitro-containing complexes 7 (IC50 = 24.73 µM)
and 8 (IC50 = 2.7 µM). Therefore, not only is the type of substituent important, but
also where it is situated on the chelating ligand. It has been demonstrated in half-
sandwich iridium(III) complexes bearing picolinamide chelating ligands that the
inclusion of a substituent atom in the arene ring of the chelating ligand increases the
activity over the un-functionalized complex.19 A further increase in activity was
observed upon the introduction of a second chlorine atom depending on its position.
However, the contrasting activities between structural isomers observed in this work
are much greater than in the picolinamide complexes.
3.4.7 Correlations Between Hydrophobicity, Iridium-Cellular
Accumulation and Potency
The complexes studied here are all neutral chlorido species in the presence of
biologically relevant concentrations of chloride. Hydrophobicity can promote
interaction with the lipophilic cell membrane64 and promote hydrophobic
interactions with protein targets.65 In general, the accumulation and potency of
organometallic complexes in cells increases with an increase in their
hydrophobicity.43,59,66,67 The relative hydrophobicity of complexes 2, 4, 7, 8 and 11-
14 (4 pairs of structural isomers) was determined by RP-HPLC (Table 3.7). As RP-
HPLC relies on the relative interaction between the hydrophilic mobile phase and
hydrophobic stationary phase, determination of the relative hydrophobicity of a
series of complexes can be based on retention times. It was found that the nature of
the substituent on the 2-PhPy ligand can dictate the hydrophobicity of the complex,
with hydroxyl complexes 11 and 12 being the least lipophilic, while complexes 13
and 14 bearing methyl groups are the most. Intriguingly, complex 12 appeared to be
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much more hydrophobic than the corresponding structural isomer 11 with retention
times of 17.8 and 15.1 min, respectively (Figure 3.11). It is apparent that not only the
type of substituent but also its position governs the hydrophobicity of the complex.
Figure 3.11. RP-HPLC traces of complexes 11 and 12. Retention times: 11 - 15.1
min and 12 - 17.8 min, showing that the position of the hydroxyl group on the 2-
PhPy ligand affects the hydrophobicity of the complexes.
To examine if structural isomers accumulate in cells to a different extent, the
cellular-iridium accumulation in A2780 cells of 2, 4, 7, 8 and 11-14 was determined
at equipotent (IC50) concentrations (Table 3.8). For isomers 2/4 and 13/14 the levels
of cellular-iridium accumulation are similar, with only small differences between
them. Isomers 7/8 show no difference between their respective iridium
accumulations. However, isomers 11/12 show contrasting levels of cellular-iridium
accumulation, with 12 being accumulated 6× more than 11 (10.2 vs. 1.6 ng Ir/106
A2780 cells).
The hydrophobicity measurements were correlated with cellular-iridium
accumulation in A2780 cells in order to investigate if hydrophobicity is important in
their ability to enter cells (Figure 3.12 a-b). There is a clear relationship between a
higher hydrophobicity and an increase in cellular accumulation (R2 = 0.969). Isomers
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13 and 14 are the most hydrophobic complexes and accumulate in A2780 cells to the
highest extent, while complex 11 with the lowest hydrophobicity showed the lowest
accumulation. It was recently demonstrated that the structurally similar iridium(III)
complex [(η5-Cp*)Ir(7,8-benzoquinoline)Cl] is transported into cells by both energy-
independent passive diffusion and energy-dependent pathways.68 Since an increase
in hydrophobicity results in an increase in cellular accumulation, it is likely that
passive diffusion plays at least a part in the mechanism of cellular accumulation for
these complexes, making hydrophobicity an important design feature.
The cellular-iridium accumulation was correlated with antiproliferative activity in
A2780 cells, which shows that a pattern exists between enhanced accumulation and
increase in potency (Figure 3.12 c). Complex 11 exhibits the lowest cellular
accumulation and second lowest potency (1.58 ng Ir/106 cells, 47.3 µM) and
complex 13 exhibits the highest cellular accumulation and potency (18.46 ng Ir/106
cells, 1.18 µM). In the case of structural isomers 11 and 12, the difference in
hydrophobicity of the complexes as a consequence of changing the position of the
hydroxyl group on the 2-PhPy ligand results in enhanced cellular-accumulation for
the more hydrophobic complex 12 which leads to a more potent complex.
Interestingly, although 2 and 8 exhibit low IC50 values (2.7 µM) they show similar
levels of cellular accumulation to their less potent structural isomers 4 (IC50 > 60
µM) and 7 (IC50 = 24.73 µM). As the iridium accumulation is performed at IC50
concentrations, this may indicate that the mechanism involved in the antiproliferative
activity of complexes 2 and 8 is more efficient over their counterparts 4 and 7.
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Figure 3.12. (a) Structures of complexes studied. (b) Relative hydrophobicity as
indicated by retention times on RP-HPLC against cellular accumulation of iridium at
IC50 concentrations in A2780 cells after exposure to complexes 2, 4, 7, 8 and 11-14
showing a dependence on hydrophobicity for cellular accumulation. (c) Comparison
of cellular accumulation of iridium and antiproliferative activity of complexes 2, 4,
7, 8 and 11-14 in A2780 cells showing a general pattern of higher cellular
accumulation resulting in more potent complexes.
3.4.8 Cellular-Iridium Distribution of Isomers 2 and 4
The distribution of iridium in A2780 human ovarian cancer cells after exposure to
structural isomers [(η5-Cp*)Ir(2-(4ˈ-fluorophenyl)pyridine)Cl] 2 and [(η5-Cp*)Ir(2-
phenyl-5-fluoropyridine)Cl] 4 follows the order of localisation: cytosol > cell
membrane and particulate > nucleus > cytoskeleton (Figure 3.10). Although both
isomers followed the same trend, they do so to different extents. Complex 4 localises
in the cytosol to a greater extent than 2 (69.2% vs. 51.4%), whereas 2 localises in the
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cell membrane and particulate to a greater extent than 4 (28.4% vs. 17.9%). The
variations in localisation preference arising from this small structural change may
reflect the differences observed in antiproliferative activity.69,70 For example, if the
biological target of these complexes is in the cell membrane and particulate fraction
then that may explain why isomer 2 is more active than 4. As the isomers exhibit
dramatically different IC50 values yet both bind to guanine and accumulate in the
nucleus to similar extents, DNA may not be the main biological target. It has also
been shown that halogen-bonding interactions could be important in rational drug
design,71 therefore the position of fluorine within the ligand may influence the way
the complexes interact with biomolecules, leading ultimately to variations in activity.
3.5 Conclusions
Interest in iridium(III) half-sandwich complexes as anticancer agents is increasing,
with new complexes being reported and novel mechanisms of action being
discovered.17,19,30,42,72 This work has focussed on the effects of electron-donating and
electron-withdrawing substituents on C,N-chelating 2-PhPy ligands on the chemical,
physio-chemical and biological activity of their complexes, with notable differences
arising between structural isomers.
DFT calculations show that the nature and position of the substituent has minimal
effect on the electronic charge at the iridium centre, Cp* or chlorido ligands, but
exerts localised changes in the electrostatic potential surface and overall electron
density of the chelating ligand.
The separation of enantiomers of the complexes was attempted and showed that the
chiral resolution using HPLC allows isolation of enantiomerically pure complexes.
Chapter 3
117
However, studies into the stability of the enantiomers once isolated showed that they
epimerise back to a racemic mixture.
All complexes hydrolysed rapidly at 310 K, but almost complete suppression of
aquation can be achieved with 4 mM NaCl implying that under physiological
conditions the complexes would exist as the neutral chlorido species. All complexes
bind strongly to the nucleobase 9-EtG, even in the presence of 4 mM NaCl. The
catalytic oxidation of NADH that was demonstrated is a potential reaction that could
occur in cells, which is an interesting property of some iridium(III) half-sandwich
anticancer complexes.31,32,73,74 The catalytic activity showed a small dependence on
the substituent present on the 2-PhPy ligand, whereby hydroxyl groups slightly
enhanced the catalytic ability of the complex compared to fluorine, which may be
due to a secondary interaction between the hydroxyl groups with NADH. The
oxidation of NADH appears to be mediated through the formation of Ir-H species, as
detected by 1H NMR spectroscopy.
The antiproliferative activity of the complexes is strongly dependent on the type of
substituent and its position on the chelating ligand, giving rise to contrasting
activities between structural isomers despite exhibiting similar chemical behaviour.
The presence of substituents on the 2-PhPy ligand can in some cases generate
complexes that are more potent than those bearing the extended CpxPh ligand, thus
providing an alternative strategy for increasing potency in these systems.
Further physicochemical analysis of these complexes showed that both the nature
and position of substituent can determine their hydrophobicity, and consequently
affect the accumulation of Ir in A2780 cells. Correlation analysis showed that an
increase in hydrophobicity results in an increase in cellular-Ir accumulation, which
generally results in an increase in potency. Cellular-Ir distribution in A2780 cells of
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a pair of structural isomers that exhibit contrasting biological activity yet similar
levels of Ir-accumulation showed that the position of the substituent can affect the
extent of localisation in cellular compartments.
This study shows that small changes in the functionalisation of the chelating ligands
in half-sandwich iridium(III) complexes can have a profound effect on the biological
activity of the complexes. Importantly, it also highlights that the inclusion of
substituents in 2-PhPy ligands can provide complexes with enhanced potency
without the use of extended cyclopentadienyl capping ligands, a strategy that could
be beneficial for the development of this class of complexes.
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Chapter 4
Influence of Chlorido and Pyridyl Monodentate Ligands on
the Properties of the Anticancer Complex
[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)X]0/+
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4.1 Introduction
The most widely employed monodentate ligand in chelated half-sandwich “piano-
stool” complexes is chloride. This is largely as a consequence of the synthetic route
from the metal arene/Cpx dimer using the readily available metal salt MCl3.nH2O (M
= Ru(III), Os(III), Ir(III), Rh(III)).1
Varying the different monodentate ligands in half-sandwich anticancer complexes
bearing three monodentate ligands has led to the development of a vast library of
complexes with various activities.2-6 Well known examples being the
[(η6-arene)Ru(1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane)(Cl)2] RAPTA series of
complexes by Dyson et al.7-10 which has yielded complexes showing promising
activity towards metastatic cancers.
The effect of substituting the chlorido monodentate ligand in chelated half-sandwich
complexes has not been so widely explored.11 Work performed with ruthenium
complexes of the type [(η6-arene)Ru(ethylenediamine)X]0/+ (X=halide, pseudo-
halide, pyridine, thiolate) showed that the ability of the monodentate ligand to
undergo hydrolysis was closely linked to cytotoxic activity, with stable monodentate
adducts commonly leading to inactive complexes.12 Aquation is believed to be a key
activation step for clinical metallodrug cisplatin, allowing it to bind to its proposed
target DNA.13 Osmium complexes of the type
[(η6-arene)Os(phenyliminopyridine)X]PF6+ (X = Cl- or I-) have shown that the
change in halide has little effect on the cytotoxicity of the complex,14 in contrast to
the structurally similar [(η6-arene)Os(phenylazopyridine)X]PF6 (X = Cl- or I-)
complexes in which the presence of the iodido ligand resulted in more potent
complexes than the chlorido analogues.15 Intriguingly, these iodido complexes do
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not hydrolyse, yet exhibit superior antiproliferative activity. As well as affecting
chemical reactivity, it has also been suggested that the monodentate ligand can affect
the transport mechanism in which Ru(II) half-sandwich complexes enter cells.16
The contrasting behaviour of the different monodentate ligands in chelated half-
sandwich iridium(III) complexes has led to the study of pyridine derivatives in place
of the chloride. In contrast to Ru(II) arene complexes, substitution of the chlorido
ligand in complex [(η5-CpxBiPh)Ir(2-PhPy)Cl] with pyridine ([(η5-CpxBiPh)Ir(2-
PhPy)pyridine]PF6) resulted in an increase in potency and selectivity towards A2780
human ovarian cancer cells over MRC5 human fibroblasts (healthy cells).17 This
increase in activity upon introduction of pyridine monodentate ligands was also
observed in the corresponding CpxPh complex.18 These pyridine complexes exhibited
enhanced aqueous stability, with little to no aquation at the monodentate site,
suggesting that enhanced stability could be an important design feature.
This Chapter seeks to investigate the chemical and biological properties that may
lead to enhanced potency in anticancer iridium(III) complexes of the type
[(η5-Cp*)Ir(2-PhPy)Cl] by replacement of the chlorido ligand in the most potent
complex discussed in Chapter 3 [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)Cl] 13,
(IC50 – 1.18 ± 0.08 µM against A2780 cells) with pyridine derivatives (Chart 4.1).
The effect these pyridine derivatives can have on the aqueous chemistry (including
hydrolysis, 9-EtG binding, NADH oxidation and reaction with GSH) and biological
behaviour has been investigated, and compared with the parent chlorido complex.
The lability of the monodentate ligand has also been probed by using pyridine
derivatives bearing either an electron-donating (-NMe2) or electron-withdrawing
group (-CF3).
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Chart 4.1. Ir(III) complexes studied in this Chapter.
4.2 Experimental Section
4.2.1 Materials
4-(Dimethylamino)pyridine (≥99%), 4-(trifluoromethyl)pyridine (97%), ammonium 
hexafluorophosphate (95%), 9-ethylguanine (≥98%), β-nicotinamide adenine
dinucleotide - reduced dipotassium salt (NADH) (≥95%) and L-glutathione reduced 
(GSH) (≥98%) were purchased from Sigma-Aldrich (UK). Pyridine was purchased 
from Fisher Scientific (UK). Solvents used for synthesis were of laboratory grade
and used without further purification. Solvents for HPLC purity examination (water
and acetonitrile) were of HPLC grade with added trifluoroacetic acid which was
purchased from Sigma-Aldrich (UK). Complex 13 was prepared as described in
Chapter 3.
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4.2.2 Synthesis
[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)pyridine]PF6 (18) [(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)Cl] (13) (50 mg, 0.094 mmol) was dissolved in MeOH (20
mL) and H2O (10 mL); silver nitrate (15 mg, 0.092 mmol) was added, the flask was
wrapped in foil and the reaction mixture was heated under reflux and N2 for 1 h.
After cooling to ambient temperature, the reaction mixture was placed in a centrifuge
(9000 RPM, 282 K, 30 min) and the solution was carefully decanted off, leaving
behind an off-white solid. Pyridine (372 mg, 380 µL, 4.7 mmol) was added to the
solution, the flask wrapped in foil and the reaction left stirring under N2 at ambient
temperature for 18 h. Ammonium hexafluorophosphate (76 mg, 0.47 mmol) was
then added and the solvent was allowed to slowly evaporate at ambient temperature
and pressure, yielding the product as a yellow precipitate which was isolated by
filtration under reduced pressure and washed with Et2O (27 mg, 40%). 1H NMR
(300 MHz, acetone-d6) δ = 9.33 (d, 1H, J = 4.2 Hz), 8.61 (dd, 2H, J = 6.5, 1.5 Hz), 
8.28 (d, 1H, J = 8.4 Hz), 8.07 (td, 1H, J = 7.6, 1.6 Hz), 7.97 (d, 1H, J = 7.3 Hz), 7.90
(tt, 1H, J = 7.7, 1.4 Hz), 7.61-7.56 (m, 1H), 7.42-7.38 (m, 2H), 7.28 (t, 1H, J = 7.5
Hz), 7.01 (d, 1H, J = 7.3 Hz), 2.66 (s, 3H), 1.66 (s, 15H). ESI-MS (MeOH) m/z =
575.2 [M-PF6]+. CHN analysis calc. for C27H30N2F6IrP C – 45.06%, H – 4.20%, N –
3.89%. Found C – 44.90%, H – 4.10%, N – 3.84%. HPLC Purity 254 nm – 99.0 %.
[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)4-(dimethylamino)pyridine]PF6 (19)
As for 18 using 4-(dimethylamino)pyridine (574 mg, 4.7 mmol) in place of pyridine.
Slow evaporation yielded yellow needle crystals (41 mg, 57%). 1H NMR (400 MHz,
acetone-d6) δ = 9.26 (dd, 1H, J = 5.7, 1.3 Hz), 8.27 (d, 1H, J = 8.4 Hz), 8.04 (td, 1H, 
J = 7.5, 1.6 Hz), 7.92 (d, 1H, J = 7.5 Hz), 7.86 (d, 2H, J = 7.4 Hz), 7.54 (ddd, 1H, J =
7.2, 5.7, 1.3 Hz), 7.24 (t, 1H, J = 7.5 Hz), 6.99 (d, 1H, J = 7.4 Hz), 6.44 (d, 2H, J =
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7.4 Hz), 2.99 (s, 6H), 2.67 (s, 3H), 1.66 (s, 15H). ESI-MS (MeOH) m/z = 618.1 [M-
PF6]+. CHN analysis calc. for C29H35N3F6IrP C – 45.66%, H – 4.63%, N – 5.51%.
Found C – 45.53%, H – 4.54%, N – 5.52%. HPLC Purity 254 nm – 99.0 %.
Crystals suitable for X-ray diffraction were obtained from a methanol/ether solution
at 278 K.
[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)4-(trifluoromethyl)pyridine]PF6 (20)
As for 18 using 4-(trifluoromethyl)pyridine (691 mg, 544 µL, 4.7 mmol) in place of
pyridine. Slow evaporation yielded yellow crystals (30 mg, 41%). 1H NMR (400
MHz, acetone-d6) δ = 9.35 (dd, 1H, J = 5.7, 1.3 Hz), 8.95 (d, 2H, J = 6.6 Hz), 8.30 
(d, 1H, J = 8.4 Hz), 8.09 (ddd, 1H, J = 8.9, 7.5, 1.6 Hz), 7.98 (d, 1H, J = 7.5 Hz),
7.72 (d, 2H, J = 6.6 Hz), 7.60 (ddd, 1H, J = 7.2, 5.7, 1.3 Hz), 7.30 (t, 1H, J = 7.5 Hz),
7.03 (d, 1H, J = 7.4 Hz), 2.66 (s, 3H), 1.67 (s, 15H). ESI-MS (MeOH) m/z = 643.1
[M-PF6]+. CHN analysis calc. for C28H29N2F9IrP C – 42.69%, H – 3.71%, N –
3.56%. Found C – 42.46%, H – 3.65%, N – 3.54%. HPLC Purity 254 nm – 98.5 %.
4.2.3 Methods
4.2.3.1 X-ray Crystallography
The structure of complex 19 was solved by Dr. Guy Clarkson (Department of
Chemistry, University of Warwick) as described in Chapter 2 (section 2.2.8).
4.2.3.2 HPLC Purity Measurements
HPLC purity determination of complexes 18-20 (ca. 100 μM 10% MeOH/90% H2O
(v/v)) were performed as described in Chapter 2 (section 2.2.5.1).
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4.2.3.3 Aqueous Stability
The stability of complexes 18-20 (ca. 500 µM) in aqueous solution and in the
presence of chloride concentrations representative of blood plasma (104 mM), the
cytoplasm (23 mM) and cell nucleus (4 mM) were determined by 1H NMR
spectroscopy over 24 h. Briefly, complexes were dissolved in 26.7% MeOD-
d4/73.3% D2O (v/v) by dissolution of complexes in MeOD-d4 followed by rapid
dilution with D2O at 310 K and NMR spectra recorded at various time intervals. All
spectra were internally referenced to 1,4-dioxane (3.75 ppm) and water suppression
was performed using Shaka techniques. Calculation of the stability was made by
peak integrations.
4.2.3.4 Reaction with 9-Ethylguanine
The reaction of complexes 18-20 (ca. 500 µM) with 9-EtG (ca. 500 µM) were
studied by 1H NMR spectroscopy. Typically, one mol equiv. of 9-EtG in D2O was
added to a solution of complex in MeOD-d4/D2O to give a final complex
concentration of ca. 500 µM in 26.7% MeOD-d4/73.3% D2O (v/v). All spectra were
internally referenced to 1,4-dioxane (3.75 ppm) and water suppression was
performed using Shaka techniques. 1H NMR spectra were recorded at various time
intervals at 310 K and samples incubated at this temperature during the course of the
reaction. Percentage binding was based on peak integrations.
4.2.3.5 Reaction with Reduced L-glutathione (GSH)
Complexes 13 and 18-20 were assessed for stability in the presence of GSH by RP-
HPLC and LC-MS. The complex was dissolved in MeOH (1.5 mM) and an aliquot
of 100 µL was diluted by addition of H2O (790 µL), 0.5 M Na2HPO4/NaH2PO4
buffer at pH 7.5 (10 µL) and 4.5 mM GSH in H2O (100 µL) to give a final complex
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concentration of 150 µM (1 mol eq.) and GSH concentration of 450 µM (3 mol eq.)
in 5 mM phosphate buffer at pH 7.5, 10% MeOH/90% H2O. Samples were incubated
at 310 K for 24 h. HPLC measurements were made at 1, 4, 8 and 24 h, LC-MS
measurement was taken at 24 h. The instrumentation for LC-MS is described in
Chapter 2 (section 2.2.6). HPLC/LC measurements were made using the Agilent
1200 system with a VWD and 100 μL loop. The column use was an Agilent Zorbax 
Eclipse Plus C18, 150 × 4.6 mm with a 5 μm pore size. The mobile phase was H2O
0.1% TFA and CH3CN 0.1% TFA, with a flow rate of 1 mL min-1. The detection
wavelength was set at 254 nm and the reference wavelength at 360 nm. Sample
injections were half the loop volume (50 μL) for HPLC measurements and either 5 
or 25 μL for LC-MS, with needle washes of MeOH and H2O between injections. The
gradient used is shown in Figure 4.1.
Figure 4.1. HPLC/LC method used for analysis of GSH reactions using H2O 0.1%
TFA (solvent A) and CH3CN 0.1% TFA (solvent B).
4.2.3.6 Catalytic Oxidation of NADH
Complexes 13 and 19 were evaluated for the catalytic oxidation of NADH to NAD+
by UV-Visible spectroscopy over a 24 h period in 0.5% MeOH/99.5% H2O at 310 K
Time (min) %B
0 2
5 2
10 20
20 40
25 40
35 80
40 80
42 2
57 2
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in 5 mM Na2HPO4/NaH2PO4 buffer, pH 7.5. The complex concentration was 2.5 µM
with an NADH concentration of 127 µM. The conversion of NADH to NAD+ was
followed by absorption at 339 nm (εNADH = 6220 cm-1 M-1) to allow evaluation of
kinetic data.
4.2.3.7 Antiproliferative Activity
Antiproliferative activity assays were performed by Dr. Isolda Romero-Canelón
(Department of Chemistry, University of Warwick) as described in Chapter 2
(section 2.2.14.2). Complexes 18-20 were evaluated for activity in the A2780 human
ovarian cancer cell line and compared with complex 13 from Chapter 3. All
complexes were also evaluated for activity in the MRC5 human fibroblast cell line.
4.2.3.8 Total ROS Production in A2780 Cancer Cells
Flow cytometry analysis of total reactive oxygen species (ROS) induction in A2780
cells caused by exposure to complexes 13 and 18-20 was carried out using the Total
ROS/ detection kit (Enzo-life sciences) according to the supplier’s instructions. This
was performed by Dr. Isolda Romero-Canelón (Department of Chemistry, University
of Warwick). Briefly, 1.0 × 106 A2780 cells per well were seeded in a 6-well plate.
Cells were pre-incubated in drug-free media at 310 K for 24 h in a 5% CO2
humidified atmosphere, and then drugs were added to triplicates at concentrations of
IC50. After 24 h of drug exposure, supernatants were removed by suction and cells
were washed and harvested. Staining was achieved by re-suspending the cell pellets
in buffer containing the green fluorescent reagent. Cells were analysed in a Becton
Dickinson FACScan Flow Cytometer using FL1 channel Ex/Em: 490/525nm. Data
were processed using Flowjo software. Positive controls for comparison purposes
were obtained by exposing A2780 cells to pyocyanin for 24 h.
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4.2.3.9 Induction of Apoptosis in A2780 Cancer Cells
Flow cytometry analysis of apoptotic populations of A2780 cells caused by exposure
to complexes 13 and 18-20 with 0 h and 24 h cell recovery time, was carried out
using the Annexin V-FITC Apoptosis Detection Kit (Sigma Aldrich) according to
the supplier’s instructions. This was performed by Dr. Isolda Romero-Canelón
(Department of Chemistry, University of Warwick). Briefly, 1.0 × 106 A2780 cells
per well were seeded in a 6-well plate. Cells were pre-incubated in drug-free media
at 310 K for 24 h, after which drugs were added at equipotent concentrations equal to
IC50 and 2 x IC50. After 24 h of drug exposure, supernatants were removed by
suction and cells were washed with PBS. Finally, cells were harvested using trypsin-
EDTA. Sample staining was achieved by re-suspending the cell pellets in buffer
containing Annexin V-FITC and PI. For positive-apoptosis controls, A2780 cells
were exposed to staurosporine (1 μg mL-1) for 2 h. Cells for apoptosis studies were
used with no previous fixing procedure as to avoid non-specific binding of the
annexin V-FITC conjugate.
4.2.3.10 ICP-OES Analysis
ICP-OES analysis of sample stocks used for biological studies was carried out as
described in Chapter 2 (section 2.2.10).
4.3 Results
4.3.1 Synthesis and Characterisation
Complexes 18-20 bearing pyridyl monodentate ligands were synthesised from the
chlorido complex 13 by reaction with 0.98 mol equiv. of AgNO3 in MeOH/H2O
under reflux, removing the chlorido ligand by precipitation as AgCl and forming the
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corresponding aqua complex. After removal of the AgCl, either 50 mol equiv. of
pyridine (Py), 4-(dimethylamino)pyridine (Py-NMe2) or 4-(trifluoromethyl)pyridine
(Py-CF3) was added to form the desired complex bearing a pyridyl monodentate
ligand. All complexes were isolated as PF6 salts. The complexes were fully
characterised by 1H NMR spectroscopy, ESI-MS, CHN analysis and purity also
determined by HPLC. Complex 13 was prepared as described in Chapter 3. Its
chemical and biological properties are compared with 18-20 in this Chapter.
Analysis of the 1H NMR spectra of complexes 18-20 showed no differences between
the observed chemical shifts of the methyl protons (on the 2-(2ˈ-
methylphenyl)pyridine and Cp* capping ligand) for each complex and little
difference among the aromatic protons on the chelating ligand. The proton adjacent
to the bonding nitrogen on the pyridyl ring of 2-(2ˈ-methylphenyl)pyridine ligand 
showed the greatest variation in chemical shift, ranging from 9.26 ppm to 9.35 ppm.
The X-ray crystal structure of complex 19 was determined and shows the expected
pseudo-octahedral half-sandwich geometry with the iridium bound to the
η5-pentamethylcyclopentadienyl ring (Ir – ring centroid 1.840 Å), the 2-(2ˈ-
methylphenyl)pyridine chelating ligand (Ir – C 2.045(5) Å, Ir – N 2.083(4) Å) and
the Py-NMe2 monodentate ligand (Ir – N 2.106(4) Å). The structure and atom
numbering scheme are shown in Figure 4.2, crystallographic data are shown in Table
4.1 and selected bond angles and lengths shown in Table 4.2. No π-π stacking 
features were observed in the X-ray crystal structure.
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Figure 4.2. X-ray crystal structure with atom numbering scheme for complex [(η5-
Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)4-(dimethylamino)pyridine]PF6 19 with thermal
ellipsoids drawn at 50%. Hydrogen atoms and PF6 counterion have been removed for
clarity.
Table 4.1. Selected X-ray crystallographic data (left) and selected bond lengths (Å)
and bond angles (°) (right) for complex [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)4-
(dimethylamino)pyridine]PF6 19.
19
Formula C29H35F6IrN3P
MW 762.77
Crystal Colour Yellow
Cryst size (mm) 0.12 x 0.10 x 0.04
λ (Å) 0.71073
Temp (K) 150
Cryst system Monoclinic
Space group P2(1)/n
a (Å) 10.1080(2)
b (Å) 19.8098(4)
c (Å) 14.8637(3)
α (°) 90
β (°) 95.0570(19)
γ (°) 90
Vol (Å3) 2964.66(11)
Z 4
R(Fo2) 0.0426
Rw(Fo2) 0.0802
GOF 1.096
Bond/angle 19
Ir-C (Cp* ring) 2.263(5)
2.242(5)
2.173(5)
2.174(5)
2.175(5)
Ir-C (centroid) 1.840
Ir-C 2.045(5)
Ir-N9 (2-PhPy) 2.083(4)
Ir-N16 (monodentate) 2.106(4)
C-Ir-N 9 77.44(19)
C-Ir-N16 (monodentate) 86.24(18)
N9-Ir-N16 (monodentate) 86.18(16)
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4.3.2 Aqueous Stability
The aqueous stability of complexes 18-20 (ca. 500 µM) was examined by 1H NMR
spectroscopy in 26.6% MeOD-d4/73.3% D2O (v/v) at 310 K over 24 h. The stability
could be determined as a function of pyridine release, which was confirmed by the
addition of the relevant pyridyl ligand to the NMR sample. The greatest stability was
observed for complex 18 with 85% of the complex still bearing the pyridyl ligand,
and the lowest for complex 20 with 76% of complex still bearing the pyridyl ligand
(Figure 4.3) after 24 h. The release of the pyridine ligand is slow, in comparison to
13 where the extent of hydrolysis reaches equilibrium within 15 min. A new set of
peaks could be observed in the low-field region which were assumed to be due to the
formation of the aqua species [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)OD2]+ (13A).
However, comparison to the 1H NMR of the chlorido complex 13 under the same
conditions shows that the new peaks do not share the same chemical shift as the
assigned adduct 13A (Figure 4.3).
Analysis of the ESI-MS of solutions of 18-20 after 24 h showed only peaks
associated with [M-PF6]+ (575.1, 618.1 and 643.1 for 18, 19 and 20, respectively)
where the pyridyl ligand is still bound, and the [M-PF6-Pyridyl]+ (496.1) species was
also observed. No aqua species was detected, but this was also the case for complex
13, which exhibits an m/z of 496.1 being the species [M-Cl]+ or [M-OD2]+. Free
chelating ligand was not detected, neither was a peak associated with a hydroxido-
bridge dimers that can occur for half-sandwich metal complexes in aqueous
solution.19,20
The pH* of each solution was measured at 0 h and 24 h to assess if the pyridyl
ligand can change the pH* of the unbuffered solution. Aqua complexes can be
sensitive to changes in pH. The pH* at 0 h was found to be between 7.3-7.5, which
Chapter 4
137
changed to 7.5-7.6 after 24 h for complexes 18-20 compared to pH* 7.5 for complex
13, making the reason for the chemical shifts differing due to a shift in the aqua
complex resonances from changes in pH* unlikely.
Figure 4.3. 1H NMR (600 MHz) spectra of complex [(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)4-(trifluoromethyl)pyridine]PF6 20 (ca. 500 µM) in 26.6%
MeOD-d4/73.3% D2O (v/v), 310 K at 15 min, 1 h, 3 h, 24 h and 24 h + large excess
of Py-4-CF3. Comparison with complex 13 under the same conditions, showing no
formation of expected aqua adduct 13A. Complex 20 = ★,Py-4-CF3 = ●, 13A = ▲ 
and = 13.
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Table 4.3. Percentage of complex (determined by 1H NMR, 600 MHz, 310 K) found
to exhibit either the chloride (13) or pyridyl (18-20) monodentate ligand in solution
after incubation in 26.6% MeOD-d4/73.3% D2O (v/v)) after 24 h.
Complex Monodentate ligand % Ir-Cl/Pyridyl (24 h)
13 Cl- 28a
18 Py 85
19 Py-NMe2 81
20 Py-CF3 76
aDetermined in Chapter 3.
The stability of complexes 18-20 (ca. 500 µM) was also examined at biologically
relevant concentrations of chloride, representing blood plasma (104 mM), the
cytoplasm (23 mM) and the cell nucleus (4 mM) by 1H NMR spectroscopy in 26.6%
MeOD-d4/73.3% D2O (v/v) at 310 K over 24 h (Figure 4.4). No changes in the 1H
NMR spectra were observed for all complexes, indicating no conversion to the
chlorido complex 13.
Figure 4.4. 1H NMR (600 MHz) spectra of complex [(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)pyridine]PF6 18 (ca. 500 µM) in 26.6% MeOD-d4/73.3%
D2O (v/v), 310 K at 24 h with either 0 mM, 4 mM, 23 mM or 104 mM NaCl.
Complex 18 =★, Py = ● and new species = ▲.
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4.3.3 Reaction with Nucleobase 9-Ethylguanine
To assess the reactivity of complexes 18-20 (ca. 500 µM) towards potential
biological targets, the reaction with DNA nucleobase 9-EtG (ca. 500 µM) was
examined by 1H NMR spectroscopy in 26.6% MeOD-d4/73.3% D2O (v/v) at 310 K
over 24 h (Figure 4.5 and Table 4.4). After 15 min, a new set of peaks were observed
and assigned as the 9-EtG adduct (13G) along with the release of the monodentate
pyridyl ligands. Between 22-38% of 13G formed during the reaction. The proton
adjacent to the binding nitrogen on the pyridyl ring of the chelating ligand is shifted
downfield by ca. 0.40 ppm upon binding of 9-EtG, whereas the H8 proton of 9-EtG
is shifted upfield by ca. 0.45 ppm compared to free 9-EtG. After 24 h no further
changes in the spectra were observed, indicating equilibrium between complexes 18-
20 and 13G had been reached within 15 min. ESI-MS of the reaction mixtures
indicated a peak of 675.3 which corresponds to [M-Py-PF6+9-EtG]+ (calculated m/z
= 675.24), confirming binding of the nucleobase.
Table 4.4. Extent of binding of complexes 13 and 18-20 (500 µM) to 9-EtG (500
µM) to form complex 13G as measured by 1H NMR spectroscopy (600 MHz, 26.6%
MeOD-d4/73.3% D2O (v/v), 310 K).
Complex Monodentate ligand % binding to 9-EtG (24 h)a
13 Cl- 100b
18 Py 24
19 Py-NMe2 22
20 Py-CF3 38
aCalculated from peak integral ratios of 13G/(13 or 18-20). bDetermined in Chapter
3.
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Figure 4.5. 600 MHz 1H NMR spectra of the reaction between complex
[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)pyridine]PF6 18 (ca. 500 µM) and 9-EtG
(ca. 500 µM) in 26.6% MeOD-d4/73.3% D2O (v/v), 310 K after 15 min and 24 h.
Complex 18 =★, 13G = ▲ and Py = ●.
4.3.4 Reaction with GSH
The interaction of metal-based drugs with GSH can cause deactivation as in the case
of cisplatin, by inhibiting the metal from reacting with biological targets and by
cellular-efflux mechanisms of metal-GSH adducts.13,21 Complexes 13 and 18-20
were investigated for their reaction with GSH in order to determine if the extent of
reaction is modulated by the type of monondentate ligand bound to the iridium
centre. The reactions of complexes 13 and 18-20 (150 µM) with GSH (450 µM) in
10% MeOH/90% H2O, 5 mM Na2HPO4/Na2HPO4 (pH = 7.5), 310 K were monitored
at different time points by RP-HPLC and the chromatograms are shown in Figure
4.6. Within 1 h, all complexes had begun to react with GSH, as was evident by the
formation of new peaks in the HPLC traces. The new species continued to increase
Chapter 4
141
in intensity during the next 23 h. With the exception of the peaks corresponding to
release of Py, Py-NMe2 and Py-CF3 (18 – tR =2.45min , 19 – tR = 9.80 min and 20 –
tR = 14.04 min, respectively), the reaction with complexes 13 and 18-20 resulted in
traces with almost identical tR. This indicates that the new species formed are likely
to be the same for all complexes.
Figure 4.6. RP-HPLC (H2O 0.1% TFA/ CH3CN 0.1% TFA, λ = 254 nm) traces for 
the reaction of complexes 13 (A), 18 (B), 19 (C) and 20 (D) (150 µM) with GSH
(450 µM) in 10% MeOH/90% H2O, 5 mM Na2HPO4/Na2HPO4 (pH = 7.5), 310 K at
various time intervals. Asterisks (*) indicate peaks that are present for each complex
before incubation with GSH.
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Figure 4.6. RP-HPLC (H2O 0.1% TFA/ CH3CN 0.1% TFA, λ = 254 nm) traces for 
the reaction of complexes 13 (A), 18 (B), 19 (C) and 20 (D) (150 µM) with GSH
(450 µM) in 10% MeOH/90% H2O, 5 mM Na2HPO4/Na2HPO4 (pH = 7.5), 310 K at
various time intervals. Asterisks (*) indicate peaks that are present for each complex
before incubation with GSH.
Determination of the products between the reaction of complex 13 and GSH after
24 h was performed by LC-MS and is shown in Figure 4.7 and Table 4.5. Two of the
peaks (4 and 7) showed no m/z signal that could be identified as either an Ir-
containing species or relevant organic fragment. Peak 8 had an m/z of 817.18 that
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contained the Ir isotopic pattern but could not be assigned. Peak 9 (m/z = 496.12)
corresponds to unreacted complex 13 (calculated m/z {[(η5-Cp*)Ir(2ˈ-
methylphenyl)pyridine)]}+ = 496.16).
Oxidised GSH (GSSG) was observed as peak 1 (m/z 613.17, calculated m/z
{GSSH+H}+ = 613.16). Peak 2 (m/z = 787.58) was assigned as an iridium GSH
bridged dimer, where three molecules of deprotonated GSH (thiolate sulphur atom
deprotonated, forming GS-) bridge two Ir centres which still bear the Cp* capping
ligand ([(η5-Cp*)Ir(µ-SG)3Ir(η5-Cp*)]2-, calculated m/z {[(η5-Cp*)Ir(µ-SG)3Ir(η5-
Cp*)]+4H}2+ = 787.70). The free bidentate ligand that would be released from the
formation of this dimer was detected as peak 3 (m/z = 169.86, calculated m/z {2ˈ-
methylphenyl)pyridine+H}+ = 170.10). Interestingly, peaks 5 (m/z = 819.19) and 6
(m/z = 835.24) were identified to be Ir-SG monodentate adducts where the chelating
ligand is still bound, however, they correspond to the sulfur-oxidised adducts [(η5-
Cp*)Ir(2ˈ-methylphenyl)pyridine)(S-O)G]- (sulfenate) (calculated m/z {[(η5-
Cp*)Ir(2ˈ-methylphenyl)pyridine)(S-O)G]+2H}+ = 819.24) and [(η5-Cp*)Ir(2ˈ-
methylphenyl)pyridine)(S-O2)G]- (sulfinate) (calculated m/z {[(η5-Cp*)Ir(2ˈ-
methylphenyl)pyridine)(S-O2)G]+2H}+ = 835.24). The unoxidised Ir-SG adduct was
not detected.
Integration of each peak that contains an iridium species (as evident from the
isotopic pattern) to determine the change in the amount of that species over time is
shown for complexes 13 and 19 in Figure 4.8. It can be seen that [(η5-Cp*)Ir(µ-
SG)3Ir(η5-Cp*)]2- remains relatively constant over time, and the extent of formation
is less for the reaction with 19 compared to 13. The reaction of 19 with GSH is
shown to be slower than 13 during the first 8 h, as evident by the higher percentage
of peaks associated with unreacted 19 compared with 13. Complexes 18 and 20
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showed little difference in rate of formation of products compared to 13. After 24 h,
the percentage of [(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)(S-O)G]-,
[(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)(S-O2)G]- and the unidentified new Ir species
is relatively the same for both 13 and 19.
Figure 4.7. Peak assignments from LC-MS data of the reaction of complex 13 (150
µM) with GSH (450 µM) in 10% MeOH/90% H2O, 5 mM Na2HPO4/Na2HPO4 (pH
= 7.5), 310 K at 24. Structures of important Ir-containing species are shown with
relevant peak numbers.
Table 4.5. LC-MS analysis for the reaction between complex 13 (1 mol equiv.) and
GSH (3 mol equiv.) under argon after 24 h, 310 K.
Peak m/z Assigned species Calculated
m/z
1 613.17 {GSSG+H}+ 613.16
2 787.58 {[(η5-Cp*)Ir(µ-SG)3Ir(η5-Cp*)]+4H}2+ 787.70
3 169.86 {2-(2ˈ-methylphenyl)pyridine+H}+ 170.10
4 n.d. n.d. n.d.
5 819.19 {[(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)(S-O)G]+2H}+ 819.24
6 835.24 {[(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)(S-O2)G]+2H}+ 835.24
7 n.d. n.d. n.d.
8 817.18 unknown n/a
9 496.12 {[(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)]}+ 496.16
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Figure 4.8. Percentage of each iridium species after various time intervals upon the
reaction of (A) 13 + GSH and (B) 19 + GSH (complex (150 µM), GSH (450 µM) in
10% MeOH/90% H2O, 5 mM Na2HPO4/Na2HPO4 (pH = 7.5), 310 K. Data obtained
by integration of HPLC peaks. The structures of Ir-dimer (green), Ir-(S-O)G (orange)
and Ir-(S-O2)G (red) are shown in Figure 4.7.
The oxidation of the sulfur atom was investigated by performing the reaction of
complex 13 under argon (including degassing solvent under argon), to elucidate
whether the oxygen is coming from O2 present in the atmosphere. The reaction was
left for 24 h and analysed by LC-MS (Figure 4.9 and Table 4.6). Formation of the
[(η5-Cp*)Ir(µ-SG)3Ir(η5-Cp*)]2- dimer (peak 1) occurred alongside release of the
chelating ligand (peak 2). Interestingly, a small peak corresponding to the species
[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)(S-O)G] was observed (peak 6), and no 
formation of [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)(S-O2)G] was detected. Two
new peaks (3 and 5) were observed with an m/z of 801.13 (1+) and 401.13 (2+),
which could correspond to the unoxidised GSH adduct
Chapter 4
146
[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)SG]-. However, {[(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)SG]+2H}+ has a calculated m/z of 803.24. Within the same
peak, m/z of 496.12 and 308.11 were observed which correspond to [(η5-Cp*)Ir(2-
(2ˈ-methylphenyl)pyridine)]+ and free GSH, respectively.
Figure 4.9. LC-MS traces of the reaction of complex 13 (150 µM) with GSH (450
µM) in 10% MeOH/90% H2O, 5 mM Na2HPO4/Na2HPO4 (pH = 7.5), 310 K at 24 h
under argon.
Table 4.6. LC-MS analysis for the reaction between complex 13 (150 µM) with
GSH (450 µM) in 10% MeOH/90% H2O, 5 mM Na2HPO4/Na2HPO4 (pH = 7.5), 310
K at 24 h under argon.
Peak m/z Assigned species Calculated
m/z
1 787.58 {[(η5-Cp*)Ir(µ-SG)3Ir(η5-Cp*)]+4H}2+ 787.70
2 169.84 {2-(2ˈ-methylphenyl)pyridine+H}+ 170.10
3 801.13 {[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)SG]+2H}+ 803.25
4 n.d. n.d. n.d.
5 801.13 {[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)SG]+2H}+ 803.25
401.13 {[(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)SG]+3H}2+ 402.13
496.13 {[(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)]}+ 496.16
308.11 {GSH+H}+ 308.09
6 819.12 {[(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)(S-O)G]+2H}+ 819.24
7 496.15 {[(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)]}+ 496.16
8 496.08 {[(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)]}+ 496.16
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4.3.5 Catalytic Oxidation of NADH to NAD+
Disruption of the NADH/NAD+ ratio in cells appears to be of importance to the
mechanism of action of iridium(III) half-sandwich complexes.17,22 The ability to
catalytically oxidise NADH (127 µM) to NAD+ was examined for complexes 13 and
19 (2.5 µM) by UV-Vis spectroscopy in 0.5% MeOH/99.5% H2O (v/v) in 5 mM
Na2HPO4/Na2HPO4 (pH = 7.5) at 310 K over a 24 h period. The conversion to NAD+
was followed by the decrease of the band at 339 nm which corresponds to NADH
(εNADH = 6220 cm-1 M-1) which allowed the calculation of the turn over number
(TON) and turn over frequency (TOF) (h-1) of the reaction (Figure 4.10). Both 13
and 19 showed mild catalytic activity, although intriguingly, both complexes
exhibited a TON of 16 and TOF of 1.4 h-1.
Figure 4.10. Plot of TON vs. Time for the reaction of complexes 13 (A) and 19 (B)
(2.5 µM) with NADH (127 µM) in 0.5% MeOH/99.5% H2O (v/v) in 5 mM
Na2HPO4/Na2HPO4 (pH = 7.5) at 310 K. TOF (h-1) calculated from the initial
gradient (first 2 h) of TON vs. Time.
4.3.6 Antiproliferative Activity
The antiproliferative activity of complexes 18-20 in A2780 human ovarian cancer
cells was evaluated and compared to complex 13, Table 4.7. The importance of cell
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recovery time was also evaluated by measuring the cell viability after 0 h and 72 h
recovery time (after the initial 24 h drug incubation period). It is evident from Table
4.7 that the complexes exhibit antiproliferative activity rapidly and within 24 h, with
IC50 values ranging from 0.65 – 4.4 µM. With 72 h recovery time, the IC50 values for
complexes 18 and 20 remain virtually the same. For the chlorido complex 13, the 72
h recovery time results in enhanced potency by almost 4 × compared with 0 h
recovery time. In contrast, the potency of complex 19 appears to be slightly reduced
with the 72 h cell recovery time, with the IC50 value increasing from 0.65 to 1.4 µM.
All of the complexes were also evaluated for activity against MRC5 human
fibroblasts, which is representative of healthy, rapidly dividing cells, after 72 h
recovery time. The selectivity factor (SF) of each complex was calculated as the ratio
between IC50 MRC5/IC50 A2780 where a higher SF is indicative of a more selective
complex towards A2780 human ovarian cancer cells over healthy fibroblasts MRC5
(Table 4.7). Small variations in activity were observed in the MRC5 cell line, with
IC50 values ranging from 2.4 – 4.6 μM. The selectivity factor index for complex 13 is
the highest showing the best selectivity (SF = 3.6), while complex 20 exhibits the
least selectivity with an SF of 0.9.
Table 4.7. Inhibition of growth of A2780 human ovarian cancer cells and MRC5
human fibroblast cells (72 h recovery time only) by complexes 13 and 18-.
Selectivity factor (SF) calculated as the ratio between IC50 MRC5/IC50 A2780 after 72 h
recovery time.
Complex Monodentate A2780 IC50 (µM) MRC5 IC50 SF
Ligand 0 h recovery 72 h recovery (µM)
13 Cl- 4.4 ± 0.4 1.18 ± 0.08a 4.6 ± 0.1 3.9
18 Py 2.00 ± 0.06 2.1 ± 0.3 2.4 ± 0.1 1.1
19 Py-NMe2 0.65 ± 0.05 1.4 ± 0.3 2.98 ± 0.04 2.1
20 Py-CF3 3.9+ ± 0.2 4.1 ± 0.9 3.6 ± 0.2 0.9
aEvaluated in Chapter 3.
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4.3.7 Induction of ROS
The induction of high levels of ROS in cancer cells may be related to the mechanism
of action of some anticancer metal complexes,23-25 where an increase of cellular ROS
levels ultimately leads to oxidative stress and cell death. The ability of complexes
13, 18, 19 and 20 to induce ROS in A2780 cells (IC50 values, 24 h incubation, 0 h
recovery time) was measured by flow cytometry and is shown in Figure 4.11. All
complexes induce high levels of ROS (as indicated by high fluorescence in the FL-1
channel reading green fluorescence) compared with untreated cells. Little difference
was observed between the parent complex 13 and pyridyl adducts 18-20. The
elevation of ROS levels is likely to contribute to the antiproliferative mechanism of
these complexes.
Figure 4.11. Induction of total ROS in A2780 cells upon incubation with complexes
13, 18, 19 and 20 (IC50 concentrations, 24 h incubation, 0 h recovery time) as
measured by flow cytometry. Percentage of cells exhibiting normal levels of ROS in
each experiment are indicated by blue bars. Percentage of cells exhibiting enhanced
levels of ROS compared to normal levels are indicated by red bars. The positive
control was pyocyanin. Students t-test for percentage of fluorescence compared with
untreated cells (** indicates p < 0.01)
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4.3.8 Induction of Apoptosis
Induction of programmed cell death (apoptosis) in A2780 cells upon exposure to
complexes 13 and 18-20 at IC50 and 2 × IC50 values for 24 h was determined by flow
cytometry, with either 0 h or 24 h cell recovery time (Figure 4.12). At 0 h recovery
time, a very small population of cells was found to be apoptotic, with the vast
majority being viable. After 24 h recovery time, a significant number of apoptotic
cells were detected from cells incubated with complexes 18 and 19 at IC50
concentrations. At 2 × IC50 concentrations, the percentage of apoptotic cells vastly
increases for 18 and 20. A2780 cells incubated with complex 13 show no significant
induction of apoptosis at either 0 h or 24 h recovery time.
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Figure 4.12. (A) – Flow cytometry dot plots of A2780 cells after exposure to
complex 19 with 0 h recovery time (i – IC50 and ii – 2 × IC50) and 24 h recovery time
(iii – IC50 and iv – 2 × IC50). Q1 = non-viable cells, Q2 = late-apoptotic cells, Q3 =
early-apoptotic cells and Q4 = viable cells. FL-1 channel = Annexin V fluorescence
and FL-2 channel = propidium iodide fluorescence. (B) Percentage of cells in each
quadrant after exposure to complexes 13 and 18-20 for 24 h at (i) IC50 and (ii) 2 ×
IC50 values with 24 h cell recovery time.
4.4 Discussion
4.4.1 X-ray Crystal Structure of Complex 19
The X-ray crystal structure of [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)4-
(dimethylamino)pyridine]PF6 19 shows the expected “piano-stool” conformation for
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pseudo-octahedral half-sandwich complexes, with no notable π-stacking features 
observed in the crystal lattice.
A search of the Cambridge Crystallographic Database showed that this is the first
example of an iridium(III) Cp* complex with a C,N-chelating ligand also bearing a
monondentate pyridine ligand. The Ir – ring centroid (1.840 Å), 2-(2ˈ-
methylphenyl)pyridine chelating ligand (Ir – C 2.045(5) Å, Ir – N 2.083(4) Å) and
the 4-dimethylaminopyridine monodentate ligand (Ir – N 2.106(4) Å) bond lengths
are similar to the previous examples of 2-PhPy with extended CpxPh and CpxBiPh with
pyridine monodentate ligands.17,18 Comparison with the X-ray crystal structures of
[(η5-Cp*)Ir(2-PhPy)Cl] complexes from Chapter 3 show that 19 exhibits similar Ir –
ring centroid and Ir – C/N bond lengths with the chelated 2-PhPy ligand,
demonstrating that little change to the solid-state structure of these complexes occurs
upon the introduction of a pyridyl ligand in place of chloride.
4.4.2 Aqueous Stability
The formation of aqua adducts in half-sandwich metal complexes is believed to be in
many cases an activation step, enabling the metal to bind covalently to possible
biological target sites via the substitution of the relatively more labile M-OH2 (M =
metal) bond.26-28 Previous studies on the aqueous behaviour of half-sandwich
iridium(III) complexes have predominantly focussed on complexes bearing chlorido
ligands.19,29 These have shown that the Ir-Cl bond is surprisingly labile, with fast
rates of ligand exchange with water observed compared to their non-“piano-stool”
octahedral counterparts.30 The fast rate of hydrolysis of complex [(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)Cl] 13 was demonstrated in Chapter 3, with 72% formation
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of the corresponding aqua adduct [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)D2O]+
13A within 15 min, remaining unchanged after 24 h.
The replacement of chlorido with pyridyl ligands in [(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)pyridine]PF6 18, Py-NMe2 [(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)4-(dimethylamino)pyridine]PF6 19 and Py-CF3 [(η5-
Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)4-(trifluoromethyl)pyridine]PF6 20, results in an
increase in the stability towards hydrolysis, with between 76-85% of the species
remaining as the pyridyl adduct over 24 h.
Ruthenium complexes containing N,N-chelating ligands, such as [(η6-
hexamethylbenzene)Ru(ethylenediamine)pyridine](PF6)212 and [(η6-p-
cymene)Ru(2,2ˈ-bipyrimidine)(4-methyl)pyridine](PF6)231 show no formation of
their corresponding aqua adducts, although they also exhibit a decrease in
antiproliferative activity compared to Ru(II) complexes bearing chlorido ligands.
The iridium complex [(η5-CpxPh)Ir(2-phenylpyridine)pyridine]PF6 also shows no
aquation,18 whereas the biphenyl complex [(η5-CpxBiPh)Ir(2-
phenylpyridine)pyridine]PF6 does show a small degree of hydrolysis over 24 h.17
This suggests that the capping Cpx ligand plays a role in governing the stability of
the pyridine adducts in Ir(III) half-sandwich complexes.
Interestingly, the formation of the expected aqua adduct 13A was not observed
(Figure 4.3). Initially, it was considered that the release of Py, Py-NMe2 and Py-CF3
could make the unbuffered aqueous solution more basic, hence resulting in a shift in
the proton resonances corresponding to the aqua complex. Py and Py-NMe2 exhibit
pKa values of 5.2 and 9.7,32 respectively. Analysis of the pH* of the solutions
showed little change compared to complex 13. Ultimately, the species could not be
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identified with certainty using NMR or MS, however, it is clear the complexes
remain predominantly as their initial Ir-pyridyl adducts over 24 h.
The stability of the pyridine complexes 18-20 in the presence of chloride
concentrations representative of the cell nucleus (4 mM), cytoplasm (23 mM) and
blood plasma (104 mM) was also examined to investigate if conversion to parent
complex 13 would occur in biological systems. Complexes 18-20 all showed
complete stability, with no formation of complex 13 detected and the same degree of
the unidentified species observed. This contradicts previous studies of similar
complexes,17 where chloride adducts were formed presumably from the aqua species
formed via hydrolysis rather than by direct substitution of the pyridyl monodentate
ligand. It was found in Chapter 3 that precipitation of the chloride complex could
occur above concentrations of 4 mM NaCl under the conditions studied, which may
result in not detecting the formation of 13. However, no precipitation was observed,
further supporting that conversion to the chloride complex had not occurred.
Complex 20 which exhibits the least aqueous stability (within the pyridyl series)
bears the electron-withdrawing -CF3 group para to the binding nitrogen on the
pyridine ligand. This is likely to increase the lability of the bond between the
nitrogen and iridium centre by electron-withdrawal, leading to enhanced pyridyl loss.
The presence of the electron-donating -NMe2 group para to the binding nitrogen on
the pyridine ligand has the opposite effect, increasing the electron-donating ability of
the pyridine and increasing the stability between the iridium-nitrogen bond.
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4.4.3 Reactions with Biomolecules
4.4.3.1 9-Ethylguanine
Since DNA is considered a major target of metal-based anticancer compounds,
reactivity towards 9-EtG was examined as a model for guanine binding in DNA. All
complexes formed the 9-EtG adduct 13G, with complex 13 exhibiting 100% binding
within 15 min. This is consistent with previous reports of similar complexes.19 The
pyridyl complexes 18-20 show a decrease in the ability to bind to 9-EtG, with only
22-38% formation of 13G after 24 h. This may indicate that pyridyl complexes 18-
20 are less likely to bind to DNA in the cell compared to complex 13 due to the more
stable Ir-N bond.18,31
The electron donating -NMe2 group on the pyridine ligand in complex 19 stabilises
the Ir-N(pyridyl) bond, reducing the reactivity of the complex with 9-EtG. The
opposite effect was observed for complex 20 which bears the electron-withdrawing –
CF3 group, resulting in a greater extent of binding to 9-EtG. The observed reactivity
towards 9-EtG parallels the expected reactivity of each complex 13 > 20 > 18 > 19
showing that modulation of activity towards DNA nucleobases can be achieved by
careful selection of the monodentate ligand.
4.4.3.2 GSH
The concentration of GSH in cells is high, ranging from 0.5 – 10 mM in mammalian
cells.33 The interaction of metallodrugs with GSH can lead to inactivation as in the
case with cisplatin where binding of GSH results in the drug being pumped out of
the cell by specific membrane transport systems,34 while thiolate adducts of cisplatin
exhibit reduced reactivity towards biological targets such as DNA.35 It has also been
demonstrated that glutathione S-transferase π (GSTπ) may play a role in the 
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detoxification of cisplatin by GSH.36 In some cases, reaction of metal complexes
with GSH may be integral to their antiproliferative activity, as in the case for some
octahedral Pt(IV)37 and Ru(III)38 complexes. The half-sandwich ruthenium(II)
complex [(η6-pcym)Ru(azpy)I]PF6 (azpy = N,N-dimethylphenyl- or hydroxyphenyl-
azopyridine) undergoes ligand-centred catalytic oxidation of GSH to GSSG resulting
in enhanced levels of ROS, where coordination of the azpy chelating ligand to the
ruthenium activates its catalytic activity.39 It is believed that adducts of GSH with
iridium complexes such as [(η5-Cpx)Ir(2-PhPy)SG] may also be less reactive,
resulting in the decreased attack on potential biological targets.17 This may be
modulated by the type of monodentate ligand present on the complex.
Within the pyridyl series, the order of stability in the presence of GSH followed from
most to least stable 19 > 18 ~ 20 (Figures 4.6 and 4.8). Complexes 18 and 20 exhibit
a similar degree of reactivity towards GSH compared to chlorido complex 13.
Modulation of reactivity by pyridyl ligands is observed only in the case of 19
indicating that the electron-donating –NMe2 group is essential for enhanced stability
in the presence of GSH. In contrast, the iridium complex [(η5-CpxBiPh)Ir(2-
PhPy)Py]PF6 shows markedly enhanced stability in the presence of GSH compared
to its chlorido analogue [(η5-CpxBiPh)Ir(2-PhPy)Cl].17 This may indicate that the
presence of the extended cyclopentadienyl capping ligand also plays a role in the
reactivity of the pyridine complex towards GSH. This could be due to steric
hindrance caused by the biphenyl rings compared with the Cp* ligand studied in this
work. It has been previously demonstrated that the use of CpxPh and CpxBiPh capping
ligands in some half-sandwich iridium(III) complexes leads to slower rates of
hydrolysis for chlorido complexes.29 This may also result in more stable pyridine
monodentate for CpxBiPh complexes compared with Cp* complexes.
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The reaction of complexes 13 and 18-20 with GSH resulted in HPLC traces with
peaks having almost identical retention times (Figure 4.6), indicating that the
reaction products are independent from the nature of the monodentate ligand. LC-
MS analysis of the reaction between complex 13 and GSH resulted in the
identification of several reaction products (Figure 4.7 and Table 4.5). The
identification of the glutathione bridged Ir dimer [(η5-Cp*)Ir(µ-SG)3Ir(η5-Cp*)]2-
was supported by a peak corresponding to free chelating ligand 2-(2ˈ-
methylphenyl)pyridine. Analysis of the formation of products over time suggests that
the bridged species forms quickly and its concentration stays constant over the 24 h
period. This may suggest that [(η5-Cp*)Ir(µ-SG)3Ir(η5-Cp*)]2- is a kinetic product of
the reaction.
In the presence of air, the Ir-GSH adducts [(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)(S-
O)G]- (sulfenate) and [(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)(S-O2)G]- (sulfinate)
were observed, but no [(η5-Cp*)Ir(2ˈ-methylphenyl)pyridine)SG]- was found. The Ir-
(S-O)G and Ir-(S-O2)G adducts appear to increase over time. As the extinction
coefficient for each species is unknown, the definitive concentration of each species
in solution cannot be determined; however, it can be deduced which species
increase/decrease in concentration during the course of the reaction in relation to the
other species present.
An unidentified Ir-containing species was also observed, which appears to be an
intermediate species, as exemplified in Figure 4.8 for the reaction between 19 and
GSH. Its concentration in solution increases during the first 8 h of reaction, but then
decreases after 24 h. The concentration of this species also decreases over time for
the reaction between 13 and GSH, but initially forms quickly due to the faster
reaction of 13 compared to 19.
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Intriguingly, binding of GSH to the iridium may result in oxidation of the sulfur
atom by dioxygen. This was further examined by performing the reaction under
argon (Figure 4.9 and Table 4.6). LC-MS analysis identified two new peaks that
could correspond to the adduct [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)SG]-. The
peaks contained m/z species including [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)]+
and free GSH, which may be dissociating during the ionisation process. An m/z of
801.13 was detected which is the exact mass of [(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)SG]-. As the LC-MS was run in positive mode, this species is
2 Daltons lower than the detectable species {[(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)SG]+2H}+ (calculated m/z of 803.25). Therefore, it cannot be
determined with certainty that the unoxidised Ir-SG adduct has been detected. The
Ir-(S-O)G adduct was detected as a minor species and no Ir-(S-O2)G was observed,
indicating that the presence of O2 gas is likely to promote the oxidation of the bound
sulfur atom. The small presence of Ir-(S-O)G may be a consequence of the exposure
of the reaction mixture to air upon injection into the LC-MS. These oxidised species
have not been previously reported for half-sandwich Ir(III) complexes unless
coupled with another reaction. Such an oxidation was demonstrated for the iridium
complex [(η5-CpxBiPh)Ir(2-PhPy)Py]PF6, but only when coupled to the catalytic
oxidation of NADH to NAD+ to produce H2O2 where oxidation of the sulfur atom
then occurs.40 Further addition of H2O2 was required to produce the glutathione-
sulfinate adduct.
The Ru(II) arene complex [(η6-biphenyl)Ru(ethylenediamine)Cl]PF6 was shown to
bind to GSH through the thiolate sulfur atom and was oxidised to the sulfenate
complex by dioxygen, although further oxidation to the sulfinate was not observed.28
This resulted in a Ru-(S-O)G adduct that then facilitated the binding to guanine,
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while the Ru-SG adduct did not. Performing the same reaction under argon
supressed the formation of the sulfenate complex. Therefore, it can be postulated that
if complexes 13 and 18-20 are capable of forming these oxidised GSH adducts, their
reactivity may not be severely decreased as the adducts formed may be more labile
than the Ir-SG adduct.
4.4.3.3 Catalytic Oxidation of NADH
The use of platinum-group chelated metal half-sandwich complexes for the catalytic
oxidation of NADH to NAD+22,41,42 and NAD+ to NADH43-45 has been well
documented, where the catalytic activity appears to take place at the monodentate
site. The catalytic oxidation of NADH to NAD+ may be an important feature of half-
sandwich iridium(III) complexes,46 and could potentially occur in cells.22 The
catalytic activity of [(η5-Cp*)Ir(2-PhPy)Cl] complexes was evaluated in Chapter 3.
They can oxidise NADH, potentially contributing to the mechanism of action
responsible for the antiproliferative activity.
The chlorido complex 13 and the less reactive Py-NMe2 complex 19 were
investigated for their catalytic activity towards the oxidation of NADH to NAD+.
Intriguingly, both 13 and 19 exhibited similar catalytic activity, with a TON after 24
h of 16 and TOF of 1.4 h-1 at an NADH concentration of 127 µM (Figure 4.10). This
implies that under the conditions used, the monodentate ligand has little effect on the
catalytic activity of the complex, despite these complexes exhibiting different
reactivities towards aquation, 9-EtG binding and GSH stability. The use of pyridyl
monodentate ligands in place of chloride may protect the complex from possible
deactivation by other reactions that can occur inside the cell (e.g. with GSH,
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proteins), whilst potentially allowing the complex to modulate the ratio of
NADH/NAD+.17,18
4.4.4 Antiproliferative Activity, ROS and Cell Death
The antiproliferative activity of complexes 18-20 was evaluated and compared to
parent complex 13 in the A2780 human ovarian cancer cell line at both 0 h and 72 h
recovery times, Table 4.7.
For pyridyl complexes 18 and 20, the potency of the complexes remains unchanged
for both 0 h and 72 h recovery times. Both complexes induce high levels of ROS in
A2780 cells within 24 h of exposure (Figure 4.11) but show no induction of
apoptosis within this time frame. Therefore, the induction of ROS could activate
another mode of cell death, such as necrosis47,48 or autophagy.49,50 However, it is also
possible that the compounds have arrested cell division during the 24 h incubation
(compared to control cells) without causing cell death, hence no detection of
dying/dead cells. Intriguingly, after 24 h cell recovery time, both 18 and 20 induce
apoptotic cell death (Figure 4.12). This could imply that the ROS induced within the
first 24 h is activating a delayed apoptosis, or, the complexes are exhibiting another
mechanism of antiproliferative action with a delayed response that can activate
apoptotic cell death. Similar wave-like behaviour has been observed by the platinum
complex trans-[PtCl2(NH3)thiazole] where non-apoptotic cell death was followed by
a prolonged period of growth arrest, then induction of apoptosis in the remaining
viable cells.51
Complex 19 which has been shown to be the most chemically stable complex studied
in this work exhibits an IC50 value of 650 nM against A2780 cells after 24 h
incubation time. This remarkably high activity is accompanied by induction of ROS
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and no apoptosis, as in the case of complexes 18 and 20. The activation of apoptosis
was only observed after 24 h of cell recovery during which cells were not exposed to
the complex. In contrast to the other pyridyl complexes, the IC50 value after 72 h
recovery time increases from 0.65 to 1.4 µM. This may imply that the cellular
damage or cell arrest incurred within the first 24 h is “reversible” and hence the cells
are able to recover and proliferate.
The parent chlorido complex 13 exhibits an IC50 value of 4.4 µM with 0 h recovery
time and 1.18 µM after 72 h recovery time. Complex 13 also induces high levels of
ROS after 24 h incubation period, but does not show any induction of apoptosis at
either 0 h or 24 h cell recovery time, in contrast to the pyridyl complexes 18-20. This
may imply that apoptosis is not activated in the mechanism of 13, or that the
apoptosis is even further delayed. As the potency of complex 13 increases with time,
this suggests that it is slower at exhibiting its antiproliferative activity than pyridyl
complexes 18-20. This implies that the greater stability of the pyridyl complexes
initially results in more potent systems and may show faster cytotoxic activity, which
may be a result of protection from deactivating reactions that may occur.
These results indicate that replacement of the chlorido ligand with pyridyl
derivatives can result in the enhancement of potency, where the potency at 0 h
recovery time after 24 h incubation with the Ir complexes is related to the stability of
the monodentate ligand (19 > 18 > 20 > 13) and appears to be independent of the
activation of apoptosis, potentially demonstrating cytostatic activity rather than
cytotoxic activity. Therefore, the monodentate ligand can play a dramatic role in the
biological behaviour of these half-sandwich iridium(III) complexes.
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4.4.5 Selectivity of Complexes Towards A2780 Cancer Cells
The selectivity towards A2780 cells over healthy cells for the pyridyl complexes
followed the order 19 > 18 > 20 (SF = 2.1, 1.1 and 0.9, respectively). There is a trend
in selectivity with greater stability of the pyridyl monodentate ligand resulting in a
more selective complex. However, parent chloride complex 13 showed the best
selectivity (SF = 3.9), despite containing the more labile chlorido ligand. Therefore,
no enhancement in selectivity occurs by replacement of the chlorido ligand with the
more stable pyridyl ligands, in contrast to iridium complex [(η5-CpxBiPh)Ir(2-
PhPy)pyridine]PF6 vis-a-vis its chloride analogue (SF of 13 vs 4).17 This may
indicate that the presence of the CpxBiPh capping ligand may play a role in governing
the selectivity of the complex in parallel with the choice of monodentate ligand.
4.5 Conclusions
The importance of incorporating different monodentate ligands in chelated half-
sandwich complexes is evident, with not only modulation of reactivity18,31 but also
cell transport mechanisms being affected.16
In this Chapter, the monodentate ligands pyridine, 4-(dimethylamino)pyridine and
4-(trifluoromethyl)pyridine were used to replace the chlorido ligand in the potent
complex [(η5-Cp*)Ir(2-(2ˈ-methylphenyl)pyridine)Cl] 13 to investigate the effects on
aqueous stability, reactivity towards potential biological targets and biological
behaviour, with the aim of increasing potency and selectivity.
The pyridyl containing complexes 18-20 all exhibit enhanced stability in aqueous
solution (76-85%) compared to parent chlorido complex 13 (28%) with respect to the
release of the monodentate ligand. The rate at which the pyridyl ligands dissociate
from the complexes are also dramatically slowed compared to the quickly reached
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(within 15 min) equilibrium between Ir-Cl and Ir-OD2/OD for 13. Upon release of
the pyridyl ligand, the formation of the aqua complex 13A does not appear to be the
new species (as determined by 1H NMR spectroscopy), although the identity of the
new species was not determined. The pyridyl complexes also resist conversion to the
parent complex in concentrations of chloride mimicking biologically relevant
conditions.
Complexes 18-20 show less binding to the guanine derivative 9-EtG (22-38%) than
the chlorido complex (100%), and an electron-donating -NMe2 substituent on the
pyridine ligand enhances the stability towards reaction with GSH. The general trend
in stability follows the order of 19 (Py-NMe2) > 18 (Py)> 20 (Py-CF3)> 13 (Cl-),
which correlates with the type of monodentate ligand present on the complex. The
electron-donating -NMe2 group in 19 stabilises the bonding of the monodentate
ligand, whereas the electron-withdrawing –CF3 group in 20 decreases the stability of
the bond. This shows that modulation of chemical reactivity at the monodentate site
can be achieved by careful selection of the ligands used.
Although the products of the reaction with GSH are independent of the
monondentate ligand, these complexes show the interesting property of promoting
the oxidation of the sulfur atom in the presence of O2. The formation of glutathione
sulfenate and glutathione sulfinate adducts, which have been shown to be more labile
than metal-SG adducts in Ru(II) arene systems,28 may allow the complex to perform
its antiproliferative mechanism without being deactivated.
Replacement of the chlorido ligand with pyridine derivatives can result in the
enhancement of antiproliferative activity.17,18 In this work, the potency after 0 h
recovery time is directly related to the stability of the Ir bond to the monodentate
ligand (19 > 18 > 20 > 13) and appears to be independent on the activation of
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apoptosis, potentially demonstrating cytostatic activity. The activity after 72 h
recovery time shows no correlation with stability. The generation of ROS is likely to
be a contributing factor to the antiproliferative activity of all of the complexes during
the initial 24 h incubation. The cell recovery time does not affect the potency of
complexes 18 and 20, but prolonged recovery decreases the activity of 19 and
enhances the activity of 13. Induction of apoptosis is only observed after 24 h for 18-
20, suggesting that they cause cell death at a faster rate than the parent complex 13.
Therefore, these monodentate ligands can play a dramatic role in the biological
behaviour of half-sandwich iridium(III) complexes.
Intriguing differences in the biological behaviour observed for these structurally
similar Cp* iridium(III) complexes arise from the use of different monodentate
ligands. The antiproliferative activity can be partially rationalised by the greater
stability of the pyridyl complexes, but further study is warranted to understand fully
the biological behaviour of these complexes.
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Chapter 5
Conjugation of the Anticancer Complex
[(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] to
Amines
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5.1 Introduction
The conjugation of organic molecules to metal complexes for biological use can
bestow new properties on the resulting complex, such as enhanced aqueous
solubility, selectivity towards cancer cells (receptor mediated delivery),1 and
delivery of the complex to a particular organelle.2 This has been widely
demonstrated with Pt(II) and Pt(IV) anticancer complexes.3,4 It has also been
demonstrated that peptides can be conjugated to metal complexes which can enhance
specific uptake5-7 and for example, localise preferentially into the cell nucleus by
attachment of nuclear localisation sequence (NLS) peptides.8
Half-sandwich iridium(III) complexes have shown great promise as anticancer
agents.9,10 More specifically, complexes of the type [(η5-Cpx)Ir(2-PhPy)Cl] (Cpx =
Cp*, CpxPh, CpxBiPh) have shown potent activity against A2780 human ovarian
cancer cells.11-13 The functionalisation of these complexes could allow further
exploration of their biological behaviour (i.e. fluorescent studies) and could further
enhance their suitability as potential drug candidates via enhancing their selectivity
through targeted delivery. Ruiz et al. demonstrated the functionalisiation of half-
sandwich complexes through addition of the levonorgestrel group to 2-PhPy by
Sonogashira coupling, followed by metallation of the functionalised 2-PhPy
chelating ligand to form the corresponding C,N-chelated Ru(II), Rh(III) and Ir(III)
piano-stool complexes.14,15 This “pre-modification” route has the advantage of not
interfering with the chemistry that the metal centre can exhibit, particularly at the
more labile monodentate site. However, the disadvantage is that each complex has to
be made from different functionalised chelating ligands.
Chapter 5
170
The alternative “post-modification” route requires a functional group on the metal
complex that would react specifically with the moiety being conjugated, minimising
any side-reactions that could occur. Previous examples of this have been shown by
Metzle-Nolte et al. using Sonogashira coupling16 and “click chemistry”17 in
ferrocene and octahedral complexes. An approach which has gained some interest is
the exploitation of the reactivity of aldehydes with primary amino groups to form
Schiff base complexes, which has been demonstrated in square-planar Pt(II)18 and
octahedral Ir(III)19 complexes. In both cases, reduction of the imine bond to the
secondary amine was achieved using a hydride source, forming hydrolytically stable
compounds.
This chapter aims to explore the post-modification of chelated half-sandwich Ir(III)
complexes by exploiting the reactivity of an aldehyde moiety on the chelating ligand
as a proof-of-concept. The reaction of a range of primary aliphatic and aromatic
amines (including a fluorescent dansyl derivative) with complex [(η5-Cp*)Ir(2-
phenyl-5-pyridinecarboxaldehyde)Cl] 6 has been performed using microwave-
assisted chemistry. The high reactivity of amines with aldehydes should result in
reduced binding of the amines toward the metal centre. The new conjugates were
characterised by 1H NMR spectroscopy, ESI-MS/HRMS and combustion analysis.
The reaction of an amine with an aldehyde results in imine bonds which are known
to be hydrolytically unstable, especially at low pH. The synthesis of a water stable
fluorescent secondary amine conjugate has been investigated using different
reduction techniques, which has led to the study of the fluorescence of the complex
in A2780 human ovarian cancer cells. Finally, an investigation into the reaction of
the aldehyde moiety with lysine residues in the peptides Substance P and [Lys-3]-
bombesin to form Ir-peptide conjugates is described. The new conjugates have been
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characterised by ultra-high resolution Fourier Transform – Ion Cyclotron Resonance
(FT-ICR) MS/MS techniques. The outline of the work performed in this Chapter is
shown in Scheme 5.1.
Scheme 5.1. Outline of the work carried out in this chapter, involving the synthesis
of new Schiff base conjugates arising from complex [(η5-Cp*)Ir(2-phenyl-5-
pyridinecarboxaldehyde)Cl] 6 with primary amines. Investigations include aqueous
stability, reduction to the secondary amine derivative and evaluating potential
applications of a fluorescent conjugate. Evaluation of the reaction of complex 6 with
lysine-containing peptides by FT-ICR-MS is also performed.
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5.2 Experimental Section
5.2.1 Materials
2-Aminophenol (99%), 4-aminophenol (≥98%), 4-(4-aminophenyl)-butyric acid 
(95%), 2-aminoethanol (99%), 2-aminoethanesulfonic acid (≥99%), tyramine (99%), 
ethylenediamine, dansyl chloride (≥99%), triethylsilane (99%), Pd(OAc)2 (≥99%) 
Substance P and [Lys-3]-bombesin were purchased from Sigma-Aldrich (UK). 2-
Methoxyethylamine was purchased from VWR International (UK). Solvents used for
synthesis were of laboratory grade and used without further purification. Solvents for
HPLC purity test and peptide incubations (water and acetonitrile) were of HPLC
grade with added trifluoroacetic acid or ammonium acetate which was purchased
from Sigma-Aldrich (UK). The synthesis of N-(2-aminoethyl)-5-
(dimethylamino)naphthalene-1-sulfonamide was performed according to a literature
procedure.20 Complex [(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] 6 was
synthesised as described in Chapter 3.
5.2.2 Synthesis
[(η5-Cp*)Ir(4-(((6-phenylpyridin-3-yl)methylene)amino)phenol)Cl] (21)
Complex 6 (25 mg, 0.0458 mmol) was dissolved in acetone (5 mL) in a microwave
vial, followed by addition of 4-aminophenol (6 mg, 0.055 mmol). The solution was
stirred for 5 min to ensure complete dissolution before being placed in the
microwave instrument (393 K, 150 W, 250 psi, 5 min). The reaction mixture was
then transferred to a round bottom flask and evaporated to dryness on a rotary
evaporator. MeOH (1 mL) was added and the solution was sonicated for 30 s
resulting in the formation of an orange precipitate. This was collected by filtration
under reduced pressure and washed with hexane yielding the product as an orange
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solid (15 mg, 51%). 1H NMR (400 MHz, acetone-d6) δ = 9.28 (d, 1H, J = 1.2 Hz), 
8.78 (s, 1H), 8.66 (bs, 1H), 8.32 (dd, 1H, J = 8.5, 1.5 Hz), 8.12 (d, 1H, J = 8.3 Hz),
7.85-7.81 (m, 2H), 7.33 (d, 2H, J = 8.6 Hz), 7.15 (t, 1H, J = 7.8 Hz), 7.01 (t, 1H, J =
7.6 Hz), 6.92 (d, 2H, J = 8.6 Hz), 1.71 (s, 15H). ESI-MS (MeOH) m/z = 601.2 [M-
Cl]+. CHN analysis calc. for C28H28N2ClIrO.CH3OH C – 52.12%, H – 4.83%, N –
4.19%. Found C – 51.98%, H – 4.39%, N – 4.33%.
[(η5-Cp*)Ir(4-(4-(((6-phenylpyridin-3-yl)methylene)amino)phenyl)butanoic
acid)Cl] (22) As for 21 using complex 6 (30 mg, 0.055 mmol), CHCl3 (10 mL), 4-
(4-aminophenyl)butyric acid (12 mg, 0.066 mmol) (dissolution aided by brief
sonication). The product was collected by filtration under reduced pressure and
washed with hexane yielding the product as an orange solid (15 mg, 39%). 1H NMR
(400 MHz, dmso-d6) δ = 12.18 (bs, 1H), 9.18 (s, 1H), 8.85 (s, 1H), 8.33 (d, 1H J = 
8.6 Hz), 8.22 (d, 1H, J = 8.6 Hz), 7.89 (d, 1H, J = 7.7 Hz), 7.75 (d, 1H, J = 7.7 Hz),
7.33 (d, 2H, J = 8.2 Hz), 7.28 (d, 2H, J = 8.2 Hz), 7.16 (t, 1H, J = 7.6 Hz), 7.03 (t,
1H, J = 7.5 Hz), 2.63 (t, 2H, J = 7.4 Hz), 2.24 (t, 2H, J = 7.3 Hz), 1.82 (quin, 2H, J =
7.6 Hz), 1.64 (s, 15H). ESI-MS (MeOH) m/z = 671.2 [M-Cl]+. CHN analysis calc.
for C32H34N2ClIrO2 C – 54.42%, H – 4.85%, N – 3.97%. Found C – 54.10%, H –
4.91%, N – 3.92%.
[(η5-Cp*)Ir(2-(((6-phenylpyridin-3-yl)methylene)amino)ethan-1-ol)Cl] (23) As
for 21 using complex 6 (50 mg, 0.0917 mmol), CHCl3 (8 mL), ethanolamine (6.72
mg, 6.64 µL, 0.11 mmol). The product was collected by filtration under reduced
pressure and washed with hexane yielding the product as an orange solid (30 mg,
56%). 1H NMR (400 MHz, dmso-d6) δ = 9.02 (s, 1H), 8.49 (s, 1H), 8.15 (bs, 2H), 
7.85 (d, 1H, J = 7.5 Hz), 7.72 (d, 1H, J = 7.6 Hz), 7.14 (t, 1H, J = 7.5 Hz), 7.01 (t,
1H, J = 7.5 Hz), 4.70 (t, 1H, J = 5.0 Hz), 3.70 (bs, 4H), 1.61 (s, 15H). ESI-MS
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(MeOH) m/z = 553.2 [M-Cl]+. CHN analysis calc. for C24H28N2ClIrO.0.1CHCl3 C –
48.24%, H – 4.72%, N – 4.67%. Found C – 48.06%, H – 4.68%, N – 4.64%.
[(η5-Cp*)Ir(N-(2-methoxyethyl)-1-(6-phenylpyridin-3-yl)methanimine)Cl] (24)
As for 21 using complex 6 (50 mg, 0.0917 mmol), CHCl3 (8 mL), 2-
methoxyethylamine (8.26 mg, 9.56 µL, 0.11 mmol). The product was collected by
filtration under reduced pressure and washed with hexane yielding the product as an
orange solid (26 mg, 47%).1H NMR (400 MHz, dmso-d6) δ = 9.01 (s, 1H), 8.51 (s, 
1H), 8.16 (bs, 2H), 7.85 (d, 1H, J = 7.5 Hz), 7.73 (d, 1H, J = 7.4 Hz), 7.15 (t, 1H, J =
7.2 Hz), 7.01 (t, 1H, J = 7.3 Hz), 3.79 (bs, 2H), 3.64 (bs, 1H), 3.28 (s, 3H), 1.61 (s,
15H). ESI-MS (MeOH) m/z = 567.2 [M-Cl]+. CHN analysis calc. for
C25H30N2ClIrO C – 49.86%, H – 5.02%, N – 4.65%. Found C – 49.55%, H – 4.92%,
N – 4.49%.
[(η5-Cp*)Ir(4-(2-(((6-phenylpyridin-3-yl)methylene)amino)ethyl)phenol)Cl] (25)
As for 21 using complex 6 (50 mg, 0.0917 mmol), CHCl3 (8 mL), tyramine (15 mg,
0.11 mmol). The product was collected by filtration under reduced pressure and
washed with hexane yielding the product as an orange solid (30 mg, 49%). 1H NMR
(400 MHz, acetone-d6) δ = 9.09 (s, 1H), 8.33 (s, 1H), 8.13 (d, 1H, J = 8.5 Hz), 8.05 
(d, 1H, J = 8.3 Hz), 7.81 (d, 1H, J = 7.3 Hz), 7.79 (d, 1H, J = 7.2 Hz), 7.13 (t, 1H, J =
7.6 Hz), 7.09 (d, 1H, J = 8.3 Hz), 6.99 (t, 1H, J = 7.5 Hz), 6.75 (d, 2H, J = 8.4Hz),
3.92-3.82 (m, 2H), 2.94-2.90 (m, 2H), 1.68 (s, 15H). ESI-MS (MeOH) m/z = 629.2
[M-Cl]+. CHN analysis calc. for C30H32N2ClIrO.0.25hexane C – 55.17%, H –
5.22%, N – 4.08%. Found C – 55.31%, H – 5.22%, N – 4.20%.
[(η5-Cp*)Ir(5-(dimethylamino)-N-(2-(((6-phenylpyridin-3-
yl)methylene)amino)ethyl)naphthalene-1-sulfonamide)Cl] (26) As for 21 using
complex 6 (60 mg, 0.110 mmol), CHCl3 (10 mL), N-(2-aminoethyl)-5-
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(dimethylamino)naphthalene-1-sulfonamide (39 mg, 0.132 mmol). The product was
collected by filtration under reduced pressure and washed with hexane yielding the
product as an orange solid (65 mg, 72%).1H NMR (400 MHz, acetone-d6) δ = 8.99 
(d, 1H, J = 1.2 Hz), 8.56 (d, 1H, J = 8.4 Hz), 8.35 (d, 1H, J = 8.6 Hz), 8.26 (dd, 1H, J
= 7.3, 0.9 Hz), 8.12 (s, 1H), 8.01 (d, 1H, J = 8.5 Hz), 7.90 (dd, 1H, J = 8.4, 1.7 Hz),
7.82-7.79 (m, 2H), 7.64 (t, 1H, J = 8.0 Hz), 7.52 (t, 1H, J = 8.2 Hz), 7.23 (d, 1H, J =
7.4 Hz), 7.14 (td, 1H, J = 7.5, 0.9 Hz), 7.00 (t, 1H, J = 7.3 Hz), 6.84 (t, 1H, J = 6.2
Hz), 3.59 (m, 2H), 3.34 (q, 2H, J = 6.1 Hz), 2.87 (s, 6H), 1.68 (s, 15H). ESI-MS
(MeOH) m/z = 785.2 [M-Cl]+. HR-MS (MeOH) calc. for C36H40N4IrO2S+ m/z –
785.2496. Found m/z – 785.2512. CHN analysis calc. for C36H40N4ClIrO2S C –
52.70%, H – 4.91%, N – 6.83%. Found C –52.36%, H – 5.23%, N – 6.47%.
5-(dimethylamino)-N-(2-(((6-phenylpyridin-3-
yl)methylene)amino)ethyl)naphthalene-1-sulfonamide (L26) 2-Phenyl-5-
pyridinecarboxaldehyde (130 mg, 0.71 mmol) was dissolved in CHCl3 (14 mL) in a
microwave vial. N-(2-aminoethyl)-5-(dimethylamino)naphthalene-1-sulfonamide
(208 mg, 0.71 mmol) was added and stirred for 5 min, then placed in the microwave
instrument (393 K, 150 W, 250 psi, 5 min). The reaction mixture was concentrated to
dryness to yield the product which was used without further purification (310 mg,
95%). 1H NMR (400 MHz, acetone-d6) δ = 8.68 (s, 1H), 8.54 (d, 1H, J = 8.5 Hz), 
8.35 (d, 1H, J = 8.9 Hz), 8.27 (d, 1H, J = 7.2 Hz), 8.17 (d, 2H, J = 7.6 Hz), 7.93 (bs,
3H), 7.62 (t, 1H, J = 7.8 Hz), 7.53-7.45 (m, 4H), 7.18 (d, 1H, J = 7.4 Hz), 6.87 (t,
1H, J = 4.8 Hz), 3.54 (t, 2H, J = 5.8 Hz), 3.35 (q, 2H, J = 5.4 Hz), 2.84 (s, 6H).
Purity = 98.8% based on 1H NMR. ESI-MS (MeOH) m/z = 459.2 [M+H]+.
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[(η5-Cp*)Ir(5-(dimethylamino)-N-(2-(((6-phenylpyridin-3-
yl)methyl)amino)ethyl)naphthalene-1-sulfonamide)Cl] (27) Complex 26 (60 mg,
0.073 mmol) was dissolved in EtOH (25 mL) under an N2 atmosphere, followed by
addition of triethylsilane (13 mg, 17.52 µL, 0.1097 mmol) and stirring for 5 min.
Pd(OAc)2 (1.64 mg, 0.0073 mmol) was added and the reaction mixture was stirred at
ambient temperature for 30 min. The solution was evaporated to dryness on a rotary
evaporator, the crude mixture was dissolved in DCM (10 mL) and purified by
automated flash silica chromatography using the conditions as described in the
methods section of this chapter (section 5.2.3.2). Product fractions were combined
and evaporated to dryness on a rotary evaporator, yielding a yellow solid (20 mg,
33%). 1H NMR (400 MHz, acetone-d6) δ = 8.66 (s, 1H), 8.56 (d, 1H, J = 8.7 Hz), 
8.40 (d, 1H, J = 8.7 Hz), 8.24 (d, 1H, J = 7.3 Hz), 7.87 (d, 1H, J = 8.4 Hz), 7.75 (d,
1H, J = 7.6 Hz), 7.72 (d, 1H, J = 7.7 Hz), 7.65-7.57 (m, 3H), 7.25 (d, 1H, J = 7.6
Hz), 7.09 (t, 1H, J = 7.2 Hz), 6.96 (t, 1H, J = 7.2 Hz), 6.70 (bs, 1H), 3.63 (s, 2H),
3.04 (t, 2H, J = 5.9 Hz), 2.85 (s, 6H), 2.64 (q, 2H, J = 5.6 Hz), 1.63 (s, 15H). ESI-
MS (MeOH) m/z = 787.2 [M-Cl]+. HR-MS (MeOH) calc. for C36H42N4IrO2S+ m/z –
787.2652. Found m/z – 787.2649. CHN analysis calc. for C36H42N2ClIrO.0.5CH2Cl2
C – 50.69%, H – 5.01%, N – 6.48%. Found C – 50.43%, H – 4.90%, N – 6.43%.
5.2.3 Methods
5.2.3.1 Automated Flash Silica Chromatography
Purification of complex 27 was carried out using the Biotage Isolera One instrument,
fitted with a UV-vis detector (detection λ = 254 nm) and running the Spektra 
package employing dichloromethane and methanol as elution solvents on a SNAP
KP-Sil 25g column. Briefly, the following conditions were used; equilibration of
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column (4 column volumes (CVs)) with 100 % of dichloromethane, elution of
product with a gradient of 0 % methanol to 10 % methanol over 10 CVs and then
holding at 10 % methanol for 4 CVs.
5.2.3.2 HPLC Purity Measurement
HPLC purity measurement of complex 27 (100 μM, 10% MeCN/90% H2O v/v) was
performed as described in Chapter 2 (section 2.2.5.1).
5.2.3.3 Aqueous Stability
The stability of complexes 21-27 (ca. 500 µM) in aqueous solution was determined
by 1H NMR spectroscopy at 298 K. Briefly, complexes were dissolved in 10%
dmso-d6/90% D2O (v/v) by dissolution of complexes in dmso-d6 (5 mM) followed
by rapid dilution with D2O at either pH 7.5, 6.2 or 4.1. All spectra were internally
referenced to 1,4-dioxane (3.75 ppm) and water suppression was performed using
Shaka techniques.21 Percentage of hydrolysis of the imine/secondary amine bond
was based on peak integrations.
5.2.3.4 UV-Vis Spectroscopy
The UV-vis spectra of complexes 6, 26 and 27 and N-(2-aminoethyl)-5-
(dimethylamino)naphthalene-1-sulfonamide in DCM and 10% MeOH/90% H2O v/v
(50 μM) were acquired as described in Chapter 2 (section 2.2.7). 
5.2.3.5 Fluorescence Measurements
Fluorescence emission spectra of complexes 6, 26 and 27 (50 μM) and N-(2-
aminoethyl)-5-(dimethylamino)naphthalene-1-sulfonamide (5 μM) in DCM and 10% 
MeOH/90% H2O (v/v) for 27 and N-(2-aminoethyl)-5-(dimethylamino)naphthalene-
1-sulfonamide (50 μM) were recorded on a Jasco FP-6500 fluorimeter using quartz 
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cuvettes. Spectra were acquired using the excitation wavelengths reported in section
5.3.8, using excitation and emission slits at 3 nm and 5 nm, respectively. The
response time was set at 0.5 s, sensitivity to medium, and scanning speed of 500 nm
min-1.
5.2.3.6 Antiproliferative Activity
Antiproliferative activity assays for complex 27 against A2780 human ovarian
cancer cells were performed by Dr. Isolda Romero-Canelón (Department of
Chemistry, University of Warwick) as described in Chapter 2 (section 2.2.14.2). The
concentration of the stock solution was determined by ICP-OES measurements.
5.2.3.7 Epifluorescence Microscopy of A2780 Cells
This work was performed by Dr. Carlos Sanchez-Cano (Department of Chemistry,
University of Warwick). A2780 ovarian carcinoma cells were seeded on 4-well
microscopy chambers (10000 cells/well; 500 µL supplemented RPMI 1640
medium), left to attach for 24 h, and then treated with 2 x IC50 of complex 27 for
another 24 h. After treatment, medium was removed, cells washed twice with PBS
and fixed with 4% paraformaldehyde solution (20 min at RT). Cell nuclei were
stained using Propidium Iodide (0.1mg mL-1; 10 min at RT; λex = 535 nm/λem =
617 nm) followed by two washes with PBS. Cells were imaged in an IX71 Olympus
microscope using a 100 x objective.
5.2.3.8 ICP-OES Analysis
ICP-OES analyses were carried out as described in Chapter 2. Calibrants were
freshly prepared at concentrations of 1000, 800, 600, 400, 200 and 100 ppb which
were spiked with NaCl to match the salt content of the samples being analysed.
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5.2.3.9 Reactions of Complex 6 with Peptides
Complex 6 (250 μM, MeCN) was incubated with either Substance P or [Lys-3]-
bombesin (1 mM, H2O) at 310 K for 24 h. The reaction solution was then analysed
by UHR-MS (section 5.2.3.10).
RP-HPLC was employed on the incubation of 6 with [Lys-3]-bombesin, using the
Agilent 1200 system with a VDW and 100 μL loop. The column used was an Agilent 
ZORBAX Eclipse Plus C18, 150 × 4.6 mm with a 5 μm pore size. Mobile phase 
used was 2 mM NH4OAc H2O/ MeCN. Flow rate was 1 mL min-1 and the detection
wavelength was set at 254 nm with the reference wavelength at 360 nm. Sample
injections were half the loop volume (50 μL). Solvent gradient used was as described 
for purity determination (section 2.2.5.1).
5.2.3.10 Ultra-High Resolution - Mass Spectrometry (UHR-MS)
Analysis of the reactions between complex 6 and peptides Substance P and [Lys-3]-
bombesin were performed using Fourier Transform Ion Cyclotron Resonance Mass
Spectrometry (FT-ICR-MS) by Mr. Christopher Wootton (Department of Chemistry,
University of Warwick).
Nano-spray (nESI) Mass spectrometry was performed on a Bruker SolariX FT-ICR
MS fitted with an Apollo II Ion source and a 12 Tesla actively-shielded magnet
(Bruker Daltonics, Bremen, Germany). Aqueous Peptide samples (5 μM) were 
spiked with 0.3% formic acid to aid in effective ionisation during nESI. Ir containing
samples were sprayed in ACN with no added acid. Full MS spectra were externally
calibrated using a mass spectrum of Agilent tune-mix (Agilent), calibration constants
from the tune-mix spectrum were then applied to spectra of interest.
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For CAD MS/MS,22 the species of interest were isolated in the first quadrupole and
accelerated into the hexapole collision cell for Collisionally Activated Dissociation
(CAD) 10-30 V and continuously accumulated for 0.1-4 s before transfer to the
Infinity Cell© for detection.
For ECD MS/MS,23 the species of interest were isolated in the first quadrupole,
externally accumulated in the collision cell for 0.1-7 s and then transferred to the
Infinity Cell© for Electron Capture Dissociation (ECD) fragmentation and detection.
Ions in the Infinity Cell© were irradiated with 1.3 eV (peptides) - 2.5 eV (Ir adducts)
electrons from a 1.5 A hollow cathode dispenser for 50-1200 mS.
The notation used to describe the peptide fragments from both CAD and ECD
MS/MS experiments are descried in Scheme 5.2.24 For CAD, the notation used for
the fragments left along the N-C and C-N directions is bn an yn, respectively, where
n = number of amino acids left in the peptide. For ECD, the notation used for the
fragments left along the N-C and C-N directions is cn an zn, respectively, where n =
number of amino acids left in the peptide.
MS/MS spectra were internally calibrated using the minimal number of unmodified
(peptide spectra) or modified (Ir adduct spectra) B/C ions and the charge reduced
species [M+nH]n-1+· where possible (species used for calibration are marked) .
Scheme 5.2. Peptide fragmentation notation used for both CAD and ECD MS/MS
experiments.
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5.3 Results
5.3.1 Reaction of Complex 6 with Ethanolamine
The reactivity of complex [(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] 6
bearing an aldehyde on the pyridyl ring towards the formation of the Schiff base
conjugate with ethanolamine (ca 1:1 mol equiv.), was examined by 1H NMR
spectroscopy in CDCl3 at 298 K over 21 h (Figure 5.1). Within 20 min a new set of
peaks had formed, which continued to grow in intensity over the following 21 h. The
formation of the peak at 8.35 ppm is indicative of the H-C=N proton in an imine
which accompanies the decrease of the CHO peak (10.04 ppm) of complex 6. The
formation of the Schiff base results in an overall high-field shift of the 2-PhPy
protons, with the H6 proton on the pyridyl ring shifting by 0.15 ppm. ESI-MS
analysis of the reaction mixture showed an m/z of 553.3 which corresponds to the
Schiff base conjugate [(η5-Cp*)Ir(2-(((6-phenylpyridin-3-yl)methylene)amino)ethan-
1-ol)]+. The reaction was also accompanied by a colour change, from red to orange.
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Figure 5.1. Low-field region of the 1H NMR spectum (400 MHz, CDCl3) for the
reaction between [(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] 6 (1 mol
equiv.) and ethanolamine (1 mol equiv.) at 298 K after various times.
5.3.2 Synthesis and Characterisation of Schiff Base Conjugates
The microwave-assisted synthesis of new Schiff base conjugates originating from
complex 6 was explored. The organic amines used in the Schiff base reactions along
with the reaction conditions and outcomes of each reaction are listed in Table 5.1.
The amines were selected to include aliphatic and aromatic amines, as well as to
provide a fluorescent tag (dansyl group) to aid in investigation of biologically
relevant interactions. These experiments resulted in the isolation and characterisation
of six Schiff base conjugates 21-26 after 5 min reaction time (Figure 5.2). It was
found that purification of the new complexes could be best achieved by evaporating
off the solvent to dryness, followed by the addition of ca 1 mL of MeOH with brief
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sonication (30 s). This resulted in precipitation of the complexes as orange solids in
moderate to good yields ranging from 39-72%.
Only two of the amines attempted did not yield Schiff base conjugates. Reaction of 6
with 2-aminophenol and 2-aminoethanesulfonic acid resulted in no detectable
product peaks by either 1H NMR or ESI-MS.
Table 5.1. Amines and reaction conditions used to synthesise Schiff base conjugates
of [(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] 6 (1 mol equiv.) (microwave
power setting of 150 W, 250 psi, 393 K and reaction time of 5 min).
Amine (1.2 mol equiv.) Solvent Yield of complex
after purification
4-aminophenol CHCl3 0%
4-aminophenol acetone 51% (21)
2-aminophenol CHCl3 0%
2-aminophenol acetone 0%
2-aminophenol MeOH 0%
4-(4-aminophenyl)butyric acid CHCl3 39% (22)
ethanolamine MeOH 0%
ethanolamine CHCl3 56% (23)
2-methoxyethylamine CHCl3 47% (24)
tyramine CHCl3 49% (25)
N-(2-aminoethyl)-5-
(dimethylamino)naphthalene-1-sulfonamide
CHCl3 72% (26)
2-aminoethanesulfonic acid CHCl3 0%
2-aminoethanesulfonic acid DMF 0%
2-aminoethanesulfonic acid MeOH 0%
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Figure 5.2. Scheme for reaction of complex 6 with the corresponding amines using
microwave-assisted synthesis (150 W, 250 psi, 393 K, 5 min) and the structures of
the isolated Schiff base conjugates 21-26.
Proton assignments were made using 1H-1H COSY measurements, that provided a
near complete assignment of the spectrum as demonstrated for complex
[(η5-Cp*)Ir(5-(dimethylamino)-N-(2-(((6-phenylpyridin-3-yl)methylene)amino)-
ethyl)naphthalene-1-sulfonamide)Cl] 26 in Figure 5.3. Coupling of the aliphatic
protons Hj to NHk was observed. The Hi protons in complex 26 exhibit a
complicated splitting pattern that can be assigned as two overlapping doublet of
triplets of doublets (dtd), where each Hi proton appears magnetically inequivalent,
resulting in 2J (13.9 Hz), 3J (5.6 Hz) and 4J (1.2 Hz) coupling to the Hi, Hj and Hh
protons, respectively, as shown in Figure 5.3 b. This was not observed for complexes
21-25.
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Figure 5.3. (A) Low-field region and (B) high-field region of 1H-1H COSY
assignment (400 MHz, acetone-d6) for [(η5-Cp*)Ir(5-(dimethylamino)-N-(2-(((6-
phenylpyridin-3-yl)methylene)amino)ethyl)naphthalene-1-sulfonamide)Cl] 26.
The synthesis of complex 26 was also attempted via a “pre-functionalisation” route
by reaction of [(η5-Cp*)IrCl2]2 with the dansyl-conjugated 2-PhPy chelating ligand
(L26) using the same conditions as described in Chapter 3 (Figure 5.4 a) The
synthesis of L26 was performed using the same synthetic procedure as for complex
26. Evaporating the solvent to dryness yielded L26 with a purity of 98.8% based on
1H NMR spectroscopy and was used without further purification. After the reaction
between [(η5-Cp*)IrCl2]2 and L26, the crude reaction mixture was analysed by 1H
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NMR. Multiple species were present in solution based on the 1H NMR spectrum
(Figure 5.4 b), including multiple Cp* peaks, indicating multiple binding modes.
Comparison to the 1H NMR spectrum of complex 26 showed little similarities in
chemical shift, implying that the desired complex had not formed during the reaction
to any appreciable extent.
Figure 5.4. (A) – Reaction scheme for the synthesis of complex 26 using L26. (B)
1H NMR (400 MHz, acetone-d6) of products formed from the reaction indicating
multiple Ir containing species.
5.3.3 Aqueous Stability of Schiff Base Conjugates
The stability of complexes 21-26 (500 µM) was investigated by 1H NMR
spectroscopy in 10% dmso-d6/90% D2O at pH* 7.5 (5 mM Na2HPO4/NaH2PO4),
pH* 6.2 and pH* 4.1 (not buffered) at 298 K over 24 h. Hydrolysis at the metal
centre appears to be supressed in the presence of high concentrations of dmso,
allowing for direct study of the stability of the imine bond. The hydrolysis of the
imine bond in complex [(η5-Cp*)Ir(4-(((6-phenylpyridin-3-yl)methylene)amino)-
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phenol)Cl] 21 at pH* 7.5 is shown in Figure 5.5 and the percentage of hydrolysis for
each complex at various time periods and at different pH* values are shown in
Figure 5.6.
Figure 5.5. 1H NMR spectrum (600 MHz, 10% dmso-d6/90% D2O) of [(η5-Cp*)Ir(4-
(((6-phenylpyridin-3-yl)methylene)amino)phenol)Cl] 21 (ca. 500 μM) in 5 mM 
Na2HPO4/NaH2PO4 buffer, pH* 7.5 after various times, indicating hydrolysis of the
imine bond in 21 forming aldehyde complex 6 and free 4-aminophenol (appears as a
converging AB system so only one chemical shift).
On decreasing the pH*, the percentage of hydrolysis products generally increases
after 15 min reaction time. After 3 h, complexes 23-26 which contain aliphatic amine
conjugates exhibit the greatest extent of hydrolysis at pH* 7.5, which was also the
case at 24 h. For complexes 21 and 22 which were synthesised from aromatic
amines, the rate of hydrolysis is greatest at more acidic pH* over the 24 h reaction
time. In particular, complex 22 showed greatly enhanced hydrolysis at pH* 6.2 and
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4.1 after just 15 min, with over 97% of imine hydrolysis occurring. Analysis of the
pH* of each solution after 24 h showed that in the unbuffered solutions the pH* of
complexes 23-26 had shifted from 4.1 and 6.2 to between 9.4-10.2, while for
complexes 21 and 22 the pH* had shifted to 7.5 and 5.7, respectively.
Figure 5.6. Percentage of imine bond hydrolysis for complexes 21-26 as determined
by 1H NMR spectroscopy (600 MHz, 10% dmso/90% H2O) at pH* 7.5 (5 mM
Na2HPO4/NaH2PO4) - orange, 6.2 - green and 4.1 - blue. A – 15 min, B – 3 h and C
– 24 h
5.3.4 Reduction of Schiff Base 26 to Secondary Amine 27
Reduction of Schiff base complex [(η5-Cp*)Ir(5-(dimethylamino)-N-(2-(((6-
phenylpyridin-3-yl)methylene)amino)ethyl)naphthalene-1-sulfonamide)Cl] 26 to the
corresponding secondary amine was performed to stabilise the fluorescent tag
towards hydrolysis. The traditional method for reducing imines to the corresponding
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secondary amine generally involves using a hydride source such as NaBH4 or
NaCNBH3. Reduction using the milder NaCNBH3 (10 mol equiv) was attempted on
complex 26 in THF under N2 at ambient temperature for 1 d. Purification by
precipitation of a CHCl3 solution with hexane resulted in many products and was
deemed unsuitable for this system.
An alternative route was attempted for the reduction using triethylsilane (1.5 mol
equiv) with Pd(OAc)2 (10% cat.) in EtOH at ambient temperature under N2, where
the reduction of organic imines to secondary amines has been reported to occur
within 20 min reaction time.25 Within 30 min, complete reduction of complex 26 to
[(η5-Cp*)Ir(5-(dimethylamino)-N-(2-(((6-phenylpyridin-3-yl)methyl)amino)ethyl)-
naphthalene-1-sulfonamide)Cl] 27 had occurred as monitored by ESI-MS.
Purification of complex 27 was attempted by recrystallisation from acetone/ether,
MeOH/ether, CHCl3/hexane, DCM/hexane and THF/pentane mixtures at different
temperatures, but pure 27 was not isolated. Purification by silica column
chromatography was attempted which yielded purified product as determined by 1H
NMR spectroscopy, HR-MS, and HPLC (94%). A comparison of the 1H NMR
spectra of complexes 26 and 27 are shown in Figure 5.7 alongside the HR-MS
spectra for each complex. The RP-HPLC trace of complex 27 (100 µM in 10%
MeCN/90% H2O) is shown in Figure 5.8. Upon reduction, the imine proton
resonance of 26 (8.12 ppm) was no longer visible and a singlet at 3.63 ppm with an
integration of two H was present in 27, corresponding to the reduced CH2 (Hh). The
pyridyl protons Hg and Hf are also shifted to high-field by 0.33 and ca. 0.40 ppm,
respectively. The reduction of 26 to 27 was also confirmed by HR-MS (m/z = [M-
Cl]+) where a 2 Dalton shift was observed (785.2512 and 787.2649 for complexes 26
and 27, respectively).
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Figure 5.7. 1H NMR spectra (400 MHz, acetone-d6) of complexes 26 and 27 with
assignments of protons for complex 27 based on a 1H-1H COSY experiment (i –
high-field region and ii – low field region of complex 27). HR-MS of complexes (iii)
26 and (iv) 27 showing that the reduction of the imine bond to the secondary amine
has occurred. Top trace shows observed MS and bottom trace shows simulated MS
trace for [M-Cl]+.
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Figure 5.8. RP-HPLC trace of complex 27 (100 µM) in 10% MeCN/90% H2O v/v
(purity = 94%).
5.3.5 Reaction between Complex 26 and Et3SiH
As Et3SiH can act as a hydride donor, with the potential to form an Ir-H species with
26, the stability of 26 in the presence of Et3SiH was also examined without the
Pd(OAc)2 catalyst. After 2 h, ESI-MS confirmed that reduction to the secondary
amine complex 27 had occurred. The crude 1H NMR of the reaction indicated that
the same species had formed when compared with the product isolated using the
Pd(II) catalyst (Figure 5.9 a). The reaction mixture also contained a new set of peaks
for the triethylsilyl species (0.95 (Ha) and 0.59 (Hb) ppm), along with a quartet (Hc)
at 3.68 ppm which appears to couple to a proton (Hd) (as observed in the 1H-1H
COSY spectrum, Figure 5.9 b) which overlaps with the residual ethanol solvent
(triplet, 1.12 ppm).26 The 1H-1H COSY NMR spectrum also showed two different
proton environments are present at around 1.12 ppm both coupled to two different
quartet peaks. Integration of the CH3 peaks in the new triethylsilyl species to nine
results in the integration of 2H for the new quartet peak at 3.68 ppm. This could
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indicate that the new triethylsilyl species is the ethoxy species Et3SiOEt. Assignment
of the new silyl species was attempted by positive mode ESI-MS (50-500 MW) but
no mass peak was detected that could correspond to a silyl species.
Figure 5.9. (A) 1H NMR (400 MHz, acetone-d6) spectra of the crude reaction
mixture between complex 26 (1 mol equiv.) and Et3SiH (1.5 mol equiv.) at ambient
temperature for 2 h and comparison to the reaction of complex 26 with Et3SiH and
cat. Pd(OAc)2 (27) showing the same product is formed. (B) 1H-1H COSY NMR
spectrum of the crude reaction mixture, showing the identification of a new ethyl
species which may correspond to Et3SiOEt.
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The reaction was also followed by 1H NMR spectroscopy (600 MHz, 298 K,
ethanol-d6) for complex 26 and 13 (control – no reducible bond) (Figure 5.10 and
5.11, respectively). The reduction of complex 26 was complete within 10 min, as
monitored by the disappearance of the original set of peaks for 26. No iridium-
hydride species was detected throughout the reaction. Another set of peaks also
formed after reduction of the imine bond had occurred, along with a slight down-
field shift in the original product peaks. Et3SiH is almost fully converted to the new
species after 30 min, as observed by the small high-field shift in the ethyl protons
(Figure 5.10 b). No peaks formed which correspond to the new siliyl adduct, which
may be due to the formation of Et3SiOCD2CD3 as the ethanol present in the reaction
is deuterated.
Figure 5.10. (A) Low field region of the 1H NMR spectrum (600 MHz, ethanol-d6,
298 K) of complex 26 (1 mol equiv.) with Et3SiH (1.5 mol equiv.) at various time
intervals. (b) High field region of reaction showing the conversion of Et3SiH to
another silyl species.
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In contrast, incubation of complex 13 with Et3SiH resulted in an iridium-hydride
peak at -12.46 ppm together with the corresponding new peaks for the Cp* and 2-
PhPy chelating ligand, were also visible within the time taken to acquire the first
spectrum (5 min) (Figure 5.11). As observed with 26, Et3SiH appears to be almost
fully converted to the hypothesised Et3SiOCD2CD3 species.
Figure 5.11. 1H NMR spectrum (600 MHz, ethanol-d6, 298 K) at various times
during the reaction between complex 13 and Et3SiH (1.5 mol equiv.), showing the
formation of the Ir-H complex 13-H after 5 min.
The reduction of the imine bond in L26 was attempted using 10% mol cat. of
complex 13 with Et3SiH (1.5 mol equiv) in ethanol at ambient temperature to
determine if 13 can catalytically reduce imine bonds in the presence of Et3SiH. The
reduction of L26 was also examined using Pd(OAc)2 (10% mol cat.) with Et3SiH
(1.5 mol equiv) and also in the presence of just Et3SiH. After 30 min, the reduction
of L26 in the presence of complex 13 was complete as monitored by ESI-MS and 1H
NMR spectroscopy (Figure 5.12). Intriguingly, no reduction had occurred in the
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presence of the Pd catalyst, even after 24 h, whereas partial reduction of L26 by just
Et3SiH was observed after 24 h.
Figure 5.12. 1H NMR (400 MHz, acetone-d6) spectra of (A) L26 and (B) reaction
between L26 + 10% mol cat. 13 + Et3SiH (1.5 mol equiv) in ethanol at ambient
temperature after 30 min.
5.3.6 Aqueous Stability of Complex 27
The aqueous stability of the secondary amine bond in complex 27 was monitored at
15 min, 24 h and 21 d in 5 mM Na2HPO4/NaH2PO4 buffer, pH 7.5, ambient
temperature by 1H NMR spectroscopy (10% dmso-d6/90% D2O), Figure 5.13. No
change in the spectrum was observed after 24 h and only minimal change after 21 d
compared to the first spectra taken (15 min), indicating that complex 27 exhibits the
expected aqueous stability compared to the hydrolytically unstable imine bond of 26.
The small changes in the spectra are likely due to competition between dmso and
aqua adducts over time.
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Figure 5.13. Stability of complex 27 monitored by 1H NMR spectroscopy (10%
dmso-d6/90% D2O) in 5 mM Na2HPO4/NaH2PO4 buffer, pH 7.5 after 15 min, 24 h
and 21 d.
5.3.7 Fluorescence of Complexes 6, 26 and 27
The luminescence properties of complexes 6, 26 and 27 were investigated in DCM
and compared to the free dansyl-amine tag (N-(2-aminoethyl)-5-
(dimethylamino)naphthalene-1-sulfonamide). UV-Vis spectra of all the compounds
(50 µM, 298 K) were recorded and the observed bands used to excite the compounds
to measure for fluorescence. The excitation wavelengths that produced the most
intense fluorescence for each compound are indicated on the UV-vis spectra in
Figure 5.14 a, where the observed fluorescence (Figure 5.14 b) and the resulting
normalised fluorescence emission spectra (Figure 5.14 c) for each compound at 5
µM for the dansyl-amine tag and 50 µM for complexes 26 and 27 are shown. Both
complexes 26 and 27 exhibited fluorescence, where the emission maximum (em
λmax) was the same at 503 nm, while the em λmax for the dansyl-amine was found at
490 nm. The complexes exhibit markedly reduced fluorescence compared to the free
dansyl-amine. No fluorescence was observed for complex 6.
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Figure 5.14. (a) UV-Vis spectra of dansyl-amine (orange dash) and complexes 26
(green dot), 27 (blue dash-dot) and 6 (purple dash) in DCM at (50 µM, 298 K) with
labelled bands being responsible for the most intense fluorescence when used to
excite the compounds. (b) Fluorescence emission spectra of dansyl-amine (5 µM)
and complexes 26 and 27 (50 µM) in DCM, 298 K (after subtraction from the DCM
blank). (c) Normalised fluorescence emission of dansyl-amine (5 µM) and
complexes 26 and 27 (50 µM).
The intensity of fluorescence for complex 27 and dansyl-amine (ca. 50 µM) were
recorded in aqueous solution (10% MeOH, 90% H2O) and are shown in Figure 5.15,
where the excitation wavelengths used for 27 and dansyl-amine were 252 nm and
246 nm, respectively. Both the dansyl-amine and 27 exhibited markedly reduced
fluorescence in aqueous solution in comparison to DCM, where the fluorescence of
27 is almost completely quenched.
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Figure 5.15. Fluorescence emission spectra of dansyl-amine (red) and complex 27
(blue) at 50 µM in 10% MeOH/90% H2O. Emission at 504 nm for complex 27 due to
excitation at 252 nm (2×λex).
5.3.8 Epifluorescence Microscopy of A2780 Cancer Cells
The ability to track complex 27 in A2780 human ovarian cancer cells was
investigated by epifluorescence microscopy. The antiproliferative activity for 27 was
determined, with an IC50 of 4.9 ± 0.2 μM, making it a reasonably potent complex. 
The cells were exposed to 27 at 2 × IC50 for 24 h, followed by fixing, staining with
propidium iodide (PI, nuclear stain) then imaging, Figure 5.16. Only
autofluorescence was observed upon excitation under UV light, demonstrating no
fluorescence due to complex 27. The control propidium iodide (PI) fluoresced upon
excitation under green light showing PI binding to DNA.
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Figure 5.16. A – control A2780 cells imaged as (i) brightfield and (ii) λex = UV
where autofluoresence was observed. B – A2780 cells stained with PI (i) brightfield
and (ii) λex = green light exhibiting fluorescence in the nucleus. C – A2780 cells
incubated with complex 27 at 2 × IC50 for 24 h (i) brightfield and (ii) λex = UV
exhibiting autofluorescence. D – A2780 cells incubated with complex 27 followed
by PI (i) brightfield, (ii) λex = UV and (iii) λex = green light. Bar = 10 microns. Only
autofluorescence was observed in cells incubated with 27 indicating no fluorescence
due to 27.
5.3.9 Reactions with Lysine-Containing Peptides
Organic compounds bearing aldehyde functional groups can react with peptides and
proteins which contain lysine residues, forming Schiff base conjugates.27,28 The
reaction of Substance P (SubP) and [Lys-3]-bombesin (L3BBS) (as model peptides
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containing lysine residues) with complex 6 after 24 h (310 K) was studied by Fourier
Transform-Ion Cyclotron Resonance (FT-ICR), using Collisionally Activated
Dissociation (CAD)22 and Electron Capture Dissociation (ECD)23 MS/MS
techniques to determine the binding sites on each peptide. In all cases, the molecular
ion peak obtained involved the loss of the chlorido monodentate ligand in detection
of the species [(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] 6, Schiff base
modifications of complex 6, and when direct binding of the peptide at the
monodentate site occurs. The denotations used to describe the species analysed are
shown in Table 5.2. Potential binding sites on Substance P and [Lys-3]-bombesin
upon reaction with metal complexes are highlighted in Figure 5.17a and include
histidine29,30 and methionine31 residues, which bind at the metal centre, as well as the
proposed reaction of lysine to the aldehyde functional group. The structures of
potential Ir-peptide conjugates are shown in Figure 5.17b.
Table 5.2. The denotations used to describe the species analysed by FT-ICR-MS in
the forthcoming MS spectra.
Species Denotation Species Denotation
[6*]+ [Peptide+6*-
H2O]+
[Peptide+6*]+ [(2×Peptide)
+6*-H2O]+
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Figure 5.17. (a) Substance P and [Lys-3]-bombesin. Potential binding sites are
highlighted on the peptide and in bold in the amino acid letter code. (b) Structures of
the possible Ir-peptide conjugates upon reaction with complex 6.
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Incubation of complex 6 (165 μM, MeCN, 66% v/v) with Substance P (330 μM, 
H2O, 33% v/v) at 310 K after 24 h led to the detection of the species [SubP+6*-
H2O+H]2+ (m/z = 918.92794, calculated m/z = 918.93143). The loss of a water
molecule is indicative of a condensation reaction such as Schiff base formation. The
Ir-peptide conjugate can be fragmented along the peptide backbone using CAD
MS/MS to deduce the binding site of the iridium complex. The notation is described
in section 5.2.3.10, where b = number of amino acids left in the peptide along the N-
C direction and y = number of amino acids left in the peptide along the C-N
direction.24 When the iridium isotopic pattern and mass of the complex are absent
after the fragmentation of a particular amino acid indicates the binding site of the
complex on the peptide. The fragmentation of the Ir-peptide conjugate narrows the
binding site of the iridium complex to lysine (Figure 5.19, mass table in Appendix
Table A1). No adducts were observed for Substance P binding at the monodentate
site. Therefore, the Ir-peptide conjugate 6+SubP-H2O appears to be the product of
the reaction (Figure 5.17 b (i)).
Figure 5.18. nESI-MS of the reaction between complex 6 and Substance P at 310 K
after 24 h, indicating that binding of the peptide to complex 6 has occurred.
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Figure 5.19. FT-ICR CAD MS/MS spectrum of the species [SubP+6*-H2O+H]2+
showing binding of the peptide via the lysine (K) residue as a consequence of Schiff
base formation with complex 6. The Ir-peptide conjugate is fragmented along the
peptide backbone, where b = number of amino acids left in the peptide along the N-
C direction and y = number of amino acids left in the peptide along the C-N
direction, allowing for precise determination of the binding site. The orange boxes in
the fragmentation map indicate the iridiated peptide fragments observed in the
MS/MS.
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Incubation of complex 6 (165 μM, MeCN, 66% v/v) with [Lys-3]-bombesin (330 
μM, H2O, 33% v/v) at 310 K after 24 h led to a more complicated spectrum (Figure
5.20), with MS peaks corresponding to the condensation product [L3BBS+6*-
H2O+H]2+ (m/z = 1040.96930, calculated m/z = 1040.97182) as well as the
[L3BBS+6*+H]2+ species (m/z = 1049.97710, calculated m/z = 1049.97406),
indicating binding to the complex in two different ways. FT-ICR CAD MS/MS was
used to assign the species [L3BBS+6*-H2O+H]2+ which is bound via the lysine
residue (Figure 5.21, mass table in Appendix Table A2) as expected. Therefore, one
of the products from the reaction is likely to be 6+L3BBS-H2O (Figure 5.17 b (iii)).
Assignment of the binding site for the species [L3BBS+6*+H]2+ proved difficult for
the incubated sample, due to the presence of unreacted peptide. Separation of the
species present was attempted using RP-HPLC (Figure 5.22 a). The peak in the
chromatogram which contained the highest degree of metal-peptide species
[L3BBS+6*-H2O+H]2+ and [L3BBS+6*+H]2+ (with minimal free L3BBS, as
determined using nESI-MS) was used to analyse the [L3BBS+6*+H]2+ binding
mode. Analysis of the [L3BBS+6+H]2+ species by FT-ICR-ECD MS/MS showed
binding via the histidine residue (Figure 5.22 b, mass table in Appendix Table A3),
therefore, the species is likely to be 6*+L3BBS(His) (Figure 5.17 b (v)). Similarly to
CAD, the fragments in ECD are labelled as such; c = number of amino acids left in
the peptide along the N-C direction and z = number of amino acids left in the peptide
along the C-N direction.24
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Figure 5.20. nESI-MS of the reaction between complex 6 and [Lys-3]-bombesin at
310 K after 24 h, indicating that more than one binding mode to complex 6 has
occurred.
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Figure 5.21. FT-ICR CAD MS/MS spectrum of the species [L3BBS+6*-H2O+H]2+
showing binding of the peptide via the lysine (K) residue as a consequence of Schiff
base formation with complex 6. The Ir-peptide conjugate is fragmented along the
peptide backbone, where b = number of amino acids left in the peptide along the N-
C direction and y = number of amino acids left in the peptide along the C-N
direction, allowing for precise determination of the binding site. The orange boxes in
the fragmentation map indicate the iridiated peptide fragments observed in the
MS/MS.
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Figure 5.22. (A) RP-HPLC (2 mM NH4OAc H2O/MeCN, sig = 254 nm) of the reaction between complex 6 and L3BBS after 24 h. (B) FT-ICR
ECD MS/MS spectrum of the species [L3BBS+6*+H]2+ as isolated by HPLC, showing binding of the peptide via the histidine (H) residue as a
consequence of binding at the monodentate site on complex 6. The Ir-peptide conjugate is fragmented along the peptide backbone, where c =
number of amino acids left in the peptide along the N-C direction and z = number of amino acids left in the peptide along the C-N direction,
allowing for precise determination of the binding site. The green boxes in the fragmentation map indicate the iridiated peptide fragments
observed in the MS/MS.
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5.4 Discussion
5.4.1 Synthesis and Characterisation of Complexes 21-26
The use of complex [(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] 6 as a
“chemical platform” for modification via formation of Schiff bases with amines was
assessed using microwave-assisted chemistry. Microwave synthesis allows reactions
to proceed at a faster rate than traditional laboratory techniques, which has been
attributed to the capacity to reach higher temperatures, as well as the ability to
induce increased solvent molecular vibrations.32
The reaction of 6 (1 mol equiv.) with amines (1.2 mol equiv., Table 5.1) produced
six novel Schiff base conjugates from both aromatic and aliphatic primary amines
within 5 min reaction time. Using traditional laboratory techniques, the formation of
imine conjugates is relatively straightforward, however, reaction times can range
from 1 – 24 h. CHCl3 and acetone were found to be the most suitable solvents
examined.
Sonication of a concentrated methanolic solution resulted in precipitation of the
desired product, with yields ranging from 39-72%. The biggest loss of yield
appeared to be in the purification step, where some product may remain in the
sonicated MeOH solution. Attempts to purify the complexes using crystallisation
from CHCl3/hexane, acetone/Et2O and THF/pentane always resulted in immediate
precipitation upon addition of the anti-solvent, which did not yield products of good
purity. This also resulted in difficulty obtaining crystals suitable for X-ray
diffraction.
The 1H NMR spectra of complexes 21-26 all exhibited the characteristic imine peak
alongside the loss of the low-field aldehyde peak. ESI-MS showed peaks
Chapter 5
209
corresponding to the loss of the chloride ligand, alongside the addition of the organic
amine with loss of a H2O molecule, which confirms that the condensation reaction
has taken place. Elemental analysis of the reaction products was generally in good
agreement with the expected values.
An alternative route to form complex 26 was investigated by reaction of
[(η5-Cp*)IrCl2]2 with the already dansyl-conjugated 2-PhPy chelating ligand (L26),
Figure 5.4. The reaction was performed using the previously described route to
synthesise C,N-chelated half-sandwich complexes. It was found that many different
products were formed, and the desired complex 26 could not be identified.
Therefore, the post-modification method is required rather than functionalising the
chelating ligand before complexation. This is presumably due to multiple binding
modes that the L26 can exhibit when reacting with [(η5-Cp*)IrCl2]2 in the presence
of a base.
5.4.2 Imine Reduction in Complex 26
As Schiff bases are susceptible to hydrolysis, investigations into stabilising the bond
by formation of the secondary amine were carried out. This was of particular
importance in the case of complex 26 (Figure 5.2) where a stable bond may allow
tracking of the complex via fluorescence microscopy. The reduction of imines to the
corresponding secondary amines is a well-established reaction. Most reduction of
imine bonds involves using a reducing agent which acts a hydride donor. It has also
been documented that chelated half-sandwich Ir(III) complexes can reduce imines
via transfer hydrogenation in the presence of a hydride source.33
The reaction of complex 26 with NaCNBH3 (which is a milder reducing agent than
NaBH4), resulted in the formation of many different products based on the 1H NMR
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spectrum. An alternative route involving Et3SiH and the catalyst Pd(OAc)2 was
investigated.25 The catalytic cycle has been proposed to involve in situ reduction of
Pd(II) to Pd(0) by Et3SiH, followed by oxidative addition of Et3SiH then reductive
elimination by reaction with ethanol to form H2 gas and the silyether Et3SiOEt
(Figure 5.23).34 The H2 gas may be absorbed onto the surface of the Pd(0) to enable
hydrogenation of the imine to occur,35 although this was originally proposed for the
hydrogenation of 1-alkenes where the same catalytic process was then applied to
imines.25 Following the experimental protocol, and purification by flash silica
chromatography, the secondary amine complex 27 was isolated in 33% yield.
Figure 5.23. Catalytic cycle for the in situ production of H2 by the reaction of
Et3SiH with Pd(OAc)2 in ethanol to reduce imine bonds.34
Most reports on the reaction of Et3SiH with Ir complexes are based on octahedral
pincer complexes.36-38 Intriguingly, the imine moiety in complex 26 was able to be
reduced to generate complex 27 in the presence of Et3SiH without the need for the
Pd catalyst as is required for organic transformations, implying involvement of the Ir
complex in the reduction process. Analysis of the crude reaction mixture (by 1H
NMR spectroscopy, Figure 5.9) showed that the product was the same as from the
reaction using the Pd catalyst. As the method used involves stirring complex 26 with
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Et3SiH for 5 min prior to adding the Pd(OAc)2, it is likely that the reduction to form
27 has already been initiated.
The reaction of complex 26 with Et3SiH (1.5 mol equiv) was followed by 1H NMR
spectroscopy, but showed no formation of an Ir-H species. (Figure 5.10). However,
complex 13 which has no reducible functional groups exhibited an Ir-H resonance at
-12.46 ppm within 5 min (Figure 5.11). Interestingly, the catalytic reduction of L26
to the secondary amine could be performed using 10% mol catalyst of complex 13
with Et3SiH (Figure 5.12), while in the presence of the Pd catalyst no reduction
occurred. This could imply that the ability to form an Ir-H species may be
responsible for the reduction of the imine bond in 26 and the presence of the Pd
catalyst is not necessary. The work reported here appears to be the first finding of the
reduction of a bond within an organo-iridium complex that is initiated via the
complex itself.
Recently, it was reported that the complex [(η5-Cp*)Ir(2-phenylpyridine)Cl] could
reduce imines to secondary amines in the presence of Et3SiH, although good yields
were only found upon removal of the chloride ligand using an additive such as
NaBArF24. The mechanism of hydrosilylation was not confirmed, but a possible
route hypothesised was via formation of the Ir-H species.39
During the reaction with complex 26, the loss of the hydride from Et3SiH appears to
result in the formation of ethoxy silyl species Et3SiOEt, as is evident from the
appearance of a new set of peaks which integrate to an ethoxy species in the 1H
NMR spectrum (Figure 5.9). At first, the Et3SiCl species would seem the most
plausible by-product, via substitution with the chlorido monodentate ligand.
However, as shown in the reaction of Et3SiH with complex 13, the chloride adduct
remains dominant in solution whilst the consumption of Et3SiH takes place. It has
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been reported that reaction of Et3SiH with InCl3 in the presence of MeOH to reduce
iminium bonds results in the formation of the methoxy silyl species Et3SiOMe,
rather than the presumed chloride species.40
A possible reduction mechanism is shown in Figure 5.24 based on the 1H NMR
experiments on 26 and 13 with Et3SiH in ethanol. Formation of an Ir-H species of 26
occurs through reaction with Et3SiH, alongside the formation of Et3SiOEt by
reaction with EtOH, followed with production of HCl (A). Protonation of the imino
nitrogen of another molecule of 26 activates the imine towards nucleophilic attack by
the Ir-H species, forming the secondary amine complex 27 (B), where association of
the chloride with the 16 electron complex [(η5-Cp*)Ir(2-PhPy)]+ re-forms 26 (C).
Due to the position of the imine bond it is unlikely that intramolecular hydride
transfer can occur, therefore, intermolecular transfer is more likely. The fast
reduction of the imine bond may be responsible for the lack of Ir-H peak observed
during the reaction with 26. Another possible mechanism could involve a sacrificial
amount of complex 26 being converted to the Ir-H species, which upon hydride
transfer, immediately forms more Ir-H upon reaction with Et3SiH, rather than re-
association with the chloride.
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Figure 5.24. Proposed reaction scheme for the reduction of complex 26 to 27 using
Et3SiH.
5.4.3 Aqueous Stability of Complexes 21-27
Imine bonds are known to be unstable in aqueous solution, and the extent of
hydrolysis tends to increase as the pH of the solution is decreased. Having a labile
bond which is pH-sensitive may be advantageous where a tag that has been used as a
targeting moiety (e.g. folic acid for uptake into FR+ cells), or possibly another
cytotoxic agent, is cleaved in the acidic microtumour environment (pH < 6.5).41 This
concept was examined with the imine conjugates 21-26 by studying the stability of
the imino bond at various pH values.
After 15 min at pH 7.5 (buffered), complexes 21-26 showed between 2-18%
hydrolysis of the imine bond, which increased to 21-86% after 3 h. There appears to
be no correlation between the type of amine conjugate (aliphatic vs. aromatic) and
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the extent of imine hydrolysis. At more acidic pH*, the extent of hydrolysis
increased after 15 min. The decrease in the extent of hydrolysis after 3 h for
complexes 23-26 at lower pH* can be attributed to the release of the aliphatic amine
in an unbuffered solution. The pKa of aliphatic amines is around 10,42 therefore
release of basic amines will increase the pH* of the solution, which was also
observed experimentally after 24 h. This may result in a decrease in the rate of
hydrolysis. The pKa of aromatic amines is lower, at around 4.5 for aniline, which
results in a less pronounced effect on the basicity of the unbuffered aqueous solution.
Therefore, it is possible that under the acidic microtumour environment, an
enhancement of imine hydrolysis may occur which could make these conjugates
suitable for cleavage inside cancer cells.
The secondary amine complex 27 exhibited excellent stability in aqueous solution,
showing that the reduction of the imine bond can yield conjugates are stable in
aqueous solution, making it more suitable for tracking the complex by fluorescence
microscopy than the imine complex 26.
5.4.4 Fluorescence of Complexes 26 and 27
The addition of a fluorescent moiety to metal complexes can be a useful strategy for
assessing the compartmentalisation of the complex and hence the study of possible
biological targets. Complexes 26 and 27 (50 μM) which bear the fluorescent dansyl-
amine tag showed fluorescence in DCM (Figure 5.14) while the parent aldehyde
complex 6 exhibited no emission, demonstrating that the presence of the fluorescent
chromophore is required. It is evident that a reduction in the fluorescence intensity is
observed upon conjugation of the fluorophore to the complexes, although causes of
this reduction were not investigated further.
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The reduced fluorescence in aqueous solution compared to organic solvents
(Figure 5.15) is a common phenomenon observed for both the dansyl-amine tag and
complex 27 (10% MeOH, 90% H2O v/v). Oxygen gas is also known to be an
effective collisional quencher of fluorescence,43 which may play a greater role in
aqueous solution over DCM. Fluorescent compounds such as PI exhibit weak
fluorescence in aqueous solution, but upon intercalation between DNA base pairs
(which leads to the fluorophore being in a more hydrophobic environment), its
fluorescence increases around 30-fold.44 Octahedral Ir(III) complexes of the type
[Ir(2-PhPy)2(N,N)]+ (N,N = dpq, dpqa, dppz, dppn) also show this behaviour, where
binding to CT-DNA results in an increase in luminescence intensity in comparison to
aqueous buffered solutions,45,46 which has been attributed to reduced hydrogen
bonding between the chelating ligand and water molecules when bound to DNA. The
fluorescence was examined for complex 27 in A2780 cells (Figure 5.16) which
showed only autofluorescence (fluorescence exhibited naturally by cells from
proteins). As 27 exhibits vastly reduced fluorescence in aqueous solution this may
mean that 27 does not interact with biological molecules that can provide a
sufficiently hydrophobic environment. Another possible factor might be the extent of
accumulation of 27 in A2780 cells is too low to provide a fluorescence signal.
Although complex 27 appears to be unsuitable for fluorescence microscopy, it has
been demonstrated that a fluorophore can be successfully conjugated to complex 6,
which may result in the exploration of other fluorescent molecules (e.g. PI, EtBr)
that can be conjugated and studied for their potential as fluorescent probes for Ir(III)
half-sandwich complexes.
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5.4.5 Reactions of Complex 6 with Lysine-Containing Peptides
There is great interest in the attachment of peptides to metal complexes, which can
be beneficial for specific uptake in cancer cells through processes such as receptor
recognition.47 The conjugation of peptides to metal complexes can be achieved via
click chemistry48 or even palladium cross-coupling,49 although an artificial peptide is
required that contains the required functional group, such as an alkyne or iodine
substituent. Traditional peptide coupling techniques using Fmoc protected amino
acids have also been demonstrated for the half-sandwich Os(II) complex [(η5-
biphenyl)Os(picolinate)Cl].5
Complex 6 reacted with the lysine residue in the peptides Substance P (SubP)
(Figures 5.18-5.19) and [Lys-3]-bombesin (L3BBS) (Figures 5.20-5.21) via the
aldehyde group on the chelating ligand, forming an imine conjugate as determined
by FT-ICR MS. It is worth noting that SubP is an important neuropeptide in pain
perception and inflammatory disease,50 and bombesin (similar in structure to
L3BBS, in which the lysine residue is originally arginine in bombesin) is a tumour
marker for small cell lung carcinoma.51 The ability to conjugate SubP to complex 6
could lead to a new method for studying pain perception (by the ability to analyse
concentration/location of iridium using MS/ICP techniques).
With further investigation, this highlights that the reaction could be the basis of a
new metal-peptide conjugation system. Interestingly, multiple binding modes can be
exhibited with peptides when histidine is present, as in the case with L3BBS.
Incubation of complex 6 with L3BBS led to two conjugates as determined by MS.
FT-ICR ECD MS/MS showed that the secondary binding mode involved iridium
binding to the histidine residue (Figure 5.22), based on the fragmentation of the
peptide backbone. Therefore, if a synthetic methodology were to be developed, it
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may be necessary to use a peptide that does not contain histidine. It appears that
sulfur-containing methionine (which has been previously been shown to bind to
metal complexes)31 does not bind in this system, however, cysteine sulfur may bind
in a similar fashion to GSH as observed for complex 13 in Chapter 4.
The conjugation of BSA (which contains surface lysine residues) at pH 8.7 to
octahedral Ir(III) complexes bearing the aldehyde C,N- chelating ligand (2-
quinolyl)benzaldehyde has been reported with the reduction of the imine being
performed using NaCNBH3 in order to make a stable Ir-BSA conjugate.19 Although
the incubations performed in this study were purely a proof-of-concept work, the
aqueous instability of the imine conjugate would require a reducing agent to form the
stable secondary amine, as purification of metal-peptide conjugates requires the use
of RP-HPLC. NaCNBH3 appears to be incompatible with the half-sandwich Ir(III)
complexes studied here. Therefore, future work into the conjugation of lysine-
containing peptides under alternative conditions (i.e. DMF) followed by reduction
using the more complex-friendly Et3SiH reducing agent may lead to new iridium-
peptide conjugates.
5.5 Conclusions
A conjugation strategy for the post-modification of the half-sandwich Ir(III)
anticancer complex [(η5-Cp*)Ir(2-phenyl-5-pyridinecarboxaldehyde)Cl] 6 bearing an
aldehyde functional group has been devised, whereby aliphatic and aromatic amines
can be conjugated to form new Schiff base complexes. Using microwave-assisted
chemistry, new conjugates were synthesised in ca. 5 min, compared with other
coupling techniques such as copper click chemistry, or palladium Sonogashira
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coupling which require catalysts, longer reaction times and oxygen-free reaction
conditions.
Aqueous stability studies showed that hydrolysis of the imine bond in Schiff base
complexes 21-26 can increase at more acidic pH, although, release of aliphatic
amines in unbuffered solutions effectively decreases the extent of hydrolysis as a
consequence of increasing the pH of the solution. This may make these conjugates
suitable for cleavage inside cancer cells where the pH is generally slightly acidic.
Further study is warranted on the possibility of exploiting this for delivery of other
cytotoxic agents, or for the cleavage of a tag that has been used for targeted delivery
of the Ir(III) complex.
Studies on stabilising the imine bond towards hydrolysis using the mild reducing
reagent Et3SiH with catalytic amounts of Pd(OAc)2 showed that the secondary amine
complex 27 could be synthesised from the corresponding Schiff base complex 26.
Intriguingly, studies into the reactivity of complex 26 with Et3SiH without the Pd
catalyst showed that reduction to 27 could be performed giving the same product as
identified by 1H NMR spectroscopy. Hence, the reduction of the imine bond is
independent on the use of the Pd catalyst. Preliminary studies into the possible
mechanism of reduction have revealed that an Ir-H species may be involved, which
can reduce the imine bond of another molecule of 26, effectively exploiting the
catalytic ability of chelated half-sandwich Ir(III) complexes to initiate the reduction.
The addition of the fluorescent dansyl group resulted in complexes that showed
fluorescence in chlorinated solvents (26 and 27), but minimal fluorescence in
aqueous media (27). Complex 27 also showed that no fluorescence in A2780 cells,
which may be as a consequence of either not residing in a sufficiently hydrophobic
environment (i.e. cytosol) or the cellular accumulation of 27 was too low for a
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fluorescence signal. However, the successful conjugation of a fluorophore to a half-
sandwich Ir(III) anticancer complex has been performed demonstrating the proof-of
principle.
Finally, the reaction of complex 6 with the lysine-containing peptides Substance P
and [Lys-3]-bomesin revealed that new Schiff bases conjugates can be formed via
reaction with lysine residues, as determined by FT-ICR-MS (MS/MS) techniques
which can accurately pinpoint the site of conjugation. This may lead to the
development of a conjugation strategy for forming iridium-peptide complexes using
mild conditions.
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Chapter 6
Phenyliminopyridyl Half-sandwich Iridium(III)
Complexes: Characterisation, Solution Chemistry and
Biological Activity
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6.1 Introduction
The success of cisplatin and its second generation counterparts carboplatin and
oxaliplatin for the treatment of cancers including testicular, ovarian and bladder has
led to a wide variety of different metals being studied as potential anticancer agents.1
Chelated piano stool complexes of Ru(II), Os(II) and Ir(III) have shown promise, in
which greater potency and selectivity than cisplatin has been observed in some
cases.2,3 Properties such as hydrophobicity can be tuned via the capping ligand4 and
functionality on the chelating ligand (as demonstrated in Chapter 3). Reactivity at the
metal centre towards biomolecules can be controlled by careful selection of the type
of chelating ligand5 (i.e. hydrogen bonding sites for enhanced interaction with
nucleobases) and monodentate ligands.6,7
Despite the increasing rise in antibacterial resistance, very little research has been
undertaken on half-sandwich metal complexes as antibacterial agents,8-10 where
Ru(II) complexes have been the most widely studied.8,11-13 The mode of antibacterial
action has not been fully elucidated, although Ru(II) complexes of the type [(η5-p-
cymene)Ru(2-methoxyphenyl-bis(3,5-dimethylpyrazol-1-yl)methane)OH2](ClO4)2
appear to bind to DNA in vitro in E. coli.10 This mechanism is similar to that
proposed for some chelated Ru(II) half-sandwich anticancer complexes.14,15
The use of Ir(III) half-sandwich complexes as antibacterial agents is limited to only a
few studies. Previously reported neutral N,O-chelated half-sandwich complexes [(η5-
Cp*)M(quinolin-8-olate)Cl] (M = Ir(III) or Rh(III)) showed good activity for the
Rh(III) complex against Gram-positive bacteria while the Ir(III) analogue was less
effective.9 Half-sandwich Ir(III) aminoacidato complexes have also been evaluated
as antibacterial agents against Mycobaterium, where the presence of hydrophobic
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side-chains (i.e. proline, valine, phenylalanine) promoted high activity.16 The
mechanism of action of these complexes has not been investigated and so desirable
properties for piano-stool Ir(III) complexes as antibacterial agents has not been
established.
There has been little reported research on the chemical and biological properties of
N-(pyrid-2-ylmethylene)amine (ImPy) half-sandwich Ir(III) complexes,17,18 although
a common ligand set for Ru(II) piano stool complexes.19-21 In general, coordination
of neutral N,N-chelating ligands results in less potent antiproliferative agents towards
mammalian cells than anionic N,N- or C,N-chelating ligands in Ir(III) complexes,22,23
presumably as a consequence of increased hydrophobicity leading to enhanced
cellular accumulation. This may be advantageous for the design of antibacterial
agents, where reduced cytotoxicity towards mammalian cells is desirable.
A set of ImPy ligands was used to synthesise novel Ir(III) Cp*, CpxPh and CpxBiPh
complexes (Chart 6.1). The synthesis, characterisation and solution chemistry are
presented, with preliminary investigations into the effect on the nature of the
chelating ligand and Cpx capping ligand on antibacterial activity against Gram
positive S. aureus, Gram negative E. coli, and their anticancer activity against A2780
human ovarian cancer cells.
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Chart 6.1. Half-sandwich iridium(III) complexes bearing phenyliminopyridine
ligands synthesised and studied in this chapter.
Complex Chelating Ligand Cpx Complex Chelating Ligand Cpx
28 ImPy Cp* 37 ImPy-F Cp*
29 ImPy-NMe2 Cp* 38 ImPy-Cl Cp*
30 ImPy-NMe2 CpxPh 39 ImPy-Br Cp*
31 ImPy-NMe2 CpxBiPh 40 ImPy-I Cp*
32 ImPy-OH Cp* 41 ImPy-I CpxPh
33 ImPy-OH CpxPh 42 ImPy-I CpxBiPh
34 ImPy-OH CpxBiPh 43 ImPy-Naphth Cp*
35 ImPy-OMe Cp* 44 ImPy-Naphth CpxPh
36 ImPy-COOH Cp* 45 ImPy-Naphth CpxBiPh
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6.2 Experimental Section
6.2.1 Materials
IrCl3.3H2O (99%) was purchased from Precious Metals Online (Australia).
1,2,3,4,5-Pentamethylcyclopentadiene (95%), 2,3,4,5-tetramethyl-2-cyclo-
pentenone (95%), 4-bromobiphenyl (98%), n-butyllithium (1.6 M in hexanes),
phenyllithium (1.6 M in dibutylether), 2-pyridinecarboxaldehyde (99%), aniline
(98%), N-N-dimethyl-p-phenylenediamine (97%), 4-aminophenol (≥98%),          
p-anisidine (≥99%), 4-aminobenzoic acid (≥99%), 4-fluoroaniline (99%),            
4-chloroaniline (98%), 4-bromoaniline (97%), 4-iodoaniline (98%),
2-naphthylamine (≥99%), ammonium hexafluorophosphate (≥95%) and NaCl 
(>99.999%) were purchased from Sigma-Aldrich (UK). Solvents used for
synthesis were of laboratory grade and used without further purification. Solvents
for HPLC purity examination and relative hydrophobicity determination (water
and acetonitrile) were of HPLC grade with added trifluoroacetic acid or NaCl
which was purchased from Sigma-Aldrich (UK). The synthesis of dimers [(η5-
Cp*)IrCl2]2, [(η5-CpxPh)IrCl2]2 and [(η5-CpxBiPh)IrCl2]2 is described in Chapter 2.
6.2.2 Syntheses
6.2.2.1 Synthesis of Iminopyridine Ligands
N-(2-Pyridylmethylene)-benzenamine (ImPy-H) 2-Pyridinecarboxaldehyde
(287 mg, 255 µL, 2.68 mmol) was dissolved in MeCN (25 mL) followed by
addition of aniline (250 mg, 245 µL, 2.68 mmol) and heated at reflux under N2 for
18 h. The reaction mixture was cooled to ambient temperature and solvent
removed under reduced pressure to yield the product as a brown oil, with no
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further purification performed (401 mg, 82%). 1H NMR (400 MHz, dmso-d6) δ = 
8.72 (dq, 1H, J = 4.8, 1.0 Hz), 8.59 (s, 1H), 8.16 (dt, 1H, J = 7.8, 1.0 Hz), 7.94 (td,
1H, J = 7.6, 1.8 Hz), 7.52 (ddd, 1H, J = 7.4, 4.8, 1.3 Hz), 7.46-7.41 (m, 2H), 7.34-
7.27 (m, 3H). ESI-MS (MeOH) m/z = 183.1 [M+H]+.
N,N-Dimethyl-N-(2-pyridylmethylene)-1,4-benzenediamine (ImPy-NMe2) As
for ImPy-H using 2-pyridinecarboxaldehyde (197 mg, 175 µL, 1.84 mmol),
MeCN (25 mL) and N-N-dimethyl-p-phenylenediamine (250 mg, 1.84 mmol).
The product was isolated as a green solid (299 mg, 90%). 1H NMR (400 MHz,
dmso-d6) δ = 8.66 (dq, 1H, J = 4.8, 1.0 Hz), 8.62 (s, 1H), 8.11 (dt, 1H, J = 8.0, 0.9 
Hz), 7.90 (td, 1H, J = 7.7, 1.6 Hz), 7.45 (ddd, 1H, J = 7.4, 4.8, 1.2 Hz), 7.36 (d,
2H, J = 9.0 Hz), 6.77 (d, 2H, J = 9.0 Hz), 2.95 (s, 6H). ESI-MS (MeOH) m/z =
226.1 [M+H]+.
4-[(2-Pyridylmethylene)amino]-phenol (ImPy-OH) As for ImPy-H using 2-
pyridinecarboxaldehyde (245 mg, 218 µL, 2.29 mmol), MeCN (25 mL) and 4-
aminophenol (250 mg, 2.29 mmol). The reaction mixture was cooled to ambient
temperature where a light green solid formed; this was isolated by filtration under
reduced pressure and washed with hexane (310 mg, 68%). 1H NMR (400 MHz,
dmso-d6) δ = 9.67 (bs, 1H), 8.68 (dq, 1H, J = 4.8, 1.0 Hz), 8.60 (s, 1H), 8.11 (dt, 
1H, J = 7.9, 1.0 Hz), 7.92 (td, 1H, J = 7.6, 1.4 Hz), 7.48 (ddd, 1H, J = 7.4, 4.8, 1.2
Hz), 7.29 (d, 2H, J = 8.8 Hz), 6.83 (d, 2H, J = 8.8 Hz). ESI-MS (MeOH) m/z =
221.0 [M+Na]+.
4-Methoxy-N-(2-pyridylmethylene)-benzenamine (ImPy-OMe) As for ImPy-
H using 2-pyridinecarboxaldehyde (217 mg, 193 µL, 2.03 mmol), MeCN (25 mL)
and p-anisidine (250 mg, 2.03 mmol). The product isolated as a brown oil (332
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mg, 77%). 1H NMR (400 MHz, CDCl3) δ = 8.68 (dq, 1H, J = 4.8, 1.0 Hz), 8.62 
(s, 1H), 8.17 (dt, 1H, J = 7.9, 1.0 Hz), 7.78 (td, 1H, J = 7.7, 1.7 Hz), 7.34-7.30 (m,
3H), 6.94 (d, 2H, J = 8.9 Hz), 3.82 (s, 3H). ESI-MS (MeOH) m/z = 213.0
[M+H]+.
4-[(2-Pyridylmethylene)amino]-benzoic acid (ImPy-COOH) As for ImPy-H
using 2-pyridinecarboxaldehyde (195 mg, 173 µL, 1.82 mmol), MeCN (25 mL)
and 4-aminobenzoic acid (250 mg, 1.82 mmol). The reaction mixture was cooled
to ambient temperature where the pale yellow solid formed which was isolated by
filtration under reduced pressure and washed with hexane (325 mg, 79%). 1H
NMR (400 MHz, dmso-d6) δ = 12.92 (bs, 1H), 8.75 (dq, 1H, J = 4.8, 1.0 Hz), 8.59 
(s, 1H), 8.17 (dt, 1H, J = 7.9, 0.9 Hz), 8.02-7.96 (m, 3H), 7.57 (ddd, 1H, J = 7.5,
4.8, 1.2 Hz), 7.38 (d, 2H, J = 8.6 Hz). ESI-MS (MeOH) m/z = 249.0 [M+Na]+.
4-Fluoro-N-(2-pyridylmethylene)-benzenamine (ImPy-F) As for ImPy-H
using 2-pyridinecarboxaldehyde (240 mg, 214 µL, 2.25 mmol), MeCN (25 mL)
and 4-fluoroaniline (250 mg, 2.25 mmol). The product isolated as a brown solid
(400 mg, 89%). 1H NMR (400 MHz, dmso-d6) δ = 8.72 (dq, 1H, J = 4.8, 1.0 Hz), 
8.60 (s, 1H), 8.14 (dt, 1H, J = 7.9, 0.9 Hz), 7.95 (td, 1H, J = 7.8, 1.7 Hz), 7.53
(ddd, 1H, J = 7.5, 4.8, 1.2 Hz), 7.44-7.39 (m, 2H), 7.30-7.24 (m, 2H). ESI-MS
(MeOH) m/z = 201.0 [M+H]+.
4-Chloro-N-(2-pyridylmethylene)-benzenamine (ImPy-Cl) As for ImPy-H
using 2-pyridinecarboxaldehyde (210 mg, 186 µL, 1.96 mmol), MeCN (25 mL)
and 4-chloroaniline (250 mg, 1.96 mmol). The product isolated as a brown solid
(370 mg, 87%). 1H NMR (400 MHz, dmso-d6) δ = 8.73 (dq, 1H, J = 4.8, 1.0 Hz), 
8.60 (s, 1H), 8.15 (dt, 1H, J = 7.9, 1.0 Hz), 7.96 (td, 1H, J = 7.6, 1.7 Hz), 7.54
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(ddd, 1H, J = 7.5, 4.8, 1.2 Hz), 7.49 (d, 2H, J = 8.7 Hz), 7.37 (d, 2H, J = 8.7 Hz).
ESI-MS (MeOH) m/z = 217.0 [M+H]+.
4-Bromo-N-(2-pyridylmethylene)-benzenamine (ImPy-Br) As for ImPy-H
using 2-pyridinecarboxaldehyde (156 mg, 138 µL, 1.45 mmol), MeCN (25 mL)
and 4-bromoaniline (250 mg, 1.45 mmol). The product isolated as a brown solid
(230 mg, 61%). 1H NMR (400 MHz, dmso-d6) δ = 8.72 (dq, 1H, J = 4.8, 1.0 Hz), 
8.59 (s, 1H), 8.14 (dt, 1H, J = 7.9, 0.9 Hz), 7.95 (td, 1H, J = 7.6, 1.6 Hz), 7.61 (d,
2H, J = 8.6 Hz), 7.54 (ddd, 1H, J = 7.5, 4.8, 1.2 Hz), 7.30 (d, 2H, J = 8.6 Hz).
ESI-MS (MeOH) m/z = 260.9 [M+H]+.
4-Iodo-N-(2-pyridylmethylene)-benzenamine (ImPy-I) As for ImPy-H using
2-pyridinecarboxaldehyde (122 mg, 109 µL, 1.14 mmol), MeCN (25 mL) and 4-
iodoaniline (250 mg, 1.14 mmol). The product isolated as a brown solid (278 mg,
79%). 1H NMR (400 MHz, dmso-d6) δ = 8.73 (dq, 1H, J = 4.8, 1.0 Hz), 8.58 (s, 
1H), 8.15 (dt, 1H, J = 7.9, 1.0 Hz), 7.96 (td, 1H, J = 7.8, 1.7 Hz), 7.78 (d, 2H, J =
8.6 Hz), 7.55 (ddd, 1H, J = 7.5, 4.8, 1.2 Hz), 7.16 (d, 2H, J = 8.6 Hz). ESI-MS
(MeOH) m/z = 308.9 [M+H]+.
N-(2-Pyridnylmethylene)-1-naphthalenamine (ImPy-Naphth) As for ImPy-H
using 2-pyridinecarboxaldehyde (187 mg, 166 µL, 1.76 mmol), MeCN (25 mL)
and 2-naphthylamine (250 mg, 1.76 mmol). The reaction mixture was cooled to
ambient temperature and solvent removed under yielding a dark brown oil. (350
mg, 85%). 1H NMR (300 MHz, acetone-d6) δ = 8.75 (d, 1H, J = 4.8Hz), 8.72 (s, 
1H), 8.43-8.38 (m, 2H), 7.99-7.90 (m, 2H), 7.82 (d, 1H, J = 8.2 Hz), 7.59-7.47 (m,
4H), 7.26 (d, 1H, J = 7.3 Hz). ESI-MS (MeOH) m/z = 233.3 [M+H]+.
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6.2.2.2 Synthesis of [(η5-Cpx)Ir(ImPy)Cl]PF6 Complexes
[(η5-Cp*)Ir(ImPy-H)Cl]PF6 (28) To [(η5-Cp*)IrCl2]2 (66 mg, 0.083 mmol),
MeOH (20 mL) was added to form a suspension which was stirred at ambient
temperature under N2 for 10 min. ImPy-NMe2 (30 mg, 0.166 mmol) was added
and the reaction mixture stirred at ambient temperature under N2 for 15 h. The
solution was concentrated to ca. 10 mL on a rotary evaporator followed by
addition of NH4PF6 (67 mg, 0.415 mmol) which resulted in a precipitate. This was
isolated via filtration under reduced pressure and washed with cold MeOH and
hexane. The solid was then dissolved in acetone and filtered through celite, where
the filtrate was concentrated to dryness and further dried under vacuum, yielding
the product as an orange crystalline solid (95 mg, 83%). 1H NMR (400 MHz,
dmso-d6) δ =9.39 (s, 1H), 9.06 (d, 1H, J = 5.2 Hz), 8.42 (dd, 1H, J = 7.6, 1.1 Hz), 
8.35 (td, 1H, J = 7.7, 1.2 Hz), 7.95 (ddd, 1H, J = 7.4, 5.6, 1.7 Hz), 7.70-7.62 (m,
4H), 7.55 (tt, 1H, J = 7.1, 1.6 Hz), 1.42 (s, 15H). ESI-MS (MeOH) m/z = 545.0
[M-PF6]+. CHN analysis calc. for C22H25N2ClF6IrP C – 38.29%, H – 3.65%, N –
4.06%. Found C – 38.44%, H – 3.61%, N – 3.94%. HPLC Purity 254 nm –
96.8 %.
[(η5-Cp*)Ir(ImPy-NMe2)Cl]PF6 (29) As for 28 using [(η5-Cp*)IrCl2]2 (66 mg,
0.083 mmol), MeOH (20 mL), ImPy-NMe2 (37 mg, 0.166 mmol) and NH4PF6 (67
mg, 0.415 mmol). The product isolated as a dark red crystalline solid (108 mg,
89%). 1H NMR (400 MHz, dmso-d6) δ =9.18 (s, 1H), 8.98 (d, 1H, J = 5.4 Hz), 
8.34-8.26 (m, 2H), 7.87 (ddd, 1H, J = 7.4, 5.6, 1.8 Hz), 7.56 (d, 2H, J = 9.0 Hz),
6.86 (d, 2H, J = 9.0 Hz), 3.03 (s, 6H), 1.44 (s, 15H). ESI-MS (MeOH) m/z =
588.1 [M-PF6]+. CHN analysis calc. for C24H30N3ClF6IrP C – 39.32%,
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H – 4.12%, N – 5.73%. Found C – 38.72%, H – 4.04%, N – 5.49%. HPLC Purity
254 nm – 99.5 %. Crystals suitable for X-ray diffraction were obtained by slow
evaporation of a methanol/acetone solution at ambient temperature.
[(η5-CpxPh)Ir(ImPy-NMe2)Cl]PF6 (30) As for 28 using [(η5-CpxPh)IrCl2]2 (30 mg,
0.0326 mmol), MeOH (15 mL), ImPy-NMe2 (15 mg, 0.0652 mmol) and NH4PF6
(26 mg, 0.163 mmol). The product isolated as a dark red solid (25 mg, 48%). 1H
NMR (400 MHz, dmso-d6) δ =9.24 (s, 1H), 8.65 (d, 1H, J = 5.4 Hz), 8.36 (d, 1H, 
J = 7.6 Hz), 8.28 (t, 1H, J = 7.6), 7.78 (d, 1H, J = 6.0 Hz), 7.55 (d, 2H, J = 8.9
Hz), 7.47-7.41 (m, 3H), 7.35 (d, 2H, J = 7.0 Hz), 6.77 (d, 2H, J = 9.0 Hz), 3.00 (s,
6H), 1.62 (s, 3H), 1.58 (s, 3H), 1.49 (s, 3H), 1.25 (s, 3H). ESI-MS (MeOH) m/z =
650.1 [M-PF6]+. CHN analysis calc. for C29H32N3ClF6IrP.H2O C – 42.83%, H –
4.21%, N – 5.28%. Found C – 42.95%, H – 3.96%, N – 5.17%. HPLC Purity 254
nm – 99.2 %.
[(η5-CpxBiPh)Ir(ImPy-NMe2)Cl]PF6 (31) As for 28 using [(η5-CpxBiPh)IrCl2]2 (70
mg, 0.0652 mmol), MeOH (25 mL), ImPy-NMe2 (30 mg, 0.1305 mmol) and
NH4PF6 (53 mg, 0.326 mmol). The product isolated as a dark red solid (80 mg,
70%). 1H NMR (400 MHz, acetone-d6) δ =9.23 (s, 1H), 8.83 (d, 1H, J = 5.5 Hz), 
8.45, (d, 1H, J = 7.9 Hz), 8.32 (td, 1H, J = 7.8, 1.3 Hz), 7.83 (ddd, 1H, J = 7.4, 5.5,
1.5 Hz), 7.78-7.72 (m, 4H), 7.68 (d, 2H, J = 9.1 Hz), 7.64 (d, 2H, J = 8.4 Hz),
7.53-7.49 (m, 2H), 7.43 (tt, 1H, J = 6.5, 1.2 Hz), 6.85 (d, 2H, J = 9.1 Hz), 3.06 (s,
6H), 1.82 (s, 3H), 1.71 (s, 3H), 1.54 (s, 3H), 1.52 (s, 3H). ESI-MS (MeOH) m/z =
726.1 [M-PF6]+. CHN analysis calc. for C35H36N3ClF6IrP C – 48.25%, H –
4.16%, N – 4.82%. Found C – 47.74%, H – 4.12%, N – 4.66%. HPLC Purity 254
nm – 99.4%.
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[(η5-Cp*)Ir(ImPy-OH)Cl]PF6 (32) As for 28 using [(η5-Cp*)IrCl2]2 (66 mg,
0.083 mmol), MeOH (20 mL), ImPy-OH (33 mg, 0.166 mmol) and NH4PF6 (67
mg, 0.415 mmol). The product isolated as an orange solid (83 mg, 71%). 1H
NMR (400 MHz, dmso-d6) δ =9.25 (s, 1H), 9.01 (d, 1H, J = 5.4 Hz), 8.38-8.30 
(m, 2H), 7.91 (ddd, 1H, J = 7.4, 5.6, 1.7 Hz), 7.53 (d, 2H, J = 8.8 Hz), 6.96 (d, 2H,
J = 8.8 Hz), 1.44 (s, 15H). ESI-MS (MeOH) m/z = 561.0 [M-PF6]+. CHN
analysis calc. for C22H25N2ClF6IrOP C – 37.42%, H – 3.57%, N – 3.97%. Found
C – 37.59%, H – 3.62%, N – 3.85%. HPLC Purity 254 nm – 99.6 %. Crystals
suitable for X-ray diffraction were obtained by slow evaporation of a
methanol/acetone solution at ambient temperature.
[(η5-CpxPh)Ir(ImPy-OH)Cl]PF6 (33) As for 28 using [(η5-CpxPh)IrCl2]2 (30 mg,
0.0326 mmol), MeOH (15 mL), ImPy-OH (13 mg, 0.0652 mmol) and NH4PF6
(26 mg, 0.163 mmol). The product isolated as an orange solid (20 mg, 40%). 1H
NMR (400 MHz, dmso-d6) δ =9.31 (s, 1H), 8.63 (d, 1H, J = 5.4 Hz), 8.41 (d, 1H, 
J = 7.7 Hz), 8.30 (t, 1H, J = 7.7 Hz), 7.82 (t, 1H, J = 6.3 Hz), 7.52-7.38 (m, 7H),
6.88 (d, 2H, J = 8.5 Hz), 1.63 (s, 3H), 1.56 (s, 3H), 1.42 (s, 3H), 1.23 (s, 3H). ESI-
MS (MeOH) m/z = 623.0 [M-PF6]+. CHN analysis calc. for C27H27N2ClF6IrOP C
– 42.22%, H – 3.54%, N – 3.65%. Found C – 42.10%, H – 3.69%, N – 3.82%.
HPLC Purity 254 nm – 99.7 %.
[(η5-CpxBiPh)Ir(ImPy-OH)Cl]PF6 (34) As for 28 using [(η5-CpxBiPh)IrCl2]2 (70
mg, 0.0652 mmol), MeOH (25 mL), ImPy-OH (26 mg, 0.1305 mmol) and
NH4PF6 (53 mg, 0.326 mmol). The product isolated as an orange solid (50 mg,
45%). 1H NMR (400 MHz, acetone-d6) δ =9.34 (s, 1H), 9.10 (bs, 1H), 8.84 (d, 
1H, J = 5.3 Hz), 8.52 (d, 1H, J = 7.0 Hz), 8.36 (td, 1H, J = 7.8, 1.4 Hz), 7.88 (ddd,
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1H, J = 7.4, 5.6, 1.5 Hz), 7.80-7.74 (m, 4H), 7.69-7.65 (m, 4H), 7.53-7.49 (m,
2H), 7.43 (tt, 1H, J = 6.5, 1.2 Hz), 7.03 (d, 2H, J = 8.8 Hz), 1.83 (s, 3H), 1.70 (s,
3H), 1.54 (s, 3H), 1.48 (s, 3H). ESI-MS (MeOH) m/z = 698.8 [M-PF6]+. CHN
analysis calc. for C33H31N2ClF6IrOP.0.5H2O C – 46.45%, H – 3.78%, N – 3.28%.
Found C – 46.51%, H – 3.76%, N – 3.17%. HPLC Purity 254 nm – 99.6 %.
[(η5-Cp*)Ir(ImPy-OMe)Cl]PF6 (35) As for 28 using [(η5-Cp*)IrCl2]2 (66 mg,
0.083 mmol), MeOH (20 mL), ImPy-OMe (35 mg, 0.166 mmol) and NH4PF6 (67
mg, 0.415 mmol). The product isolated as an orange solid (90 mg, 75%). 1H
NMR (400 MHz, dmso-d6) δ =9.30 (s, 1H), 9.03 (d, 1H, J = 5.4 Hz), 8.40-8.31 
(m, 2H), 7.92 (ddd, 1H, J = 7.4, 5.6, 1.7 Hz), 7.65 (d, 2H, J = 8.9 Hz), 7.18 (d, 2H,
J = 8.9 Hz), 3.86 (s, 3H), 1.44 (s, 15H). ESI-MS (MeOH) m/z = 575.0 [M-PF6]+.
CHN analysis calc. for C23H27N2ClF6IrOP C – 38.36%, H – 3.78%, N – 3.89%.
Found C – 38.34%, H – 3.70%, N – 3.80%. HPLC Purity 254 nm – 98.3 %.
[(η5-Cp*)Ir(ImPy-COOH)Cl]PF6 (36) As for 28 using [(η5-Cp*)IrCl2]2 (66 mg,
0.083 mmol), MeOH (20 mL), ImPy-COOH (38 mg, 0.166 mmol) and NH4PF6
(67 mg, 0.415 mmol). The product isolated as an orange solid (102 mg, 84%). 1H
NMR (400 MHz, dmso-d6) δ =9.45 (s, 1H), 9.08 (d, 1H, J = 5.5 Hz), 8.45 (d, 1H, 
J = 6.8 Hz), 8.36 (td, 1H, J = 7.7, 1.2 Hz), 8.18 (d, 2H, J = 8.5 Hz), 7.97 (ddd, 1H,
J = 7.4, 5.6, 1.7 Hz), 7.76 (d, 2H, J = 8.5 Hz), 1.43 (s, 15H). ESI-MS (MeOH)
m/z = 589.0 [M-PF6]+. CHN analysis calc. for C23H25N2ClF6IrO2P C – 37.63%, H
– 3.43%, N – 3.82%. Found C – 37.75%, H – 3.44%, N – 3.63%. HPLC Purity
254 nm – 98.5 %.
[(η5-Cp*)Ir(ImPy-F)Cl]PF6 (37) As for 28 using [(η5-Cp*)IrCl2]2 (66 mg, 0.083
mmol), MeOH (20 mL), ImPy-F (33 mg, 0.166 mmol) and NH4PF6 (67 mg, 0.415
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mmol). The product isolated as an orange solid (96 mg, 82%). 1H NMR (400
MHz, dmso-d6) δ =9.38 (s, 1H), 9.06 (d, 1H, J = 5.4 Hz), 8.42 (d, 1H, J = 6.9 Hz), 
8.35 (td, 1H, J = 7.7, 1.1 Hz), 7.96 (ddd, 1H, J = 7.3, 5.6, 1.4 Hz), 7.77-7.71 (m,
2H), 7.54-7.49 (m, 2H), 1.44 (s, 15H). ESI-MS (MeOH) m/z = 563.0 [M-PF6]+.
CHN analysis calc. for C22H24N2ClF7IrP C – 37.32%, H – 3.42%, N – 3.96%.
Found C – 37.01%, H – 3.32%, N – 3.84%. HPLC Purity 254 nm – 98.0 %.
[(η5-Cp*)Ir(ImPy-Cl)Cl]PF6 (38) As for 28 using [(η5-Cp*)IrCl2]2 (66 mg, 0.083
mmol), MeOH (20 mL), ImPy-Cl (36 mg, 0.166 mmol) and NH4PF6 (67 mg,
0.415 mmol). The product isolated as an orange solid (94 mg, 78%). 1H NMR
(400 MHz, dmso-d6) δ =9.39 (s, 1H), 9.06 (d, 1H, J = 5.4 Hz), 8.43 (d, 1H, J = 7.3 
Hz), 8.35 (td, 1H, J = 7.7, 1.1 Hz), 7.96 (ddd, 1H, J = 7.3, 5.6, 1.4 Hz), 7.76-7.70
(m, 4H), 1.44 (s, 15H). ESI-MS (MeOH) m/z = 579.0 [M-PF6]+. CHN analysis
calc. for C22H24N2Cl2F6IrP C – 36.47%, H – 3.34%, N – 3.87%. Found C –
36.62%, H – 3.32%, N – 3.77 %. HPLC Purity 254 nm – 99.0 %.
[(η5-Cp*)Ir(ImPy-Br)Cl]PF6 (39) As for 28 using [(η5-Cp*)IrCl2]2 (66 mg, 0.083
mmol), MeOH (20 mL), ImPy-Br (43 mg, 0.166 mmol) and NH4PF6 (67 mg,
0.415 mmol). The product isolated as an orange solid (98 mg, 77%). 1H NMR
(400 MHz, dmso-d6) δ =9.39 (s, 1H), 9.06 (d, 1H, J = 5.4 Hz), 8.43 (d, 1H, J = 7.4 
Hz), 8.35 (td, 1H, J = 7.7, 1.2 Hz), 7.96 (ddd, 1H, J = 7.3, 5.6, 1.4 Hz), 7.87 (d,
2H, J = 8.7 Hz), 7.64 (d, 2H, J = 8.7 Hz), 1.44 (s, 15H). ESI-MS (MeOH) m/z =
623.1 [M-PF6]+. CHN analysis calc. for C22H24N2BrClF6IrP C – 34.36%, H –
3.15%, N – 3.64%. Found C – 34.44%, H – 3.10%, N – 3.49%. HPLC Purity 254
nm – 99.3 %.
Chapter 6
236
[(η5-Cp*)Ir(ImPy-I)Cl]PF6 (40) As for 28 using [(η5-Cp*)IrCl2]2 (66 mg, 0.083
mmol), MeOH (20 mL), ImPy-I (51 mg, 0.166 mmol) and NH4PF6 (67 mg, 0.415
mmol). The product isolated as an orange solid (114 mg, 84%). 1H NMR (400
MHz, dmso-d6) δ =9.37 (s, 1H), 9.06 (d, 1H, J = 5.4 Hz), 8.43 (d, 1H, J = 7.8 Hz), 
8.35 (td, 1H, J = 7.7, 1.2 Hz), 8.03 (d, 2H, J = 8.6 Hz), 7.96 (ddd, 1H, J = 7.3, 5.6,
1.5 Hz), 7.48 (d, 2H, J = 8.6 Hz), 1.43 (s, 15H). ESI-MS (MeOH) m/z = 671.1
[M-PF6]+. CHN analysis calc. for C22H24N2ClF6IIrP.H2O C – 31.68%, H –
3.14%, N – 3.36%. Found C – 31.72%, H – 2.86%, N – 3.24%. HPLC Purity 254
nm – 99.5 %.
[(η5-CpxPh)Ir(ImPy-I)Cl]PF6 (41) As for 28 using [(η5-CpxPh)IrCl2]2 (30 mg,
0.0326 mmol), MeOH (15 mL), ImPy-I (20 mg, 0.0652 mmol) and NH4PF6 (26
mg, 0.163 mmol). The product isolated as an orange solid (35 mg, 61%). 1H
NMR (400 MHz, dmso-d6) δ =9.43 (s, 1H), 8.64 (d, 1H, J = 5.3 Hz), 8.46 (d, 1H, 
J = 7.5 Hz), 8.34 (t, 1H, J = 7.9 Hz), 7.95 (d, 2H, J = 8.2 Hz), 7.86 (t, 1H, J = 6.3
Hz), 7.51-7.38 (m, 7H), 1.64 (s, 3H), 1.54 (s, 3H), 1.38 (s, 3H), 1.30 (s, 3H). ESI-
MS (MeOH) m/z = 732.9 [M-PF6]+. CHN analysis calc. for
C27H26N2ClF6IIrP.H2O C – 36.19%, H – 3.15%, N – 3.13%. Found C – 36.19%,
H – 2.94%, N – 3.20%. HPLC Purity 254 nm – 99.2 %. Crystals suitable for X-
ray diffraction were obtained by slow evaporation of a methanol/acetone solution
at ambient temperature.
[(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 (42) As for 28 using [(η5-CpxBiPh)IrCl2]2 (70 mg,
0.0652 mmol), MeOH (25 mL), ImPy-I (40 mg, 0.1305 mmol) and NH4PF6 (53
mg, 0.326 mmol). The product isolated as an orange solid (50 mg, 40%). 1H
NMR (400 MHz, acetone-d6) δ =9.48 (s, 1H), 8.88 (d, 1H, J = 5.4 Hz), 8.59 (d, 
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1H, J = 6.9 Hz), 8.40 (td, 1H, J = 7.8, 1.3 Hz), 8.01 (d, 2H, J = 8.6 Hz), 7.93 (ddd,
1H, J = 7.6, 5.6, 1.5 Hz), 7.79 (d, 2H, J = 8.3 Hz), 7.76-7.73 (m, 2H), 7.66 (d, 2H,
J = 8.3 Hz), 7.59 (d, 2H, J = 8.5 Hz), 7.53-7.50 (m, 2H), 7.44 (tt, 1H, J = 7.4, 1.2
Hz), 1.84 (s, 3H), 1.71 (s, 3H), 1.58 (s, 3H), 1.45 (s, 3H). ESI-MS (MeOH) m/z =
809.0 [M-PF6]+. CHN analysis calc. for C33H30N2ClF6IIrP C – 41.54%, H –
3.17%, N – 2.94%. Found C – 41.31%, H – 3.19%, N – 2.78%. HPLC Purity 254
nm – 98.4 %. Crystals suitable for X-ray diffraction were obtained by slow
evaporation of a methanol/acetone solution at 278 K.
Complexes 43-45 were characterised by 1H NMR spectroscopy at 353 K due to
dynamic behaviour observed in solution. This is discussed further in section 6.3.2.
[(η5-Cp*)Ir(ImPy-Naphth)Cl]PF6 (43) As for 28 using [(η5-Cp*)IrCl2]2 (66 mg,
0.083 mmol), MeOH (20 mL), ImPy-Naphth (39 mg, 0.166 mmol) and NH4PF6
(67 mg, 0.415 mmol). The product isolated as an orange solid (77 mg, 63%). 1H
NMR (600 MHz, dmso-d6, 353 K) δ =9.63 (s, 1H), 9.09 (d, 1H, J = 5.3 Hz), 8.47 
(d, 1H, J = 7.8 Hz), 8.37 (t, 1H, J = 7.8 Hz), 8.14 (d, 1H, J = 7.8 Hz), 8.10 (d, 1H,
J = 8.3 Hz), 8.01 (t, 1H, J = 6.7 Hz), 7.81 (bs, 2H), 7.75-7.69 (m, 2H), 7.66-7.63
(m, 1H), 1.32 (s, 15H). ESI-MS (MeOH) m/z = 595.1 [M-PF6]+. CHN analysis
calc. for C26H27N2ClF6IrP C – 42.19%, H – 3.68%, N – 3.78%. Found C –
41.98%, H – 3.65%, N – 3.70%. HPLC Purity 254 nm – 98.3%. Crystals suitable
for X-ray diffraction were obtained by slow evaporation of a methanol/acetone
solution at 278 K.
[(η5-CpxPh)Ir(ImPy-Naphth)Cl]PF6 (44) As for 28 using [(η5-CpxPh)IrCl2]2 (30
mg, 0.0326 mmol), MeOH (15 mL), ImPy-Naphth (15 mg, 0.0652 mmol) and
NH4PF6 (26 mg, 0.163 mmol). The product isolated as an orange crystalline solid
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(29 mg, 55%). 1H NMR (600 MHz, dmso-d6, 353 K) δ =9.68 (s, 1H), 8.75 (d, 1H, 
J = 5.7 Hz), 8.52 (d, 1H, J = 7.8 Hz), 8.39 (t, 1H, J = 7.8 Hz), 8.10 (d, 1H, J = 8.1
Hz), 8.05 (d, 1H, J = 8.5 Hz), 7.94 (t, 1H, J = 6.70 Hz), 7.67-7.63 (m, 2H), 7.56 (t,
1H, J = 7.6 Hz), 7.49 (t, 1H, J = 7.3 Hz), 7.44-7.39 (m, 4H), 6.89 (bs, 2H), 1.60 (s,
3H), 1.36 (s, 3H), 1.20 (s, 3H), 1.12 (s, 3H). HR-MS (MeOH) ESI-MS (MeOH)
m/z = 657.1 [M-PF6]+. CHN analysis calc. for C31H29N2ClF6IrP C – 46.41%, H –
3.64%, N – 3.49%. Found C – 46.22%, H – 3.21%, N – 3.51%. HPLC Purity 254
nm – 98.5%. Crystals suitable for X-ray diffraction were obtained by slow
evaporation of a methanol/acetone solution at 278 K.
[(η5-CpxBiPh)Ir(ImPy-Naphth)Cl]PF6 (45) As for 28 using [(η5-CpxBiPh)IrCl2]2
(70 mg, 0.0652 mmol), MeOH (25 mL), ImPy-Naphth (31 mg, 0.1305 mmol) and
NH4PF6 (53 mg, 0.326 mmol). The product isolated as an orange solid (64 mg,
56%). 1H NMR (600 MHz, dmso-d6) δ =9.69 (s, 1H), 8.82 (d, 1H, J = 5.7 Hz), 
8.54 (d, 1H, J = 7.5 Hz), 8.40 (t, 1H, J = 7.7 Hz), 8.10 (d, 1H, J = 8.2 Hz), 8.06 (d,
1H, J = 8.2 Hz), 7.96 (d, 2H, J = 6.8 Hz), 7.74-7.72 (m, 4H), 7.66 (t, 1H, J = 7.3
Hz), 7.57-7.49 (m, 5H), 7.43 (t, 1H, J = 7.4 Hz), 6.87 (bs, 2H), 1.65 (s, 3H), 1.40
(s, 3H), 1.21 (s, 6H). ESI-MS (MeOH) m/z = 733.2 [M-PF6]+. CHN analysis
calc. for C37H33N2ClF6IrP.H2O C – 49.58%, H – 3.94%, N – 3.13%. Found C –
49.47%, H – 3.76%, N – 2.93%. HPLC Purity 254 nm – 99.0 %.
6.2.3 Methods
6.2.3.1 X-ray Crystallography
The X-ray crystal structures of complexes 29, 32 and 41-44 were solved by Dr.
Guy Clarkson (Department of Chemistry, University of Warwick). The details of
the diffraction instrumentation are described in Chapter 2 (section 2.2.8).
Chapter 6
239
6.2.3.2 Computation
DFT calculations were performed using the Guassian 03 package as described in
Chapter 2 (section 2.2.9). Electrostatic potential surfaces (EPS) for complexes 29,
32 and 41-44 where the EPSs are shown in space (with positive and negative
regions in blue and red, respectively) and mapped on electron density (isovalue
0.04) of the molecules. The electrostatic potential is represented with a colour
scale ranging from red (0.000 au) to blue (+0.450 au).
6.2.3.3 HPLC
6.2.3.3.1 Purity Measurements
HPLC purity measurements on freshly prepared samples of complexes 28-45 (ca.
100 μM, 10% MeOH/90% H2O) were performed as described in Chapter 2
(2.2.5.1).
6.2.3.3.2 Relative Hydrophobicity Measurements
The relative hydrophobicity of complexes 29, 32-34, 40-43 (100 µM, 1:9
MeOH:H2O in 50 mM NaCl) was determined by RP-HPLC as described in
Chapter 2 (section 2.2.5.2).
6.2.3.4 Variable Temperature (VT) 1H NMR
VT-1H NMR measurements on complexes 43-45 were performed using a Bruker
AV III 600 NMR spectrometer in acetone-d6 over a temperature range of 223-328
K.
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The rate constant (kc at coalescence temperature) for the hindered rotation of the
naphthyl group in complexes 43-45 (2 mM, acetone-d6) was calculated using the
equations for an unequally populated states24 based on the imino proton:
   =  (   −   ) 
where νa – νb is the difference between the two chemical shifts and X is the
solution to the polynomial equation25:
   − 6   + [12 − 27(Δ ) ]   − 8 = 0
where Δp = population of proton a – population of proton b 
The Gibbs free energy of activation (ΔG‡) was calculated using the following
equation25:
ΔG‡ =     10.319 + log    
  
  
  = 1.914 × 10   (for kJ mol  )
where T = coalescence temperature (K). The error in the value of ΔG‡ was
estimated by evaluating the value of ΔG‡ at ± 2 K from the stated coalescence
temperature.
6.2.3.5 Nuclear Overhauser NMR Spectroscopy (NOESY)
Complex 44 (2 mM, acetone-d6) was analysed by 2D NOESY 1H NMR to
determine the conformation of the major species in solution at 223 K using a 0.4 s
mixing time. This was performed with the assistance of Dr. Ivan Prokes
(Department of Chemistry, University of Warwick).
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6.2.3.6 Stability in Aqueous Solution by 1H NMR spectroscopy
The stability of complexes (ca. 500 µM) in aqueous solution and in 4 mM NaCl
was monitored by 1H NMR spectroscopy. Briefly, complexes were dissolved in
26.7% MeOD-d4/73.3% D2O (v/v) by dissolution of complexes in MeOD-d4
followed by rapid dilution with D2O at 310 K and spectra were taken at various
time intervals. Stability at different pH* was also investigated using the same
method as described above, with D2O solutions being prepared at differing pH*
by addition of either DClO4 or NaOD. All spectra were internally referenced to
1,4-dioxane (3.75 ppm) and water suppression was performed using Shaka
techniques.26 The change in chemical shift arising from the conversion of Ir-OD2
to Ir-OD as a function of pH* was also assessed to estimate the acidity of the aqua
adduct, as described in Chapter 2 (section 2.2.13).
6.2.3.7 Stability in Aqueous Solution and Lysogeny Broth (LB)
by LC-MS
The stability of complexes 32 and 42 (ca. 100 μM) was evaluated by LC-MS in 
the presence of water (10% MeOH/90% H2O) and LB media (2% dmso/98%
H2O) used for bacterial cell viability experiments. Measurements were performed
after 24 h incubation at 310 K. The MS instrumentation used is described in
Chapter 2 (section 2.2.6). In both cases, the measurements were performed using
the Agilent 1200 system with a VWD and 100 μL loop. The column was an 
Agilent Zorbax Eclipse Plus C18, 150 × 4.6 mm with a 5 μM pore size. The 
mobile phase was H2O 0.1% TFA and CH3CN 0.1% TFA, with a flow rate of 1
Chapter 6
242
mL min-1. The detection wavelength was set at 254 nm, with sample injections of
5 μL. The gradient was the same used for purity determination (section 2.2.5.1). 
6.2.3.8 Antibacterial Activity against S. aureus and E. coli
Determination of the minimum inhibitory concentration (MIC) and minimum
bactericidal concentration (MBC) of complexes 39-45 against S. aureus and E.
coli was performed as described in Chapter 2 (section 2.2.15.2) in collaboration
with Dr. Evyenia Shaili (Department of Chemistry, University of Warwick).
6.2.3.9 Membrane Integrity of S. aureus
Membrane integrity of S. aureus after incubation with complexes 31, 34, 42 and
45 was examined using the BacLight DEAD/ALIVE™ Assay (LifeScience
Technologies) as described in Chapter 2 (section 2.2.15.3) in collaboration with
Dr. Evyenia Shaili (Department of Chemistry, University of Warwick). They were
compared to positive (nisin) and negative (vancomycin) controls for the disruption
of the cell membrane after short incubation periods (25 min, 310 K).
6.2.3.10 Antiproliferative Activity against Eukaryotic Cells
Antiproliferative activity assays were performed by Dr. Isolda Romero-Canelón
(Department of Chemistry, University of Warwick) as described in Chapter 2
(section 2.2.14.2). Complexes 29-45 were evaluated for activity in the A2780
human ovarian cancer cell line and complexes 31, 34, 42 and 45 were evaluated
for activity in the MRC5 human fibroblast cell lines.
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6.2.3.11 ICP-OES Analysis
ICP-OES analysis of stock solutions used for eukaryotic cell work was carried out
as described in Chapter 2 (section 2.2.10).
6.3 Results
6.3.1 Synthesis and Characterisation
Eighteen iridium(III) cyclopentadienyl complexes bearing iminopyridine
chelating ligands derived from the Schiff base reaction between
pyridinecarboxaldehyde and aniline derivatives have been synthesised and
characterised by 1H NMR spectroscopy, ESI-MS and elemental analysis.
Complexes 29-42 contain para-substituted N-(pyrid-2-ylmethylene)phenylamines
and complexes 43-45 bear N-(2-pyridnylmethylene)-1-naphthalenamine
(ImPy-Naphth) as the chelating ligand. Complexes 28, 29, 32, 35-40 and 43 have
a η5-Cp* ring, complexes 30, 33, 41 and 44 contain a η5-CpxPh ring and complexes
31, 34, 42 and 45 bear a η5-CpxBiPh as the five coordinate ligand (Chart 6.1).
Complexes 30, 31, 33, 34, 41, 44, 44 and 45 are the first examples of ImPy half-
sandwich Ir(III) complexes containing an extended cyclopentadienyl ring system
to be reported. Complexes 28-45 all contain chloride as the monodentate ligand
and were isolated as PF6 salts.
Complexes 28, 35 and 38 have been previously prepared27 but no biological
activity has been reported. The complexes synthesised are all chiral at the metal
centre resulting in a racemate solution of R and S enantiomers, however, no
attempts were made to isolate each enantiomer.
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The ImPy ligands were all synthesised by the reaction of 1 mol equivalent of
pyridine carboxaldehyde with 1 mol equivalent of aniline derivative in acetonitrile
and heated under reflux for 18 h. After either evaporating to dryness or isolating
the precipitated ligand, the N-(pyrid-2-ylmethylene)amine ligands were isolated in
good yields without further purification. Complexes 28-45 were synthesised by
the addition of 2 mol equivalents of iminopyridine ligand to 1 mol equivalent of
iridium dimer in methanol under nitrogen for 15 h with stirring. Concentration of
the reaction mixture followed by addition of ammonium hexafluorophosphate led
to the precipitation of the desired complex. Dissolution of the isolated solid in
acetone and filtration through celite allowed removal of excess ammonium
hexafluorophosphate, where concentrating the solution to dryness followed by
further drying on a Schlenk line yielded products of good purity.
The molecular structure of complexes [(η5-Cp*)Ir(ImPy-NMe2)Cl]PF6 29,
[(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32, [(η5-CpxPh)Ir(ImPy-I)Cl]PF6 41,
[(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42, [(η5-Cp*)Ir(ImPy-Naphth)Cl]PF6 43 and
[(η5-CpxPh)Ir(ImPy-Naphth)Cl]PF6 44 were characterised by X-ray
crystallography and are shown in Figure 6.1, with selected crystallographic data
shown in Table 6.1 and selected bond distances and angles shown in Table 6.2.
All complexes exhibit the pseudo-octahedral “piano-stool” structure expected for
half-sandwich metal complexes, with Ir – ring centroid distances ranging from
1.785 – 1.796 Å, Ir – N (pyridyl) distances of 2.080 – 2.103 Å, Ir – N (aniline)
distances of 2.052 – 2.097 Å and Ir –Cl distances of 2.3704 – 2.4002 Å.
The unit cell of complex [(η5-CpxPh)Ir(ImPy-Naphth)Cl]PF6 44 contained two
crystallographically independent molecules (44a and 44b) which possess different
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bond lengths/angles and are described separately in Table 6.2. The unit cell of 44
contains 4 molecules where both 44a and 44b are represented in a 1:1 ratio, in
which 44a and 44b contain both R and S enantiomers.
Figure 6.1. X-ray crystal structures with atom numbering scheme for complexes
[(η5-Cp*)Ir(ImPy-NMe2)Cl]PF6 29 (A), [(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32 (B),
[(η5-CpxPh)Ir(ImPy-I)Cl]PF6 41 (C), [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 (D), [(η5-
Cpx*)Ir(ImPy-Naphth)Cl]PF6 43 (E) and [(η5-CpBiPh)Ir(ImPy-Naphth)Cl]PF6 44a-
b (Fi-ii) with thermal ellipsoids drawn at 50%. Hydrogen atoms, PF6 counterion
and solvent molecules have been omitted for clarity.
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Table 6.1. Selected X-ray crystallographic data for complexes [(η5-Cp*)Ir(ImPy-NMe2)Cl]PF6 29, [(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32 [(η5-
CpxPh)Ir(ImPy-I)Cl]PF6, 41 [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42, [(η5-Cpx*)Ir(ImPy-Naphth)Cl]PF6 43 and [(η5-CpBiPh)Ir(ImPy-Naphth)Cl]PF6 44.
29 32 41 42.1.75H2O 43 44
Formula C24H30ClF6IrN3P C22H25ClF6IrN2OP C27H26ClF6IIrN2P C33H33.5ClF6IIrN2O1.75P C26H27ClF6IrN2P C31H29ClF6IrN2P
MW 733.13 706.06 878.02 985.64 740.11 802.18
Crystal Colour Red Orange Orange Orange Orange Orange
Cryst size (mm) 0.4 x 0.1 x 0.02 0.3 x 0.28 x 0.22 0.2 × 0.2 × 0.01 0.32 x 0.26 x 0.12 0.38 x 0.24 x 0.2 0.22× 0.20 × 0.08
λ (Å) 0.71073 0.71073 0.71073 0.71073 0.71073 0.71073
Temp(K) 100 150 150 150 150 150
Cryst system Monoclinic Monoclinic Triclinic Triclinic Monoclinic Triclinic
Space group P2(1)/n P2(1)/n P-1 P-1 P2(1)/n P-1
a (Å) 9.9617(4) 8.7481(3) 9.46480(16) 9.70259(18) 10.8265(2) 11.1277(2)
b (Å) 11.4829(3) 20.8057(8) 12.0044(2) 13.8280(2) 11.99174(17) 16.7111(3)
c (Å) 23.0094(7) 13.3561(5) 13.2050(2) 14.8398(2) 20.6677(5) 17.20802(4)
α (°) 90 90 91.4727(14) 113.8378(16) 90 71.8791(16)
β (°) 97.960(3) 95.593(3) 102.6397(15) 91.9104(14) 101.476(2) 72.1957(19)
γ (°) 90 90 100.0312(15) 101.0453(15) 90 80.6946(15)
Vol (Å3) 2606.65(14) 2426.16(16) 1438.41(4) 1773.78(6) 2629.61(9) 2887.71(11)
Z 4 4 2 2 4 4
R(Fo2) 0.0316 0.0295 0.0320 0.046 0.0513 0.0453
Rw(Fo2) 0.0653 0.0577 0.0690 0.1232 0.1222 0.0947
GOF 1.055 1.051 1.029 1.159 1.060 1.031
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Table 6.2. Selected bond lengths (Å) and bond angles (°) for complexes [(η5-Cp*)Ir(ImPy-NMe2)Cl]PF6 29, [(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32,
[(η5-CpxPh)Ir(ImPy-I)Cl]PF6 41, [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42, [(η5-Cpx*)Ir(ImPy-Naphth)Cl]PF6 43 and complex [(η5-CpBiPh)Ir(ImPy-
Naphth)Cl]PF6 44a an 44b.
Bond/angle 29 32 41 42.1.75H2O 43 Bond/angle 44a 44b
Ir-C (Cp ring) 2.177(4) 2.190(4) 2.161(3) 2.155(7) 2.162(6) Ir1-C (Cp ring) 2.200(4) Ir2-C (Cp ring) 2.156(4)
2.195(3) 2.159(3) 2.183(3) 2.190(8) 2.150(6) 2.148(4) 2.188(4)
2.166(3) 2.162(3) 2.168(3) 2.167(7) 2.171(5) 2.181(5) 2.168(4)
2.151(3) 2.148(4) 2.172(3) 2.160(7) 2.187(6) 2.164(5) 2.160(4)
2.154(3) 2.195(4) 2.188(3) 2.188(7) 2.143(6) 2.168(5) 2.177(4)
Ir-C (centroid) 1.789 1.793 1.796 1.796 1.785 Ir1-C (centroid) 1.794 Ir2-C (centroid) 1.790
Ir-N1 2.090(3) 2.095(3) 2.093(3) 2.103(5) 2.080(4) Ir1-N101 2.099(4) Ir2-N201 2.081(3)
Ir-N8 2.097(3) 2.094(3) 2.096(3) 2.088(5) 2.052(5) Ir1-N108 2.067(4) Ir2-N208 2.078(4)
Ir-Cl 2.3704(8) 2.3948(9) 2.3926(8) 2.3810(15) 2.4002(15) Ir1-Cl1 2.3878(11) Ir2-Cl2 2.3806(16)
N1-Ir-N8 76.55(11) 76.22(12) 76.32(10) 76.23(19) 77.06(18) N101-Ir1-N108 76.18(16) N201-Ir2-N208 76.71(14)
N1-Ir-Cl 84.45(8) 86.09(8) 84.32(8) 85.01(13) 84.33(13) N101-Ir1-Cl1 84.21(10) N201-Ir2-Cl2 83.37(10)
N8-Ir-Cl 84.14(8) 86.75(8) 85.98(7) 87.32(14) 85.55(14) N108-Ir1-Cl1 85.28(12) N208-Ir2-Cl2 87.84(12)
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The angle between the mean plane of the pyridyl ring connected to the imine carbon
and the mean plane of the aniline ring in complexes 29, 32, 41 and 44 is similar,
ranging from 50.34–58.57° while the angles exhibited in complexes 43 and 44a-b
which bear the naphthyl group are more obtuse, with angles of 63.41, 73.44 and
65.71° for 43, 44a and 44b, respectively.
The propeller twist exhibited by the extended cyclopentadienyl rings between the
phenyl and Cp ring in 41 is 65.89° whereas in 42 the twist is 55.31° followed by a
further twist between the two phenyl rings at an angle of 32.58°. The propeller twist
between the phenyl and Cp ring in 44a and 44b is 66.49° and 53.74°, respectively,
showing significant difference between the two crystallographically independent
molecules.
Weak intermolecular π-π stacking was observed in the crystal structures of 
complexes 32 and 42 (Figure 6.2) between pyridyl rings of neighbouring molecules,
with a centroid – centroid distance of 3.739 and 4.258 Å, respectively. Hydrogen-
bonding was also observed in the crystal structure of complex 32 between the –OH
on the aniline ring and the F-PF5 counterion (Figure 6.3) with a OH – F-PF5 distance
of 2.319 Å at an angle of 170.10°.
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Figure 6.2. The π-π stacking interaction in the X-ray crystal structures of complexes 
[(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32 (A) and [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 (B) where
the centroid – centroid distance between pyridyl rings of independent molecules is
3.739 and 4.256 Å for 32 and 42, respectively. Thermal ellipsoids drawn at 50%
with hydrogen atoms, PF6 counterion and solvent molecules omitted for clarity.
Figure 6.3. The hydrogen-bonding interaction in the X-ray crystal structure of
complex [(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32 between the –OH of the aniline ring and
the F-PF5 counterion. The bond distance is 2.319 Å with an OH – F-PF5 angle of
170.10°. Thermal ellipsoids drawn at 50%.
DFT calculations based on the X-ray crystal structures of complexes 29, 32 and 41-
44 were made at the PBE0/LanL2DZ/6-31+G** level to determine the electrostatic
potential surfaces (Figure 6.4). The surfaces of the complexes are relatively non-
polar, with an even distribution of electronic charge and no significant differences
among the complexes. The phenyl ring in CpxPh complexes 41 and 44 has a higher
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electronic charge density than the Ir – bound cyclopentadienyl ring while the
terminal phenyl ring in CpxBiPh complex 42 has a higher electronic charge density
than the first phenyl ring. In most cases, the monodentate chlorido ligand exhibits the
most negative electrostatic potential surface, with the exception of complex 32 where
the oxygen in the –OH functionalised aniline has a slightly more negative surface.
Figure 6.4. Electrostatic potential surfaces of complexes 29, 32 and 41-44 calculated
at the PBE0/LanL2DZ/6-31+G** level using DFT methods. EPS surfaces are shown
both in space (with positive and negative regions in blue and red, respectively) and
mapped on electron density (isovalue 0.04) of the molecules. The electrostatic
potential is represented with a colour scale ranging from red (0.000 au) to blue
(+0.450 au).
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6.3.2 Dynamic Behaviour of Complexes 43-45 in Solution
Characterisation of complexes 43-45 by 1H NMR spectroscopy in dmso-d6 at
ambient temperature showed that two conformational isomers were present in
solution. Upon heating to 353 K, one set of peaks was observed. As rotation around
the imino nitrogen – naphthyl carbon (σ-bond) in the ImPy chelating ligand is 
possible, it is likely that the presence of the bulky naphthyl group results in hindered
rotation around this bond, due to steric hindrance by the Cpx rings.
VT-1H NMR was used to investigate this behaviour in acetone-d6 over a temperature
range of 223 – 323 K and is shown for complexes 43 and 44 in Figure 6.5 (45
exhibits similar behaviour compared with 44). The imine proton in each complex
gave rise to two clearly identifiable species and is shown in Figure 6.5. At 223 K,
two clearly defined resonances were observed with a ratio of around 1:2. Upon an
increase in temperature, the two imine peaks start to converge. For complexes 44
(CpxPh) and 45 (CpxBiPh), the temperature at which the imine peaks coalesce is ca.
300 K whereas for complex 43 (Cp*) the coalescence temperature is ca. 310 K.
Above these temperatures the imine peak appears as a singlet which sharpens at
higher temperatures. Similar behaviour is observed for the other proton resonances,
although it is not as easy to distinguish the point of coalescence.
Thermodynamic parameters were calculated using the equations as described in the
experimental section and are shown in Table 6.3. The population of the two species
(at 223 K) and all thermodynamic data (including coalescence temperature) were
based on the imine proton resonance. It is evident that the Gibbs free energy of
activation (ΔG‡) is similar for all complexes, with calculated values ranging from
64-65 kJ mol-1. This shows that the barrier to rotation is relatively independent of the
type of cyclopentadienyl ring.
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Figure 6.5. Low-field region of 1H NMR (600 MHz, acetone-d6) of complex 43 (A)
and 44 (B) at 2 mM at various temperatures, showing dynamic behaviour due to
hindered rotation of naphthyl group.
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Table 6.3. Thermodynamic parameters for the rotation of the naphthyl group as
calculated from the dynamic NMR spectra of complexes 43-45. Δv = difference 
between chemical shifts (at low exchange), Tc = coalescence temperature, kc = rate
constant (coalescence temperature) and ΔG‡ = Gibbs free energy of activation.
It can be hypothesised that the two species present in solution belong to two different
conformations (C1 – naphthyl group points away from chloride and C2 – naphthyl
group points towards chloride) of the naphthylamine ring as demonstrated for
complex 43 in Figure 6.6.
Figure 6.6. Possible conformational isomers (C1 and C2) of complex 43 which
differ in the orientation of the naphthyl ring.
2D 1H NMR COSY and NOESY experiments were used to assign the conformation
of the major isomer that exists at 223 K for complex 43, Figure 6.7 a-b and 6.8. The
NOESY experiments show cross peaks associated with the imine proton of the major
species which appear to be in close proximity to two protons which appear as
doublet peaks at 8.60 and 8.24 ppm. The resonance at 8.60 ppm has been assigned as
Hd on the pyrdiyl ring of the chelating ligand (Figure 6.8 a). This was based on the
Complex Δv (Hz) Tc (K) kc (s-1) ΔG‡ (kJ mol-1)
43 42.6 310 ± 2 60.4 65.4 ± 0.5
44 28.68 300 ± 2 40.7 64.2 ± 0.5
45 21.9 300 ± 2 42.5 64.1 ± 0.5
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COSY coupling (Figure 6.8 b) which showed that the proton belonged to a ring
system bearing four protons, where another proton (doublet) present exhibits two
NOE cross peak with Cp* protons of both conformational isomers (Figure 6.7 b) and
was assigned as Ha, hence belonging to the pyridyl ring.
The proton at 8.24 ppm (doublet) appears to couple to a proton presenting as a
triplet, which is coupled to another proton (triplet) which couples to a proton
(doublet), based on COSY assignment. Therefore, the proton at 8.24 ppm
presumably belongs to the naphthyl ring which bears four protons and has been
assigned as Hf. This would imply that the major isomer in solution is the
conformation where the naphthyl group points away from the chloride ligand (C1).
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Figure 6.7. (A) Low-field region of 1H NMR 2D NOESY spectrum of complex 43
(600 MHz, 0.4 s mixing time, acetone-d6) at 223 K, showing cross peaks of the
imine proton (He) of the major isomer with two protons at 8.60 and 8.24 ppm. (B)
High-field region of 1H NMR NOESY spectrum showing cross peaks with the low-
field protons on the pyridyl ring of the chelating ligand (Ha) with the Cp* resonances
of the two species.
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Figure 6.8. (A) Labelling of protons of complex 43 in the two conformations C1 and
C2. (B) Assignment of 2D 1H NMR COSY spectrum of complex 43 (600 MHz,
acetone-d6) at 223 K. Major species in solution assigned as conformational isomer
C1 where the naphthyl group points away from the chlorido ligand. (* = exhibit
NOE cross peaks with imine proton eC1 and † = exhibit NOE cross peaks with Cp*
protons of C1 and C2).
6.3.3 Aqueous Chemistry
The behaviour of the complexes in aqueous solution was analysed by both 1H NMR
spectroscopy and LC-MS to ascertain the species in solution.
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6.3.3.1 1H NMR Spectroscopy
The aqueous solution chemistry of complexes 29-34, 37 and 40-42 (ca. 500 µM) was
investigated by 1H NMR spectroscopy in 26.7% MeOD-d4/73.3% D2O (v/v) at
310 K over a 24 h period. They were selected to represent different ImPy chelating
ligands and the effect of different Cpx capping ligands on the behaviour observed.
15 min (first spectra obtained) after dissolution, three sets of peaks were visible in
the low-field region for the Cp* complexes, alongside three sets of peaks for the
methyl protons on the Cp* ring, as exemplified for complexes [(η5-Cp*)Ir(ImPy-
OH)Cl]PF6 32 and [(η5-Cp*)Ir(ImPy-I)Cl]PF6 40 in Figure 6.9 a and 6.10,
respectively. In contrast, the CpxPh (30, 33 and 41) and CpxBiPh (31, 34 and 42)
exhibited two sets of peaks, as exemplified for complex [(η5-CpxBiPh)Ir(ImPy-
OH)Cl]PF6 34 in Figure 6.9 b. It is likely that one of the species in all cases is the Ir-
OD2/OD adduct. To confirm that a hydrolysis process had taken place, the 1H NMR
spectra were also recorded in 4 mM NaCl. Only one set of peaks were dominant for
all complexes, likely belonging to the Ir-Cl adduct, which also had the same
chemical shift as the major species in the absence of NaCl. This remained constant
over a 24 h period. Therefore, hydrolysis appears to be almost completely supressed
in the presence of biologically relevant chloride concentrations. Higher
concentrations of NaCl resulted in precipitation of some of the complexes under the
conditions studied. The percentage of chloride adduct for each complex after 15 min
is shown in Table 6.4. In general, an increase in the substitution of the Cpx ligand
results in less hydrolysis.
After 24 h (in the absence of NaCl), complex [(η5-Cp*)Ir(ImPy-I)Cl]PF6 40 (which
appears to hydrolyse to the greatest extent after 15 min) displayed formation of an
unidentified new species, as evident by peaks in the high- and low-field region
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(Figure 6.10). For all of the other complexes, the formation of a new species after 24
h occurred, but was minor in comparison to 40. Comparison of the 1H NMR spectra
with free chelating ligand showed no similarities in chemical shift. The chloride
adduct in all cases appears to remain the dominant species in solution.
Figure 6.9. 1H NMR spectra of complex [(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32 (A) and
[(η5-CpxBiPh)Ir(ImPy-OH)Cl]PF6 34 (B) (ca. 500 µM) in 26.7% MeOD-d4/73.3%
D2O, 310 K at 15 min, 4 h, 24 h and in the presence of 4 mM NaCl. Star = chloride
species and triangle = aqua/hydroxido species. The peaks due to the unidentified new
species are highlighted.
Chapter 6
259
Figure 6.10. 1H NMR spectra of complex [(η5-Cp*)Ir(ImPy-I)Cl]PF6 40 (ca. 500
µM) in 26.7% MeOD-d4/73.3% D2O, 310 K at 15 min, 4 h, 24 h and in the presence
of 4 mM NaCl. Star = chloride species and triangle = aqua/hydroxido species. The
peaks due to the unidentified new species are highlighted.
Table 6.4. Percentage of chloride adduct of complexes 29-34, 37 and 40-42 (ca. 500
µM) as determined by 1H NMR spectroscopy (600 MHz, 26.7% MeOD-d4/73.3%
D2O at 310K) after 15 min based on peak integration of the imine proton.
Complex Cpx ligand Chelating ligand % Ir-Cl
29 Cp* ImPy-NMe2 72
30 CpxPh ImPy-NMe2 82
31 CpxPBih ImPy-NMe2 84
32 Cp* ImPy-OH 81
33 CpxPh ImPy-OH 87
34 CpxBiPh ImPy-OH 88
37 Cp* ImPy-F 84
40 Cp* ImPy-I 56
41 CpxPh ImPy-I 58
42 CpxBiPh ImPy-I 60
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The pH* dependence on the stability of the complexes was also investigated after
24 h. The pH* of the D2O solution was adjusted, using either DClO4 or NaOD, to
give a pH* range of 2.2-8.1 before adding to the concentrated methanolic stock
solutions. At low pH* (2.2-4.2), the chlorido adduct appears to be the dominant
species, with small peaks associated with aqua/hydroxido species. Upon an increase
in pH* (6.2-8.1), the new unidentified species is formed as exemplified for complex
[(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32 in Figure 6.11, which increases in intensity as the
pH* increases. The formation of the new species appears to be sensitive to the pH*
of the solution, which may imply involvement of the coordinated aqua ligand.
Figure 6.11. Low-field region of 1H NMR spectra of complex [(η5-Cp*)Ir(ImPy-
OH)Cl]PF6 32 (ca. 500 µM) in 26.7% MeOD-d4/73.3% D2O, 298 K after 24 h over a
pH* range of 2.2 – 8.1.
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Determination of the pKa* (pH* at which half of the aqua adducts are deprotonated)
of the coordinated aqua ligand was attempted for complexes [(η5-Cp*)Ir(ImPy-
OH)Cl]PF6 32 and [(η5-Cp*)Ir(ImPy-I)Cl]PF6 40 (1H NMR, 600 MHz, 26.7%
MeOD-d4/73.3% D2O, 298K) by preparing aqua complexes from the addition of
0.98 mol equiv. of AgNO3 at pH* 2.0. This resulted in chloride and aqua adducts
being present in solution, allowing for detection of any changes in the proton
resonances of either species upon a change in pH*. For complex 40 (Figure 6.12 a)
fitting the curve to the Henderson-Hasselbalch equation results in a pKa* value 4.6 ±
0.1, however, the change in chemical shift between pH* 4.1 and 4.9 of the aqua
adduct was sharp (9.35-9.25 ppm) and so the error in the pKa* could be high. As
expected, no change in the chloride adduct resonances was observed. The pKa* of
the aqua adduct of complex 32 could not be determined due to complication with the
phenolic proton on the chelating ligand, resulting in two pKa* curves overlapping
(Figure 6.12 b). This was confirmed by monitoring the change in shift of the
chlorido adduct resonances which showed changes at high pH* presumably due to
deprotonation of the phenolic proton. However, it can be estimated that the pKa* of
the aqua adduct is likely to be higher than for complex 40, as evident by the starting
point of the pKa* curve for 32 (around pH* 5.5).
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Figure 6.12. pH* titration curves as a function of the imine proton resonance for
each species in (A) aqua adduct of complex 40 and (B) aqua and chloride adduct of
complex 32. The two pKa* curves for complex 32 are due to the aqua ligand
(pKa1*) and phenol group (pKa2*).
6.3.3.2 LC-MS
The species present in aqueous solution for complexes [(η5-Cp*)Ir(ImPy-OH)Cl]PF6
32 and [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 (ca. 100 µM, 10% MeOH/90% H2O,
unbuffered) were also analysed by LC-MS. The LC trace for each complex is shown
in Figure 6.13 with assigned peaks corresponding to the MS data obtained (Table 6.5
(32) and 6.6 (42)). Some peaks in each trace did not show any m/z signal, preventing
full assignment of the hydrolysis products (shown as n.d. in the tables). No aqua
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adducts were detected for 32 and 42, only chlorido and TFA adducts (mobile phase
contained 0.1% TFA). Intriguingly, both complexes exhibited peaks corresponding
to the species [(Cpx)Ir(MeCN)3]2+ indicating release of the chelating ligand (H2O and
MeCN were used as mobile phase). Complex 32 exhibited an m/z peak containing
the iridium isotopic distribution an m/z of 634.17 that was not assignable. Release of
the chelating ligand in aqueous solution was detected as peak 1 for complex 42.
Table 6.5. LC-MS analysis of complex [(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32
(ca. 100 µM, 10% MeOH/90% H2O).
Table 6.6. LC-MS analysis of complex [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42
(ca. 100 µM, 10% MeOH/90% H2O).
Peak m/z Assigned species Calculated m/z
1 639.10 [(η5-Cp*)Ir(ImPy-OH)O-(C=O)CF3]+ 639.14
2 450.10 ([(η5-Cp*)Ir(MeCN)3])-H+ 450.15
3 634.17 Unassignable n/a
4 n.d. n.d. n.d.
5 561.09 [(η5-Cp*)Ir(ImPy-OH)Cl]+ 561.13
Peak m/z Assigned species Calculated m/z
1 308.09 [ImPy-I+H]+ 308.99
2 588.12 ([(η5-CpxBiPh)Ir(MeCN)3])-H+ 588.20
3 887.05 [(η5-CpxBiPh)Ir(ImPy-I) O-(C=O)CF3]+ 887.09
4 n.d. n.d. n.d.
5 809.04 [(η5-CpxBiPh)Ir(ImPy-I)Cl]+ 809.08
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Figure 6.13. LC (λ = 254 nm) traces of complexes [(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32
(A) and [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 (B) (100 µM) after 24 h incubation at
310 K in 10% MeOH/90% H2O. Peak numbers indicate species analysed by LC-MS.
The stability of complex [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 (ca. 100 µM) in LB media
(2% dmso/98% LB) which is used in antibacterial assays was also determined after
24 h incubation at 310 K by LC-MS. The peaks in the first 10 min are due to the LB
media and so were not analysed. Only two peaks were observed after 10 min which
both contained m/z peaks containing the iridium isotopic pattern (see section 1.4)
and are indicated in Figure 6.14 and Table 6.7. Peak 1 contained dmso and TFA
adducts of 42 and peak 2 was assigned as the chlorido adduct.
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Figure 6.14. LC trace of complex [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 (ca. 100 µM, 2%
dmso/98% LB media) after 24 h incubation at 310 K.
Table 6.7. LC-MS analysis of complex [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 (ca. 100
µM, 2% dmso/98% LB media).
6.3.4 Relative Hydrophobicity
Comparison of the retention times (tR) of complexes 29, 32-34 and 40-43 (100 µM,
1:9 MeOH:H2O) by RP-HPLC, where a longer retention time is indicative of a more
hydrophobic complex, allows for evaluation of the relative hydrophobicity.
Suppression of hydrolysis was achieved by dissolving the complexes in 50 mM
NaCl where the complexes should exist as just the chlorido adduct. The resulting
HPLC traces are shown in Figure 6.15 with the average tR indicated for each
complex in Table 6.8. No tR was found for complex 42 as the conditions used for
dissolution of the complexes resulted in precipitation. Complex [(η5-Cp*)Ir(ImPy-
Peak m/z Assigned species Calculated m/z
1 887.00 [(η5-CpxBiPh)Ir(ImPy-I)dmso]Cl+ 887.09
[(η5-CpxBiPh)Ir(ImPy-I) O-(C=O)CF3]+ 887.09
2 809.04 [(η5-CpxBiPh)Ir(ImPy-I)Cl]+ 809.08
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OH)Cl]PF6 32 is the most hydrophilic with an average tR of 10.73 min, while the
most hydrophobic complex is [(η5-CpxPh)Ir(ImPy-I)Cl]PF6 41 with an average tR of
21.90 min. As expected, the addition of phenyl substituents to the cyclopentadienyl
ligand results in more hydrophobic complexes.
Figure 6.15. RP-HPLC traces (signal = 254 nm, ref = 360 nm) of complexes 29, 32-
34 and 40-43 (100 µM, 1:9 MeOH:H2O) in the presence of 50 mM NaCl to supress
hydrolysis.
Table 6.8. Retention times (tR) obtained by RP-HPLC for complexes 29, 32-34 and
40-43 as a measurement of relative hydrophobicity. tR and standard deviations are
based upon triplicate measurements. Complex 43 precipitated out of solution and so
no tR could be found.
Complex tR (min)
[(η5-Cp*)Ir(ImPy-NMe3)Cl]PF6 29 15.4 ± 0.3
[(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32 10.73 ± 0.03
[(η5-CpxPh)Ir(ImPy-OH)Cl]PF6 33 15.02 ± 0.03
[(η5-CpxBiPh)Ir(ImPy-OH)Cl]PF6 34 20.86 ± 0.03
[(η5-Cp*)Ir(ImPy-I)Cl]PF640 16.52 ± 0.05
[(η5-CpxPh)Ir(ImPy-I)Cl]PF6 41 21.90 ± 0.02
[(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 n.d.
[(η5-Cp*)Ir(ImPy-Naphth)Cl]PF6 43 16.73 ± 0.00
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6.3.5 Antibacterial Activity
The antibacterial activity of complexes 29-45 was evaluated against the Gram-
positive bacterium Staphylococcus aureus (S. aureus) and the Gram-negative
bacterium Escherichia coli (E. coli). Antibacterial activity was assessed by
determining the minimum inhibitory concentration (MIC) which is the lowest
concentration that inhibits visible growth of a microorganism over a given
incubation period (22 h), and was compared with the known antibacterial agents
vancomycin, kanamycin and nisin, Table 6.9. There was minimal antibacterial
activity against the Gram-negative E. coli, with the most potent complexes (all
CpxBiPh complexes) exhibiting MICs of 100 μM. Antibacterial activity was observed 
against the Gram-positive S. aureus with MIC values generally ranging from
8 – 100 µM. The antibacterial activity appears to increase upon introduction of the
extended CpxBiPh ligand with complexes 31, 34, 42 and 45 exhibiting MIC values of
between 8-15 µM. The potency of antibacterial action follows the trend CpxBiPh >
CpxPh ~ Cp*.
The minimum bactericidal concentration (MBC - minimum concentration that will
kill a particular bacterium) of some complexes against S. aureus was also determined
and is shown on Table 6.6. It is evident that the MBC value is dependent on the
cyclopentadienyl ligand, with the extended CpxBiPh giving the lowest MBC values,
showing the complexes are bactericidal rather than bacteriostatic.
To assess whether the extended CpxBiPh ligand is responsible for the antibacterial
activity of the complexes, the free ligand (CpxBiPhH) was assessed for activity against
S. aureus, alongside the iridium dimer [(CpxBiPh)IrCl2]2 used as the common starting
material to synthesise the half-sandwich complexes. The CpxBiPhH ligand exhibited
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no antibacterial activity while the dimer [(CpxBiPh)IrCl2]2 exhibited a MIC of 30 µM,
Table 6.9.
Table 6.9. MIC and MBC values for complexes 29-45 against E. coli and S. aureus.
MIC (µM) MBC (µM)
Complex/
Compound
Cpx ImPy E. coli S. aureus S. aureus
29 Cp* ImPy-NMe2 >100 >100 n.d.
30 CpxPh ImPy-NMe2 >100 >100 n.d.
31 CpxBiPh ImPy-NMe2 n.d. 10 30
32 Cp* ImPy-OH >100 >100 n.d.
33 CpxPh ImPy-OH >100 >100 n.d.
34 CpxBiPh ImPy-OH >100 10-15 30
35 Cp* ImPy-OMe >100 100 n.d.
36 Cp* ImPy-COOH >100 100 n.d.
37 Cp* ImPy-F >100 100 n.d.
38 Cp* ImPy-Cl >100 100 n.d.
39 Cp* ImPy-Br >100 100 n.d.
40 Cp*
p
ImPy-I >100 100 >100
41 CpxPh ImPy-I >100 50-60 100
42 CpxBiPh ImPy-I 100 8-10 10
43 Cp* ImPy-Naphth >100 50 n.d.
44 CpxPh ImPy-Naphth >100 50 n.d.
45 CpxBiPh ImPy-Naphth 100 8 10
CpxBiPhH CpxBiPh n.a. >100 >100 n.d.
[(η5-CpxBiPh)IrCl2]2 CpxBiPh n.a. >100 30 n.d.
Vancomycin n.a. n.a. n.d. 1 n.d.
Kanamycin n.a. n.a. 0.05 n.d. n.d.
Nisin n.a. n.a. n.d. 8 n.d.
MIC = the lowest concentration that inhibits visible growth of a microorganism over
a given incubation period (22 h)
MBC = minimum concentration that will kill a particular bacterium
6.3.6 Membrane Integrity of S. aureus
To investigate the effect on the cytoplasmic membrane structure of S. aureus upon
incubation with highly active antibacterial complexes [(η5-CpxBiPh)Ir(ImPy-
NMe2)Cl]PF6 31, [(η5-CpxBiPh)Ir(ImPy-OH)Cl]PF6 34, [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6
42 and [(η5-CpxBiPh)Ir(ImPy-Naphth)Cl]PF6 45, the BacLight™ DEAD/ALIVE assay
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was used.28 After a short incubation time (25 min, 310 K) of the complexes at 4 ×
MIC with S. aureus, fluorescent dyes SYTO 9 and PI were added. SYTO 9 can
penetrate through non-damaged cell membranes and fluoresces green (alive), while
PI only enters membrane-damaged cells and fluoresces red (dead) upon binding to
DNA. The ratio of green/red fluorescence gives a measure of the pore-forming
ability of the antibacterial agents. The ratio is compared with a set of standards that
have been prepared to include a given population dead (membrane damaged, red
fluorescing) cells and alive (membrane intact, green fluorescing) cells. The green/red
fluorescence ratios for complexes 31, 34, 42 and 45 are shown in Figure 6.16 and
compared with the known pore-forming antimicrobial peptide nisin29 and the non-
pore-forming vancomycin.30 The results indicate that complexes 31, 42 and 45 are
membrane damaging agents after a short incubation time, while complex 34 showed
a mild ability to disrupt the membrane; therefore it is likely that their mechanism of
action involves interaction with the cytoplasmic membrane.
Fluorescence confocal microscopy was performed on S. aureus upon incubation with
complex [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42, and compared with cells incubated with
nisin. The overlaid images of green and red fluorescence for 42 and nisin show either
red or orange/yellow images, which is indicative of membrane permeabilisation
(Figure 6.17).
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Figure 6.16 Extent of membrane damage in S. aureus as determined by the
BacLight™ DEAD/ALIVE assay. (A) – Calibration curve for determination of
percentage viable cells (non-membrane damaged) as the ratio of green
(λem = 530 nm, alive) and red (λem = 630 nm, dead) fluorescence after excitation at 
470 nm. R2 = 0.9987. (B) – Percentage of viable cells (alive) after incubation
(25 min, 310 K) with complexes [(η5-CpxBiPh)Ir(ImPy-NMe2)Cl]PF6 31,
[(η5-CpxBiPh)Ir(ImPy-OH)Cl]PF6 34, [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 and
[(η5-CpxBiPh)Ir(ImPy-Naphth)Cl]PF6 45 at 4 × MIC and compared with positive
control nisin (pore-former) and negative controls 1% dmso and vancomycin at 4 ×
MIC (non-pore-forming).
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Figure 6.17. Confocal fluorescence microscopy images of S. aureus. (A-C) images
of standards used for determining the extent of membrane-damage upon exposure to
antibacterial agents. A – 0% alive cells (all membrane damaged so fluoresce red), B
– 50% alive cells (1:1 ratio of membrane damaged and membrane intact cells) and C
– 100% live cells (all membrane intact so fluoresce green). D – S. aureus after
exposure to complex [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 at 4 × MIC showing
red/orange fluorescence indicative of membrane damage. E - – S. aureus after
exposure to control nisin at 4 × MIC showing orange fluorescence indicative of
membrane damage. Some cells present are still membrane intact and so fluoresce
green.
6.3.7 Antiproliferative Activity in Human Cell Lines
The antiproliferative action of complexes 29-44 was determined against the A2780
human ovarian cancer cell line (Table 6.10). In general, complexes bearing the Cp*
ligand were inactive, with IC50 values of >100 µM. Only Cp* complexes 29 and 43
showed any activity with IC50 values of 39.6 and 13.3 µM, respectively. Upon
introduction of extended CpxPh and CpxBiPh ligands, the antiproliferative activity
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increased. Within any given set of complexes bearing the same ImPy ligand, the
order of potency was CpxBiPh > CpxPh > Cp*. It is apparent that the presence of the -
NMe2 and naphthyl group in complexes 29-31 and 43-45, respectively, result in
more potent complexes.
The antiproliferative action against the MRC5 human fibroblast cell line (healthy
cell model) for complexes 31, 34, 42 and 45 which exhibited the best antibacterial
action was determined. All complexes were active, with IC50 values ranging from
0.35 – 6.7 µM, Table 6.10.
Table 6.10. IC50 values for complexes 29-45 in the A2780 human ovarian cancer
cell line and complexes 31, 34, 42 and 45 in the MRCF human fibroblast cell line.
Drug exposure time was 24 h followed by a 72 h recovery time.
IC50 (µM)
Complex Cpx ImPy A2780 MRC5
29 Cp* ImPy-NMe2 38.64 ± 0.85 n.d.
30 CpxPh ImPy-NMe2 1.07 ± 0.04 n.d.
31 CpxBiPh ImPy-NMe2 0.64 ± 0.01 0.35 ± 0.04
32 Cp* ImPy-OH >100 n.d.
33 CpxPh ImPy-OH 34 ± 1 n.d.
34 CpxBiPh ImPy-OH 5.59 ± 0.09 6.7 ± 0.6
35 Cp* ImPy-OMe >100 n.d.
36 Cp* ImPy-COOH >100 n.d.
37 Cp* ImPy-F >100 n.d.
38 Cp* ImPy-Cl >100 n.d.
39 Cp* ImPy-Br >100 n.d.
40 Cp* ImPy-I >100 n.d.
41 CpxPh ImPy-I 8.9 ± 0.06 n.d.
42 CpxBiPh ImPy-I 6.2 ± 0.2 3.57 ± 0.04
43 Cp* ImPy-Naphth 13.3 ± 0.3 n.d.
44 CpxPh ImPy-Naphth 4.44 ± 0.2 n.d.
45 CpxBiPh ImPy-Naphth 1.11 ± 0.07 3.9 ± 0.3
Cisplatin n.a. n.a. 1.2 ± 0.2 13.2 ± 0.4
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6.4 Discussion
6.4.1 Characterisation
A search of the Cambridge Crystallographic Database showed only two previous
reports of a Cp* iridium(III) half-sandwich complexes bearing a N-(pyrid-2-
ylmethylene)amine chelating ligand.17,27 Complexes [(η5-CpxPh)Ir(ImPy-I)Cl]PF6 41,
[(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42, and [(η5-CpxPh)Ir(ImPy-Naphth)Cl]PF6 44 are the
first reported X-ray crystal structures of iminopyridine complexes bearing an
extended cyclopentadienyl capping ligand.
In general, the Ir – C ring centroid distances do not vary, with the Cp* complexes 29,
32 and 43 exhibiting distances of between 1.785 – 1.793 Å while the extended CpxPh
and CpxBiPh complexes 41, 42 and 44a-b exhibit distances of 1.790 – 1.796 Å. The
Ir-Cl bond lengths range from 2.3704 - 2.4002 Å with no relation to the type of Cpx
capping ligand or chelating ligand evident. There appears to be no major effect on
the structure of the complexes by extension of the Cpx capping ligand. The angle
between the mean plane of the pyridyl ring and the mean plane of the aniline ring
was made significantly more obtuse by the presence of the naphthyl group in the
chelating ligand of complexes 43 and 44a-b (65.71 – 73.44°) compared to the para-
substituted complexes 29, 32, 41 and 42 (50.34 – 58.57°).
Comparison with the previously reported structurally-similar Ir(III) complexes [(η5-
Cp*)Ir(4-propyl-N-(2-pyridylmethylene)-benzenamine)Cl]PF618 and [(η5-Cp*)Ir(N-
(2-pyridylmethylene)-(R)-1-phenylethylamine)-benzenamine)Cl]SbF631 showed that
the complexes reported here exhibit bond lengths and angles within same ranges.
DFT analysis of the electrostatic potential surfaces of the complexes showed they are
relatively non-polar; the aniline ring has slightly higher electronic density than the
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pyridyl ring. The electrostatic potential surface is more positive than for the neutral
[(η5-Cp*)Ir(2-PhPy)Cl] complexes studied in Chapter 3, which is inherently due to
the cationic nature of these phenyliminopyridyl complexes.
6.4.2 Hindered Rotation of Complexes 43-45
The naphthyl group of the N-(2-pyridnylmethylene)-1-naphthalenamine (ImPy-
Naphth) free ligand is able to rotate in solution. When coordinated to iridium(III),
the presence of the Cpx rings produces steric hindrance which restricts rotation of the
naphthyl group. This leads to conformational isomerism and two isomers in which
the naphthyl group either points away (C1) or towards (C2) the chlorido ligand
(Figure 6.6).
Interestingly, analysis of the Gibbs free energy of activation (ΔG‡) showed that the
energy barrier to overcome the transition state for the rotation is relatively
independent of the Cpx ligand present in the complex, with ΔG‡ for 43 (Cp*) of 65.4
± 0.5 kJ mol-1 being similar to 44 (CpxPh) and 45 (CpxBiPh) (ΔG‡ of 64.2 ± 0.5 and
64.1± 0.5 kJ mol-1, respectively). Therefore, the addition of a large phenyl/biphenyl
substituent in place of a methyl group on Cp* does not affect the rotation of the
naphthyl ring. This is likely due to the fast rotation exhibited by the Cpx capping
ligand itself.
The ImPy-Naphth chelating has been studied before in the half-sandwich Ru(II)
complex [(η6-1,3,5-triisopropybenzene)Ru(ImPy-Naphth)Cl]Cl where hindered
rotation was also observed. Although, the related complex [(η6-
hexamethylbenzene)Ru(N-(2-quinolinyl-methylene)-8-hydroxy-1-napthalenamine)-
Cl]Cl (which bears a hydroxyl substituent on the naphthyl group) exhibits no
hindered rotation.20
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Hindered rotation of ligands due to the presence of the Cpx ligand in metal
complexes has not been widely observed.32,33 The Rh(III) and Ir(III) Cp* complexes
[(η5-Cp*)M(dfppe)Cl]BF4 (M = Rh or Ir, dfppe = 1,2-bis(dipentafluorophenyl
phosphino)ethane showed two fluxional processes due to steric hindrance with
different ΔG‡ values.34 The two processes are likely to be due to the interaction of
the pentafluorphenyl rings against the Cp* ligand and the interaction of the
pentafluorphenyl ring against the other fluorinated ring bound to the phosphine. The
value of ΔG‡ (as calculated from 19F NMR data) showed lower barriers to rotation
for the Ir(III) complex than for those studied here (41.5 and 50.0 kJ mol-1 compared
with 65.4 kJ mol-1 for complex 43). This may be attributed to the longer bond
distance of the Ir – P bonds (2.3278(14) and 2.311(2) Å) than the Ir – imino nitrogen
bond of 43 (2.052(5) Å), reducing the steric hindrance.
1H NMR NOESY experiments (Figure 6.7) were performed on complex 43 to
investigate which protons on the naphthyl group are close in space to the imine
protons, followed by assignment of the protons based on COSY experiments (Figure
6.8). No NOE cross peaks were observed for the minor isomer, but two cross peaks
were observed for the major isomer. Analysis indicated that in the major isomer in
solution the naphthyl ring points away from the chlorido ligand (C1). The X-ray
crystal structures of complexes 43 and 44 also exhibit this conformation. The Hf
proton on the naphthyl group (Figure 6.8) appears to be low-field-shifted by ca. 0.7
ppm in the C2 conformation compared to C1, due to being in close proximity to the
chlorido ligand. The 2:1 ratio of C1:C2 observed in solution suggests that the isomer
C2 is led favoured due to clash of the naphthyl group with the chlorido ligand.
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6.4.3 Aqueous Chemistry and Stability
In many chelated piano-stool metal complexes, hydrolysis of the monodentate ligand
can be an activation process for the observed biological activity.5,35 The M-OH2
bond is believed to be present in the “active species” for many metal-based
anticancer complexes, including the clinical drug cisplatin.36 The aqueous behaviour
of representative Ir(III) complexes (29-34, 37 and 40-42) was studied by 1H NMR
spectroscopy at 310 K. Either two or three sets of peaks were observed in the
aromatic region after 15 min, which may be assigned as the chlorido and
aqua/hydroxido adducts (Figure 6.9 and 6.10). The origin of the third species is
unknown, but could be a methoxy adduct from the methanol present in the sample.
The extent of hydrolysis after 15 min appears to correlate with the Cpx capping
ligand, following the trend Cp* > CpxPh > CpxBiPh. The hydrolysis after 15 min was
markedly less than the complexes studied in Chapter 3 which contain the negatively
charged 2-PhPy chelating ligand. This is presumably due to extra negative charge on
the 2-PhPy complexes which can aid the loss of the chloride ligand. The ImPy
chelating ligand is also a π-acceptor, withdrawing electron-density from the metal 
centre through backbonding. The increase in the positive nature of the metal centre
decreases the extent of aquation.
Within 24 h, only two of the initial three peaks for the Cp* complexes remained
present in the aromatic region, accompanied by the appearance of a new set of peaks
in the high- and low-field regions, implying conversion over time to a new species.
A previous study on the formation of aqua adducts in the series of structurally
similar Ir(III) complexes of the type [(η5-Cp*)Ir(N-(2-pyridylmethylene)-(R)-1-
phenylethylamine)Cl]SbF6, used as Diels-Alder catalysts, reported that the
complexes could not be isolated due to instability of the aqua species.31 However, no
Chapter 6
277
investigations into the reasons behind this were carried out. Recently, the related
Ir(III) complex [(η5-Cp*)Ir(4-hydroxymethyl-N-(2-pyridylmethylene)-
benzenamine)Cl]PF6 was reported to exhibit complete stability in aqueous solution.17
The aqueous stability was measured in the presence of a high concentration of dmso
(50% v/v), which may result in suppression of hydrolysis through formation of a
dmso adduct, which as has been demonstrated for other half-sandwich metal
complexes.37
Examination on the effect of the pH* of the solutions by 1H NMR after 24 h
incubation (Figure 6.11) showed that at low pH* (2.2-4.2) the unidentified species
was not present. Upon an increase in pH* (>6.2) the peaks formed, indicating that
the stability of the complexes in aqueous solution is pH dependent. Determination of
the pKa* values of the aqua adducts of complexes [(η5-Cp*)Ir(ImPy-OH)Cl]PF6 32
and [(η5-Cp*)Ir(ImPy-I)Cl]PF6 40 (where the chlorido monodentate ligand is
replaced with OD2, Figure 6.12) showed that the pKa* is likely to be less than
physiological pH (complex 40 ~ 4.6, 32 – not determined due to interference of the
pH* titration by the phenolic proton on the chelating ligand, but appears to be
between 5.5-7), therefore, likely existing as Ir-OD species rather than Ir-OD2 at
neutral pH. Interestingly, complex 40 shows the largest extent of formation of the
new unidentified species, as well as exhibiting a more acidic aqua adduct compared
with 32. This implies that the formation of the new species may be dependent on the
formation of a hydroxido adduct. The π-accepting ImPy chelating ligand which can 
increase the positive nature of the metal centre, can lower the pKa of an aqua adduct
by pulling electron density away from the bound oxygen atom, making the protons
on the bound aqua ligand more acidic.
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The formation of hydroxido adducts can result in hydroxido bridged dimers.
Previously reported Ru(II) and Os(II) half-sandwich complexes with N,N-, N,O- and
O,O-chelated ligands have been shown to form hydroxido bridged dimers alongside
loss of the chelating ligand in aqueous solution, which all exhibit pKa values below
physiological pH.38,39 This instability has also been observed in titanocene dichloride
where the oxido-bridged oligomers results in the formation of insoluble TiO2.40,41
The formation of hydroxido-bridged dimers has been reported for half-sandwich
Ir(III) complexes bearing C,N-chelated ligands which was accompanied by the
release of free chelating ligand, although this only occurred at high pH (>8.7).42
However, no free chelating ligand was observed in the 1H NMR spectra for the
complexes studied here. In contrast, the LC-MS of complexes [(η5-Cp*)Ir(ImPy-
OH)Cl]PF6 32 and [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 40 in aqueous solution exhibited
peaks that contained the m/z fragment ([(η5-Cpx)Ir(MeCN)3]-H)+ which implies loss
of the chelating ligand (Tables 6.5 and 6.6) The incubation of complex 42 also
resulted in a peak which corresponds to free ImPy-I chelating ligand. Further
analysis of the solution by LC-MS showed that the peak with the longest retention
time for both complexes could be assigned as the chlorido adduct. TFA adducts were
also detected at shorter retention times which may correspond to the aqua
complexes.
Conflicting data from 1H NMR and LC-MS make identification of the new species
formed difficult, but it can be speculated that formation of a bridged hydroxy-dimer
is feasible, which would result in loss of the chelating ligand (Figure 6.18 a).
Alternatively, an hydroxy-bridged species which retains the chelating ligand could
also be the new species formed, which may explain the two Cp* peaks observed for
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40 along with the new low-field aromatic resonances which were not due to free-
chelating ligand (Figure 6.18 b).
Figure 6.18. Possible species formed in water (in the absence of added chloride) for
[(η5-Cpx)Ir(ImPy)Cl]+ complexes based on 1H NMR and LC-MS data. (A) Hydroxy-
bridged dimer resulting in release of the chelating ligand and (B) hydroxy-bridged
dimer with chelating ligand bound.
However, in the presence of 4 mM NaCl, the complexes appear to exist primarily as
the chlorido adduct even after 24 h, as observed by 1H NMR spectroscopy (Figures
6.9 and 6.10). This suggests that minimal hydrolysis will take place under biological
relevant conditions (intracellular [Cl-]) and the complexes remain intact. Therefore,
the observed behaviour in the absence of Cl- in aqueous solution may not be
representative of the behaviour of the complexes in a biological medium. The
stability of complex 42 in LB (media used for antibacterial testing which contains
171 mM of NaCl, Figure 6.14) was also evaluated and showed that the complex
exists as dmso and chlorido adducts after 24 h incubation, further supporting that the
presence of chloride appears to prevent the hydrolysis products from forming.
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6.4.4 Biological Activity
6.4.4.1 Antibacterial Activity
Due to the rise of antibacterial resistance, new compounds are urgently required that
can overcome this resistance. The antibacterial action of complexes 29-45 were
evaluated in E. coli and S. aureus as representatives of Gram-negative and Gram-
positive bacteria, respectively. It was found that the complexes exhibit little
antibacterial action against the Gram-negative E. coli (MIC values of 100 μM), while 
MICs reached as low as 8-15 μM for complexes [(η5-CpxBiPh)Ir(ImPy-NMe2)Cl]PF6
31, [(η5-CpxBiPh)Ir(ImPy-OH)Cl]PF6 34, [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 and [(η5-
CpxBiPh)Ir(ImPy-Naphth)Cl]PF6 45 against the Gram-positive S. aureus, Table 6.9.
The difference in antibacterial action may be attributed to the differences in the cell
wall. The composition of the outer membrane of Gram-negative bacteria includes
lipopolysaccharides (LPS)43 which are highly negatively-charged molecules
stabilised by the presence of small metal ions such as Mg2+ and Ca2+.44 This extra
outer membrane layer is not present in Gram-positive bacteria and makes Gram-
negative bacteria less permeable to antibacterial agents, which increases their
antibacterial resistance.45
The antibacterial activity against S. aureus of the Cp* was only moderate with MICs
of 100 μM (with the exception of complexes 29 and 32 which showed no growth
inhibition). Upon introduction of the extended CpxPh capping ligand, the MIC
dropped to between 40 – 50 μM for the complexes bearing the ImPy-I and ImPy-
Naphth chelating ligands, while the MIC remained >100 μM for complexes bearing 
the ImPy-NMe2 and ImPy-OH chelating ligands. Therefore, there is a dependence on
the antibacterial activity on the nature of the chelating. Upon introduction of the
extended CpxBiPh capping ligand, the MIC values dropped to between 8 – 15 μM. 
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This effect is demonstrated by the growth curves of S. aureus upon incubation with
complexes 32-34 and 40-42, Figure 6.19. The increase in hydrophobicity as a
consequence of the extension of the Cpx capping ligand (as observed within this
series of complex, Table 6.8) may play a role in the enhanced antibacterial
activity.46,47 There is also an increase in the lag phase (period in which bacteria adapt
to their environment and do not multiply) upon an increase in hydrophobicity. The
free capping ligand CpxBiPhH exhibits no biological activity implying that the
presence of the metal as well as the capping ligand are required for activity. Previous
reports of Ir(III) complexes studied for antibacterial action against S. aureus showed
little to no activity for cationic complexes bearing the Cp* capping ligand,8 whilst
the neutral [(η5-Cp*)Ir(aminoacidato)Cl] complexes showed good activity,16
suggesting that hydrophobicity is an important design feature.
The addition of a biphenyl substituent leading to enhanced activity has been
observed in the lipoglycopeptide oritavancin (similar in structure to vancomycin),
where the 4ˈ-chlorobiphenylmethyl group is proposed to disrupt the membrane 
integrity of S. aureus,48 as well as inhibiting cell wall biosynthesis (independently
from the presence of the biphenyl system).49 Investigations into the effect that
complexes 31, 34, 42 and 45 on the membrane integrity against S. aureus was
assessed using the BacLight™ DEAD/ALIVE assay. Complexes 31, 42 and 45 all
caused disruption of the cytoplasmic membrane, while complex 34 caused loss of
membrane integrity but to a lesser extent (Figure 6.14). Therefore, the mechanism of
antibacterial action is likely to involve disruption of the membrane integrity which is
enhanced by the presence of the biphenyl substituent in CpxBiPh complexes. This may
be a consequence of the highly lipophilic nature of the complexes that could result in
accumulation in the cytoplasmic membrane. However, further investigations are
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required to elucidate whether interaction with other biological targets such as DNA10
are also responsible for the mechanism of action.
Figure 6.19. Growth curves for S. aureus with incubation of (A) – ImPy-OH
complexes 32 (100 µM, Cp*), 33 (100 µM, CpxPh) and 34 (15 µM, CpxBiPh) and (B) –
ImPy-I complexes 40 (50 µM), 41 (50 µM, CpxPh) and 42 (8 µM, CpxBiPh) showing
the effect of functionalising the cyclopentadienyl ring and different ImPy ligands on
the MIC values. Controls with 1% dmso are shown for comparison.
Comparison to currently used antibacterial agents shows that they can exhibit
comparable potency to the membrane-damaging agent nisin. However, they are
around eight times less active than vancomycin. Although not as active, they may
still show use for development as it is unlikely that bacteria will already exhibit an
intrinsic resistance towards them.
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6.4.4.2 Antiproliferative Activity towards Eukaryotic Cells
Half-sandwich Ir(III) complexes show promise as anticancer agents.50-52 In general,
the Cp* complexes exhibit no activity against A2780 human ovarian cancer cells,
with the exception of complexes [(η5-Cp*)Ir(ImPy-NMe2)Cl]PF6 29 and
[(η5-Cp*)Ir(ImPy-Naphth)Cl]PF6 43 which exhibit modest IC50 values of 38.64 and
13.3 μM, respectively (Table 6.10). The presence of the naphthyl group in 43 may
enhance the antiproliferative activity due to the extended phenyl ring, by either
increasing the intercalative ability between DNA base pairs53 or by enhancing
hydrophobicity, both of which have been demonstrated to be of importance towards
the design of Ir(III) anticancer agents.42,54 The –NMe2 group significantly increases
the antiproliferative activity of these complexes. Although not fully understood, this
effect has been previously observed in half-sandwich Os(II) phenyliminopyridine55
and phenylazopyridine2 complexes, suggesting that this functional group may
provide promise for further organometallic anticancer drug development.
The introduction of extended Cpx ligands enhances the antiproliferative activity in all
cases, with the CpxBiPh complexes [(η5-CpxBiPh)Ir(ImPy-NMe2)Cl]PF6 31,
[(η5-CpxBiPh)Ir(ImPy-OH)Cl]PF6 34, [(η5-CpxBiPh)Ir(ImPy-I)Cl]PF6 42 and
[(η5-CpxBiPh)Ir(ImPy-Naphth)Cl]PF6 45 showing the greatest potency with IC50
values ranging from 0.64 – 6.2 μM. The activity of these complexes in the MRC5 
healthy human fibroblast model showed IC50 values ranging from 0.35 – 6.7 μM, 
therefore showing minimal selectivity between cancerous and healthy cells. The
enhanced antiproliferative action via extension of the Cpx capping ligand has been
previously demonstrated for Ir(III) complexes.42,54 This is again likely due to
enhanced hydrophobicity, which was also demonstrated to be of importance in the 2-
PhPy complexes studied in Chapter 3.
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Although not investigated in this study, previous work on the possible biological
targets/mechanism of actions of half-sandwich Ir(III) anticancer complexes have
shown that a multi-targeting mechanism is likely to exist.56 They are capable of
binding to DNA via the monodentate site,54 as well as through intercalative
mechanisms through extended planar systems.57 Inhibition of thioredoxin reductase
1 (Trx-R)50, as well as the modulation of NADH/NAD+ may also play role in the
antiproliferative activity.58 However, this study has further supported the hypothesis
that hydrophobicity is a key property for the biological activity of piano-stool Ir(III)
complexes, which can be enhanced by the type of Cpx capping ligand and chelating
ligand used.
6.4.4.3 Structure Activity Relationships (SARs)
Based on the findings from this study, initial structure activity relationships can be
formulated for antibacterial and anticancer activity for complexes of the type
[(η5-Cpx)Ir(ImPy)Cl]PF6. Figure 6.20 shows the differences between hydrophilic
(ImPy-OH) and hydrophobic (ImPy-I) chelating ligands. An increase in
hydrophobicity as a consequence of functionalisation of the Cpx or chelating ligand
results in enhanced antibacterial activity against Gram-positive S. aureus but has
little effect on Gram-negative E. coli. The antiproliferative activity against A2780
cells is also dependent on the hydrophobicity of the complex. The complexes that
exhibit the most promising antibacterial activity are also potent mammalian
antiproliferative agents, perhaps making them unsuitable for further development as
antibacterial agents. However, the antibacterial activity observed is promising and
may provide insight for future design features for half-sandwich Ir(III) antibacterial
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agents, with further investigation into mono-, bi-, and tri-dentate ligands being
potentially interesting avenues of research to explore.
Figure 6.20. Structure activity relationships for [(η5-Cpx)Ir(ImPy)Cl]PF6 complexes
towards antibacterial and anticancer activity based on extension of the Cpx capping
ligand and differences between hydrophilic (ImPy-OH, blue bars) and hydrophobic
(ImPy-I, red bars) chelating ligands. (A) Hydrophobicity, (B) antibacterial activity
against S. aureus, (C) antibacterial activity against E. coli and (D) antiproliferative
activity against A2780 human ovarian cancer cells. n.d. = not determined
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6.5 Conclusion
This chapter has dealt with the synthesis and characterisation of N-(pyrid-2-
ylmethylene)amine half-sandwich Ir(III) complexes, with studies of their solution
chemistry, as well as investigations into their biological activity as antibacterial and
anticancer agents.
Studies of the solution chemistry of complexes 43-45 which bear the naphthyl group
on the chelating ligand N-(2-pyridnylmethylene)-1-naphthalenamine indicated that
two isomers are present in solution. These are due to conformational isomerism
arising from hindered rotation of the naphthyl group against the Cpx capping ligand.
VT-NMR studies have shown that the energy barrier to overcome the transition state
for rotation is relatively independent on the type of Cpx capping ligand.
Investigations into their aqueous chemistry showed that they exhibit more
complicated speciation compared with previously studied chelated half-sandwich
Ir(III) complexes,42,54 which appears to be initiated via hydrolysis at the monodentate
site and formation of hydroxido adducts. LC-MS studies show that the chelating
ligand may dissociate from the metal centre, which often occurs in half-sandwich
metal complexes upon the formation of the hyroxido-bridged dimers.38,42 This
implies that the hydroxido adducts are formed which is due to a low pKa value of the
coordinated water molecule (as observed for complexes 32 and 40). However,
studies in the presence of biologically relevant concentrations of chloride have
shown that the complexes are stable and do not hydrolyse, existing primarily as the
chlorido adduct. They also exhibit good stability in the biological media used in
antibacterial assays (LB).
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No significant biological activity was observed against the Gram-negative bacterium
E. coli, but activity against the Gram-positive S. aureus was observed, with MICs as
low as 8-15 μM. The activity is largely governed by the presence of the extended 
CpxBiPh capping ligand, suggesting that hydrophobicity is important for their activity.
There appears to be a dependence on the nature of the chelating ligand, which may
also be linked to the overall hydrophobicity of the complexes. The mechanism of
action appears, at least in part, to involve reducing the integrity of the lipophilic
cytoplasmic cell membrane, which is enhanced in CpxBiPh complexes that are
inherently more hydrophobic than the other complexes studied.
Some of the complexes exhibit high antiproliferative activity against A2780 human
ovarian cancer cells, in particular, complex [(η5-CpxBiPh)Ir(ImPy-NMe2)Cl]PF6 31
has an IC50 value of 0.64 μM. Potency increases in the order of the substitution of the 
capping ligand Cp* < CpxPh < CpxBiPh indicating that hydrophobicity is likely to be an
important design feature which has been established in previous Ir(III) anticancer
agents.22,54 Functionality of the ImPy chelating ligand also affects the
antiproliferative activity, which again is likely as a consequence of hydrophobic
properties. There is little selectivity over healthy MRC5 human fibroblast cells,
therefore, further modifications to the complex are required (i.e. replacement of the
chloride monodentate ligand with pyridine), which may result in more selective
compounds.3 The importance of the biphenyl substituent on the Cpx capping ligand
in ImPy complexes for good biological activity is apparent, which will be useful for
future research into Ir(III) complexes as antibacterial and anticancer agents.
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7.1 Conclusions
The main focus of this thesis has been investigations into the effects that
functionality of the chelating ligand and monodentate ligand have on the chemical
and anticancer properties of complexes of the type [(η5-Cp*)Ir(2-PhPy)X]0/+. This
work covers three of the four results chapters.
In Chapter 3, it was found that the introduction of an electron-donating (-CH3, -OH,
-CH2OH and –OCH3) or electron-withdrawing (-F, -CF3 -CHO and –NO2) group
into the 2-PhPy ligand in [(η5-Cp*)Ir(2-PhPy)Cl] complexes can dramatically change
the anticancer activity. Studies into their aqueous chemistry showed that hydrolysis
to the corresponding aqua complex was always rapid but easily supressed by
addition of NaCl; hydrolysis was almost completely supressed at 4 mM NaCl which
is representative of the chloride concentration in the cell nucleus. Interactions via the
monodentate site with model DNA nucleobases 9-EtG and 9-MeA showed a
definitive preference for binding to 9-EtG, with very little difference observed
amongst the functionally diverse complexes. The ability to oxidise the coenzyme
NADH to NAD+ catalytically was demonstrated for both “active” and “inactive”
complexes, demonstrating that another factor may be responsible for determining
potency, rather than chemical reactivity.
Analysis of the relative hydrophobicity of the complexes showed that both the type
and position of the substituent affects the hydrophobicity, which appears to correlate
with the extent of metal accumulation in A2780 cells, perhaps demonstrating that
passive diffusion into the cell is an important mechanism for cellular accumulation.
Correlation analysis between iridium accumulation and potency against A2780 cells
showed an apparent trend in which high accumulation results in higher potency. The
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position of the substituent can also influence the localisation in cellular
compartments, which could have implications on the resulting cytotoxic activities of
structural isomers Therefore, it appears that the physicochemical properties arising
from the use of different substituents plays a greater role than chemical reactivity in
determining the potency in this system.
Chapter 4 investigated the potential to enhance the antiproliferative activity of the
most potent complex found in the previous chapter, [(η5-Cp*)Ir(2-(2ˈ-
methylphenyl)pyridine)Cl] 13 (IC50 against A2780 cells = 1.18 μM), with pyridine 
monodentate ligands through modulation of chemical reactivity. It was demonstrated
that the extent of monodentate ligand release and the reactivity towards 9-EtG was
decreased for pyridyl containing complexes compared with the parent chlorido
complex. Interestingly, release of the pyridyl ligands did not result in the detection of
the expected aqua adduct, as previously observed in similar systems. The reactivity
towards GSH decreased only in the complex bearing the pyridyl monodentate ligand
4-(dimethylamino)pyridine, presumably due to enhanced stability from electron
donation from the N-dimethyl group para to bonding nitrogen atom. The reactions of
all the complexes with GSH do not appear to form the expected Ir-SG adduct, but the
oxidised sulfenate (Ir-(S-O)G) and sulfinate (Ir-(S-O2)G) adducts from O2 present in
the reaction. Intriguingly, the catalysis of NADH was independent on the
monodentate ligand.
The antiproliferative activity against A2780 cells indicates no enhancement in
potency for the pyridyl complexes over the parent chlorido complex when cells are
allowed to recover for 72 h in drug-free media. However, when allowing no cell
recovery time after the initial 24 h drug exposure time, the IC50 values show greater
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variance, with the more chemically-stable pyridyl complexes being more active than
the reactive parent chlorido complex. This may indicate that the initial
antiproliferative activity is dependent on greater chemical stability. Further
biological study shows that the induction of total ROS is high in A2780 cells upon
exposure to all complexes, and is likely to contribute to the antiproliferative
mechanism. More interestingly, the ability to induce apoptosis after 0 h and 24 h cell
recovery time showed that the parent chlorido complex does not induce apoptosis,
whereas the pyridyl complexes do induce apoptotic cell death after 24 h recovery
time, implying faster action towards cell death for the pyridyl complexes. The initial
antiproliferative activity may be showing cytostatic activity rather than cytotoxic
activity. Therefore, the change from a chlorido to a pyridyl monodentate ligand not
only affects the chemical reactivity, but also the biological activity.
The reactivity of the aldehyde-bearing complex [(η5-Cp*)Ir(2-phenyl-5-
carboxaldehydepyridine)Cl] 6 towards amines was investigated in Chapter 5 to
explore the possibility of functionalising the complex via Schiff base formation.
Both aliphatic and aromatic organic primary amines were conjugated to complex 6
using microwave-assisted chemistry to form new conjugates using short reaction
times (5 min). The reaction of 6 with the lysine-containing peptides Substance P and
[Lys-3]-bombesin was analysed by ultra-high resolution FT-ICR-MS techniques,
which confirmed that binding of the peptides to 6 could occur via Schiff base
formation with the lysine residue.
The stability of the new Schiff base conjugates towards imine hydrolysis in water
was low over a 24 h period. Reduction of the imine bond in the dansyl-conjuated
complex 26 to the secondary amine 27 was performed using Et3SiH as a hydride
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source. Initially, it was believed that the presence of the Pd catalyst Pd(OAc)2 was
required to reduce the imine bond, as in the case for organic compounds. However,
further analysis of the reaction showed that the Ir centre is involved in the reduction
of the imine bond via formation of an Ir-H species that can then transfer the hydride
to the imine, forming the desired product. The ability to track the secondary amine
complex 27 bearing the fluorescent dansyl group was investigated using fluorescence
confocal microscopy. A reduction in fluorescence intensity was observed in aqueous
solution compared to organic solvents, and no fluorescence was observed in A2780
cells incubated with 27. This suggests that the 27 does not reside in a sufficiently
hydrophobic environment to promote fluorescence, or the cellular accumulation was
too low to detect a fluorescence signal.
Finally, the synthesis of a new set of ImPy complexes of the type
[(η5-Cpx)Ir(ImPy)Cl]PF6 and the evaluation of their chemical and biological
properties was described in Chapter 6. The addition of a sterically bulky naphthyl
group to the aniline ring can incur hindered rotation in solution against the Cpx
capping ligands as observed by 1H NMR spectroscopy, although the presence of
extended arenes on the Cpx ring had little effect on the energy barrier to rotation.
These complexes exhibit complicated aqueous behaviour as studied by NMR and
LC-MS methods, which may be due to the low pKa of the coordinated aqua ligand
upon hydrolysis of the chlorido ligand. However, hydrolysis was supressed by the
presence of 4 mM NaCl, similarly to the 2-PhPy complexes. The complexes are also
stable in the presence of the LB medium used in antibacterial assays. The
hydrophobicity of the complexes is dependent on the type of functional group
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present on the chelating ligand and increases as a function of the Cpx capping ligand:
CpxBiPh > CpxPh > Cp*.
The antibacterial activity of the complexes was investigated and showed minimal
activity against the Gram-negative E. coli. The complexes were more active against
Gram-positive S. aureus with MIC values reaching as low as 8-15 μM, and are some 
of the most active iridium complexes reported to date. The activity was strongly
dependent on the presence of the CpxBiPh capping ligand. Initial studies into the MoA
showed that the active complexes disrupt the membrane integrity of S. aureus after
short incubation times (25 min). The most active antibacterial complexes were also
active against A2780 human ovarian cancer cells and MRC5 healthy human
fibroblasts, therefore, further development is required to gain more selective
antibacterial agents. However, the antiproliferative activity against mammalian cells
of these ImPy complexes bearing the CpxBiPh capping ligand was an order of
magnitude lower than analogous N,N-chelated complexes bearing the same capping
ligand.
7.2 Future Work
The following describes work that could stem from the results and observations of
the research described in this thesis and some initial studies that have been
undertaken.
7.2.1 Reactivity of Functional Groups in Cells
It was demonstrated in Chapter 3 that the presence of functional groups could
strongly dictate the observed anticancer activities, despite exhibiting similar
reactivity at the iridium centre. Studies showed that this may be as a consequence of
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hydrophobicity and the extent of iridium-accumulation. However, some of these
functional groups could exhibit interesting chemistry within the cell.
For example, as described in Chapter 5, the aldehyde functionality in complex
[(η5-Cp*)Ir(2-phenyl-5-carboxaldehydepyridine)Cl] 6 can react with lysine-
containing peptides to form new iridium-peptide conjugates bound via the lysine
residue. Indeed, the reactivity of aldehydes towards peptides and proteins has been
exploited with cross-linking reagents such as glutaraldehyde.1 This kind of
interaction of metallodrugs with peptides and proteins has not been widely reported,
and could offer new mechanisms of action, perhaps by disrupting protein function.
Alternatively, labelling peptides with iridium may offer scope for high-throughput
analysis by HR-MS due to the distinct iridium isotopic pattern.
The incorporation of the nitro functional group into the 2-PhPy chelating ligands
resulted in two complexes with contrasting anticancer activities [(η5-Cp*)Ir(2-
phenyl)pyridine)Cl] 7 and [(η5-Cp*)Ir(2-phenyl -4-nitropyridine)Cl] 8 (IC50 A2780 =
24.73 and 2.7 μM, respectively), despite exhibiting similar physicochemical 
properties. The cytoplasm of cells is known to be a reducing environment due to the
presence of reductants such as GSH, ascorbic acid and NADH. It has been
demonstrated that the nitro functionality in imidazole compounds can be reduced in
mammalian cells using NADH and flavo-proteins like NADPH cytochrome P450
reductase,2 which can then lead to DNA damage by strand breakage.3 It would be of
interest to study the fate of the nitro group in complexes 7 and 8 in a reducing
environment (i.e. using electrochemistry) to determine if reduction potentials could
be of importance to their mechanism. The reactivity in the presence of NADH,
which is already known to be a hydride donor to this series of complex, may also be
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of interest, as it may be possible to reduce the nitro group to the hydroxylamine or
possibly primary amine.
7.2.2 Functionalising Complexes with Cell/Organelle-Targeting
Moieties
The use of complex [(η5-Cp*)Ir(2-phenyl-5-carboxaldehydepyridine)Cl] 6 as a
“chemical platform” for modification with amines was described in Chapter 5
which showed that new Schiff base conjugates could be synthesised readily. The
further reduction of the water-sensitive imine bond to the stable secondary amine
was also achieved. Therefore, further investigations into the types of conjugates that
could be made are worth exploring. An interesting avenue may be to attach
organelle-targeting molecules such as triphenylphosphonium salts (Figure 7.1 a)
which localise in the mitochondria due to their liphophilic and cationic nature.4 It is
believed that half-sandwich iridium(III) complexes cause mitochondrial
dysfunction,5,6 which may be enhanced if the compounds target that organelle.
Recently, it was reported that conjugation of triphenylphosphonium to
phosphorescent octahedral Ir(III) complexes leads to high localisation in the
mitochondria.7
Also worth exploring is the attachment of molecules that could exploit receptor-
mediated delivery, with the aim of achieving selective uptake into cancerous cells
over healthy cells. Folic acid has been widely studied as a vector for platinum
anticancer agents.8 Modification of folic acid to provide a reactive primary amine
group may make it suitable for conjugation to complex 6 (Figure 7.1 b).
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Figure 7.1. (a) Triphenylphosphonium and (b) folic acid conjugated to [(η5-
Cp*)Ir(2-phenyl-5-carboxaldehydepyridine)Cl] 6 to form complexes with
cell/organelle –targeting functions using the method developed in Chapter 5.
7.2.3 N,N,N-Tridentate Complexes as Antibacterial Agents
The antibacterial activity of the chelated half-sandwich ImPy complexes studied in
Chapter 6 is dependent on the presence of the CpxBiPh capping ligand. This has been
proposed to be due to enhanced hydrophobicity, which may lead to greater
accumulation in the bacterial cell membrane of S. aureus, resulting in disruption of
membrane integrity. The presence of biphenyl substituents aids antibacterial activity
of organic compounds via disruption of the cell membrane.9 Therefore, it may be
postulated that the complexes act as a structural scaffold for membrane disruption,
although the mechanism by which this would occur is currently unknown. Further
investigation into the effect on the structures of micelles made of various lipids may
give some insight into their mechanism of action.
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However, the degree of toxicity towards mammalian cells also increases as the Cpx
capping ligand is extended, presumably as a consequence of increased accumulation
and potential DNA intercalation, perhaps making the complexes unsuitable as
antibacterial agents. It is believed that the monodentate site in chelated “piano-stool”
complexes of iridium is likely to be involved in the antiproliferative mechanism,
either through direct binding to guanine or enabling the oxidation of NADH.10
No previously reported work has evaluated the biological activity of iridium(III)
half-sandwich complexes with N,N,N-tridentate ligands. It may be fruitful to explore
tridentate ligands such as diethylenetriamine and tris(pyrazolyl)methane (Figure 7.2)
for their antibacterial and anticancer activities, in order to evaluate the dependency
on a reactive site at the metal centre on biological activity. This could provide
complexes that exhibit more selective antibacterial activity and hence reduce the
toxicity towards mammalian cells. Such a study would also provide information as to
whether a reactive site is required for antibacterial activity or if the presence of the
CpxBiPh capping ligand is enough.
Figure 7.2. Proposed half-sandwich Ir(III) complexes containing the tridentate
ligands diethylenetriamine (a) and tris(pyrazolyl)methane (b) for further antibacterial
work.
Chapter 7
302
7.2.4 Bi-metallic Complexes
The presence of two metals in one compound could be a useful strategy for
increasing the antiproliferative activity of metallodrugs, through providing enhanced
reactivity to the compounds, or even combining properties such as luminescence to
enable tracking in cells. Bi-metallic and polynuclear complexes have shown
excellent anticancer activity in vitro.11,12
A novel ligand has been developed that provides both N,N- and C,N- coordination
modes (Figure 7.3 a), using the synthesis of substituted imidazoles as reported by
Steck and Day.13 The reactivity towards metallation is controlled by two things; the
presence/absence of a base, and the order of the reaction. The coordination of a metal
to the N,N- site occurs selectively in the first step of the reaction. The isolated metal
complex can then be used to react another metal at the C,N- coordination site in the
presence of a mild base (NaOAc), resulting in a bi-metallic complex (Figure 7.3 b).
As the N,N- site is already blocked, the new metal can bind only at the C,N- site.
Initial studies on forming an N,N- and C,N-chelated iridium system were made,
where the yields of product were 78% and 62% for the mono and bi-metallic
complexes, respectively (1H NMR assignments shown in Appendix Figures A1 and
A2). Both heterometallic systems incorporating p-cymene Ru(II) and Os(II)
compounds, as well as Cp* Rh(III) (Figure 7.3 b) were also formed. Evaluation of
the biological activity of these complexes is yet to be performed. Within this general
structure, a vast collection of compounds could be synthesised. For example,
octahedral Ru(II) and Ir(III) complexes (via N,N-chelation) to give
photoactive/luminescent complexes attached to an organometallic anticancer agent
(via C,N-chelation).
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Synthesis of a Pt(II)-Ir(III) analogue was unsuccessful due to the poor solubility of
the Pt(II)-N,N-chelated complex in most organic solvents. It may be interesting to
form the more inert Pt(IV) species via oxidation using H2O2, perhaps allowing
formation of a drug that also contains a “pro-drug” unit that can be activated by
irradiation with light or intracellular reduction.14,15
Figure 7.3. Bi-metallic complexes synthesised via N,N-chelation, followed by a
second reaction with a base to form a C,N- coordinated site.
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Appendix
Table A1. FT-ICR-MS CAD fragmentation data of the species 6+SubP-H2O from
Chapter 5.
Fragment Observed m/z Exact m/z Error/ppm
[b3+6*-H2O]+ 871.37390 871.376815 -3.35
[b4+6*-H2O]+ 968.42327 968.429575 -6.51
[b5+6*-H2O]+ 1096.48806 1096.488155 -0.09
[b6+6*-H2O]+ 1224.54686 1224.546735 0.10
[b7+6*-H2O]+ 1371.61247 1371.615145 -1.95
[b8+6*-H2O]+ 1518.66610 1518.683555 -11.49
[b9+6*-H2O]+ 1575.70497 1575.705015 -0.03
[b10+6*-H2O]+ 1688.78945 1688.789075 0.22
[b8+6*-H2O]2+ 759.33597 759.3417775 -7.65
[b9+6*-H2O]2+ 787.85204 787.8525075 -0.59
[y5]+ 597.30610 597.29793 13.68
[y8-H]+ 949.46042 949.460025 0.42
[y9+6*-H2O]+ 1596.69507 1596.685715 5.86
[y10+6*-H2O]+ 1693.73084 1693.738475 -4.51
Table A2. FT-ICR-MS CAD fragmentation of the species 6+L3BBS-H2O from
Chapter 5.
Fragment Observed m/z Exact m/z Error/ppm
b3+(6*-H2O)-H+ 857.313 857.313005 -0.01
b4+(6*-H2O)-H+ 970.39702 970.397065 -0.05
b5+(6*-H2O)-H+ 1027.41868 1027.418525 0.15
b6+(6*-H2O)-H+ 1141.46129 1141.461455 -0.14
b7+(6*-H2O)-H+ 1269.52003 1269.520035 0.00
b8+(6*-H2O)-H+ 1455.59958 1455.599345 0.16
b9+(6*-H2O)-H+ 1526.63602 1526.636455 -0.28
b10+(6*-H2O)-H+ 1625.70466 1625.704865 -0.13
b11+(6*-H2O)-H+ 1682.72557 1682.726325 -0.45
b12+(6*-H2O)-H+ 1819.78479 1819.785235 -0.24
b13+(6*-H2O)-H+ 1932.86903 1932.869295 -0.14
b8+(6*-H2O)-H+-NH3 1438.57279 1438.5728 -0.01
b9+(6*-H2O)-H+-NH3 1509.60922 1509.60991 -0.46
b10+(6*-H2O)-H+- 1608.67813 1608.67832 -0.12
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b8+(6*-H2O)-H+-CO 1427.60488 1427.60443 0.32
b9+(6*-H2O)-H+-CO 1498.64119 1498.64154 -0.23
b10+(6*-H2O)-H+-CO 1597.71107 1597.70995 0.70
b8+(6*-H2O)-H+-CO2 1411.60967 1411.609516 0.11
y5 (+1) 555.30719 555.30715 0.07
y6 (+1) 626.3443 626.34426 0.06
y7 (+1) 812.42356 812.42357 -0.01
y8 (+1) 940.48218 940.48215 0.03
y9 (+1) 1054.52498 1054.52508 -0.09
y10 (+1) 1111.54644 1111.54654 -0.09
y11 (+1) 1224.63048 1224.6306 -0.10
y5-NH3 538.2806 538.280605 -0.01
y6-NH3 609.31776 609.317715 0.07
y7-NH3 795.39692 795.397025 -0.13
y8-NH3 923.45555 923.455605 -0.06
y10-NH3 1094.51992 1094.519995 -0.07
y11-NH3 1207.60419 1207.604055 0.11
b10 -H+ (+2) 813.35599 813.3560725 -0.10
b12 -H+ (+2) 910.39616 910.3962575 -0.11
b13 -H+ (+2) 966.93832 966.9382875 0.03
b13 -H NH3-(+2) 958.42511 958.425013 0.10
b13 -H+-CO (+2) 952.94074 952.94083 -0.09
b13 -H+-CO-NH3 (+2) 944.42731 944.4275555 -0.26
[(6*-H2O)+L3BBS] + 1040.97159 1040.971808 -0.21
[(6*-H2O)+L3BBS] + 1032.45839 1032.458533 -0.14
[(6*-H2O)+L3BBS] + 1023.94508 1023.945259 -0.17
y ion+(6*-H2O)-H+ 921.4265 921.426775 -0.30
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Table A3. FT-ICR-MS ECD fragmentation of the species 6+L3BBS(His) from
Chapter 5
Fragment Observed m/z Exact m/z Error/ppm
z3dot+6* 891.33643 891.33657 -0.16
z6dot+6* 1118.46426 1118.464091 0.15
z7+6* 1303.53558 1303.53558 0.00
z7dot+6* 1304.54389 1304.543401 0.37
z8+6* 1431.59435 1431.59416 0.13
z8dot+6* 1432.60186 1432.601981 -0.08
z9+6* 1545.63665 1545.63709 -0.28
z9dot+6* 1546.64474 1546.644911 -0.11
z10+6* 1602.65836 1602.65855 -0.12
z10dot+6* 1603.66588 1603.666371 -0.31
z11+6* 1715.7425 1715.74261 -0.06
z12+6* 1843.83686 1843.83757 -0.39
c12+6* 1854.82214 1854.821796 0.19
c13+6* 1967.90497 1967.905856 -0.45
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Figure A1. 1H NMR (400 MHZ, dmso-d6) spectra of the mono-iridium complex
discussed in section 7.2.4.
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Figure A2. 1H NMR (300 MHZ, dmso-d6) spectra of the bi-iridium complex
discussed in section 7.2.4.
